tofacitinib vs upadacitinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Rheumatoid Arthritis

Shared mechanism: JAK · full Rheumatoid Arthritis pipeline

tofacitinib · Xeljanz

Marketed by Pfizer

Approved in Rheumatoid ArthritisSmall molecule (pan-JAK inhibitor)
Weak signal

NCT01262118 · Phase 1 · completed

This was a single-arm, open-label, unblinded study that tracked lipid biomarker levels before and after treatment in one group of patients, with no randomized or treated comparator arm and no statistical test of a treatment effect.

Next expected readout: January 2027 · NCT06945666 (registry estimate)

Reported efficacy

High-density Lipoprotein Cholesterol (HDL-C) Concentration at Baseline; High-density Lipoprotein Cholesterol (HDL-C) Concentration at Week 6; Cholesterol Ester Production Rate at Baseline; Cholesterol Ester Production Rate at Week 6: HDL cholesterol in the rheumatoid arthritis cohort on tofacitinib 10 mg twice daily: mean 54.30 mg/dL (SD 12.52) at baseline and 62.34 mg/dL (SD 15.24) at Week 6. The untreated healthy-volunteer cohort (63.43 mg/dL at baseline) is a reference group only. No statistical analysis is posted. (not_applicable)

Result source: NCT01262118

upadacitinib · Rinvoq

Marketed by AbbVie

Approved in Rheumatoid ArthritisSmall molecule (JAK1-selective inhibitor)
Reliable signal

NCT02675426 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial in 661 patients using two validated rheumatoid arthritis disease-activity measures as co-primary endpoints, and both upadacitinib doses produced significantly higher response rates than placebo on both measures (all comparisons p<0.001).

Next expected readout: March 2027 · NCT07636057 (registry estimate)

Reported efficacy

Change From Baseline in Disease Activity Score (DAS) 28 C-Reactive Protein (CRP) at Week 12 (Non-inferiority) (Baseline and Week 12): Change from baseline DAS28-CRP at week 12: -2.52 (95% CI -2.66 to -2.37) upadacitinib vs -2.00 (95% CI -2.14 to -1.85) abatacept; upadacitinib met primary non-inferiority and key secondary superiority endpoints. (met)

Result source: NCT03086343

Results for Rheumatoid Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointtofacitinibupadacitinib
ACR2052.7% vs 31.2%+21.5 vs placebo5 mg · wk 24 · n 311NCT00856544
273 other results
  • 51.5% vs 28.3% 5 mg twice daily · wk 24 · n 196 · Phase 3 · primary NCT00853385
  • 51.5% vs 25.3% 5 mg · wk 24 · n 309 · Phase 3 · primary NCT00847613
  • 59.8% vs 26.7% 5 mg · wk 12 · n 241 · Phase 3 · primary NCT00814307
  • 41.7% vs 24.4% 5 mg · wk 12 · n 132 · Phase 3 · primary NCT00960440
  • 58.3% vs 31.2% 10 mg · wk 24 · n 309 · Phase 3 · primary NCT00856544
  • 52.5% vs 28.3% 10 mg twice daily · wk 24 · n 196 · Phase 3 · primary NCT00853385
  • 61.8% vs 25.3% 10 mg · wk 24 · n 309 · Phase 3 · primary NCT00847613
  • 65.7% vs 26.7% 10 mg · wk 12 · n 242 · Phase 3 · primary NCT00814307
  • 48.1% vs 24.4% 10 mg · wk 12 · n 133 · Phase 3 · primary NCT00960440
  • 52.7% vs 31.2% 5 mg · wk 26 · n 311 · Phase 3 · secondary NCT00856544
  • 50.8% vs 25.5% 5 mg · wk 19.5 · n 311 · Phase 3 · secondary NCT00856544
  • 56.3% vs 27.4% 5 mg · wk 13 · n 311 · Phase 3 · secondary NCT00856544
  • 60.7% vs 26.4% 5 mg twice daily · wk 13 · n 196 · Phase 3 · secondary NCT00853385
  • 56.3% vs 27.3% 5 mg · wk 13 · n 309 · Phase 3 · secondary NCT00847613
  • 56.9% vs 25.8% 5 mg · wk 8.67 · n 241 · Phase 3 · secondary NCT00814307
  • 54.0% vs 26.1% 5 mg · wk 8.67 · n 311 · Phase 3 · secondary NCT00856544
  • 46.5% vs 21.7% 5 mg · wk 4.33 · n 241 · Phase 3 · secondary NCT00814307
  • 38.6% vs 22.9% 5 mg · wk 4.33 · n 311 · Phase 3 · secondary NCT00856544
  • 41.2% vs 16.0% 5 mg twice daily · wk 4.33 · n 196 · Phase 3 · secondary NCT00853385
  • 41.4% vs 16.3% 5 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00847613
  • 42.4% vs 27.5% 5 mg · wk 4.33 · n 132 · Phase 3 · secondary NCT00960440
  • 29.6% vs 11.8% 5 mg · wk 2 · n 241 · Phase 3 · secondary NCT00814307
  • 27.3% vs 10.9% 5 mg · wk 2 · n 311 · Phase 3 · secondary NCT00856544
  • 27.7% vs 16.7% 5 mg · wk 2 · n 132 · Phase 3 · secondary NCT00960440
  • 58.3% vs 31.2% 10 mg · wk 26 · n 309 · Phase 3 · secondary NCT00856544
  • 57.9% vs 25.5% 10 mg · wk 19.5 · n 309 · Phase 3 · secondary NCT00856544
  • 64.7% vs 27.4% 10 mg · wk 13 · n 309 · Phase 3 · secondary NCT00856544
  • 58.7% vs 26.4% 10 mg twice daily · wk 13 · n 196 · Phase 3 · secondary NCT00853385
  • 66.3% vs 27.3% 10 mg · wk 13 · n 309 · Phase 3 · secondary NCT00847613
  • 60.7% vs 25.8% 10 mg · wk 8.67 · n 242 · Phase 3 · secondary NCT00814307
  • 64.4% vs 26.1% 10 mg · wk 8.67 · n 309 · Phase 3 · secondary NCT00856544
  • 52.1% vs 21.7% 10 mg · wk 4.33 · n 242 · Phase 3 · secondary NCT00814307
  • 48.5% vs 22.9% 10 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00856544
  • 45.9% vs 16.0% 10 mg twice daily · wk 4.33 · n 196 · Phase 3 · secondary NCT00853385
  • 52.1% vs 16.3% 10 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00847613
  • 44.4% vs 27.5% 10 mg · wk 4.33 · n 133 · Phase 3 · secondary NCT00960440
  • 39.2% vs 11.8% 10 mg · wk 2 · n 242 · Phase 3 · secondary NCT00814307
  • 32.3% vs 10.9% 10 mg · wk 2 · n 309 · Phase 3 · secondary NCT00856544
  • 32.8% vs 16.7% 10 mg · wk 2 · n 133 · Phase 3 · secondary NCT00960440
  • 71.3% vs 50.5% 5 mg BID · wk 26 · n 369 · Phase 3 · secondary NCT01039688
  • 69.9% vs 51.6% 5 mg BID · wk 13 · n 369 · Phase 3 · secondary NCT01039688
  • 49.5% vs 47.2% 5 mg twice daily · wk 39 · n 196 · Phase 3 · secondary NCT00853385
  • 72.1% vs 55.4% 5 mg BID · wk 39 · n 369 · Phase 3 · secondary NCT01039688
  • 63.6% vs 42.4% 5 mg BID · wk 8.67 · n 369 · Phase 3 · secondary NCT01039688
  • 49.3% vs 21.2% 5 mg BID · wk 4.33 · n 369 · Phase 3 · secondary NCT01039688
  • 49.5% vs 49.3% 5 mg twice daily · wk 52 · n 196 · Phase 3 · secondary NCT00853385
  • 67.8% vs 51.1% 5 mg BID · wk 52 · n 369 · Phase 3 · secondary NCT01039688
  • 68.8% vs 47.3% 5 mg BID · wk 65 · n 369 · Phase 3 · secondary NCT01039688
  • 64.2% vs 46.7% 5 mg BID · wk 78 · n 369 · Phase 3 · secondary NCT01039688
  • 65.0% vs 45.1% 5 mg BID · wk 91 · n 369 · Phase 3 · secondary NCT01039688
  • 64.2% vs 42.4% 5 mg BID · wk 104 · n 369 · Phase 3 · secondary NCT01039688
  • 76.1% vs 50.5% 10 mg BID · wk 26 · n 394 · Phase 3 · secondary NCT01039688
  • 77.9% vs 51.6% 10 mg BID · wk 13 · n 394 · Phase 3 · secondary NCT01039688
  • 50.5% vs 47.2% 10 mg twice daily · wk 39 · n 196 · Phase 3 · secondary NCT00853385
  • 73.6% vs 55.4% 10 mg BID · wk 39 · n 394 · Phase 3 · secondary NCT01039688
  • 71.6% vs 42.4% 10 mg BID · wk 8.67 · n 394 · Phase 3 · secondary NCT01039688
  • 58.3% vs 21.2% 10 mg BID · wk 4.33 · n 394 · Phase 3 · secondary NCT01039688
  • 49.5% vs 49.3% 10 mg twice daily · wk 52 · n 196 · Phase 3 · secondary NCT00853385
  • 71.6% vs 51.1% 10 mg BID · wk 52 · n 394 · Phase 3 · secondary NCT01039688
  • 66.2% vs 47.3% 10 mg BID · wk 65 · n 394 · Phase 3 · secondary NCT01039688
  • 66.0% vs 46.7% 10 mg BID · wk 78 · n 394 · Phase 3 · secondary NCT01039688
  • 62.2% vs 45.1% 10 mg BID · wk 91 · n 394 · Phase 3 · secondary NCT01039688
  • 64.2% vs 42.4% 10 mg BID · wk 104 · n 394 · Phase 3 · secondary NCT01039688
  • 73.1% vs 15.4% 5 mg · wk 12 · n 52 · Phase 2 · primary NCT00687193
  • 61.2% vs 23.7% 5 mg · wk 12 · n 49 · Phase 2 · primary NCT00550446
  • 96.3% vs 14.3% 5 mg · wk 12 · n 27 · Phase 2 · primary NCT00603512
  • 56.3% vs 36.2% 5 mg · wk 12 · n 71 · Phase 2 · primary NCT00413660
  • 70.5% vs 29.2% 5 mg BID · wk 6 · n 61 · Phase 2 · primary NCT00147498
  • 84.9% vs 15.4% 10 mg · wk 12 · n 53 · Phase 2 · primary NCT00687193
  • 72.1% vs 23.7% 10 mg · wk 12 · n 61 · Phase 2 · primary NCT00550446
  • 80.8% vs 14.3% 10 mg · wk 12 · n 26 · Phase 2 · primary NCT00603512
  • 58.1% vs 36.2% 10 mg · wk 12 · n 74 · Phase 2 · primary NCT00413660
  • 76.8% vs 29.2% 30 mg BID · wk 6 · n 69 · Phase 2 · primary NCT00147498
  • 56.3% vs 36.2% 20 mg · wk 12 · n 80 · Phase 2 · primary NCT00413660
  • 90.7% vs 15.4% 15 mg · wk 12 · n 54 · Phase 2 · primary NCT00687193
  • 71.9% vs 23.7% 15 mg · wk 12 · n 57 · Phase 2 · primary NCT00550446
  • 56% vs 36.2% 15 mg · wk 12 · n 75 · Phase 2 · primary NCT00413660
  • 81.2% vs 29.2% 15 mg BID · wk 6 · n 69 · Phase 2 · primary NCT00147498
  • 67.9% vs 15.4% 3 mg · wk 12 · n 53 · Phase 2 · primary NCT00687193
  • 45.1% vs 23.7% 3 mg · wk 12 · n 51 · Phase 2 · primary NCT00550446
  • 77.8% vs 14.3% 3 mg · wk 12 · n 27 · Phase 2 · primary NCT00603512
  • 55.9% vs 36.2% 3 mg · wk 12 · n 68 · Phase 2 · primary NCT00413660
  • 37.7% vs 15.4% 1 mg · wk 12 · n 53 · Phase 2 · primary NCT00687193
  • 31.5% vs 23.7% 1 mg · wk 12 · n 54 · Phase 2 · primary NCT00550446
  • 64.3% vs 14.3% 1 mg · wk 12 · n 28 · Phase 2 · primary NCT00603512
  • 47.1% vs 36.2% 1 mg · wk 12 · n 70 · Phase 2 · primary NCT00413660
  • 57.1% vs 47.1% 5 mg · wk 24 · n 49 · Phase 2 · secondary NCT00550446
  • 59.2% vs 47.1% 5 mg · wk 24 · n 71 · Phase 2 · secondary NCT00413660
  • 69.4% vs 32.4% 5 mg · wk 20 · n 49 · Phase 2 · secondary NCT00550446
  • 57.7% vs 47.1% 5 mg · wk 20 · n 71 · Phase 2 · secondary NCT00413660
  • 67.3% vs 35.3% 5 mg · wk 16 · n 49 · Phase 2 · secondary NCT00550446
  • 53.5% vs 43.1% 5 mg · wk 16 · n 71 · Phase 2 · secondary NCT00413660
  • 57.1% vs 23.7% 5 mg · wk 10 · n 49 · Phase 2 · secondary NCT00550446
  • 67.3% vs 11.5% 5 mg · wk 8 · n 52 · Phase 2 · secondary NCT00687193
  • 63.3% vs 27.1% 5 mg · wk 8 · n 49 · Phase 2 · secondary NCT00550446
  • 96.3% vs 21.4% 5 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • 54.9% vs 33.3% 5 mg · wk 8 · n 71 · Phase 2 · secondary NCT00413660
  • 50% vs 28.9% 5 mg BID · wk 8 · n 61 · Phase 2 · secondary NCT00147498
  • 63.3% vs 25.4% 5 mg · wk 6 · n 49 · Phase 2 · secondary NCT00550446
  • 57.8% vs 37.7% 5 mg · wk 6 · n 71 · Phase 2 · secondary NCT00413660
  • 61.5% vs 9.6% 5 mg · wk 4 · n 52 · Phase 2 · secondary NCT00687193
  • 40.8% vs 27.1% 5 mg · wk 4 · n 49 · Phase 2 · secondary NCT00550446
  • 88.9% vs 10.7% 5 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • 46.5% vs 24.6% 5 mg · wk 4 · n 71 · Phase 2 · secondary NCT00413660
  • 63.9% vs 30.8% 5 mg BID · wk 4 · n 61 · Phase 2 · secondary NCT00147498
  • 34.6% vs 5.8% 5 mg · wk 2 · n 52 · Phase 2 · secondary NCT00687193
  • 32.6% vs 15.3% 5 mg · wk 2 · n 49 · Phase 2 · secondary NCT00550446
  • 63.0% vs 10.7% 5 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • 31.0% vs 15.9% 5 mg · wk 2 · n 71 · Phase 2 · secondary NCT00413660
  • 50.8% vs 20% 5 mg BID · wk 2 · n 61 · Phase 2 · secondary NCT00147498
  • 29.6% vs 3.6% 5 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • 27.9% vs 12.3% 5 mg BID · wk 1 · n 61 · Phase 2 · secondary NCT00147498
  • 73.8% vs 47.1% 10 mg · wk 24 · n 61 · Phase 2 · secondary NCT00550446
  • 66.2% vs 47.1% 10 mg · wk 24 · n 74 · Phase 2 · secondary NCT00413660
  • 73.8% vs 32.4% 10 mg · wk 20 · n 61 · Phase 2 · secondary NCT00550446
  • 62.2% vs 47.1% 10 mg · wk 20 · n 74 · Phase 2 · secondary NCT00413660
  • 70.5% vs 35.3% 10 mg · wk 16 · n 61 · Phase 2 · secondary NCT00550446
  • 64.9% vs 43.1% 10 mg · wk 16 · n 74 · Phase 2 · secondary NCT00413660
  • 75.4% vs 23.7% 10 mg · wk 10 · n 61 · Phase 2 · secondary NCT00550446
  • 86.8% vs 11.5% 10 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 65.6% vs 27.1% 10 mg · wk 8 · n 61 · Phase 2 · secondary NCT00550446
  • 56.8% vs 33.3% 10 mg · wk 8 · n 74 · Phase 2 · secondary NCT00413660
  • 55.4% vs 37.7% 10 mg · wk 6 · n 74 · Phase 2 · secondary NCT00413660
  • 81.1% vs 9.6% 10 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 46.0% vs 24.6% 10 mg · wk 4 · n 74 · Phase 2 · secondary NCT00413660
  • 66% vs 5.8% 10 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 70.6% vs 28.9% 30 mg BID · wk 8 · n 69 · Phase 2 · secondary NCT00147498
  • 75.4% vs 30.8% 30 mg BID · wk 4 · n 69 · Phase 2 · secondary NCT00147498
  • 68.1% vs 20% 30 mg BID · wk 2 · n 69 · Phase 2 · secondary NCT00147498
  • 56.5% vs 12.3% 30 mg BID · wk 1 · n 69 · Phase 2 · secondary NCT00147498
  • 62.7% vs 47.1% 20 mg · wk 24 · n 80 · Phase 2 · secondary NCT00413660
  • 64.2% vs 47.1% 20 mg · wk 20 · n 80 · Phase 2 · secondary NCT00413660
  • 64.2% vs 43.1% 20 mg · wk 16 · n 80 · Phase 2 · secondary NCT00413660
  • 56.3% vs 33.3% 20 mg · wk 8 · n 80 · Phase 2 · secondary NCT00413660
  • 50% vs 37.7% 20 mg · wk 6 · n 80 · Phase 2 · secondary NCT00413660
  • 51.3% vs 24.6% 20 mg · wk 4 · n 80 · Phase 2 · secondary NCT00413660
  • 33.8% vs 15.9% 20 mg · wk 2 · n 80 · Phase 2 · secondary NCT00413660
  • 80.8% vs 21.4% 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT00603512
  • 63.9% vs 25.4% 10 mg · wk 6 · n 61 · Phase 2 · secondary NCT00550446
  • 52.5% vs 27.1% 10 mg · wk 4 · n 61 · Phase 2 · secondary NCT00550446
  • 76.9% vs 10.7% 10 mg · wk 4 · n 26 · Phase 2 · secondary NCT00603512
  • 50.8% vs 15.3% 10 mg · wk 2 · n 61 · Phase 2 · secondary NCT00550446
  • 50% vs 10.7% 10 mg · wk 2 · n 26 · Phase 2 · secondary NCT00603512
  • 31.1% vs 15.9% 10 mg · wk 2 · n 74 · Phase 2 · secondary NCT00413660
  • 38.5% vs 3.6% 10 mg · wk 1 · n 26 · Phase 2 · secondary NCT00603512
  • 68.4% vs 47.1% 15 mg · wk 24 · n 57 · Phase 2 · secondary NCT00550446
  • 65.3% vs 47.1% 15 mg · wk 24 · n 75 · Phase 2 · secondary NCT00413660
  • 71.9% vs 32.4% 15 mg · wk 20 · n 57 · Phase 2 · secondary NCT00550446
  • 61.3% vs 47.1% 15 mg · wk 20 · n 75 · Phase 2 · secondary NCT00413660
  • 71.9% vs 35.3% 15 mg · wk 16 · n 57 · Phase 2 · secondary NCT00550446
  • 62.7% vs 43.1% 15 mg · wk 16 · n 75 · Phase 2 · secondary NCT00413660
  • 75.4% vs 23.7% 15 mg · wk 10 · n 57 · Phase 2 · secondary NCT00550446
  • 87% vs 11.5% 15 mg · wk 8 · n 54 · Phase 2 · secondary NCT00687193
  • 71.9% vs 27.1% 15 mg · wk 8 · n 57 · Phase 2 · secondary NCT00550446
  • 64% vs 33.3% 15 mg · wk 8 · n 75 · Phase 2 · secondary NCT00413660
  • 66.1% vs 28.9% 15 mg BID · wk 8 · n 69 · Phase 2 · secondary NCT00147498
  • 66.7% vs 25.4% 15 mg · wk 6 · n 57 · Phase 2 · secondary NCT00550446
  • 56% vs 37.7% 15 mg · wk 6 · n 75 · Phase 2 · secondary NCT00413660
  • 77.8% vs 9.6% 15 mg · wk 4 · n 54 · Phase 2 · secondary NCT00687193
  • 63.2% vs 27.1% 15 mg · wk 4 · n 57 · Phase 2 · secondary NCT00550446
  • 54.7% vs 24.6% 15 mg · wk 4 · n 75 · Phase 2 · secondary NCT00413660
  • 75.4% vs 30.8% 15 mg BID · wk 4 · n 69 · Phase 2 · secondary NCT00147498
  • 53.7% vs 5.8% 15 mg · wk 2 · n 54 · Phase 2 · secondary NCT00687193
  • 38.6% vs 15.3% 15 mg · wk 2 · n 57 · Phase 2 · secondary NCT00550446
  • 40% vs 15.9% 15 mg · wk 2 · n 75 · Phase 2 · secondary NCT00413660
  • 71.0% vs 20% 15 mg BID · wk 2 · n 69 · Phase 2 · secondary NCT00147498
  • 43.5% vs 12.3% 15 mg BID · wk 1 · n 69 · Phase 2 · secondary NCT00147498
  • 58.8% vs 47.1% 3 mg · wk 24 · n 51 · Phase 2 · secondary NCT00550446
  • 65.5% vs 47.1% 3 mg · wk 24 · n 68 · Phase 2 · secondary NCT00413660
  • 64.7% vs 32.4% 3 mg · wk 20 · n 51 · Phase 2 · secondary NCT00550446
  • 67.3% vs 47.1% 3 mg · wk 20 · n 68 · Phase 2 · secondary NCT00413660
  • 58.8% vs 35.3% 3 mg · wk 16 · n 51 · Phase 2 · secondary NCT00550446
  • 60% vs 43.1% 3 mg · wk 16 · n 68 · Phase 2 · secondary NCT00413660
  • 37.3% vs 23.7% 3 mg · wk 10 · n 51 · Phase 2 · secondary NCT00550446
  • 62.3% vs 11.5% 3 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 47.1% vs 27.1% 3 mg · wk 8 · n 51 · Phase 2 · secondary NCT00550446
  • 66.7% vs 21.4% 3 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • 54.4% vs 33.3% 3 mg · wk 8 · n 68 · Phase 2 · secondary NCT00413660
  • 47.1% vs 25.4% 3 mg · wk 6 · n 51 · Phase 2 · secondary NCT00550446
  • 54.4% vs 37.7% 3 mg · wk 6 · n 68 · Phase 2 · secondary NCT00413660
  • 47.2% vs 9.6% 3 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 37.3% vs 27.1% 3 mg · wk 4 · n 51 · Phase 2 · secondary NCT00550446
  • 55.6% vs 10.7% 3 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • 45.6% vs 24.6% 3 mg · wk 4 · n 68 · Phase 2 · secondary NCT00413660
  • 34% vs 5.8% 3 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 31.4% vs 15.3% 3 mg · wk 2 · n 51 · Phase 2 · secondary NCT00550446
  • 40.7% vs 10.7% 3 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • 36.8% vs 15.9% 3 mg · wk 2 · n 68 · Phase 2 · secondary NCT00413660
  • 14.8% vs 3.6% 3 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • 35.1% vs 47.1% 1 mg · wk 24 · n 54 · Phase 2 · secondary NCT00550446
  • 59.2% vs 47.1% 1 mg · wk 24 · n 70 · Phase 2 · secondary NCT00413660
  • 45.9% vs 32.4% 1 mg · wk 20 · n 54 · Phase 2 · secondary NCT00550446
  • 59.2% vs 47.1% 1 mg · wk 20 · n 70 · Phase 2 · secondary NCT00413660
  • 51.4% vs 35.3% 1 mg · wk 16 · n 54 · Phase 2 · secondary NCT00550446
  • 63.3% vs 43.1% 1 mg · wk 16 · n 70 · Phase 2 · secondary NCT00413660
  • 35.2% vs 23.7% 1 mg · wk 10 · n 54 · Phase 2 · secondary NCT00550446
  • 37.7% vs 11.5% 1 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 37.0% vs 27.1% 1 mg · wk 8 · n 54 · Phase 2 · secondary NCT00550446
  • 67.9% vs 21.4% 1 mg · wk 8 · n 28 · Phase 2 · secondary NCT00603512
  • 50% vs 33.3% 1 mg · wk 8 · n 70 · Phase 2 · secondary NCT00413660
  • 38.9% vs 25.4% 1 mg · wk 6 · n 54 · Phase 2 · secondary NCT00550446
  • 44.3% vs 37.7% 1 mg · wk 6 · n 70 · Phase 2 · secondary NCT00413660
  • 35.8% vs 9.6% 1 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 22.2% vs 27.1% 1 mg · wk 4 · n 54 · Phase 2 · secondary NCT00550446
  • 50% vs 10.7% 1 mg · wk 4 · n 28 · Phase 2 · secondary NCT00603512
  • 37.1% vs 24.6% 1 mg · wk 4 · n 70 · Phase 2 · secondary NCT00413660
  • 18.9% vs 5.8% 1 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 16.7% vs 15.3% 1 mg · wk 2 · n 54 · Phase 2 · secondary NCT00550446
  • 82.6% vs 65.2% wk 12 · n 50 · Phase 2 · secondary NCT01059864
  • 76% vs 76.6% wk 6 · n 50 · Phase 2 · secondary NCT01059864
  • 0% vs 47.1% 20 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 47.1% 20 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 43.1% 20 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 47.1% 3 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 47.1% 3 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 43.1% 3 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 47.1% 1 mg to 5 mg (R) · wk 24 · n 21 · Phase 2 · secondary NCT00413660
  • 0% vs 47.1% 1 mg to 5 mg (R) · wk 20 · n 21 · Phase 2 · secondary NCT00413660
  • 0% vs 43.1% 1 mg to 5 mg (R) · wk 16 · n 21 · Phase 2 · secondary NCT00413660
  • 32.1% vs 10.7% 1 mg · wk 2 · n 28 · Phase 2 · secondary NCT00603512
  • 21.4% vs 15.9% 1 mg · wk 2 · n 70 · Phase 2 · secondary NCT00413660
  • 28.6% vs 3.6% 1 mg · wk 1 · n 28 · Phase 2 · secondary NCT00603512
  • 60% vs 0% wk 4 · n 15 · Phase 2 · secondary NCT00976599
  • 68.7% vs 67.6% 5 mg BID · wk 26 · n 1455 · Phase 4 · secondary NCT02092467
  • 67.3% vs 63.6% 5 mg BID · wk 13 · n 1455 · Phase 4 · secondary NCT02092467
  • 70% vs 68% 5 mg BID · wk 39 · n 1455 · Phase 4 · secondary NCT02092467
  • 57.2% vs 56% 5 mg BID · wk 8.67 · n 1455 · Phase 4 · secondary NCT02092467
  • 71% vs 66.6% 5 mg BID · wk 52 · n 1455 · Phase 4 · secondary NCT02092467
  • 69.9% vs 66.8% 5 mg BID · wk 65 · n 1455 · Phase 4 · secondary NCT02092467
  • 67.4% vs 64.6% 5 mg BID · wk 78 · n 1455 · Phase 4 · secondary NCT02092467
  • 65.6% vs 65.4% 5 mg BID · wk 91 · n 1455 · Phase 4 · secondary NCT02092467
  • 65.7% vs 63.5% 5 mg BID · wk 104 · n 1455 · Phase 4 · secondary NCT02092467
  • 66% vs 62.9% 5 mg BID · wk 117 · n 1455 · Phase 4 · secondary NCT02092467
  • 64.1% vs 64.2% 5 mg BID · wk 130 · n 1455 · Phase 4 · secondary NCT02092467
  • 64.3% vs 63.5% 5 mg BID · wk 143 · n 1455 · Phase 4 · secondary NCT02092467
  • 62.3% vs 61.1% 5 mg BID · wk 156 · n 1455 · Phase 4 · secondary NCT02092467
  • 61.6% vs 61.1% 5 mg BID · wk 169 · n 1455 · Phase 4 · secondary NCT02092467
  • 62.2% vs 60.9% 5 mg BID · wk 182 · n 1455 · Phase 4 · secondary NCT02092467
  • 53.6% vs 54.4% 5 mg BID · wk 195 · n 1455 · Phase 4 · secondary NCT02092467
  • 44.9% vs 44% 5 mg BID · wk 208 · n 1455 · Phase 4 · secondary NCT02092467
  • 36.8% vs 35.7% 5 mg BID · wk 221 · n 1455 · Phase 4 · secondary NCT02092467
  • 29.8% vs 27.6% 5 mg BID · wk 234 · n 1455 · Phase 4 · secondary NCT02092467
  • 23.2% vs 20.8% 5 mg BID · wk 247 · n 1455 · Phase 4 · secondary NCT02092467
  • 16.7% vs 16% 5 mg BID · wk 260 · n 1455 · Phase 4 · secondary NCT02092467
  • 11.2% vs 11.1% 5 mg BID · wk 273 · n 1455 · Phase 4 · secondary NCT02092467
  • 5.8% vs 6.1% 5 mg BID · wk 286 · n 1455 · Phase 4 · secondary NCT02092467
  • 1.8% vs 2.5% 5 mg BID · wk 299 · n 1455 · Phase 4 · secondary NCT02092467
  • 0.3% vs 0.7% 5 mg BID · wk 312 · n 1455 · Phase 4 · secondary NCT02092467
  • 69.5% vs 67.6% 10 mg BID · wk 26 · n 1456 · Phase 4 · secondary NCT02092467
  • 68.1% vs 63.6% 10 mg BID · wk 13 · n 1456 · Phase 4 · secondary NCT02092467
  • 69% vs 68% 10 mg BID · wk 39 · n 1456 · Phase 4 · secondary NCT02092467
  • 59.5% vs 56% 10 mg BID · wk 8.67 · n 1456 · Phase 4 · secondary NCT02092467
  • 68.1% vs 66.6% 10 mg BID · wk 52 · n 1456 · Phase 4 · secondary NCT02092467
  • 68.9% vs 66.8% 10 mg BID · wk 65 · n 1456 · Phase 4 · secondary NCT02092467
  • 66.9% vs 64.6% 10 mg BID · wk 78 · n 1456 · Phase 4 · secondary NCT02092467
  • 65.5% vs 65.4% 10 mg BID · wk 91 · n 1456 · Phase 4 · secondary NCT02092467
  • 63.3% vs 63.5% 10 mg BID · wk 104 · n 1456 · Phase 4 · secondary NCT02092467
  • 63% vs 62.9% 10 mg BID · wk 117 · n 1456 · Phase 4 · secondary NCT02092467
  • 61.7% vs 64.2% 10 mg BID · wk 130 · n 1456 · Phase 4 · secondary NCT02092467
  • 61% vs 63.5% 10 mg BID · wk 143 · n 1456 · Phase 4 · secondary NCT02092467
  • 60.5% vs 61.1% 10 mg BID · wk 156 · n 1456 · Phase 4 · secondary NCT02092467
  • 57.9% vs 61.1% 10 mg BID · wk 169 · n 1456 · Phase 4 · secondary NCT02092467
  • 58.2% vs 60.9% 10 mg BID · wk 182 · n 1456 · Phase 4 · secondary NCT02092467
  • 49.3% vs 54.4% 10 mg BID · wk 195 · n 1456 · Phase 4 · secondary NCT02092467
  • 40.3% vs 44% 10 mg BID · wk 208 · n 1456 · Phase 4 · secondary NCT02092467
  • 33.3% vs 35.7% 10 mg BID · wk 221 · n 1456 · Phase 4 · secondary NCT02092467
  • 27.2% vs 27.6% 10 mg BID · wk 234 · n 1456 · Phase 4 · secondary NCT02092467
  • 22% vs 20.8% 10 mg BID · wk 247 · n 1456 · Phase 4 · secondary NCT02092467
  • 16.3% vs 16% 10 mg BID · wk 260 · n 1456 · Phase 4 · secondary NCT02092467
  • 11.4% vs 11.1% 10 mg BID · wk 273 · n 1456 · Phase 4 · secondary NCT02092467
  • 6.9% vs 6.1% 10 mg BID · wk 286 · n 1456 · Phase 4 · secondary NCT02092467
  • 2.5% vs 2.5% 10 mg BID · wk 299 · n 1456 · Phase 4 · secondary NCT02092467
  • 1% vs 0.7% 10 mg BID · wk 312 · n 1456 · Phase 4 · secondary NCT02092467
63.8% vs 35.7%+28.1 vs placebo15 mg · wk 12 · n 221NCT02675426
49 other results
  • 64.6% vs 28.4% 15 mg · wk 12 · n 164 · Phase 3 · primary NCT02706847
  • 71.6% vs 31.4% 15 mg · wk 12 · n 169 · Phase 3 · primary NCT02955212
  • 66.2% vs 35.7% 30 mg · wk 12 · n 219 · Phase 3 · primary NCT02675426
  • 56.4% vs 28.4% 30 mg · wk 12 · n 165 · Phase 3 · primary NCT02706847
  • 83.7% vs 42.9% 15 mg · wk 12 · n 49 · Phase 2/3 · primary NCT02720523
  • 80% vs 42.9% 30 mg · wk 12 · n 50 · Phase 2/3 · primary NCT02720523
  • 75.5% vs 42.9% 7.5 mg · wk 12 · n 49 · Phase 2/3 · primary NCT02720523
  • 67.7% vs 41.2% 15 mg · wk 14 · n 217 · Phase 3 · primary NCT02706951
  • 75.7% vs 54.1% 15 mg · wk 12 · n 317 · Phase 3 · primary NCT02706873
  • 71.2% vs 41.2% 30 mg · wk 14 · n 215 · Phase 3 · primary NCT02706951
  • 77.1% vs 54.1% 30 mg · wk 12 · n 314 · Phase 3 · primary NCT02706873
  • 22.2% vs 8.6% 15 mg · wk 1 · n 221 · Phase 3 · secondary NCT02675426
  • 27.4% vs 10.7% 15 mg · wk 1 · n 164 · Phase 3 · secondary NCT02706847
  • 25.4% vs 5.9% 15 mg · wk 1 · n 169 · Phase 3 · secondary NCT02955212
  • 28.3% vs 8.6% 30 mg · wk 1 · n 219 · Phase 3 · secondary NCT02675426
  • 24.8% vs 10.7% 30 mg · wk 1 · n 165 · Phase 3 · secondary NCT02706847
  • 24.5% vs 8.2% 15 mg · wk 1 · n 49 · Phase 2/3 · secondary NCT02720523
  • 34% vs 8.2% 30 mg · wk 1 · n 50 · Phase 2/3 · secondary NCT02720523
  • 30.6% vs 8.2% 7.5 mg · wk 1 · n 49 · Phase 2/3 · secondary NCT02720523
  • 78.9% vs 58.6% 15 mg · wk 24 · n 317 · Phase 3 · secondary NCT02706873
  • 78% vs 58.6% 30 mg · wk 24 · n 314 · Phase 3 · secondary NCT02706873
  • 85.2% vs 57.1% 15 mg · wk 12 · n 27 · Phase 3 · secondary NCT02706873
  • 78.6% vs 57.1% 30 mg · wk 12 · n 28 · Phase 3 · secondary NCT02706873
  • 85.5% vs 57.1% 7.5 mg · wk 12 · n 55 · Phase 3 · secondary NCT02706873
  • 81.6% vs 50% 24 mg QD · wk 12 · n 49 · Phase 2 · primary NCT02066389
  • 76.6% vs 50% 18 mg BID · wk 12 · n 47 · Phase 2 · primary NCT02066389
  • 70.9% vs 35.2% 18 mg BID · wk 12 · n 55 · Phase 2 · primary NCT01960855
  • 81.6% vs 50% 12 mg BID · wk 12 · n 49 · Phase 2 · primary NCT02066389
  • 72.7% vs 35.2% 12 mg BID · wk 12 · n 55 · Phase 2 · primary NCT01960855
  • 73.5% vs 50% 6 mg BID · wk 12 · n 49 · Phase 2 · primary NCT02066389
  • 63.5% vs 35.2% 6 mg BID · wk 12 · n 52 · Phase 2 · primary NCT01960855
  • 64.6% vs 50% 3 mg BID · wk 12 · n 48 · Phase 2 · primary NCT02066389
  • 55.6% vs 35.2% 3 mg BID · wk 12 · n 54 · Phase 2 · primary NCT01960855
  • 41.5% vs 47.4% 60 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 39% vs 36.8% 60 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 29.3% vs 42.1% 60 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 24.4% vs 21.1% 60 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705
  • 30.8% vs 47.4% 20 mg · wk 12 · n 39 · Phase 2 · secondary NCT03682705
  • 30.8% vs 36.8% 20 mg · wk 8 · n 39 · Phase 2 · secondary NCT03682705
  • 23.1% vs 42.1% 20 mg · wk 4 · n 39 · Phase 2 · secondary NCT03682705
  • 12.8% vs 21.1% 20 mg · wk 2 · n 39 · Phase 2 · secondary NCT03682705
  • 64.5% vs 47.4% 15 mg/60 mg · wk 12 · n 62 · Phase 2 · secondary NCT03682705
  • 64.5% vs 36.8% 15 mg/60 mg · wk 8 · n 62 · Phase 2 · secondary NCT03682705
  • 51.6% vs 42.1% 15 mg/60 mg · wk 4 · n 62 · Phase 2 · secondary NCT03682705
  • 45.2% vs 21.1% 15 mg/60 mg · wk 2 · n 62 · Phase 2 · secondary NCT03682705
  • 34.1% vs 47.4% 5 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 39% vs 36.8% 5 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 22% vs 42.1% 5 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 14.6% vs 21.1% 5 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705
ACR5033.8% vs 12.7%+21 vs placebo5 mg · wk 26 · n 311NCT00856544
275 other results
  • 36.7% vs 12.3% 5 mg twice daily · wk 26 · n 196 · Phase 3 · secondary NCT00853385
  • 32.4% vs 8.4% 5 mg · wk 26 · n 309 · Phase 3 · secondary NCT00847613
  • 28.0% vs 8.3% 5 mg · wk 19.5 · n 311 · Phase 3 · secondary NCT00856544
  • 31.1% vs 12.5% 5 mg · wk 13 · n 241 · Phase 3 · secondary NCT00814307
  • 27.3% vs 9.6% 5 mg · wk 13 · n 311 · Phase 3 · secondary NCT00856544
  • 34.2% vs 6.6% 5 mg twice daily · wk 13 · n 196 · Phase 3 · secondary NCT00853385
  • 28.8% vs 7.8% 5 mg · wk 13 · n 309 · Phase 3 · secondary NCT00847613
  • 26.5% vs 8.4% 5 mg · wk 13 · n 132 · Phase 3 · secondary NCT00960440
  • 32.7% vs 20% 5 mg · wk 39 · n 309 · Phase 3 · secondary NCT00847613
  • 26.1% vs 5.8% 5 mg · wk 8.67 · n 241 · Phase 3 · secondary NCT00814307
  • 23.1% vs 4.5% 5 mg · wk 8.67 · n 311 · Phase 3 · secondary NCT00856544
  • 17.4% vs 4.2% 5 mg · wk 4.33 · n 241 · Phase 3 · secondary NCT00814307
  • 11.6% vs 1.3% 5 mg · wk 4.33 · n 311 · Phase 3 · secondary NCT00856544
  • 14.9% vs 4.7% 5 mg twice daily · wk 4.33 · n 196 · Phase 3 · secondary NCT00853385
  • 16.8% vs 1.3% 5 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00847613
  • 12.9% vs 6.1% 5 mg · wk 4.33 · n 132 · Phase 3 · secondary NCT00960440
  • 5.8% vs 4.2% 5 mg · wk 2 · n 241 · Phase 3 · secondary NCT00814307
  • 5.8% vs 1.3% 5 mg · wk 2 · n 311 · Phase 3 · secondary NCT00856544
  • 7.7% vs 1.6% 5 mg · wk 2 · n 132 · Phase 3 · secondary NCT00960440
  • 32.7% vs 16% 5 mg · wk 52 · n 309 · Phase 3 · secondary NCT00847613
  • 36.6% vs 12.7% 10 mg · wk 26 · n 309 · Phase 3 · secondary NCT00856544
  • 34.7% vs 12.3% 10 mg twice daily · wk 26 · n 196 · Phase 3 · secondary NCT00853385
  • 43.7% vs 8.4% 10 mg · wk 26 · n 309 · Phase 3 · secondary NCT00847613
  • 33.3% vs 8.3% 10 mg · wk 19.5 · n 309 · Phase 3 · secondary NCT00856544
  • 36.8% vs 12.5% 10 mg · wk 13 · n 242 · Phase 3 · secondary NCT00814307
  • 34.0% vs 9.6% 10 mg · wk 13 · n 309 · Phase 3 · secondary NCT00856544
  • 27.6% vs 6.6% 10 mg twice daily · wk 13 · n 196 · Phase 3 · secondary NCT00853385
  • 36.3% vs 7.8% 10 mg · wk 13 · n 309 · Phase 3 · secondary NCT00847613
  • 27.8% vs 8.4% 10 mg · wk 13 · n 133 · Phase 3 · secondary NCT00960440
  • 44.0% vs 20% 10 mg · wk 39 · n 309 · Phase 3 · secondary NCT00847613
  • 33.9% vs 5.8% 10 mg · wk 8.67 · n 242 · Phase 3 · secondary NCT00814307
  • 29.8% vs 4.5% 10 mg · wk 8.67 · n 309 · Phase 3 · secondary NCT00856544
  • 24.0% vs 4.2% 10 mg · wk 4.33 · n 242 · Phase 3 · secondary NCT00814307
  • 18.1% vs 1.3% 10 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00856544
  • 16.3% vs 4.7% 10 mg twice daily · wk 4.33 · n 196 · Phase 3 · secondary NCT00853385
  • 18.4% vs 1.3% 10 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00847613
  • 17.3% vs 6.1% 10 mg · wk 4.33 · n 133 · Phase 3 · secondary NCT00960440
  • 12.9% vs 4.2% 10 mg · wk 2 · n 242 · Phase 3 · secondary NCT00814307
  • 8.1% vs 1.3% 10 mg · wk 2 · n 309 · Phase 3 · secondary NCT00856544
  • 5.5% vs 1.6% 10 mg · wk 2 · n 133 · Phase 3 · secondary NCT00960440
  • 41.1% vs 16% 10 mg · wk 52 · n 309 · Phase 3 · secondary NCT00847613
  • 46.6% vs 26.6% 5 mg BID · wk 26 · n 369 · Phase 3 · secondary NCT01039688
  • 40.1% vs 20.1% 5 mg BID · wk 13 · n 369 · Phase 3 · secondary NCT01039688
  • 35.7% vs 29.1% 5 mg twice daily · wk 39 · n 196 · Phase 3 · secondary NCT00853385
  • 49.9% vs 35.3% 5 mg BID · wk 39 · n 369 · Phase 3 · secondary NCT01039688
  • 32.6% vs 11.4% 5 mg BID · wk 8.67 · n 369 · Phase 3 · secondary NCT01039688
  • 18.0% vs 3.8% 5 mg BID · wk 4.33 · n 369 · Phase 3 · secondary NCT01039688
  • 36.7% vs 33.7% 5 mg twice daily · wk 52 · n 196 · Phase 3 · secondary NCT00853385
  • 49.9% vs 33.7% 5 mg BID · wk 52 · n 369 · Phase 3 · secondary NCT01039688
  • 50.7% vs 33.1% 5 mg BID · wk 65 · n 369 · Phase 3 · secondary NCT01039688
  • 48.0% vs 30.4% 5 mg BID · wk 78 · n 369 · Phase 3 · secondary NCT01039688
  • 49.0% vs 30.4% 5 mg BID · wk 91 · n 369 · Phase 3 · secondary NCT01039688
  • 49.3% vs 28.3% 5 mg BID · wk 104 · n 369 · Phase 3 · secondary NCT01039688
  • 56.4% vs 26.6% 10 mg BID · wk 26 · n 394 · Phase 3 · secondary NCT01039688
  • 50% vs 20.1% 10 mg BID · wk 13 · n 394 · Phase 3 · secondary NCT01039688
  • 37.2% vs 29.1% 10 mg twice daily · wk 39 · n 196 · Phase 3 · secondary NCT00853385
  • 56.9% vs 35.3% 10 mg BID · wk 39 · n 394 · Phase 3 · secondary NCT01039688
  • 40.1% vs 11.4% 10 mg BID · wk 8.67 · n 394 · Phase 3 · secondary NCT01039688
  • 28.0% vs 3.8% 10 mg BID · wk 4.33 · n 394 · Phase 3 · secondary NCT01039688
  • 35.7% vs 33.7% 10 mg twice daily · wk 52 · n 196 · Phase 3 · secondary NCT00853385
  • 55.6% vs 33.7% 10 mg BID · wk 52 · n 394 · Phase 3 · secondary NCT01039688
  • 54.3% vs 33.1% 10 mg BID · wk 65 · n 394 · Phase 3 · secondary NCT01039688
  • 51.8% vs 30.4% 10 mg BID · wk 78 · n 394 · Phase 3 · secondary NCT01039688
  • 50.5% vs 30.4% 10 mg BID · wk 91 · n 394 · Phase 3 · secondary NCT01039688
  • 49.2% vs 28.3% 10 mg BID · wk 104 · n 394 · Phase 3 · secondary NCT01039688
  • 36.7% vs 17.6% 5 mg · wk 24 · n 49 · Phase 2 · secondary NCT00550446
  • 39.4% vs 31.4% 5 mg · wk 24 · n 71 · Phase 2 · secondary NCT00413660
  • 32.7% vs 17.6% 5 mg · wk 20 · n 49 · Phase 2 · secondary NCT00550446
  • 38% vs 31.4% 5 mg · wk 20 · n 71 · Phase 2 · secondary NCT00413660
  • 34.7% vs 20.6% 5 mg · wk 16 · n 49 · Phase 2 · secondary NCT00550446
  • 38% vs 21.6% 5 mg · wk 16 · n 71 · Phase 2 · secondary NCT00413660
  • 46.2% vs 7.7% 5 mg · wk 12 · n 52 · Phase 2 · secondary NCT00687193
  • 38.8% vs 10.2% 5 mg · wk 12 · n 49 · Phase 2 · secondary NCT00550446
  • 81.5% vs 14.3% 5 mg · wk 12 · n 27 · Phase 2 · secondary NCT00603512
  • 36.6% vs 17.4% 5 mg · wk 12 · n 71 · Phase 2 · secondary NCT00413660
  • 34.7% vs 6.8% 5 mg · wk 10 · n 49 · Phase 2 · secondary NCT00550446
  • 44.2% vs 1.9% 5 mg · wk 8 · n 52 · Phase 2 · secondary NCT00687193
  • 24.5% vs 8.5% 5 mg · wk 8 · n 49 · Phase 2 · secondary NCT00550446
  • 70.4% vs 7.1% 5 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • 32.4% vs 17.4% 5 mg · wk 8 · n 71 · Phase 2 · secondary NCT00413660
  • 17.9% vs 13.3% 5 mg BID · wk 8 · n 61 · Phase 2 · secondary NCT00147498
  • 14.3% vs 6.8% 5 mg · wk 6 · n 49 · Phase 2 · secondary NCT00550446
  • 31.0% vs 8.7% 5 mg · wk 6 · n 71 · Phase 2 · secondary NCT00413660
  • 32.8% vs 6.2% 5 mg BID · wk 6 · n 61 · Phase 2 · secondary NCT00147498
  • 28.8% vs 1.9% 5 mg · wk 4 · n 52 · Phase 2 · secondary NCT00687193
  • 10.2% vs 5.1% 5 mg · wk 4 · n 49 · Phase 2 · secondary NCT00550446
  • 29.6% vs 3.6% 5 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • 11.3% vs 2.9% 5 mg · wk 4 · n 71 · Phase 2 · secondary NCT00413660
  • 32.8% vs 6.2% 5 mg BID · wk 4 · n 61 · Phase 2 · secondary NCT00147498
  • 11.5% vs 0% 5 mg · wk 2 · n 52 · Phase 2 · secondary NCT00687193
  • 8.2% vs 1.7% 5 mg · wk 2 · n 49 · Phase 2 · secondary NCT00550446
  • 25.9% vs 0% 5 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • 5.6% vs 2.9% 5 mg · wk 2 · n 71 · Phase 2 · secondary NCT00413660
  • 9.8% vs 3.1% 5 mg BID · wk 2 · n 61 · Phase 2 · secondary NCT00147498
  • 0% vs 0% 5 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • 6.6% vs 3.1% 5 mg BID · wk 1 · n 61 · Phase 2 · secondary NCT00147498
  • 45.9% vs 17.6% 10 mg · wk 24 · n 61 · Phase 2 · secondary NCT00550446
  • 39.2% vs 31.4% 10 mg · wk 24 · n 74 · Phase 2 · secondary NCT00413660
  • 42.6% vs 17.6% 10 mg · wk 20 · n 61 · Phase 2 · secondary NCT00550446
  • 40.5% vs 31.4% 10 mg · wk 20 · n 74 · Phase 2 · secondary NCT00413660
  • 42.6% vs 20.6% 10 mg · wk 16 · n 61 · Phase 2 · secondary NCT00550446
  • 36.5% vs 21.6% 10 mg · wk 16 · n 74 · Phase 2 · secondary NCT00413660
  • 69.8% vs 7.7% 10 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • 45.9% vs 10.2% 10 mg · wk 12 · n 61 · Phase 2 · secondary NCT00550446
  • 50.8% vs 6.8% 10 mg · wk 10 · n 61 · Phase 2 · secondary NCT00550446
  • 62.3% vs 1.9% 10 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 29.5% vs 8.5% 10 mg · wk 8 · n 61 · Phase 2 · secondary NCT00550446
  • 36.1% vs 6.8% 10 mg · wk 6 · n 61 · Phase 2 · secondary NCT00550446
  • 54.7% vs 1.9% 10 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 31.1% vs 5.1% 10 mg · wk 4 · n 61 · Phase 2 · secondary NCT00550446
  • 32.1% vs 0% 10 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 18.0% vs 1.7% 10 mg · wk 2 · n 61 · Phase 2 · secondary NCT00550446
  • 25% vs 2.9% 20 mg · wk 4 · n 80 · Phase 2 · secondary NCT00413660
  • 15% vs 2.9% 20 mg · wk 2 · n 80 · Phase 2 · secondary NCT00413660
  • 57.7% vs 14.3% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT00603512
  • 28.4% vs 17.4% 10 mg · wk 12 · n 74 · Phase 2 · secondary NCT00413660
  • 50% vs 7.1% 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT00603512
  • 28.4% vs 17.4% 10 mg · wk 8 · n 74 · Phase 2 · secondary NCT00413660
  • 27.0% vs 8.7% 10 mg · wk 6 · n 74 · Phase 2 · secondary NCT00413660
  • 34.6% vs 3.6% 10 mg · wk 4 · n 26 · Phase 2 · secondary NCT00603512
  • 20.3% vs 2.9% 10 mg · wk 4 · n 74 · Phase 2 · secondary NCT00413660
  • 26.9% vs 0% 10 mg · wk 2 · n 26 · Phase 2 · secondary NCT00603512
  • 4.0% vs 2.9% 10 mg · wk 2 · n 74 · Phase 2 · secondary NCT00413660
  • 45.1% vs 13.3% 30 mg BID · wk 8 · n 69 · Phase 2 · secondary NCT00147498
  • 50.7% vs 6.2% 30 mg BID · wk 6 · n 69 · Phase 2 · secondary NCT00147498
  • 42.0% vs 6.2% 30 mg BID · wk 4 · n 69 · Phase 2 · secondary NCT00147498
  • 29.0% vs 3.1% 30 mg BID · wk 2 · n 69 · Phase 2 · secondary NCT00147498
  • 18.8% vs 3.1% 30 mg BID · wk 1 · n 69 · Phase 2 · secondary NCT00147498
  • 46.3% vs 31.4% 20 mg · wk 24 · n 80 · Phase 2 · secondary NCT00413660
  • 47.8% vs 31.4% 20 mg · wk 20 · n 80 · Phase 2 · secondary NCT00413660
  • 41.8% vs 21.6% 20 mg · wk 16 · n 80 · Phase 2 · secondary NCT00413660
  • 36.3% vs 17.4% 20 mg · wk 12 · n 80 · Phase 2 · secondary NCT00413660
  • 32.5% vs 17.4% 20 mg · wk 8 · n 80 · Phase 2 · secondary NCT00413660
  • 27.5% vs 8.7% 20 mg · wk 6 · n 80 · Phase 2 · secondary NCT00413660
  • 7.7% vs 0% 10 mg · wk 1 · n 26 · Phase 2 · secondary NCT00603512
  • 54.4% vs 17.6% 15 mg · wk 24 · n 57 · Phase 2 · secondary NCT00550446
  • 46.7% vs 31.4% 15 mg · wk 24 · n 75 · Phase 2 · secondary NCT00413660
  • 59.6% vs 17.6% 15 mg · wk 20 · n 57 · Phase 2 · secondary NCT00550446
  • 48% vs 31.4% 15 mg · wk 20 · n 75 · Phase 2 · secondary NCT00413660
  • 56.1% vs 20.6% 15 mg · wk 16 · n 57 · Phase 2 · secondary NCT00550446
  • 40% vs 21.6% 15 mg · wk 16 · n 75 · Phase 2 · secondary NCT00413660
  • 72.2% vs 7.7% 15 mg · wk 12 · n 54 · Phase 2 · secondary NCT00687193
  • 50.9% vs 10.2% 15 mg · wk 12 · n 57 · Phase 2 · secondary NCT00550446
  • 44% vs 17.4% 15 mg · wk 12 · n 75 · Phase 2 · secondary NCT00413660
  • 43.9% vs 6.8% 15 mg · wk 10 · n 57 · Phase 2 · secondary NCT00550446
  • 66.7% vs 1.9% 15 mg · wk 8 · n 54 · Phase 2 · secondary NCT00687193
  • 49.1% vs 8.5% 15 mg · wk 8 · n 57 · Phase 2 · secondary NCT00550446
  • 41.3% vs 17.4% 15 mg · wk 8 · n 75 · Phase 2 · secondary NCT00413660
  • 30.4% vs 13.3% 15 mg BID · wk 8 · n 69 · Phase 2 · secondary NCT00147498
  • 42.1% vs 6.8% 15 mg · wk 6 · n 57 · Phase 2 · secondary NCT00550446
  • 32% vs 8.7% 15 mg · wk 6 · n 75 · Phase 2 · secondary NCT00413660
  • 53.6% vs 6.2% 15 mg BID · wk 6 · n 69 · Phase 2 · secondary NCT00147498
  • 46.3% vs 1.9% 15 mg · wk 4 · n 54 · Phase 2 · secondary NCT00687193
  • 40.4% vs 5.1% 15 mg · wk 4 · n 57 · Phase 2 · secondary NCT00550446
  • 26.7% vs 2.9% 15 mg · wk 4 · n 75 · Phase 2 · secondary NCT00413660
  • 42.0% vs 6.2% 15 mg BID · wk 4 · n 69 · Phase 2 · secondary NCT00147498
  • 22.2% vs 0% 15 mg · wk 2 · n 54 · Phase 2 · secondary NCT00687193
  • 17.5% vs 1.7% 15 mg · wk 2 · n 57 · Phase 2 · secondary NCT00550446
  • 17.3% vs 2.9% 15 mg · wk 2 · n 75 · Phase 2 · secondary NCT00413660
  • 23.2% vs 3.1% 15 mg BID · wk 2 · n 69 · Phase 2 · secondary NCT00147498
  • 8.7% vs 3.1% 15 mg BID · wk 1 · n 69 · Phase 2 · secondary NCT00147498
  • 44.1% vs 17.6% 3 mg · wk 24 · n 51 · Phase 2 · secondary NCT00550446
  • 34.5% vs 31.4% 3 mg · wk 24 · n 68 · Phase 2 · secondary NCT00413660
  • 44.1% vs 17.6% 3 mg · wk 20 · n 51 · Phase 2 · secondary NCT00550446
  • 45.5% vs 31.4% 3 mg · wk 20 · n 68 · Phase 2 · secondary NCT00413660
  • 38.2% vs 20.6% 3 mg · wk 16 · n 51 · Phase 2 · secondary NCT00550446
  • 43.6% vs 21.6% 3 mg · wk 16 · n 68 · Phase 2 · secondary NCT00413660
  • 26.4% vs 7.7% 3 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • 25.5% vs 10.2% 3 mg · wk 12 · n 51 · Phase 2 · secondary NCT00550446
  • 44.4% vs 14.3% 3 mg · wk 12 · n 27 · Phase 2 · secondary NCT00603512
  • 29.4% vs 17.4% 3 mg · wk 12 · n 68 · Phase 2 · secondary NCT00413660
  • 17.6% vs 6.8% 3 mg · wk 10 · n 51 · Phase 2 · secondary NCT00550446
  • 37.7% vs 1.9% 3 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 21.6% vs 8.5% 3 mg · wk 8 · n 51 · Phase 2 · secondary NCT00550446
  • 29.6% vs 7.1% 3 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • 32.4% vs 17.4% 3 mg · wk 8 · n 68 · Phase 2 · secondary NCT00413660
  • 15.7% vs 6.8% 3 mg · wk 6 · n 51 · Phase 2 · secondary NCT00550446
  • 29.4% vs 8.7% 3 mg · wk 6 · n 68 · Phase 2 · secondary NCT00413660
  • 22.6% vs 1.9% 3 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 13.7% vs 5.1% 3 mg · wk 4 · n 51 · Phase 2 · secondary NCT00550446
  • 22.2% vs 3.6% 3 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • 16.2% vs 2.9% 3 mg · wk 4 · n 68 · Phase 2 · secondary NCT00413660
  • 9.4% vs 0% 3 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 7.8% vs 1.7% 3 mg · wk 2 · n 51 · Phase 2 · secondary NCT00550446
  • 7.4% vs 0% 3 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • 5.9% vs 2.9% 3 mg · wk 2 · n 68 · Phase 2 · secondary NCT00413660
  • 3.7% vs 0% 3 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • 10.8% vs 17.6% 1 mg · wk 24 · n 54 · Phase 2 · secondary NCT00550446
  • 44.9% vs 31.4% 1 mg · wk 24 · n 70 · Phase 2 · secondary NCT00413660
  • 18.9% vs 17.6% 1 mg · wk 20 · n 54 · Phase 2 · secondary NCT00550446
  • 38.8% vs 31.4% 1 mg · wk 20 · n 70 · Phase 2 · secondary NCT00413660
  • 18.9% vs 20.6% 1 mg · wk 16 · n 54 · Phase 2 · secondary NCT00550446
  • 38.8% vs 21.6% 1 mg · wk 16 · n 70 · Phase 2 · secondary NCT00413660
  • 13.5% vs 7.7% 1 mg · wk 12 · n 52 · Phase 2 · secondary NCT00687193
  • 11.1% vs 10.2% 1 mg · wk 12 · n 54 · Phase 2 · secondary NCT00550446
  • 32.1% vs 14.3% 1 mg · wk 12 · n 28 · Phase 2 · secondary NCT00603512
  • 22.9% vs 17.4% 1 mg · wk 12 · n 70 · Phase 2 · secondary NCT00413660
  • 13.0% vs 6.8% 1 mg · wk 10 · n 54 · Phase 2 · secondary NCT00550446
  • 11.5% vs 1.9% 1 mg · wk 8 · n 52 · Phase 2 · secondary NCT00687193
  • 13.0% vs 8.5% 1 mg · wk 8 · n 54 · Phase 2 · secondary NCT00550446
  • 28.6% vs 7.1% 1 mg · wk 8 · n 28 · Phase 2 · secondary NCT00603512
  • 17.1% vs 17.4% 1 mg · wk 8 · n 70 · Phase 2 · secondary NCT00413660
  • 14.8% vs 6.8% 1 mg · wk 6 · n 54 · Phase 2 · secondary NCT00550446
  • 10% vs 8.7% 1 mg · wk 6 · n 70 · Phase 2 · secondary NCT00413660
  • 9.6% vs 1.9% 1 mg · wk 4 · n 52 · Phase 2 · secondary NCT00687193
  • 9.3% vs 5.1% 1 mg · wk 4 · n 54 · Phase 2 · secondary NCT00550446
  • 10.7% vs 3.6% 1 mg · wk 4 · n 28 · Phase 2 · secondary NCT00603512
  • 4.3% vs 2.9% 1 mg · wk 4 · n 70 · Phase 2 · secondary NCT00413660
  • 1.9% vs 0% 1 mg · wk 2 · n 52 · Phase 2 · secondary NCT00687193
  • 1.9% vs 1.7% 1 mg · wk 2 · n 54 · Phase 2 · secondary NCT00550446
  • 7.1% vs 0% 1 mg · wk 2 · n 28 · Phase 2 · secondary NCT00603512
  • 1.4% vs 2.9% 1 mg · wk 2 · n 70 · Phase 2 · secondary NCT00413660
  • 67.4% vs 45.7% wk 12 · n 50 · Phase 2 · secondary NCT01059864
  • 48% vs 42.6% wk 6 · n 50 · Phase 2 · secondary NCT01059864
  • 0% vs 31.4% 20 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 31.4% 20 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 21.6% 20 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 31.4% 3 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 31.4% 3 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 21.6% 3 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 31.4% 1 mg to 5 mg (R) · wk 24 · n 21 · Phase 2 · secondary NCT00413660
  • 0% vs 31.4% 1 mg to 5 mg (R) · wk 20 · n 21 · Phase 2 · secondary NCT00413660
  • 0% vs 21.6% 1 mg to 5 mg (R) · wk 16 · n 21 · Phase 2 · secondary NCT00413660
  • 7.1% vs 0% 1 mg · wk 1 · n 28 · Phase 2 · secondary NCT00603512
  • 40% vs 0% wk 4 · n 15 · Phase 2 · secondary NCT00976599
  • 41.6% vs 36.7% 5 mg BID · wk 26 · n 1455 · Phase 4 · secondary NCT02092467
  • 36.3% vs 31.7% 5 mg BID · wk 13 · n 1455 · Phase 4 · secondary NCT02092467
  • 42.6% vs 39.8% 5 mg BID · wk 39 · n 1455 · Phase 4 · secondary NCT02092467
  • 27.6% vs 23.2% 5 mg BID · wk 8.67 · n 1455 · Phase 4 · secondary NCT02092467
  • 43.4% vs 39.8% 5 mg BID · wk 52 · n 1455 · Phase 4 · secondary NCT02092467
  • 44.8% vs 40.1% 5 mg BID · wk 65 · n 1455 · Phase 4 · secondary NCT02092467
  • 43.5% vs 42% 5 mg BID · wk 78 · n 1455 · Phase 4 · secondary NCT02092467
  • 41.7% vs 41.9% 5 mg BID · wk 91 · n 1455 · Phase 4 · secondary NCT02092467
  • 42.7% vs 40.8% 5 mg BID · wk 104 · n 1455 · Phase 4 · secondary NCT02092467
  • 42.6% vs 41.1% 5 mg BID · wk 117 · n 1455 · Phase 4 · secondary NCT02092467
  • 41.2% vs 42% 5 mg BID · wk 130 · n 1455 · Phase 4 · secondary NCT02092467
  • 40.2% vs 40.9% 5 mg BID · wk 143 · n 1455 · Phase 4 · secondary NCT02092467
  • 41.4% vs 40.8% 5 mg BID · wk 156 · n 1455 · Phase 4 · secondary NCT02092467
  • 40.9% vs 38.7% 5 mg BID · wk 169 · n 1455 · Phase 4 · secondary NCT02092467
  • 40.7% vs 40.5% 5 mg BID · wk 182 · n 1455 · Phase 4 · secondary NCT02092467
  • 35.8% vs 35.8% 5 mg BID · wk 195 · n 1455 · Phase 4 · secondary NCT02092467
  • 29% vs 29.2% 5 mg BID · wk 208 · n 1455 · Phase 4 · secondary NCT02092467
  • 24.1% vs 23.8% 5 mg BID · wk 221 · n 1455 · Phase 4 · secondary NCT02092467
  • 19.5% vs 18.5% 5 mg BID · wk 234 · n 1455 · Phase 4 · secondary NCT02092467
  • 13.7% vs 14.4% 5 mg BID · wk 247 · n 1455 · Phase 4 · secondary NCT02092467
  • 10.4% vs 10.3% 5 mg BID · wk 260 · n 1455 · Phase 4 · secondary NCT02092467
  • 6.9% vs 7.1% 5 mg BID · wk 273 · n 1455 · Phase 4 · secondary NCT02092467
  • 3.6% vs 3.8% 5 mg BID · wk 286 · n 1455 · Phase 4 · secondary NCT02092467
  • 1.1% vs 1.9% 5 mg BID · wk 299 · n 1455 · Phase 4 · secondary NCT02092467
  • 0.2% vs 0.5% 5 mg BID · wk 312 · n 1455 · Phase 4 · secondary NCT02092467
  • 42.2% vs 36.7% 10 mg BID · wk 26 · n 1456 · Phase 4 · secondary NCT02092467
  • 38.5% vs 31.7% 10 mg BID · wk 13 · n 1456 · Phase 4 · secondary NCT02092467
  • 44.7% vs 39.8% 10 mg BID · wk 39 · n 1456 · Phase 4 · secondary NCT02092467
  • 31% vs 23.2% 10 mg BID · wk 8.67 · n 1456 · Phase 4 · secondary NCT02092467
  • 44.9% vs 39.8% 10 mg BID · wk 52 · n 1456 · Phase 4 · secondary NCT02092467
  • 45.9% vs 40.1% 10 mg BID · wk 65 · n 1456 · Phase 4 · secondary NCT02092467
  • 44.2% vs 42% 10 mg BID · wk 78 · n 1456 · Phase 4 · secondary NCT02092467
  • 42.8% vs 41.9% 10 mg BID · wk 91 · n 1456 · Phase 4 · secondary NCT02092467
  • 42.3% vs 40.8% 10 mg BID · wk 104 · n 1456 · Phase 4 · secondary NCT02092467
  • 41.3% vs 41.1% 10 mg BID · wk 117 · n 1456 · Phase 4 · secondary NCT02092467
  • 41.8% vs 42% 10 mg BID · wk 130 · n 1456 · Phase 4 · secondary NCT02092467
  • 42% vs 40.9% 10 mg BID · wk 143 · n 1456 · Phase 4 · secondary NCT02092467
  • 38.9% vs 40.8% 10 mg BID · wk 156 · n 1456 · Phase 4 · secondary NCT02092467
  • 40.4% vs 38.7% 10 mg BID · wk 169 · n 1456 · Phase 4 · secondary NCT02092467
  • 39.7% vs 40.5% 10 mg BID · wk 182 · n 1456 · Phase 4 · secondary NCT02092467
  • 33% vs 35.8% 10 mg BID · wk 195 · n 1456 · Phase 4 · secondary NCT02092467
  • 26.4% vs 29.2% 10 mg BID · wk 208 · n 1456 · Phase 4 · secondary NCT02092467
  • 22% vs 23.8% 10 mg BID · wk 221 · n 1456 · Phase 4 · secondary NCT02092467
  • 18.6% vs 18.5% 10 mg BID · wk 234 · n 1456 · Phase 4 · secondary NCT02092467
  • 14.4% vs 14.4% 10 mg BID · wk 247 · n 1456 · Phase 4 · secondary NCT02092467
  • 10.4% vs 10.3% 10 mg BID · wk 260 · n 1456 · Phase 4 · secondary NCT02092467
  • 7.1% vs 7.1% 10 mg BID · wk 273 · n 1456 · Phase 4 · secondary NCT02092467
  • 4.7% vs 3.8% 10 mg BID · wk 286 · n 1456 · Phase 4 · secondary NCT02092467
  • 1.4% vs 1.9% 10 mg BID · wk 299 · n 1456 · Phase 4 · secondary NCT02092467
  • 0.4% vs 0.5% 10 mg BID · wk 312 · n 1456 · Phase 4 · secondary NCT02092467
52.1% vs 28.3%vs Methotrexate15 mg · wk 12 · n 317NCT02706873
41 other results
  • 56.4% vs 28.3% 30 mg · wk 12 · n 314 · Phase 3 · primary NCT02706873
  • 38% vs 14.9% 15 mg · wk 12 · n 221 · Phase 3 · secondary NCT02675426
  • 34.1% vs 11.8% 15 mg · wk 12 · n 164 · Phase 3 · secondary NCT02706847
  • 40.8% vs 8.3% 15 mg · wk 12 · n 169 · Phase 3 · secondary NCT02955212
  • 43.4% vs 14.9% 30 mg · wk 12 · n 219 · Phase 3 · secondary NCT02675426
  • 35.8% vs 11.8% 30 mg · wk 12 · n 165 · Phase 3 · secondary NCT02706847
  • 65.3% vs 16.3% 15 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 58% vs 16.3% 30 mg · wk 12 · n 50 · Phase 2/3 · secondary NCT02720523
  • 40.8% vs 16.3% 7.5 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 60.3% vs 33.4% 15 mg · wk 24 · n 317 · Phase 3 · secondary NCT02706873
  • 41.9% vs 15.3% 15 mg · wk 14 · n 217 · Phase 3 · secondary NCT02706951
  • 65.6% vs 33.4% 30 mg · wk 24 · n 314 · Phase 3 · secondary NCT02706873
  • 52.1% vs 15.3% 30 mg · wk 14 · n 215 · Phase 3 · secondary NCT02706951
  • 66.7% vs 21.4% 15 mg · wk 12 · n 27 · Phase 3 · secondary NCT02706873
  • 71.4% vs 21.4% 30 mg · wk 12 · n 28 · Phase 3 · secondary NCT02706873
  • 60% vs 21.4% 7.5 mg · wk 12 · n 55 · Phase 3 · secondary NCT02706873
  • 29.3% vs 21.1% 60 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 19.5% vs 5.3% 60 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 17.1% vs 10.5% 60 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 4.9% vs 0% 60 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705
  • 43.8% vs 19.6% 24 mg QD · wk 12 · n 48 · Phase 2 · secondary NCT02066389
  • 12.8% vs 21.1% 20 mg · wk 12 · n 39 · Phase 2 · secondary NCT03682705
  • 12.8% vs 5.3% 20 mg · wk 8 · n 39 · Phase 2 · secondary NCT03682705
  • 2.6% vs 10.5% 20 mg · wk 4 · n 39 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 20 mg · wk 2 · n 39 · Phase 2 · secondary NCT03682705
  • 44.7% vs 19.6% 18 mg BID · wk 12 · n 47 · Phase 2 · secondary NCT02066389
  • 40% vs 17% 18 mg BID · wk 12 · n 55 · Phase 2 · secondary NCT01960855
  • 45.2% vs 21.1% 15 mg/60 mg · wk 12 · n 62 · Phase 2 · secondary NCT03682705
  • 41.9% vs 5.3% 15 mg/60 mg · wk 8 · n 62 · Phase 2 · secondary NCT03682705
  • 19.4% vs 10.5% 15 mg/60 mg · wk 4 · n 62 · Phase 2 · secondary NCT03682705
  • 16.1% vs 0% 15 mg/60 mg · wk 2 · n 62 · Phase 2 · secondary NCT03682705
  • 50% vs 19.6% 12 mg BID · wk 12 · n 50 · Phase 2 · secondary NCT02066389
  • 43.6% vs 17% 12 mg BID · wk 12 · n 55 · Phase 2 · secondary NCT01960855
  • 49% vs 19.6% 6 mg BID · wk 12 · n 49 · Phase 2 · secondary NCT02066389
  • 38.5% vs 17% 6 mg BID · wk 12 · n 52 · Phase 2 · secondary NCT01960855
  • 17.1% vs 21.1% 5 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 7.3% vs 5.3% 5 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 4.9% vs 10.5% 5 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 5 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705
  • 39.6% vs 19.6% 3 mg BID · wk 12 · n 48 · Phase 2 · secondary NCT02066389
  • 24.1% vs 17% 3 mg BID · wk 12 · n 54 · Phase 2 · secondary NCT01960855
ACR7025.4% vs 12.1%vs MTX5 mg BID · wk 24 · n 366NCT01039688
271 other results
  • 37.3% vs 12.1% 10 mg BID · wk 24 · n 391 · Phase 3 · primary NCT01039688
  • 13.2% vs 3.2% 5 mg · wk 26 · n 311 · Phase 3 · secondary NCT00856544
  • 19.9% vs 1.9% 5 mg twice daily · wk 26 · n 196 · Phase 3 · secondary NCT00853385
  • 14.6% vs 1.3% 5 mg · wk 26 · n 309 · Phase 3 · secondary NCT00847613
  • 11.9% vs 3.2% 5 mg · wk 19.5 · n 311 · Phase 3 · secondary NCT00856544
  • 15.3% vs 5.8% 5 mg · wk 13 · n 241 · Phase 3 · secondary NCT00814307
  • 8.4% vs 1.9% 5 mg · wk 13 · n 311 · Phase 3 · secondary NCT00856544
  • 12.2% vs 1.9% 5 mg twice daily · wk 13 · n 196 · Phase 3 · secondary NCT00853385
  • 10.7% vs 2.6% 5 mg · wk 13 · n 309 · Phase 3 · secondary NCT00847613
  • 13.6% vs 1.5% 5 mg · wk 13 · n 132 · Phase 3 · secondary NCT00960440
  • 10.0% vs 3.3% 5 mg · wk 8.67 · n 241 · Phase 3 · secondary NCT00814307
  • 9% vs 1.3% 5 mg · wk 8.67 · n 311 · Phase 3 · secondary NCT00856544
  • 5.0% vs 1.7% 5 mg · wk 4.33 · n 241 · Phase 3 · secondary NCT00814307
  • 3.5% vs 0% 5 mg · wk 4.33 · n 311 · Phase 3 · secondary NCT00856544
  • 2.6% vs 0.9% 5 mg twice daily · wk 4.33 · n 196 · Phase 3 · secondary NCT00853385
  • 3.9% vs 0% 5 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00847613
  • 7.6% vs 0% 5 mg · wk 4.33 · n 132 · Phase 3 · secondary NCT00960440
  • 2.1% vs 0% 5 mg · wk 2 · n 241 · Phase 3 · secondary NCT00814307
  • 0.3% vs 0% 5 mg · wk 2 · n 311 · Phase 3 · secondary NCT00856544
  • 2.3% vs 0% 5 mg · wk 2 · n 132 · Phase 3 · secondary NCT00960440
  • 16.2% vs 3.2% 10 mg · wk 26 · n 309 · Phase 3 · secondary NCT00856544
  • 21.9% vs 1.9% 10 mg twice daily · wk 26 · n 196 · Phase 3 · secondary NCT00853385
  • 22.3% vs 1.3% 10 mg · wk 26 · n 309 · Phase 3 · secondary NCT00847613
  • 18.1% vs 3.2% 10 mg · wk 19.5 · n 309 · Phase 3 · secondary NCT00856544
  • 20.3% vs 5.8% 10 mg · wk 13 · n 242 · Phase 3 · secondary NCT00814307
  • 14.2% vs 1.9% 10 mg · wk 13 · n 309 · Phase 3 · secondary NCT00856544
  • 14.8% vs 1.9% 10 mg twice daily · wk 13 · n 196 · Phase 3 · secondary NCT00853385
  • 17.1% vs 2.6% 10 mg · wk 13 · n 309 · Phase 3 · secondary NCT00847613
  • 10.5% vs 1.5% 10 mg · wk 13 · n 133 · Phase 3 · secondary NCT00960440
  • 19.0% vs 3.3% 10 mg · wk 8.67 · n 242 · Phase 3 · secondary NCT00814307
  • 10.4% vs 1.3% 10 mg · wk 8.67 · n 309 · Phase 3 · secondary NCT00856544
  • 9.1% vs 1.7% 10 mg · wk 4.33 · n 242 · Phase 3 · secondary NCT00814307
  • 7.1% vs 0% 10 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00856544
  • 4.1% vs 0.9% 10 mg twice daily · wk 4.33 · n 196 · Phase 3 · secondary NCT00853385
  • 3.6% vs 0% 10 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00847613
  • 6.8% vs 0% 10 mg · wk 4.33 · n 133 · Phase 3 · secondary NCT00960440
  • 4.6% vs 0% 10 mg · wk 2 · n 242 · Phase 3 · secondary NCT00814307
  • 2.3% vs 0% 10 mg · wk 2 · n 309 · Phase 3 · secondary NCT00856544
  • 2.3% vs 0% 10 mg · wk 2 · n 133 · Phase 3 · secondary NCT00960440
  • 19.9% vs 5.5% 5 mg BID · wk 13 · n 366 · Phase 3 · secondary NCT01039688
  • 18.4% vs 11.1% 5 mg twice daily · wk 39 · n 196 · Phase 3 · secondary NCT00853385
  • 29.2% vs 13.2% 5 mg BID · wk 39 · n 366 · Phase 3 · secondary NCT01039688
  • 16.2% vs 3.3% 5 mg BID · wk 8.67 · n 366 · Phase 3 · secondary NCT01039688
  • 5.2% vs 0.6% 5 mg BID · wk 4.33 · n 366 · Phase 3 · secondary NCT01039688
  • 23.0% vs 16.6% 5 mg twice daily · wk 52 · n 196 · Phase 3 · secondary NCT00853385
  • 28.7% vs 15.4% 5 mg BID · wk 52 · n 366 · Phase 3 · secondary NCT01039688
  • 30.1% vs 17.0% 5 mg BID · wk 65 · n 366 · Phase 3 · secondary NCT01039688
  • 32.2% vs 15.9% 5 mg BID · wk 78 · n 366 · Phase 3 · secondary NCT01039688
  • 32.2% vs 17.6% 5 mg BID · wk 91 · n 366 · Phase 3 · secondary NCT01039688
  • 34.1% vs 15.4% 5 mg BID · wk 104 · n 366 · Phase 3 · secondary NCT01039688
  • 26.6% vs 5.5% 10 mg BID · wk 13 · n 391 · Phase 3 · secondary NCT01039688
  • 21.9% vs 11.1% 10 mg twice daily · wk 39 · n 196 · Phase 3 · secondary NCT00853385
  • 37.9% vs 13.2% 10 mg BID · wk 39 · n 391 · Phase 3 · secondary NCT01039688
  • 23.0% vs 3.3% 10 mg BID · wk 8.67 · n 391 · Phase 3 · secondary NCT01039688
  • 9.2% vs 0.6% 10 mg BID · wk 4.33 · n 391 · Phase 3 · secondary NCT01039688
  • 23.5% vs 16.6% 10 mg twice daily · wk 52 · n 196 · Phase 3 · secondary NCT00853385
  • 37.9% vs 15.4% 10 mg BID · wk 52 · n 391 · Phase 3 · secondary NCT01039688
  • 37.9% vs 17.0% 10 mg BID · wk 65 · n 391 · Phase 3 · secondary NCT01039688
  • 36.6% vs 15.9% 10 mg BID · wk 78 · n 391 · Phase 3 · secondary NCT01039688
  • 36.8% vs 17.6% 10 mg BID · wk 91 · n 391 · Phase 3 · secondary NCT01039688
  • 37.6% vs 15.4% 10 mg BID · wk 104 · n 391 · Phase 3 · secondary NCT01039688
  • 22.4% vs 11.8% 5 mg · wk 24 · n 49 · Phase 2 · secondary NCT00550446
  • 21.1% vs 9.8% 5 mg · wk 24 · n 71 · Phase 2 · secondary NCT00413660
  • 18.4% vs 8.8% 5 mg · wk 20 · n 49 · Phase 2 · secondary NCT00550446
  • 23.9% vs 13.7% 5 mg · wk 20 · n 71 · Phase 2 · secondary NCT00413660
  • 20.4% vs 0% 5 mg · wk 16 · n 49 · Phase 2 · secondary NCT00550446
  • 18.3% vs 9.8% 5 mg · wk 16 · n 71 · Phase 2 · secondary NCT00413660
  • 26.9% vs 1.9% 5 mg · wk 12 · n 52 · Phase 2 · secondary NCT00687193
  • 14.3% vs 3.4% 5 mg · wk 12 · n 49 · Phase 2 · secondary NCT00550446
  • 33.3% vs 3.6% 5 mg · wk 12 · n 27 · Phase 2 · secondary NCT00603512
  • 18.3% vs 5.8% 5 mg · wk 12 · n 71 · Phase 2 · secondary NCT00413660
  • 16.3% vs 1.7% 5 mg · wk 10 · n 49 · Phase 2 · secondary NCT00550446
  • 25% vs 1.9% 5 mg · wk 8 · n 52 · Phase 2 · secondary NCT00687193
  • 8.2% vs 1.7% 5 mg · wk 8 · n 49 · Phase 2 · secondary NCT00550446
  • 33.3% vs 3.6% 5 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • 11.3% vs 5.8% 5 mg · wk 8 · n 71 · Phase 2 · secondary NCT00413660
  • 8.9% vs 8.9% 5 mg BID · wk 8 · n 61 · Phase 2 · secondary NCT00147498
  • 4.1% vs 1.7% 5 mg · wk 6 · n 49 · Phase 2 · secondary NCT00550446
  • 16.9% vs 4.3% 5 mg · wk 6 · n 71 · Phase 2 · secondary NCT00413660
  • 13.1% vs 3.1% 5 mg BID · wk 6 · n 61 · Phase 2 · secondary NCT00147498
  • 17.3% vs 0% 5 mg · wk 4 · n 52 · Phase 2 · secondary NCT00687193
  • 2.0% vs 1.7% 5 mg · wk 4 · n 49 · Phase 2 · secondary NCT00550446
  • 14.8% vs 0% 5 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • 0% vs 1.4% 5 mg · wk 4 · n 71 · Phase 2 · secondary NCT00413660
  • 9.8% vs 1.5% 5 mg BID · wk 4 · n 61 · Phase 2 · secondary NCT00147498
  • 1.9% vs 0% 5 mg · wk 2 · n 52 · Phase 2 · secondary NCT00687193
  • 2.0% vs 0% 5 mg · wk 2 · n 49 · Phase 2 · secondary NCT00550446
  • 11.1% vs 0% 5 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • 1.4% vs 0% 5 mg · wk 2 · n 71 · Phase 2 · secondary NCT00413660
  • 4.9% vs 1.5% 5 mg BID · wk 2 · n 61 · Phase 2 · secondary NCT00147498
  • 0% vs 0% 5 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • 1.6% vs 0% 5 mg BID · wk 1 · n 61 · Phase 2 · secondary NCT00147498
  • 37.7% vs 11.8% 10 mg · wk 24 · n 61 · Phase 2 · secondary NCT00550446
  • 18.9% vs 9.8% 10 mg · wk 24 · n 74 · Phase 2 · secondary NCT00413660
  • 31.1% vs 8.8% 10 mg · wk 20 · n 61 · Phase 2 · secondary NCT00550446
  • 24.3% vs 13.7% 10 mg · wk 20 · n 74 · Phase 2 · secondary NCT00413660
  • 29.5% vs 0% 10 mg · wk 16 · n 61 · Phase 2 · secondary NCT00550446
  • 18.9% vs 9.8% 10 mg · wk 16 · n 74 · Phase 2 · secondary NCT00413660
  • 49.1% vs 1.9% 10 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • 24.6% vs 3.4% 10 mg · wk 12 · n 61 · Phase 2 · secondary NCT00550446
  • 12.2% vs 5.8% 10 mg · wk 12 · n 74 · Phase 2 · secondary NCT00413660
  • 37.7% vs 1.9% 10 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 16.2% vs 5.8% 10 mg · wk 8 · n 74 · Phase 2 · secondary NCT00413660
  • 9.5% vs 4.3% 10 mg · wk 6 · n 74 · Phase 2 · secondary NCT00413660
  • 26.4% vs 0% 10 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 11.5% vs 1.7% 10 mg · wk 4 · n 61 · Phase 2 · secondary NCT00550446
  • 9.4% vs 0% 10 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 3.3% vs 0% 10 mg · wk 2 · n 61 · Phase 2 · secondary NCT00550446
  • 27.4% vs 8.9% 30 mg BID · wk 8 · n 69 · Phase 2 · secondary NCT00147498
  • 27.5% vs 3.1% 30 mg BID · wk 6 · n 69 · Phase 2 · secondary NCT00147498
  • 21.7% vs 1.5% 30 mg BID · wk 4 · n 69 · Phase 2 · secondary NCT00147498
  • 10.1% vs 1.5% 30 mg BID · wk 2 · n 69 · Phase 2 · secondary NCT00147498
  • 4.3% vs 0% 30 mg BID · wk 1 · n 69 · Phase 2 · secondary NCT00147498
  • 28.4% vs 9.8% 20 mg · wk 24 · n 80 · Phase 2 · secondary NCT00413660
  • 28.4% vs 13.7% 20 mg · wk 20 · n 80 · Phase 2 · secondary NCT00413660
  • 22.4% vs 9.8% 20 mg · wk 16 · n 80 · Phase 2 · secondary NCT00413660
  • 23.8% vs 5.8% 20 mg · wk 12 · n 80 · Phase 2 · secondary NCT00413660
  • 17.5% vs 5.8% 20 mg · wk 8 · n 80 · Phase 2 · secondary NCT00413660
  • 12.5% vs 4.3% 20 mg · wk 6 · n 80 · Phase 2 · secondary NCT00413660
  • 12.5% vs 1.4% 20 mg · wk 4 · n 80 · Phase 2 · secondary NCT00413660
  • 2.5% vs 0% 20 mg · wk 2 · n 80 · Phase 2 · secondary NCT00413660
  • 34.6% vs 3.6% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT00603512
  • 26.2% vs 1.7% 10 mg · wk 10 · n 61 · Phase 2 · secondary NCT00550446
  • 18.0% vs 1.7% 10 mg · wk 8 · n 61 · Phase 2 · secondary NCT00550446
  • 26.9% vs 3.6% 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT00603512
  • 19.7% vs 1.7% 10 mg · wk 6 · n 61 · Phase 2 · secondary NCT00550446
  • 7.7% vs 0% 10 mg · wk 4 · n 26 · Phase 2 · secondary NCT00603512
  • 14.9% vs 1.4% 10 mg · wk 4 · n 74 · Phase 2 · secondary NCT00413660
  • 3.9% vs 0% 10 mg · wk 2 · n 26 · Phase 2 · secondary NCT00603512
  • 1.4% vs 0% 10 mg · wk 2 · n 74 · Phase 2 · secondary NCT00413660
  • 3.9% vs 0% 10 mg · wk 1 · n 26 · Phase 2 · secondary NCT00603512
  • 33.3% vs 11.8% 15 mg · wk 24 · n 57 · Phase 2 · secondary NCT00550446
  • 32% vs 9.8% 15 mg · wk 24 · n 75 · Phase 2 · secondary NCT00413660
  • 31.6% vs 8.8% 15 mg · wk 20 · n 57 · Phase 2 · secondary NCT00550446
  • 28% vs 13.7% 15 mg · wk 20 · n 75 · Phase 2 · secondary NCT00413660
  • 33.3% vs 0% 15 mg · wk 16 · n 57 · Phase 2 · secondary NCT00550446
  • 24% vs 9.8% 15 mg · wk 16 · n 75 · Phase 2 · secondary NCT00413660
  • 51.9% vs 1.9% 15 mg · wk 12 · n 54 · Phase 2 · secondary NCT00687193
  • 26.3% vs 3.4% 15 mg · wk 12 · n 57 · Phase 2 · secondary NCT00550446
  • 24% vs 5.8% 15 mg · wk 12 · n 75 · Phase 2 · secondary NCT00413660
  • 21.1% vs 1.7% 15 mg · wk 10 · n 57 · Phase 2 · secondary NCT00550446
  • 40.7% vs 1.9% 15 mg · wk 8 · n 54 · Phase 2 · secondary NCT00687193
  • 24.6% vs 1.7% 15 mg · wk 8 · n 57 · Phase 2 · secondary NCT00550446
  • 16% vs 5.8% 15 mg · wk 8 · n 75 · Phase 2 · secondary NCT00413660
  • 14.3% vs 8.9% 15 mg BID · wk 8 · n 69 · Phase 2 · secondary NCT00147498
  • 17.5% vs 1.7% 15 mg · wk 6 · n 57 · Phase 2 · secondary NCT00550446
  • 16% vs 4.3% 15 mg · wk 6 · n 75 · Phase 2 · secondary NCT00413660
  • 21.7% vs 3.1% 15 mg BID · wk 6 · n 69 · Phase 2 · secondary NCT00147498
  • 16.7% vs 0% 15 mg · wk 4 · n 54 · Phase 2 · secondary NCT00687193
  • 8.8% vs 1.7% 15 mg · wk 4 · n 57 · Phase 2 · secondary NCT00550446
  • 13.3% vs 1.4% 15 mg · wk 4 · n 75 · Phase 2 · secondary NCT00413660
  • 17.4% vs 1.5% 15 mg BID · wk 4 · n 69 · Phase 2 · secondary NCT00147498
  • 7.4% vs 0% 15 mg · wk 2 · n 54 · Phase 2 · secondary NCT00687193
  • 7.0% vs 0% 15 mg · wk 2 · n 57 · Phase 2 · secondary NCT00550446
  • 6.7% vs 0% 15 mg · wk 2 · n 75 · Phase 2 · secondary NCT00413660
  • 4.3% vs 1.5% 15 mg BID · wk 2 · n 69 · Phase 2 · secondary NCT00147498
  • 4.3% vs 0% 15 mg BID · wk 1 · n 69 · Phase 2 · secondary NCT00147498
  • 23.5% vs 11.8% 3 mg · wk 24 · n 51 · Phase 2 · secondary NCT00550446
  • 23.6% vs 9.8% 3 mg · wk 24 · n 68 · Phase 2 · secondary NCT00413660
  • 17.6% vs 8.8% 3 mg · wk 20 · n 51 · Phase 2 · secondary NCT00550446
  • 29.1% vs 13.7% 3 mg · wk 20 · n 68 · Phase 2 · secondary NCT00413660
  • 26.5% vs 0% 3 mg · wk 16 · n 51 · Phase 2 · secondary NCT00550446
  • 21.8% vs 9.8% 3 mg · wk 16 · n 68 · Phase 2 · secondary NCT00413660
  • 13.2% vs 1.9% 3 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • 11.8% vs 3.4% 3 mg · wk 12 · n 51 · Phase 2 · secondary NCT00550446
  • 14.8% vs 3.6% 3 mg · wk 12 · n 27 · Phase 2 · secondary NCT00603512
  • 20.6% vs 5.8% 3 mg · wk 12 · n 68 · Phase 2 · secondary NCT00413660
  • 7.8% vs 1.7% 3 mg · wk 10 · n 51 · Phase 2 · secondary NCT00550446
  • 13.2% vs 1.9% 3 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 3.9% vs 1.7% 3 mg · wk 8 · n 51 · Phase 2 · secondary NCT00550446
  • 7.4% vs 3.6% 3 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • 14.7% vs 5.8% 3 mg · wk 8 · n 68 · Phase 2 · secondary NCT00413660
  • 2.0% vs 1.7% 3 mg · wk 6 · n 51 · Phase 2 · secondary NCT00550446
  • 13.2% vs 4.3% 3 mg · wk 6 · n 68 · Phase 2 · secondary NCT00413660
  • 3.8% vs 0% 3 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 5.9% vs 1.7% 3 mg · wk 4 · n 51 · Phase 2 · secondary NCT00550446
  • 7.4% vs 0% 3 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • 7.3% vs 1.4% 3 mg · wk 4 · n 68 · Phase 2 · secondary NCT00413660
  • 0% vs 0% 3 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 2.0% vs 0% 3 mg · wk 2 · n 51 · Phase 2 · secondary NCT00550446
  • 3.7% vs 0% 3 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • 1.5% vs 0% 3 mg · wk 2 · n 68 · Phase 2 · secondary NCT00413660
  • 0% vs 0% 3 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • 8.1% vs 11.8% 1 mg · wk 24 · n 54 · Phase 2 · secondary NCT00550446
  • 28.6% vs 9.8% 1 mg · wk 24 · n 70 · Phase 2 · secondary NCT00413660
  • 10.8% vs 8.8% 1 mg · wk 20 · n 54 · Phase 2 · secondary NCT00550446
  • 20.4% vs 13.7% 1 mg · wk 20 · n 70 · Phase 2 · secondary NCT00413660
  • 10.8% vs 0% 1 mg · wk 16 · n 54 · Phase 2 · secondary NCT00550446
  • 16.3% vs 9.8% 1 mg · wk 16 · n 70 · Phase 2 · secondary NCT00413660
  • 7.5% vs 1.9% 1 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • 5.6% vs 3.4% 1 mg · wk 12 · n 54 · Phase 2 · secondary NCT00550446
  • 7.1% vs 3.6% 1 mg · wk 12 · n 28 · Phase 2 · secondary NCT00603512
  • 4.3% vs 5.8% 1 mg · wk 12 · n 70 · Phase 2 · secondary NCT00413660
  • 3.7% vs 1.7% 1 mg · wk 10 · n 54 · Phase 2 · secondary NCT00550446
  • 5.7% vs 1.9% 1 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 9.3% vs 1.7% 1 mg · wk 8 · n 54 · Phase 2 · secondary NCT00550446
  • 3.6% vs 3.6% 1 mg · wk 8 · n 28 · Phase 2 · secondary NCT00603512
  • 8.6% vs 5.8% 1 mg · wk 8 · n 70 · Phase 2 · secondary NCT00413660
  • 3.7% vs 1.7% 1 mg · wk 6 · n 54 · Phase 2 · secondary NCT00550446
  • 1.4% vs 4.3% 1 mg · wk 6 · n 70 · Phase 2 · secondary NCT00413660
  • 1.9% vs 0% 1 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 0% vs 1.7% 1 mg · wk 4 · n 54 · Phase 2 · secondary NCT00550446
  • 0% vs 0% 1 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 1.9% vs 0% 1 mg · wk 2 · n 54 · Phase 2 · secondary NCT00550446
  • 34.8% vs 30.4% wk 12 · n 50 · Phase 2 · secondary NCT01059864
  • 20% vs 19.1% wk 6 · n 50 · Phase 2 · secondary NCT01059864
  • 0% vs 9.8% 20 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 13.7% 20 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 9.8% 20 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 9.8% 3 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 13.7% 3 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 9.8% 3 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 9.8% 1 mg to 5 mg (R) · wk 24 · n 21 · Phase 2 · secondary NCT00413660
  • 0% vs 13.7% 1 mg to 5 mg (R) · wk 20 · n 21 · Phase 2 · secondary NCT00413660
  • 0% vs 9.8% 1 mg to 5 mg (R) · wk 16 · n 21 · Phase 2 · secondary NCT00413660
  • 3.6% vs 0% 1 mg · wk 4 · n 28 · Phase 2 · secondary NCT00603512
  • 2.9% vs 1.4% 1 mg · wk 4 · n 70 · Phase 2 · secondary NCT00413660
  • 0% vs 0% 1 mg · wk 2 · n 28 · Phase 2 · secondary NCT00603512
  • 1.4% vs 0% 1 mg · wk 2 · n 70 · Phase 2 · secondary NCT00413660
  • 0% vs 0% 1 mg · wk 1 · n 28 · Phase 2 · secondary NCT00603512
  • 6.7% vs 0% wk 4 · n 15 · Phase 2 · secondary NCT00976599
  • 19.4% vs 16.1% 5 mg BID · wk 26 · n 1455 · Phase 4 · secondary NCT02092467
  • 17.4% vs 13.7% 5 mg BID · wk 13 · n 1455 · Phase 4 · secondary NCT02092467
  • 22.5% vs 20.1% 5 mg BID · wk 39 · n 1455 · Phase 4 · secondary NCT02092467
  • 10.4% vs 7.8% 5 mg BID · wk 8.67 · n 1455 · Phase 4 · secondary NCT02092467
  • 23.2% vs 19.6% 5 mg BID · wk 52 · n 1455 · Phase 4 · secondary NCT02092467
  • 24.7% vs 21% 5 mg BID · wk 65 · n 1455 · Phase 4 · secondary NCT02092467
  • 24.6% vs 22.4% 5 mg BID · wk 78 · n 1455 · Phase 4 · secondary NCT02092467
  • 24.9% vs 22.2% 5 mg BID · wk 91 · n 1455 · Phase 4 · secondary NCT02092467
  • 24% vs 22.6% 5 mg BID · wk 104 · n 1455 · Phase 4 · secondary NCT02092467
  • 25.7% vs 23.6% 5 mg BID · wk 117 · n 1455 · Phase 4 · secondary NCT02092467
  • 25.4% vs 24.7% 5 mg BID · wk 130 · n 1455 · Phase 4 · secondary NCT02092467
  • 24.5% vs 24.5% 5 mg BID · wk 143 · n 1455 · Phase 4 · secondary NCT02092467
  • 24.9% vs 24.2% 5 mg BID · wk 156 · n 1455 · Phase 4 · secondary NCT02092467
  • 25.5% vs 23.3% 5 mg BID · wk 169 · n 1455 · Phase 4 · secondary NCT02092467
  • 25.8% vs 23.6% 5 mg BID · wk 182 · n 1455 · Phase 4 · secondary NCT02092467
  • 21.5% vs 20.5% 5 mg BID · wk 195 · n 1455 · Phase 4 · secondary NCT02092467
  • 17.6% vs 16.4% 5 mg BID · wk 208 · n 1455 · Phase 4 · secondary NCT02092467
  • 14.8% vs 13.7% 5 mg BID · wk 221 · n 1455 · Phase 4 · secondary NCT02092467
  • 10.9% vs 11% 5 mg BID · wk 234 · n 1455 · Phase 4 · secondary NCT02092467
  • 8.8% vs 8.1% 5 mg BID · wk 247 · n 1455 · Phase 4 · secondary NCT02092467
  • 5.4% vs 6.3% 5 mg BID · wk 260 · n 1455 · Phase 4 · secondary NCT02092467
  • 4% vs 4.4% 5 mg BID · wk 273 · n 1455 · Phase 4 · secondary NCT02092467
  • 1.7% vs 2.4% 5 mg BID · wk 286 · n 1455 · Phase 4 · secondary NCT02092467
  • 0.5% vs 1% 5 mg BID · wk 299 · n 1455 · Phase 4 · secondary NCT02092467
  • 0.1% vs 0.3% 5 mg BID · wk 312 · n 1455 · Phase 4 · secondary NCT02092467
  • 22.7% vs 16.1% 10 mg BID · wk 26 · n 1456 · Phase 4 · secondary NCT02092467
  • 18.4% vs 13.7% 10 mg BID · wk 13 · n 1456 · Phase 4 · secondary NCT02092467
  • 25.2% vs 20.1% 10 mg BID · wk 39 · n 1456 · Phase 4 · secondary NCT02092467
  • 13.3% vs 7.8% 10 mg BID · wk 8.67 · n 1456 · Phase 4 · secondary NCT02092467
  • 25.6% vs 19.6% 10 mg BID · wk 52 · n 1456 · Phase 4 · secondary NCT02092467
  • 26.8% vs 21% 10 mg BID · wk 65 · n 1456 · Phase 4 · secondary NCT02092467
  • 26.2% vs 22.4% 10 mg BID · wk 78 · n 1456 · Phase 4 · secondary NCT02092467
  • 25.4% vs 22.2% 10 mg BID · wk 91 · n 1456 · Phase 4 · secondary NCT02092467
  • 26.5% vs 22.6% 10 mg BID · wk 104 · n 1456 · Phase 4 · secondary NCT02092467
  • 26.8% vs 23.6% 10 mg BID · wk 117 · n 1456 · Phase 4 · secondary NCT02092467
  • 27.3% vs 24.7% 10 mg BID · wk 130 · n 1456 · Phase 4 · secondary NCT02092467
  • 26.9% vs 24.5% 10 mg BID · wk 143 · n 1456 · Phase 4 · secondary NCT02092467
  • 23.6% vs 24.2% 10 mg BID · wk 156 · n 1456 · Phase 4 · secondary NCT02092467
  • 24.8% vs 23.3% 10 mg BID · wk 169 · n 1456 · Phase 4 · secondary NCT02092467
  • 23.5% vs 23.6% 10 mg BID · wk 182 · n 1456 · Phase 4 · secondary NCT02092467
  • 20.5% vs 20.5% 10 mg BID · wk 195 · n 1456 · Phase 4 · secondary NCT02092467
  • 15.7% vs 16.4% 10 mg BID · wk 208 · n 1456 · Phase 4 · secondary NCT02092467
  • 13.4% vs 13.7% 10 mg BID · wk 221 · n 1456 · Phase 4 · secondary NCT02092467
  • 11.2% vs 11% 10 mg BID · wk 234 · n 1456 · Phase 4 · secondary NCT02092467
  • 8.7% vs 8.1% 10 mg BID · wk 247 · n 1456 · Phase 4 · secondary NCT02092467
  • 5.7% vs 6.3% 10 mg BID · wk 260 · n 1456 · Phase 4 · secondary NCT02092467
  • 3.9% vs 4.4% 10 mg BID · wk 273 · n 1456 · Phase 4 · secondary NCT02092467
  • 2.6% vs 2.4% 10 mg BID · wk 286 · n 1456 · Phase 4 · secondary NCT02092467
  • 1% vs 1% 10 mg BID · wk 299 · n 1456 · Phase 4 · secondary NCT02092467
  • 0.3% vs 0.3% 10 mg BID · wk 312 · n 1456 · Phase 4 · secondary NCT02092467
20.8% vs 5.9%+14.9 vs placebo15 mg · wk 12 · n 221NCT02675426
41 other results
  • 11.6% vs 6.5% 15 mg · wk 12 · n 164 · Phase 3 · secondary NCT02706847
  • 21.3% vs 3.6% 15 mg · wk 12 · n 169 · Phase 3 · secondary NCT02955212
  • 26.5% vs 5.9% 30 mg · wk 12 · n 219 · Phase 3 · secondary NCT02675426
  • 23% vs 6.5% 30 mg · wk 12 · n 165 · Phase 3 · secondary NCT02706847
  • 34.7% vs 2% 15 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 28% vs 2% 30 mg · wk 12 · n 50 · Phase 2/3 · secondary NCT02720523
  • 20.4% vs 2% 7.5 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 44.5% vs 18.5% 15 mg · wk 24 · n 317 · Phase 3 · secondary NCT02706873
  • 22.6% vs 2.8% 15 mg · wk 14 · n 217 · Phase 3 · secondary NCT02706951
  • 32.5% vs 14% 15 mg · wk 12 · n 317 · Phase 3 · secondary NCT02706873
  • 49.7% vs 18.5% 30 mg · wk 24 · n 314 · Phase 3 · secondary NCT02706873
  • 33% vs 2.8% 30 mg · wk 14 · n 215 · Phase 3 · secondary NCT02706951
  • 36.9% vs 14% 30 mg · wk 12 · n 314 · Phase 3 · secondary NCT02706873
  • 51.9% vs 0% 15 mg · wk 12 · n 27 · Phase 3 · secondary NCT02706873
  • 64.3% vs 0% 30 mg · wk 12 · n 28 · Phase 3 · secondary NCT02706873
  • 34.5% vs 0% 7.5 mg · wk 12 · n 55 · Phase 3 · secondary NCT02706873
  • 14.6% vs 15.8% 60 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 4.9% vs 0% 60 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 4.9% vs 0% 60 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 2.4% vs 0% 60 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705
  • 25% vs 6.5% 24 mg QD · wk 12 · n 48 · Phase 2 · secondary NCT02066389
  • 5.1% vs 15.8% 20 mg · wk 12 · n 39 · Phase 2 · secondary NCT03682705
  • 2.6% vs 0% 20 mg · wk 8 · n 39 · Phase 2 · secondary NCT03682705
  • 2.6% vs 0% 20 mg · wk 4 · n 39 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 20 mg · wk 2 · n 39 · Phase 2 · secondary NCT03682705
  • 27.7% vs 6.5% 18 mg BID · wk 12 · n 47 · Phase 2 · secondary NCT02066389
  • 21.8% vs 3.6% 18 mg BID · wk 12 · n 55 · Phase 2 · secondary NCT01960855
  • 25.8% vs 15.8% 15 mg/60 mg · wk 12 · n 62 · Phase 2 · secondary NCT03682705
  • 17.7% vs 0% 15 mg/60 mg · wk 8 · n 62 · Phase 2 · secondary NCT03682705
  • 9.7% vs 0% 15 mg/60 mg · wk 4 · n 62 · Phase 2 · secondary NCT03682705
  • 8.1% vs 0% 15 mg/60 mg · wk 2 · n 62 · Phase 2 · secondary NCT03682705
  • 16% vs 6.5% 12 mg BID · wk 12 · n 50 · Phase 2 · secondary NCT02066389
  • 21.8% vs 3.6% 12 mg BID · wk 12 · n 55 · Phase 2 · secondary NCT01960855
  • 30.6% vs 6.5% 6 mg BID · wk 12 · n 49 · Phase 2 · secondary NCT02066389
  • 26.9% vs 3.6% 6 mg BID · wk 12 · n 52 · Phase 2 · secondary NCT01960855
  • 9.8% vs 15.8% 5 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 5 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 5 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 5 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705
  • 23.4% vs 6.5% 3 mg BID · wk 12 · n 47 · Phase 2 · secondary NCT02066389
  • 13% vs 3.6% 3 mg BID · wk 12 · n 54 · Phase 2 · secondary NCT01960855
DAS28-CRP remission23.0% vs 5.2%+17.8 vs placebo5 mg · wk 26 · n 309NCT00847613
174 other results
  • 20.4% vs 5.2% 5 mg · wk 13 · n 309 · Phase 3 · secondary NCT00847613
  • 11.3% vs 2.0% 5 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00847613
  • 36.4% vs 5.2% 10 mg · wk 26 · n 308 · Phase 3 · secondary NCT00847613
  • 26.9% vs 5.2% 10 mg · wk 13 · n 308 · Phase 3 · secondary NCT00847613
  • 9.1% vs 2.0% 10 mg · wk 4.33 · n 308 · Phase 3 · secondary NCT00847613
  • 31.3% vs 15.2% 5 mg BID · wk 26 · n 367 · Phase 3 · secondary NCT01039688
  • 25.9% vs 9.8% 5 mg BID · wk 13 · n 367 · Phase 3 · secondary NCT01039688
  • 36.2% vs 17.4% 5 mg BID · wk 39 · n 367 · Phase 3 · secondary NCT01039688
  • 20.4% vs 5.4% 5 mg BID · wk 8.67 · n 367 · Phase 3 · secondary NCT01039688
  • 7.4% vs 2.7% 5 mg BID · wk 4.33 · n 367 · Phase 3 · secondary NCT01039688
  • 36.5% vs 20.6% 5 mg BID · wk 52 · n 367 · Phase 3 · secondary NCT01039688
  • 37.6% vs 19.6% 5 mg BID · wk 65 · n 367 · Phase 3 · secondary NCT01039688
  • 38.4% vs 19.0% 5 mg BID · wk 78 · n 367 · Phase 3 · secondary NCT01039688
  • 37.1% vs 17.4% 5 mg BID · wk 91 · n 367 · Phase 3 · secondary NCT01039688
  • 38.4% vs 18.5% 5 mg BID · wk 104 · n 367 · Phase 3 · secondary NCT01039688
  • 47.2% vs 15.2% 10 mg BID · wk 26 · n 394 · Phase 3 · secondary NCT01039688
  • 37.8% vs 9.8% 10 mg BID · wk 13 · n 394 · Phase 3 · secondary NCT01039688
  • 45.7% vs 17.4% 10 mg BID · wk 39 · n 394 · Phase 3 · secondary NCT01039688
  • 28.7% vs 5.4% 10 mg BID · wk 8.67 · n 394 · Phase 3 · secondary NCT01039688
  • 14.1% vs 2.7% 10 mg BID · wk 4.33 · n 394 · Phase 3 · secondary NCT01039688
  • 49.5% vs 20.6% 10 mg BID · wk 52 · n 394 · Phase 3 · secondary NCT01039688
  • 49.2% vs 19.6% 10 mg BID · wk 65 · n 394 · Phase 3 · secondary NCT01039688
  • 44.7% vs 19.0% 10 mg BID · wk 78 · n 394 · Phase 3 · secondary NCT01039688
  • 44.7% vs 17.4% 10 mg BID · wk 91 · n 394 · Phase 3 · secondary NCT01039688
  • 43.9% vs 18.5% 10 mg BID · wk 104 · n 394 · Phase 3 · secondary NCT01039688
  • 65.9% vs 30% 5 mg · wk 24 · n 40 · Phase 2 · secondary NCT00550446
  • 22% vs 15% 5 mg · wk 24 · n 48 · Phase 2 · secondary NCT00550446
  • 41.5% vs 19.4% 5 mg · wk 24 · n 63 · Phase 2 · secondary NCT00413660
  • 68.9% vs 16.7% 5 mg · wk 20 · n 40 · Phase 2 · secondary NCT00550446
  • 20% vs 5.6% 5 mg · wk 20 · n 48 · Phase 2 · secondary NCT00550446
  • 35.1% vs 13.9% 5 mg · wk 20 · n 63 · Phase 2 · secondary NCT00413660
  • 69.6% vs 35% 5 mg · wk 16 · n 40 · Phase 2 · secondary NCT00550446
  • 28.3% vs 15% 5 mg · wk 16 · n 48 · Phase 2 · secondary NCT00550446
  • 24.1% vs 8.1% 5 mg · wk 16 · n 63 · Phase 2 · secondary NCT00413660
  • 62.2% vs 6.7% 5 mg · wk 12 · n 40 · Phase 2 · secondary NCT00550446
  • 24.4% vs 6.7% 5 mg · wk 12 · n 48 · Phase 2 · secondary NCT00550446
  • 16.7% vs 6.7% 5 mg · wk 12 · n 63 · Phase 2 · secondary NCT00413660
  • 65.8% vs 3.3% 5 mg · wk 10 · n 40 · Phase 2 · secondary NCT00550446
  • 21.7% vs 4.3% 5 mg · wk 10 · n 48 · Phase 2 · secondary NCT00550446
  • 66.7% vs 9.7% 5 mg · wk 8 · n 40 · Phase 2 · secondary NCT00550446
  • 14.9% vs 4.4% 5 mg · wk 8 · n 48 · Phase 2 · secondary NCT00550446
  • 19.4% vs 6.9% 5 mg · wk 8 · n 63 · Phase 2 · secondary NCT00413660
  • 56.4% vs 5.9% 5 mg · wk 6 · n 40 · Phase 2 · secondary NCT00550446
  • 8.9% vs 1.9% 5 mg · wk 6 · n 48 · Phase 2 · secondary NCT00550446
  • 13.6% vs 3.5% 5 mg · wk 6 · n 63 · Phase 2 · secondary NCT00413660
  • 62.2% vs 5.7% 5 mg · wk 4 · n 40 · Phase 2 · secondary NCT00550446
  • 4.4% vs 1.9% 5 mg · wk 4 · n 48 · Phase 2 · secondary NCT00550446
  • 8.1% vs 3.3% 5 mg · wk 4 · n 63 · Phase 2 · secondary NCT00413660
  • 62.5% vs 2.7% 5 mg · wk 2 · n 40 · Phase 2 · secondary NCT00550446
  • 4.2% vs 0% 5 mg · wk 2 · n 48 · Phase 2 · secondary NCT00550446
  • 1.6% vs 3.3% 5 mg · wk 2 · n 63 · Phase 2 · secondary NCT00413660
  • 72.7% vs 30% 10 mg · wk 24 · n 45 · Phase 2 · secondary NCT00550446
  • 36.4% vs 15% 10 mg · wk 24 · n 60 · Phase 2 · secondary NCT00550446
  • 36.5% vs 19.4% 10 mg · wk 24 · n 68 · Phase 2 · secondary NCT00413660
  • 88.7% vs 16.7% 10 mg · wk 20 · n 45 · Phase 2 · secondary NCT00550446
  • 43.4% vs 5.6% 10 mg · wk 20 · n 60 · Phase 2 · secondary NCT00550446
  • 37.1% vs 13.9% 10 mg · wk 20 · n 68 · Phase 2 · secondary NCT00413660
  • 78.2% vs 35% 10 mg · wk 16 · n 45 · Phase 2 · secondary NCT00550446
  • 36.4% vs 15% 10 mg · wk 16 · n 60 · Phase 2 · secondary NCT00550446
  • 30.2% vs 8.1% 10 mg · wk 16 · n 68 · Phase 2 · secondary NCT00413660
  • 75.6% vs 6.7% 10 mg · wk 12 · n 45 · Phase 2 · secondary NCT00550446
  • 33.3% vs 6.7% 10 mg · wk 12 · n 60 · Phase 2 · secondary NCT00550446
  • 32.3% vs 6.7% 10 mg · wk 12 · n 68 · Phase 2 · secondary NCT00413660
  • 90.7% vs 3.3% 10 mg · wk 10 · n 45 · Phase 2 · secondary NCT00550446
  • 31.6% vs 4.3% 10 mg · wk 10 · n 60 · Phase 2 · secondary NCT00550446
  • 78.6% vs 9.7% 10 mg · wk 8 · n 45 · Phase 2 · secondary NCT00550446
  • 21.4% vs 4.4% 10 mg · wk 8 · n 60 · Phase 2 · secondary NCT00550446
  • 21.3% vs 6.9% 10 mg · wk 8 · n 68 · Phase 2 · secondary NCT00413660
  • 79.5% vs 5.9% 10 mg · wk 6 · n 45 · Phase 2 · secondary NCT00550446
  • 24.1% vs 1.9% 10 mg · wk 6 · n 60 · Phase 2 · secondary NCT00550446
  • 24.2% vs 3.5% 10 mg · wk 6 · n 68 · Phase 2 · secondary NCT00413660
  • 83.7% vs 5.7% 10 mg · wk 4 · n 45 · Phase 2 · secondary NCT00550446
  • 17.5% vs 1.9% 10 mg · wk 4 · n 60 · Phase 2 · secondary NCT00550446
  • 19.1% vs 3.3% 10 mg · wk 4 · n 68 · Phase 2 · secondary NCT00413660
  • 71.1% vs 2.7% 10 mg · wk 2 · n 45 · Phase 2 · secondary NCT00550446
  • 5% vs 0% 10 mg · wk 2 · n 60 · Phase 2 · secondary NCT00550446
  • 4.4% vs 3.3% 10 mg · wk 2 · n 68 · Phase 2 · secondary NCT00413660
  • 32.7% vs 19.4% 20 mg · wk 24 · n 74 · Phase 2 · secondary NCT00413660
  • 30.9% vs 13.9% 20 mg · wk 20 · n 74 · Phase 2 · secondary NCT00413660
  • 29.1% vs 8.1% 20 mg · wk 16 · n 74 · Phase 2 · secondary NCT00413660
  • 24.6% vs 6.7% 20 mg · wk 12 · n 74 · Phase 2 · secondary NCT00413660
  • 20.9% vs 6.9% 20 mg · wk 8 · n 74 · Phase 2 · secondary NCT00413660
  • 10.1% vs 3.5% 20 mg · wk 6 · n 74 · Phase 2 · secondary NCT00413660
  • 10% vs 3.3% 20 mg · wk 4 · n 74 · Phase 2 · secondary NCT00413660
  • 4.0% vs 3.3% 20 mg · wk 2 · n 74 · Phase 2 · secondary NCT00413660
  • 84.6% vs 30% 15 mg · wk 24 · n 39 · Phase 2 · secondary NCT00550446
  • 50% vs 15% 15 mg · wk 24 · n 57 · Phase 2 · secondary NCT00550446
  • 39.3% vs 19.4% 15 mg · wk 24 · n 68 · Phase 2 · secondary NCT00413660
  • 76.9% vs 16.7% 15 mg · wk 20 · n 39 · Phase 2 · secondary NCT00550446
  • 42.3% vs 5.6% 15 mg · wk 20 · n 57 · Phase 2 · secondary NCT00550446
  • 38.6% vs 13.9% 15 mg · wk 20 · n 68 · Phase 2 · secondary NCT00413660
  • 82.4% vs 35% 15 mg · wk 16 · n 39 · Phase 2 · secondary NCT00550446
  • 43.1% vs 15% 15 mg · wk 16 · n 57 · Phase 2 · secondary NCT00550446
  • 37.9% vs 8.1% 15 mg · wk 16 · n 68 · Phase 2 · secondary NCT00413660
  • 68.6% vs 6.7% 15 mg · wk 12 · n 39 · Phase 2 · secondary NCT00550446
  • 40.4% vs 6.7% 15 mg · wk 12 · n 57 · Phase 2 · secondary NCT00550446
  • 37.1% vs 6.7% 15 mg · wk 12 · n 68 · Phase 2 · secondary NCT00413660
  • 79.4% vs 3.3% 15 mg · wk 10 · n 39 · Phase 2 · secondary NCT00550446
  • 38.5% vs 4.3% 15 mg · wk 10 · n 57 · Phase 2 · secondary NCT00550446
  • 75% vs 9.7% 15 mg · wk 8 · n 39 · Phase 2 · secondary NCT00550446
  • 41.5% vs 4.4% 15 mg · wk 8 · n 57 · Phase 2 · secondary NCT00550446
  • 23.9% vs 6.9% 15 mg · wk 8 · n 68 · Phase 2 · secondary NCT00413660
  • 67.6% vs 5.9% 15 mg · wk 6 · n 39 · Phase 2 · secondary NCT00550446
  • 32.7% vs 1.9% 15 mg · wk 6 · n 57 · Phase 2 · secondary NCT00550446
  • 22.7% vs 3.5% 15 mg · wk 6 · n 68 · Phase 2 · secondary NCT00413660
  • 62.2% vs 5.7% 15 mg · wk 4 · n 39 · Phase 2 · secondary NCT00550446
  • 15.1% vs 1.9% 15 mg · wk 4 · n 57 · Phase 2 · secondary NCT00550446
  • 16.9% vs 3.3% 15 mg · wk 4 · n 68 · Phase 2 · secondary NCT00413660
  • 66.7% vs 2.7% 15 mg · wk 2 · n 39 · Phase 2 · secondary NCT00550446
  • 7.0% vs 0% 15 mg · wk 2 · n 57 · Phase 2 · secondary NCT00550446
  • 13.2% vs 3.3% 15 mg · wk 2 · n 68 · Phase 2 · secondary NCT00413660
  • 46.4% vs 30% 3 mg · wk 24 · n 33 · Phase 2 · secondary NCT00550446
  • 39.3% vs 15% 3 mg · wk 24 · n 50 · Phase 2 · secondary NCT00550446
  • 35.7% vs 19.4% 3 mg · wk 24 · n 63 · Phase 2 · secondary NCT00413660
  • 58.6% vs 16.7% 3 mg · wk 20 · n 33 · Phase 2 · secondary NCT00550446
  • 20.7% vs 5.6% 3 mg · wk 20 · n 50 · Phase 2 · secondary NCT00550446
  • 43.2% vs 13.9% 3 mg · wk 20 · n 63 · Phase 2 · secondary NCT00413660
  • 53.3% vs 35% 3 mg · wk 16 · n 33 · Phase 2 · secondary NCT00550446
  • 30% vs 15% 3 mg · wk 16 · n 50 · Phase 2 · secondary NCT00550446
  • 41.9% vs 8.1% 3 mg · wk 16 · n 63 · Phase 2 · secondary NCT00413660
  • 42.9% vs 6.7% 3 mg · wk 12 · n 33 · Phase 2 · secondary NCT00550446
  • 8.9% vs 6.7% 3 mg · wk 12 · n 50 · Phase 2 · secondary NCT00550446
  • 30.9% vs 6.7% 3 mg · wk 12 · n 63 · Phase 2 · secondary NCT00413660
  • 53.3% vs 3.3% 3 mg · wk 10 · n 33 · Phase 2 · secondary NCT00550446
  • 8.5% vs 4.3% 3 mg · wk 10 · n 50 · Phase 2 · secondary NCT00550446
  • 46.7% vs 9.7% 3 mg · wk 8 · n 33 · Phase 2 · secondary NCT00550446
  • 12.8% vs 4.4% 3 mg · wk 8 · n 50 · Phase 2 · secondary NCT00550446
  • 22.0% vs 6.9% 3 mg · wk 8 · n 63 · Phase 2 · secondary NCT00413660
  • 43.3% vs 5.9% 3 mg · wk 6 · n 33 · Phase 2 · secondary NCT00550446
  • 12.8% vs 1.9% 3 mg · wk 6 · n 50 · Phase 2 · secondary NCT00550446
  • 19.7% vs 3.5% 3 mg · wk 6 · n 63 · Phase 2 · secondary NCT00413660
  • 33.3% vs 5.7% 3 mg · wk 4 · n 33 · Phase 2 · secondary NCT00550446
  • 6.5% vs 1.9% 3 mg · wk 4 · n 50 · Phase 2 · secondary NCT00550446
  • 14.8% vs 3.3% 3 mg · wk 4 · n 63 · Phase 2 · secondary NCT00413660
  • 33.3% vs 2.7% 3 mg · wk 2 · n 33 · Phase 2 · secondary NCT00550446
  • 4% vs 0% 3 mg · wk 2 · n 50 · Phase 2 · secondary NCT00550446
  • 3.2% vs 3.3% 3 mg · wk 2 · n 63 · Phase 2 · secondary NCT00413660
  • 33.3% vs 30% 1 mg · wk 24 · n 43 · Phase 2 · secondary NCT00550446
  • 16.7% vs 15% 1 mg · wk 24 · n 53 · Phase 2 · secondary NCT00550446
  • 23.1% vs 19.4% 1 mg · wk 24 · n 64 · Phase 2 · secondary NCT00413660
  • 46.2% vs 16.7% 1 mg · wk 20 · n 43 · Phase 2 · secondary NCT00550446
  • 19.2% vs 5.6% 1 mg · wk 20 · n 53 · Phase 2 · secondary NCT00550446
  • 20.5% vs 13.9% 1 mg · wk 20 · n 64 · Phase 2 · secondary NCT00413660
  • 48.1% vs 35% 1 mg · wk 16 · n 43 · Phase 2 · secondary NCT00550446
  • 22.2% vs 15% 1 mg · wk 16 · n 53 · Phase 2 · secondary NCT00550446
  • 14.3% vs 8.1% 1 mg · wk 16 · n 64 · Phase 2 · secondary NCT00413660
  • 22.2% vs 6.7% 1 mg · wk 12 · n 43 · Phase 2 · secondary NCT00550446
  • 9.3% vs 6.7% 1 mg · wk 12 · n 53 · Phase 2 · secondary NCT00550446
  • 6.6% vs 6.7% 1 mg · wk 12 · n 64 · Phase 2 · secondary NCT00413660
  • 26.3% vs 3.3% 1 mg · wk 10 · n 43 · Phase 2 · secondary NCT00550446
  • 10.9% vs 4.3% 1 mg · wk 10 · n 53 · Phase 2 · secondary NCT00550446
  • 25.6% vs 9.7% 1 mg · wk 8 · n 43 · Phase 2 · secondary NCT00550446
  • 2.1% vs 4.4% 1 mg · wk 8 · n 53 · Phase 2 · secondary NCT00550446
  • 7.9% vs 6.9% 1 mg · wk 8 · n 64 · Phase 2 · secondary NCT00413660
  • 20.5% vs 5.9% 1 mg · wk 6 · n 43 · Phase 2 · secondary NCT00550446
  • 8.5% vs 1.9% 1 mg · wk 6 · n 53 · Phase 2 · secondary NCT00550446
  • 3.2% vs 3.5% 1 mg · wk 6 · n 64 · Phase 2 · secondary NCT00413660
  • 30% vs 5.7% 1 mg · wk 4 · n 43 · Phase 2 · secondary NCT00550446
  • 6% vs 1.9% 1 mg · wk 4 · n 53 · Phase 2 · secondary NCT00550446
  • 4.6% vs 3.3% 1 mg · wk 4 · n 64 · Phase 2 · secondary NCT00413660
  • 25.6% vs 2.7% 1 mg · wk 2 · n 43 · Phase 2 · secondary NCT00550446
  • 1.9% vs 0% 1 mg · wk 2 · n 53 · Phase 2 · secondary NCT00550446
  • 1.6% vs 3.3% 1 mg · wk 2 · n 64 · Phase 2 · secondary NCT00413660
  • 16.7% vs 19.4% 20 mg to 5 mg (R) · wk 24 · n 12 · Phase 2 · secondary NCT00413660
  • 0% vs 13.9% 20 mg to 5 mg (R) · wk 20 · n 12 · Phase 2 · secondary NCT00413660
  • 11.1% vs 8.1% 20 mg to 5 mg (R) · wk 16 · n 12 · Phase 2 · secondary NCT00413660
  • 15.4% vs 19.4% 3 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • 15.4% vs 13.9% 3 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • 23.1% vs 8.1% 3 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • 25% vs 19.4% 1 mg to 5 mg (R) · wk 24 · n 21 · Phase 2 · secondary NCT00413660
  • 28.6% vs 13.9% 1 mg to 5 mg (R) · wk 20 · n 21 · Phase 2 · secondary NCT00413660
  • 9.5% vs 8.1% 1 mg to 5 mg (R) · wk 16 · n 21 · Phase 2 · secondary NCT00413660
  • 24% vs 22.4% 11mg MR · wk 24 · n 100 · Phase 2 · secondary NCT04413617
  • 40.8% vs 22.4% 400mg MR + 11mg MR · wk 24 · n 103 · Phase 2 · secondary NCT04413617
48.3% vs 18.5%vs Methotrexate15 mg · wk 24 · n 317NCT02706873
22 other results
  • 50% vs 18.5% 30 mg · wk 24 · n 314 · Phase 3 · primary NCT02706873
  • 30.8% vs 10% 15 mg · wk 12 · n 221 · Phase 3 · secondary NCT02675426
  • 29.6% vs 5.3% 15 mg · wk 12 · n 169 · Phase 3 · secondary NCT02955212
  • 28.3% vs 10% 30 mg · wk 12 · n 219 · Phase 3 · secondary NCT02675426
  • 57.1% vs 6.1% 15 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 50% vs 6.1% 30 mg · wk 12 · n 50 · Phase 2/3 · secondary NCT02720523
  • 36.7% vs 6.1% 7.5 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 28.1% vs 8.3% 15 mg · wk 14 · n 217 · Phase 3 · secondary NCT02706951
  • 30% vs 13.3% 15 mg QD · wk 12 · n 303 · Phase 3 · secondary NCT03086343
  • 40.5% vs 8.3% 30 mg · wk 14 · n 215 · Phase 3 · secondary NCT02706951
  • 70.4% vs 17.9% 15 mg · wk 24 · n 27 · Phase 3 · secondary NCT02706873
  • 82.1% vs 17.9% 30 mg · wk 24 · n 28 · Phase 3 · secondary NCT02706873
  • 67.3% vs 17.9% 7.5 mg · wk 24 · n 55 · Phase 3 · secondary NCT02706873
  • 19.5% vs 10.5% 60 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 22.4% vs 14.9% 24 mg QD · wk 12 · n 49 · Phase 2 · secondary NCT02066389
  • 7.7% vs 10.5% 20 mg · wk 12 · n 39 · Phase 2 · secondary NCT03682705
  • 42.9% vs 14.9% 18 mg BID · wk 12 · n 49 · Phase 2 · secondary NCT02066389
  • 32.3% vs 10.5% 15 mg/60 mg · wk 12 · n 62 · Phase 2 · secondary NCT03682705
  • 34% vs 14.9% 12 mg BID · wk 12 · n 50 · Phase 2 · secondary NCT02066389
  • 38.8% vs 14.9% 6 mg BID · wk 12 · n 49 · Phase 2 · secondary NCT02066389
  • 9.8% vs 10.5% 5 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 36.7% vs 14.9% 3 mg BID · wk 12 · n 49 · Phase 2 · secondary NCT02066389
HAQ-DI, change-0.5 vs -0.2−0.3 vs placebo5 mg · wk 13 · n 240NCT00814307
233 other results
  • -0.5 vs -0.2 5 mg · wk 13 · n 311 · Phase 3 · primary NCT00856544
  • -0.5 vs -0.2 5 mg twice daily · wk 13 · n 201 · Phase 3 · primary NCT00853385
  • -0.3 vs -0.1 5 mg · wk 13 · n 315 · Phase 3 · primary NCT00847613
  • -0.4 vs -0.2 5 mg · wk 13 · n 132 · Phase 3 · primary NCT00960440
  • -0.5 vs -0.2 10 mg · wk 13 · n 241 · Phase 3 · primary NCT00814307
  • -0.5 vs -0.2 10 mg · wk 13 · n 315 · Phase 3 · primary NCT00856544
  • -0.6 vs -0.2 10 mg twice daily · wk 13 · n 199 · Phase 3 · primary NCT00853385
  • -0.4 vs -0.1 10 mg · wk 13 · n 309 · Phase 3 · primary NCT00847613
  • -0.4 vs -0.2 10 mg · wk 13 · n 134 · Phase 3 · primary NCT00960440
  • -0.8 vs -0.6 5 mg BID · wk 26 · n 365 · Phase 3 · secondary NCT01039688
  • -0.8 vs -0.5 5 mg BID · wk 13 · n 365 · Phase 3 · secondary NCT01039688
  • -0.8 vs -0.7 5 mg BID · wk 39 · n 365 · Phase 3 · secondary NCT01039688
  • -0.7 vs -0.3 5 mg BID · wk 8.67 · n 365 · Phase 3 · secondary NCT01039688
  • -0.5 vs -0.2 5 mg BID · wk 4.33 · n 365 · Phase 3 · secondary NCT01039688
  • -0.9 vs -0.7 5 mg BID · wk 52 · n 365 · Phase 3 · secondary NCT01039688
  • -0.9 vs -0.7 5 mg BID · wk 65 · n 365 · Phase 3 · secondary NCT01039688
  • -0.9 vs -0.7 5 mg BID · wk 78 · n 365 · Phase 3 · secondary NCT01039688
  • -0.9 vs -0.7 5 mg BID · wk 91 · n 365 · Phase 3 · secondary NCT01039688
  • -0.9 vs -0.7 5 mg BID · wk 104 · n 365 · Phase 3 · secondary NCT01039688
  • -0.9 vs -0.6 10 mg BID · wk 26 · n 391 · Phase 3 · secondary NCT01039688
  • -0.8 vs -0.5 10 mg BID · wk 13 · n 391 · Phase 3 · secondary NCT01039688
  • -0.9 vs -0.7 10 mg BID · wk 39 · n 391 · Phase 3 · secondary NCT01039688
  • -0.8 vs -0.3 10 mg BID · wk 8.67 · n 391 · Phase 3 · secondary NCT01039688
  • -0.6 vs -0.2 10 mg BID · wk 4.33 · n 391 · Phase 3 · secondary NCT01039688
  • -1.0 vs -0.7 10 mg BID · wk 52 · n 391 · Phase 3 · secondary NCT01039688
  • -1.0 vs -0.7 10 mg BID · wk 65 · n 391 · Phase 3 · secondary NCT01039688
  • -1.0 vs -0.7 10 mg BID · wk 78 · n 391 · Phase 3 · secondary NCT01039688
  • -1 vs -0.7 10 mg BID · wk 91 · n 391 · Phase 3 · secondary NCT01039688
  • -1.0 vs -0.7 10 mg BID · wk 104 · n 391 · Phase 3 · secondary NCT01039688
  • -0.5 vs -0.4 5 mg · wk 24 · n 48 · Phase 2 · secondary NCT00550446
  • -0.6 vs -0.4 5 mg · wk 24 · n 68 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.3 5 mg · wk 20 · n 48 · Phase 2 · secondary NCT00550446
  • -0.6 vs -0.4 5 mg · wk 20 · n 68 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.3 5 mg · wk 16 · n 48 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.3 5 mg · wk 16 · n 68 · Phase 2 · secondary NCT00413660
  • -0.6 vs 0.2 5 mg · wk 12 · n 52 · Phase 2 · secondary NCT00687193
  • -0.4 vs -0.2 5 mg · wk 12 · n 48 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.1 5 mg · wk 12 · n 27 · Phase 2 · secondary NCT00603512
  • -0.5 vs -0.1 5 mg · wk 12 · n 68 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.2 5 mg · wk 10 · n 48 · Phase 2 · secondary NCT00550446
  • -0.5 vs 0.2 5 mg · wk 8 · n 52 · Phase 2 · secondary NCT00687193
  • -0.4 vs -0.2 5 mg · wk 8 · n 48 · Phase 2 · secondary NCT00550446
  • -0.5 vs 0.0 5 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • -0.4 vs -0.1 5 mg · wk 8 · n 68 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.2 5 mg BID · wk 8 · n 59 · Phase 2 · secondary NCT00147498
  • -0.3 vs -0.2 5 mg · wk 6 · n 48 · Phase 2 · secondary NCT00550446
  • -0.4 vs -0.1 5 mg · wk 6 · n 68 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.2 5 mg BID · wk 6 · n 59 · Phase 2 · secondary NCT00147498
  • -0.4 vs 0.0 5 mg · wk 4 · n 52 · Phase 2 · secondary NCT00687193
  • -0.3 vs -0.1 5 mg · wk 4 · n 48 · Phase 2 · secondary NCT00550446
  • -0.4 vs -0.1 5 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • -0.3 vs -0.1 5 mg · wk 4 · n 68 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.1 5 mg BID · wk 4 · n 59 · Phase 2 · secondary NCT00147498
  • -0.3 vs 0.1 5 mg · wk 2 · n 52 · Phase 2 · secondary NCT00687193
  • -0.2 vs -0.0 5 mg · wk 2 · n 48 · Phase 2 · secondary NCT00550446
  • -0.3 vs -0.0 5 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • -0.2 vs -0.1 5 mg · wk 2 · n 68 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.1 5 mg BID · wk 2 · n 59 · Phase 2 · secondary NCT00147498
  • -0.1 vs 0 5 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • -0.3 vs -0.1 5 mg BID · wk 1 · n 59 · Phase 2 · secondary NCT00147498
  • -0.6 vs -0.4 10 mg · wk 24 · n 59 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.4 10 mg · wk 24 · n 73 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.3 10 mg · wk 20 · n 59 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.4 10 mg · wk 20 · n 73 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.3 10 mg · wk 16 · n 59 · Phase 2 · secondary NCT00550446
  • -0.4 vs -0.3 10 mg · wk 16 · n 73 · Phase 2 · secondary NCT00413660
  • -0.7 vs 0.2 10 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • -0.6 vs -0.2 10 mg · wk 12 · n 59 · Phase 2 · secondary NCT00550446
  • -0.6 vs -0.2 10 mg · wk 10 · n 59 · Phase 2 · secondary NCT00550446
  • -0.6 vs 0.2 10 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • -0.5 vs -0.2 10 mg · wk 8 · n 59 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.2 10 mg · wk 6 · n 59 · Phase 2 · secondary NCT00550446
  • -0.3 vs -0.1 10 mg · wk 6 · n 73 · Phase 2 · secondary NCT00413660
  • -0.5 vs 0.0 10 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • -0.4 vs -0.1 10 mg · wk 4 · n 59 · Phase 2 · secondary NCT00550446
  • -0.4 vs 0.1 10 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • -0.3 vs -0.0 10 mg · wk 2 · n 59 · Phase 2 · secondary NCT00550446
  • -0.3 vs -0.1 20 mg · wk 4 · n 79 · Phase 2 · secondary NCT00413660
  • -0.2 vs -0.1 20 mg · wk 2 · n 79 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.1 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT00603512
  • -0.4 vs -0.1 10 mg · wk 12 · n 73 · Phase 2 · secondary NCT00413660
  • -0.5 vs 0.0 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT00603512
  • -0.4 vs -0.1 10 mg · wk 8 · n 73 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.1 10 mg · wk 4 · n 26 · Phase 2 · secondary NCT00603512
  • -0.3 vs -0.1 10 mg · wk 4 · n 73 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.0 10 mg · wk 2 · n 26 · Phase 2 · secondary NCT00603512
  • -0.2 vs -0.1 10 mg · wk 2 · n 73 · Phase 2 · secondary NCT00413660
  • -0.7 vs -0.2 30 mg BID · wk 8 · n 64 · Phase 2 · secondary NCT00147498
  • -0.7 vs -0.2 30 mg BID · wk 6 · n 64 · Phase 2 · secondary NCT00147498
  • -0.7 vs -0.1 30 mg BID · wk 4 · n 64 · Phase 2 · secondary NCT00147498
  • -0.6 vs -0.1 30 mg BID · wk 2 · n 64 · Phase 2 · secondary NCT00147498
  • -0.4 vs -0.1 30 mg BID · wk 1 · n 64 · Phase 2 · secondary NCT00147498
  • -0.7 vs -0.4 20 mg · wk 24 · n 79 · Phase 2 · secondary NCT00413660
  • -0.7 vs -0.4 20 mg · wk 20 · n 79 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.3 20 mg · wk 16 · n 79 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.1 20 mg · wk 12 · n 79 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.1 20 mg · wk 8 · n 79 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.1 20 mg · wk 6 · n 79 · Phase 2 · secondary NCT00413660
  • -0.3 vs 0 10 mg · wk 1 · n 26 · Phase 2 · secondary NCT00603512
  • -0.8 vs -0.4 15 mg · wk 24 · n 57 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.4 15 mg · wk 24 · n 73 · Phase 2 · secondary NCT00413660
  • -0.9 vs -0.3 15 mg · wk 20 · n 57 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.4 15 mg · wk 20 · n 73 · Phase 2 · secondary NCT00413660
  • -0.9 vs -0.3 15 mg · wk 16 · n 57 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.3 15 mg · wk 16 · n 73 · Phase 2 · secondary NCT00413660
  • -0.7 vs 0.2 15 mg · wk 12 · n 54 · Phase 2 · secondary NCT00687193
  • -0.8 vs -0.2 15 mg · wk 12 · n 57 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.1 15 mg · wk 12 · n 73 · Phase 2 · secondary NCT00413660
  • -0.8 vs -0.2 15 mg · wk 10 · n 57 · Phase 2 · secondary NCT00550446
  • -0.6 vs 0.2 15 mg · wk 8 · n 54 · Phase 2 · secondary NCT00687193
  • -0.7 vs -0.2 15 mg · wk 8 · n 57 · Phase 2 · secondary NCT00550446
  • -0.4 vs -0.1 15 mg · wk 8 · n 73 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.2 15 mg BID · wk 8 · n 68 · Phase 2 · secondary NCT00147498
  • -0.7 vs -0.2 15 mg · wk 6 · n 57 · Phase 2 · secondary NCT00550446
  • -0.3 vs -0.1 15 mg · wk 6 · n 73 · Phase 2 · secondary NCT00413660
  • -0.7 vs -0.2 15 mg BID · wk 6 · n 68 · Phase 2 · secondary NCT00147498
  • -0.5 vs 0.0 15 mg · wk 4 · n 54 · Phase 2 · secondary NCT00687193
  • -0.6 vs -0.1 15 mg · wk 4 · n 57 · Phase 2 · secondary NCT00550446
  • -0.3 vs -0.1 15 mg · wk 4 · n 73 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.1 15 mg BID · wk 4 · n 68 · Phase 2 · secondary NCT00147498
  • -0.4 vs 0.1 15 mg · wk 2 · n 54 · Phase 2 · secondary NCT00687193
  • -0.4 vs -0.0 15 mg · wk 2 · n 57 · Phase 2 · secondary NCT00550446
  • -0.2 vs -0.1 15 mg · wk 2 · n 73 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.1 15 mg BID · wk 2 · n 68 · Phase 2 · secondary NCT00147498
  • -0.3 vs -0.1 15 mg BID · wk 1 · n 68 · Phase 2 · secondary NCT00147498
  • -0.5 vs -0.4 3 mg · wk 24 · n 51 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.4 3 mg · wk 24 · n 66 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.3 3 mg · wk 20 · n 51 · Phase 2 · secondary NCT00550446
  • -0.6 vs -0.4 3 mg · wk 20 · n 66 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.3 3 mg · wk 16 · n 51 · Phase 2 · secondary NCT00550446
  • -0.6 vs -0.3 3 mg · wk 16 · n 66 · Phase 2 · secondary NCT00413660
  • -0.4 vs 0.2 3 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • -0.4 vs -0.2 3 mg · wk 12 · n 51 · Phase 2 · secondary NCT00550446
  • -0.4 vs -0.1 3 mg · wk 12 · n 27 · Phase 2 · secondary NCT00603512
  • -0.5 vs -0.1 3 mg · wk 12 · n 66 · Phase 2 · secondary NCT00413660
  • -0.3 vs -0.2 3 mg · wk 10 · n 51 · Phase 2 · secondary NCT00550446
  • -0.4 vs 0.2 3 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • -0.4 vs -0.2 3 mg · wk 8 · n 51 · Phase 2 · secondary NCT00550446
  • -0.3 vs 0.0 3 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • -0.4 vs -0.1 3 mg · wk 8 · n 66 · Phase 2 · secondary NCT00413660
  • -0.3 vs -0.2 3 mg · wk 6 · n 51 · Phase 2 · secondary NCT00550446
  • -0.4 vs -0.1 3 mg · wk 6 · n 66 · Phase 2 · secondary NCT00413660
  • -0.3 vs 0.0 3 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • -0.3 vs -0.1 3 mg · wk 4 · n 51 · Phase 2 · secondary NCT00550446
  • -0.3 vs -0.1 3 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • -0.4 vs -0.1 3 mg · wk 4 · n 66 · Phase 2 · secondary NCT00413660
  • -0.1 vs 0.1 3 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • -0.3 vs -0.0 3 mg · wk 2 · n 51 · Phase 2 · secondary NCT00550446
  • -0.2 vs -0.0 3 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • -0.2 vs -0.1 3 mg · wk 2 · n 66 · Phase 2 · secondary NCT00413660
  • -0.1 vs 0 3 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • -0.6 vs -0.4 1 mg · wk 24 · n 54 · Phase 2 · secondary NCT00550446
  • -0.6 vs -0.4 1 mg · wk 24 · n 68 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.3 1 mg · wk 20 · n 54 · Phase 2 · secondary NCT00550446
  • -0.6 vs -0.4 1 mg · wk 20 · n 68 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.3 1 mg · wk 16 · n 54 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.3 1 mg · wk 16 · n 68 · Phase 2 · secondary NCT00413660
  • -0.2 vs 0.2 1 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • -0.3 vs -0.2 1 mg · wk 12 · n 54 · Phase 2 · secondary NCT00550446
  • -0.4 vs -0.1 1 mg · wk 12 · n 28 · Phase 2 · secondary NCT00603512
  • -0.4 vs -0.1 1 mg · wk 12 · n 68 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.2 1 mg · wk 10 · n 54 · Phase 2 · secondary NCT00550446
  • -0.2 vs 0.2 1 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • -0.3 vs -0.2 1 mg · wk 8 · n 54 · Phase 2 · secondary NCT00550446
  • -0.4 vs 0.0 1 mg · wk 8 · n 28 · Phase 2 · secondary NCT00603512
  • -0.3 vs -0.1 1 mg · wk 8 · n 68 · Phase 2 · secondary NCT00413660
  • -0.3 vs -0.2 1 mg · wk 6 · n 54 · Phase 2 · secondary NCT00550446
  • -0.3 vs -0.1 1 mg · wk 6 · n 68 · Phase 2 · secondary NCT00413660
  • -0.1 vs 0.0 1 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • -0.1 vs -0.1 1 mg · wk 4 · n 54 · Phase 2 · secondary NCT00550446
  • -0.2 vs -0.1 1 mg · wk 4 · n 28 · Phase 2 · secondary NCT00603512
  • -0.2 vs -0.1 1 mg · wk 4 · n 68 · Phase 2 · secondary NCT00413660
  • -0.1 vs 0.1 1 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • -0.1 vs -0.0 1 mg · wk 2 · n 54 · Phase 2 · secondary NCT00550446
  • -0.1 vs -0.0 1 mg · wk 2 · n 28 · Phase 2 · secondary NCT00603512
  • -0.1 vs -0.1 1 mg · wk 2 · n 68 · Phase 2 · secondary NCT00413660
  • -0.3 vs -0.2 wk 10 · n 90 · Phase 1 · secondary NCT01484561
  • 0.1 vs -0.1 wk 10 · n 90 · Phase 1 · secondary NCT01484561
  • -0.4 vs -0.0 wk 6 · n 93 · Phase 1 · secondary NCT01484561
  • -0.5 vs -0.4 20 mg to 5 mg (R) · wk 24 · n 12 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.4 20 mg to 5 mg (R) · wk 20 · n 12 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.3 20 mg to 5 mg (R) · wk 16 · n 12 · Phase 2 · secondary NCT00413660
  • -0.2 vs -0.4 3 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • -0.1 vs -0.4 3 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • -0.1 vs -0.3 3 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • -0.2 vs -0.4 1 mg to 5 mg (R) · wk 24 · n 21 · Phase 2 · secondary NCT00413660
  • -0.2 vs -0.4 1 mg to 5 mg (R) · wk 20 · n 21 · Phase 2 · secondary NCT00413660
  • -0.2 vs -0.3 1 mg to 5 mg (R) · wk 16 · n 21 · Phase 2 · secondary NCT00413660
  • -0.1 vs 0 1 mg · wk 1 · n 28 · Phase 2 · secondary NCT00603512
  • -0.5 vs -0.5 5 mg BID · wk 26 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.4 5 mg BID · wk 13 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 39 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.4 vs -0.4 5 mg BID · wk 8.67 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 52 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 65 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 78 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 91 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 104 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 117 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 130 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 143 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 156 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 169 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 182 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 195 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 208 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 221 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 234 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 247 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 260 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 273 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 26 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.4 10 mg BID · wk 13 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 39 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.4 10 mg BID · wk 8.67 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 52 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 65 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 78 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 91 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 104 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 117 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 130 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 143 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 156 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 169 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 182 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 195 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 208 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 221 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 234 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 247 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 260 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 273 · n 1390 · Phase 4 · secondary NCT02092467
-0.6 vs -0.3−0.3 vs placebo15 mg · wk 12 · n 216NCT02675426
32 other results
  • -0.4 vs -0.2 15 mg · wk 12 · n 163 · Phase 3 · secondary NCT02706847
  • -0.6 vs -0.2 15 mg · wk 12 · n 169 · Phase 3 · secondary NCT02955212
  • -0.5 vs -0.3 30 mg · wk 12 · n 219 · Phase 3 · secondary NCT02675426
  • -0.4 vs -0.2 30 mg · wk 12 · n 160 · Phase 3 · secondary NCT02706847
  • -0.5 vs -0.1 15 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • -0.5 vs -0.1 30 mg · wk 12 · n 50 · Phase 2/3 · secondary NCT02720523
  • -0.4 vs -0.1 7.5 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • -0.9 vs -0.6 15 mg · wk 24 · n 317 · Phase 3 · secondary NCT02706873
  • -0.7 vs -0.3 15 mg · wk 14 · n 216 · Phase 3 · secondary NCT02706951
  • -0.8 vs -0.5 15 mg · wk 12 · n 317 · Phase 3 · secondary NCT02706873
  • -0.9 vs -0.6 30 mg · wk 24 · n 310 · Phase 3 · secondary NCT02706873
  • -0.7 vs -0.3 30 mg · wk 14 · n 215 · Phase 3 · secondary NCT02706951
  • -0.9 vs -0.5 30 mg · wk 12 · n 310 · Phase 3 · secondary NCT02706873
  • -0.9 vs -0.2 15 mg · wk 12 · n 27 · Phase 3 · secondary NCT02706873
  • -0.9 vs -0.2 30 mg · wk 12 · n 28 · Phase 3 · secondary NCT02706873
  • -0.8 vs -0.2 7.5 mg · wk 12 · n 55 · Phase 3 · secondary NCT02706873
  • -0.3 vs -0.3 60 mg · wk 12 · n 39 · Phase 2 · secondary NCT03682705
  • -0.3 vs -0.2 60 mg · wk 8 · n 39 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.4 60 mg · wk 4 · n 39 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.2 60 mg · wk 2 · n 39 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.3 20 mg · wk 12 · n 35 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.2 20 mg · wk 8 · n 35 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.4 20 mg · wk 4 · n 35 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.2 20 mg · wk 2 · n 35 · Phase 2 · secondary NCT03682705
  • -0.5 vs -0.3 15 mg/60 mg · wk 12 · n 59 · Phase 2 · secondary NCT03682705
  • -0.5 vs -0.2 15 mg/60 mg · wk 8 · n 59 · Phase 2 · secondary NCT03682705
  • -0.4 vs -0.4 15 mg/60 mg · wk 4 · n 59 · Phase 2 · secondary NCT03682705
  • -0.3 vs -0.2 15 mg/60 mg · wk 2 · n 59 · Phase 2 · secondary NCT03682705
  • -0.2 vs -0.3 5 mg · wk 12 · n 40 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.2 5 mg · wk 8 · n 40 · Phase 2 · secondary NCT03682705
  • -0.2 vs -0.4 5 mg · wk 4 · n 40 · Phase 2 · secondary NCT03682705
  • -0.2 vs -0.2 5 mg · wk 2 · n 40 · Phase 2 · secondary NCT03682705
Modified Sharp score, change0.1 vs 0.5−0.3 vs placebo5 mg · wk 26 · n 286NCT00847613
7 other results
  • 0.1 vs 0.5 10 mg · wk 26 · n 295 · Phase 3 · primary NCT00847613
  • 0.2 vs 0.7 5 mg BID · wk 24 · n 346 · Phase 3 · primary NCT01039688
  • 0.1 vs 0.7 10 mg BID · wk 24 · n 370 · Phase 3 · primary NCT01039688
  • 0.4 vs 1.2 5 mg BID · wk 52 · n 346 · Phase 3 · secondary NCT01039688
  • 0.6 vs 2.1 5 mg BID · wk 104 · n 346 · Phase 3 · secondary NCT01039688
  • 0.2 vs 1.2 10 mg BID · wk 52 · n 371 · Phase 3 · secondary NCT01039688
  • 0.3 vs 2.1 10 mg BID · wk 104 · n 371 · Phase 3 · secondary NCT01039688
0.1 vs 0.7vs Methotrexate15 mg · wk 24 · n 279NCT02706873
4 other results
  • 0.1 vs 0.7 30 mg · wk 24 · n 270 · Phase 3 · primary NCT02706873
  • 0.2 vs 2.6 15 mg · wk 24 · n 26 · Phase 3 · secondary NCT02706873
  • 0.2 vs 2.6 30 mg · wk 24 · n 24 · Phase 3 · secondary NCT02706873
  • 0.9 vs 2.6 7.5 mg · wk 24 · n 51 · Phase 3 · secondary NCT02706873

ACR20

tofacitinib
52.7% vs 31.2%+21.5 vs placebo5 mg · wk 24 · n 311NCT00856544
273 other results
  • 51.5% vs 28.3% 5 mg twice daily · wk 24 · n 196 · Phase 3 · primary NCT00853385
  • 51.5% vs 25.3% 5 mg · wk 24 · n 309 · Phase 3 · primary NCT00847613
  • 59.8% vs 26.7% 5 mg · wk 12 · n 241 · Phase 3 · primary NCT00814307
  • 41.7% vs 24.4% 5 mg · wk 12 · n 132 · Phase 3 · primary NCT00960440
  • 58.3% vs 31.2% 10 mg · wk 24 · n 309 · Phase 3 · primary NCT00856544
  • 52.5% vs 28.3% 10 mg twice daily · wk 24 · n 196 · Phase 3 · primary NCT00853385
  • 61.8% vs 25.3% 10 mg · wk 24 · n 309 · Phase 3 · primary NCT00847613
  • 65.7% vs 26.7% 10 mg · wk 12 · n 242 · Phase 3 · primary NCT00814307
  • 48.1% vs 24.4% 10 mg · wk 12 · n 133 · Phase 3 · primary NCT00960440
  • 52.7% vs 31.2% 5 mg · wk 26 · n 311 · Phase 3 · secondary NCT00856544
  • 50.8% vs 25.5% 5 mg · wk 19.5 · n 311 · Phase 3 · secondary NCT00856544
  • 56.3% vs 27.4% 5 mg · wk 13 · n 311 · Phase 3 · secondary NCT00856544
  • 60.7% vs 26.4% 5 mg twice daily · wk 13 · n 196 · Phase 3 · secondary NCT00853385
  • 56.3% vs 27.3% 5 mg · wk 13 · n 309 · Phase 3 · secondary NCT00847613
  • 56.9% vs 25.8% 5 mg · wk 8.67 · n 241 · Phase 3 · secondary NCT00814307
  • 54.0% vs 26.1% 5 mg · wk 8.67 · n 311 · Phase 3 · secondary NCT00856544
  • 46.5% vs 21.7% 5 mg · wk 4.33 · n 241 · Phase 3 · secondary NCT00814307
  • 38.6% vs 22.9% 5 mg · wk 4.33 · n 311 · Phase 3 · secondary NCT00856544
  • 41.2% vs 16.0% 5 mg twice daily · wk 4.33 · n 196 · Phase 3 · secondary NCT00853385
  • 41.4% vs 16.3% 5 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00847613
  • 42.4% vs 27.5% 5 mg · wk 4.33 · n 132 · Phase 3 · secondary NCT00960440
  • 29.6% vs 11.8% 5 mg · wk 2 · n 241 · Phase 3 · secondary NCT00814307
  • 27.3% vs 10.9% 5 mg · wk 2 · n 311 · Phase 3 · secondary NCT00856544
  • 27.7% vs 16.7% 5 mg · wk 2 · n 132 · Phase 3 · secondary NCT00960440
  • 58.3% vs 31.2% 10 mg · wk 26 · n 309 · Phase 3 · secondary NCT00856544
  • 57.9% vs 25.5% 10 mg · wk 19.5 · n 309 · Phase 3 · secondary NCT00856544
  • 64.7% vs 27.4% 10 mg · wk 13 · n 309 · Phase 3 · secondary NCT00856544
  • 58.7% vs 26.4% 10 mg twice daily · wk 13 · n 196 · Phase 3 · secondary NCT00853385
  • 66.3% vs 27.3% 10 mg · wk 13 · n 309 · Phase 3 · secondary NCT00847613
  • 60.7% vs 25.8% 10 mg · wk 8.67 · n 242 · Phase 3 · secondary NCT00814307
  • 64.4% vs 26.1% 10 mg · wk 8.67 · n 309 · Phase 3 · secondary NCT00856544
  • 52.1% vs 21.7% 10 mg · wk 4.33 · n 242 · Phase 3 · secondary NCT00814307
  • 48.5% vs 22.9% 10 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00856544
  • 45.9% vs 16.0% 10 mg twice daily · wk 4.33 · n 196 · Phase 3 · secondary NCT00853385
  • 52.1% vs 16.3% 10 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00847613
  • 44.4% vs 27.5% 10 mg · wk 4.33 · n 133 · Phase 3 · secondary NCT00960440
  • 39.2% vs 11.8% 10 mg · wk 2 · n 242 · Phase 3 · secondary NCT00814307
  • 32.3% vs 10.9% 10 mg · wk 2 · n 309 · Phase 3 · secondary NCT00856544
  • 32.8% vs 16.7% 10 mg · wk 2 · n 133 · Phase 3 · secondary NCT00960440
  • 71.3% vs 50.5% 5 mg BID · wk 26 · n 369 · Phase 3 · secondary NCT01039688
  • 69.9% vs 51.6% 5 mg BID · wk 13 · n 369 · Phase 3 · secondary NCT01039688
  • 49.5% vs 47.2% 5 mg twice daily · wk 39 · n 196 · Phase 3 · secondary NCT00853385
  • 72.1% vs 55.4% 5 mg BID · wk 39 · n 369 · Phase 3 · secondary NCT01039688
  • 63.6% vs 42.4% 5 mg BID · wk 8.67 · n 369 · Phase 3 · secondary NCT01039688
  • 49.3% vs 21.2% 5 mg BID · wk 4.33 · n 369 · Phase 3 · secondary NCT01039688
  • 49.5% vs 49.3% 5 mg twice daily · wk 52 · n 196 · Phase 3 · secondary NCT00853385
  • 67.8% vs 51.1% 5 mg BID · wk 52 · n 369 · Phase 3 · secondary NCT01039688
  • 68.8% vs 47.3% 5 mg BID · wk 65 · n 369 · Phase 3 · secondary NCT01039688
  • 64.2% vs 46.7% 5 mg BID · wk 78 · n 369 · Phase 3 · secondary NCT01039688
  • 65.0% vs 45.1% 5 mg BID · wk 91 · n 369 · Phase 3 · secondary NCT01039688
  • 64.2% vs 42.4% 5 mg BID · wk 104 · n 369 · Phase 3 · secondary NCT01039688
  • 76.1% vs 50.5% 10 mg BID · wk 26 · n 394 · Phase 3 · secondary NCT01039688
  • 77.9% vs 51.6% 10 mg BID · wk 13 · n 394 · Phase 3 · secondary NCT01039688
  • 50.5% vs 47.2% 10 mg twice daily · wk 39 · n 196 · Phase 3 · secondary NCT00853385
  • 73.6% vs 55.4% 10 mg BID · wk 39 · n 394 · Phase 3 · secondary NCT01039688
  • 71.6% vs 42.4% 10 mg BID · wk 8.67 · n 394 · Phase 3 · secondary NCT01039688
  • 58.3% vs 21.2% 10 mg BID · wk 4.33 · n 394 · Phase 3 · secondary NCT01039688
  • 49.5% vs 49.3% 10 mg twice daily · wk 52 · n 196 · Phase 3 · secondary NCT00853385
  • 71.6% vs 51.1% 10 mg BID · wk 52 · n 394 · Phase 3 · secondary NCT01039688
  • 66.2% vs 47.3% 10 mg BID · wk 65 · n 394 · Phase 3 · secondary NCT01039688
  • 66.0% vs 46.7% 10 mg BID · wk 78 · n 394 · Phase 3 · secondary NCT01039688
  • 62.2% vs 45.1% 10 mg BID · wk 91 · n 394 · Phase 3 · secondary NCT01039688
  • 64.2% vs 42.4% 10 mg BID · wk 104 · n 394 · Phase 3 · secondary NCT01039688
  • 73.1% vs 15.4% 5 mg · wk 12 · n 52 · Phase 2 · primary NCT00687193
  • 61.2% vs 23.7% 5 mg · wk 12 · n 49 · Phase 2 · primary NCT00550446
  • 96.3% vs 14.3% 5 mg · wk 12 · n 27 · Phase 2 · primary NCT00603512
  • 56.3% vs 36.2% 5 mg · wk 12 · n 71 · Phase 2 · primary NCT00413660
  • 70.5% vs 29.2% 5 mg BID · wk 6 · n 61 · Phase 2 · primary NCT00147498
  • 84.9% vs 15.4% 10 mg · wk 12 · n 53 · Phase 2 · primary NCT00687193
  • 72.1% vs 23.7% 10 mg · wk 12 · n 61 · Phase 2 · primary NCT00550446
  • 80.8% vs 14.3% 10 mg · wk 12 · n 26 · Phase 2 · primary NCT00603512
  • 58.1% vs 36.2% 10 mg · wk 12 · n 74 · Phase 2 · primary NCT00413660
  • 76.8% vs 29.2% 30 mg BID · wk 6 · n 69 · Phase 2 · primary NCT00147498
  • 56.3% vs 36.2% 20 mg · wk 12 · n 80 · Phase 2 · primary NCT00413660
  • 90.7% vs 15.4% 15 mg · wk 12 · n 54 · Phase 2 · primary NCT00687193
  • 71.9% vs 23.7% 15 mg · wk 12 · n 57 · Phase 2 · primary NCT00550446
  • 56% vs 36.2% 15 mg · wk 12 · n 75 · Phase 2 · primary NCT00413660
  • 81.2% vs 29.2% 15 mg BID · wk 6 · n 69 · Phase 2 · primary NCT00147498
  • 67.9% vs 15.4% 3 mg · wk 12 · n 53 · Phase 2 · primary NCT00687193
  • 45.1% vs 23.7% 3 mg · wk 12 · n 51 · Phase 2 · primary NCT00550446
  • 77.8% vs 14.3% 3 mg · wk 12 · n 27 · Phase 2 · primary NCT00603512
  • 55.9% vs 36.2% 3 mg · wk 12 · n 68 · Phase 2 · primary NCT00413660
  • 37.7% vs 15.4% 1 mg · wk 12 · n 53 · Phase 2 · primary NCT00687193
  • 31.5% vs 23.7% 1 mg · wk 12 · n 54 · Phase 2 · primary NCT00550446
  • 64.3% vs 14.3% 1 mg · wk 12 · n 28 · Phase 2 · primary NCT00603512
  • 47.1% vs 36.2% 1 mg · wk 12 · n 70 · Phase 2 · primary NCT00413660
  • 57.1% vs 47.1% 5 mg · wk 24 · n 49 · Phase 2 · secondary NCT00550446
  • 59.2% vs 47.1% 5 mg · wk 24 · n 71 · Phase 2 · secondary NCT00413660
  • 69.4% vs 32.4% 5 mg · wk 20 · n 49 · Phase 2 · secondary NCT00550446
  • 57.7% vs 47.1% 5 mg · wk 20 · n 71 · Phase 2 · secondary NCT00413660
  • 67.3% vs 35.3% 5 mg · wk 16 · n 49 · Phase 2 · secondary NCT00550446
  • 53.5% vs 43.1% 5 mg · wk 16 · n 71 · Phase 2 · secondary NCT00413660
  • 57.1% vs 23.7% 5 mg · wk 10 · n 49 · Phase 2 · secondary NCT00550446
  • 67.3% vs 11.5% 5 mg · wk 8 · n 52 · Phase 2 · secondary NCT00687193
  • 63.3% vs 27.1% 5 mg · wk 8 · n 49 · Phase 2 · secondary NCT00550446
  • 96.3% vs 21.4% 5 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • 54.9% vs 33.3% 5 mg · wk 8 · n 71 · Phase 2 · secondary NCT00413660
  • 50% vs 28.9% 5 mg BID · wk 8 · n 61 · Phase 2 · secondary NCT00147498
  • 63.3% vs 25.4% 5 mg · wk 6 · n 49 · Phase 2 · secondary NCT00550446
  • 57.8% vs 37.7% 5 mg · wk 6 · n 71 · Phase 2 · secondary NCT00413660
  • 61.5% vs 9.6% 5 mg · wk 4 · n 52 · Phase 2 · secondary NCT00687193
  • 40.8% vs 27.1% 5 mg · wk 4 · n 49 · Phase 2 · secondary NCT00550446
  • 88.9% vs 10.7% 5 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • 46.5% vs 24.6% 5 mg · wk 4 · n 71 · Phase 2 · secondary NCT00413660
  • 63.9% vs 30.8% 5 mg BID · wk 4 · n 61 · Phase 2 · secondary NCT00147498
  • 34.6% vs 5.8% 5 mg · wk 2 · n 52 · Phase 2 · secondary NCT00687193
  • 32.6% vs 15.3% 5 mg · wk 2 · n 49 · Phase 2 · secondary NCT00550446
  • 63.0% vs 10.7% 5 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • 31.0% vs 15.9% 5 mg · wk 2 · n 71 · Phase 2 · secondary NCT00413660
  • 50.8% vs 20% 5 mg BID · wk 2 · n 61 · Phase 2 · secondary NCT00147498
  • 29.6% vs 3.6% 5 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • 27.9% vs 12.3% 5 mg BID · wk 1 · n 61 · Phase 2 · secondary NCT00147498
  • 73.8% vs 47.1% 10 mg · wk 24 · n 61 · Phase 2 · secondary NCT00550446
  • 66.2% vs 47.1% 10 mg · wk 24 · n 74 · Phase 2 · secondary NCT00413660
  • 73.8% vs 32.4% 10 mg · wk 20 · n 61 · Phase 2 · secondary NCT00550446
  • 62.2% vs 47.1% 10 mg · wk 20 · n 74 · Phase 2 · secondary NCT00413660
  • 70.5% vs 35.3% 10 mg · wk 16 · n 61 · Phase 2 · secondary NCT00550446
  • 64.9% vs 43.1% 10 mg · wk 16 · n 74 · Phase 2 · secondary NCT00413660
  • 75.4% vs 23.7% 10 mg · wk 10 · n 61 · Phase 2 · secondary NCT00550446
  • 86.8% vs 11.5% 10 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 65.6% vs 27.1% 10 mg · wk 8 · n 61 · Phase 2 · secondary NCT00550446
  • 56.8% vs 33.3% 10 mg · wk 8 · n 74 · Phase 2 · secondary NCT00413660
  • 55.4% vs 37.7% 10 mg · wk 6 · n 74 · Phase 2 · secondary NCT00413660
  • 81.1% vs 9.6% 10 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 46.0% vs 24.6% 10 mg · wk 4 · n 74 · Phase 2 · secondary NCT00413660
  • 66% vs 5.8% 10 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 70.6% vs 28.9% 30 mg BID · wk 8 · n 69 · Phase 2 · secondary NCT00147498
  • 75.4% vs 30.8% 30 mg BID · wk 4 · n 69 · Phase 2 · secondary NCT00147498
  • 68.1% vs 20% 30 mg BID · wk 2 · n 69 · Phase 2 · secondary NCT00147498
  • 56.5% vs 12.3% 30 mg BID · wk 1 · n 69 · Phase 2 · secondary NCT00147498
  • 62.7% vs 47.1% 20 mg · wk 24 · n 80 · Phase 2 · secondary NCT00413660
  • 64.2% vs 47.1% 20 mg · wk 20 · n 80 · Phase 2 · secondary NCT00413660
  • 64.2% vs 43.1% 20 mg · wk 16 · n 80 · Phase 2 · secondary NCT00413660
  • 56.3% vs 33.3% 20 mg · wk 8 · n 80 · Phase 2 · secondary NCT00413660
  • 50% vs 37.7% 20 mg · wk 6 · n 80 · Phase 2 · secondary NCT00413660
  • 51.3% vs 24.6% 20 mg · wk 4 · n 80 · Phase 2 · secondary NCT00413660
  • 33.8% vs 15.9% 20 mg · wk 2 · n 80 · Phase 2 · secondary NCT00413660
  • 80.8% vs 21.4% 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT00603512
  • 63.9% vs 25.4% 10 mg · wk 6 · n 61 · Phase 2 · secondary NCT00550446
  • 52.5% vs 27.1% 10 mg · wk 4 · n 61 · Phase 2 · secondary NCT00550446
  • 76.9% vs 10.7% 10 mg · wk 4 · n 26 · Phase 2 · secondary NCT00603512
  • 50.8% vs 15.3% 10 mg · wk 2 · n 61 · Phase 2 · secondary NCT00550446
  • 50% vs 10.7% 10 mg · wk 2 · n 26 · Phase 2 · secondary NCT00603512
  • 31.1% vs 15.9% 10 mg · wk 2 · n 74 · Phase 2 · secondary NCT00413660
  • 38.5% vs 3.6% 10 mg · wk 1 · n 26 · Phase 2 · secondary NCT00603512
  • 68.4% vs 47.1% 15 mg · wk 24 · n 57 · Phase 2 · secondary NCT00550446
  • 65.3% vs 47.1% 15 mg · wk 24 · n 75 · Phase 2 · secondary NCT00413660
  • 71.9% vs 32.4% 15 mg · wk 20 · n 57 · Phase 2 · secondary NCT00550446
  • 61.3% vs 47.1% 15 mg · wk 20 · n 75 · Phase 2 · secondary NCT00413660
  • 71.9% vs 35.3% 15 mg · wk 16 · n 57 · Phase 2 · secondary NCT00550446
  • 62.7% vs 43.1% 15 mg · wk 16 · n 75 · Phase 2 · secondary NCT00413660
  • 75.4% vs 23.7% 15 mg · wk 10 · n 57 · Phase 2 · secondary NCT00550446
  • 87% vs 11.5% 15 mg · wk 8 · n 54 · Phase 2 · secondary NCT00687193
  • 71.9% vs 27.1% 15 mg · wk 8 · n 57 · Phase 2 · secondary NCT00550446
  • 64% vs 33.3% 15 mg · wk 8 · n 75 · Phase 2 · secondary NCT00413660
  • 66.1% vs 28.9% 15 mg BID · wk 8 · n 69 · Phase 2 · secondary NCT00147498
  • 66.7% vs 25.4% 15 mg · wk 6 · n 57 · Phase 2 · secondary NCT00550446
  • 56% vs 37.7% 15 mg · wk 6 · n 75 · Phase 2 · secondary NCT00413660
  • 77.8% vs 9.6% 15 mg · wk 4 · n 54 · Phase 2 · secondary NCT00687193
  • 63.2% vs 27.1% 15 mg · wk 4 · n 57 · Phase 2 · secondary NCT00550446
  • 54.7% vs 24.6% 15 mg · wk 4 · n 75 · Phase 2 · secondary NCT00413660
  • 75.4% vs 30.8% 15 mg BID · wk 4 · n 69 · Phase 2 · secondary NCT00147498
  • 53.7% vs 5.8% 15 mg · wk 2 · n 54 · Phase 2 · secondary NCT00687193
  • 38.6% vs 15.3% 15 mg · wk 2 · n 57 · Phase 2 · secondary NCT00550446
  • 40% vs 15.9% 15 mg · wk 2 · n 75 · Phase 2 · secondary NCT00413660
  • 71.0% vs 20% 15 mg BID · wk 2 · n 69 · Phase 2 · secondary NCT00147498
  • 43.5% vs 12.3% 15 mg BID · wk 1 · n 69 · Phase 2 · secondary NCT00147498
  • 58.8% vs 47.1% 3 mg · wk 24 · n 51 · Phase 2 · secondary NCT00550446
  • 65.5% vs 47.1% 3 mg · wk 24 · n 68 · Phase 2 · secondary NCT00413660
  • 64.7% vs 32.4% 3 mg · wk 20 · n 51 · Phase 2 · secondary NCT00550446
  • 67.3% vs 47.1% 3 mg · wk 20 · n 68 · Phase 2 · secondary NCT00413660
  • 58.8% vs 35.3% 3 mg · wk 16 · n 51 · Phase 2 · secondary NCT00550446
  • 60% vs 43.1% 3 mg · wk 16 · n 68 · Phase 2 · secondary NCT00413660
  • 37.3% vs 23.7% 3 mg · wk 10 · n 51 · Phase 2 · secondary NCT00550446
  • 62.3% vs 11.5% 3 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 47.1% vs 27.1% 3 mg · wk 8 · n 51 · Phase 2 · secondary NCT00550446
  • 66.7% vs 21.4% 3 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • 54.4% vs 33.3% 3 mg · wk 8 · n 68 · Phase 2 · secondary NCT00413660
  • 47.1% vs 25.4% 3 mg · wk 6 · n 51 · Phase 2 · secondary NCT00550446
  • 54.4% vs 37.7% 3 mg · wk 6 · n 68 · Phase 2 · secondary NCT00413660
  • 47.2% vs 9.6% 3 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 37.3% vs 27.1% 3 mg · wk 4 · n 51 · Phase 2 · secondary NCT00550446
  • 55.6% vs 10.7% 3 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • 45.6% vs 24.6% 3 mg · wk 4 · n 68 · Phase 2 · secondary NCT00413660
  • 34% vs 5.8% 3 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 31.4% vs 15.3% 3 mg · wk 2 · n 51 · Phase 2 · secondary NCT00550446
  • 40.7% vs 10.7% 3 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • 36.8% vs 15.9% 3 mg · wk 2 · n 68 · Phase 2 · secondary NCT00413660
  • 14.8% vs 3.6% 3 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • 35.1% vs 47.1% 1 mg · wk 24 · n 54 · Phase 2 · secondary NCT00550446
  • 59.2% vs 47.1% 1 mg · wk 24 · n 70 · Phase 2 · secondary NCT00413660
  • 45.9% vs 32.4% 1 mg · wk 20 · n 54 · Phase 2 · secondary NCT00550446
  • 59.2% vs 47.1% 1 mg · wk 20 · n 70 · Phase 2 · secondary NCT00413660
  • 51.4% vs 35.3% 1 mg · wk 16 · n 54 · Phase 2 · secondary NCT00550446
  • 63.3% vs 43.1% 1 mg · wk 16 · n 70 · Phase 2 · secondary NCT00413660
  • 35.2% vs 23.7% 1 mg · wk 10 · n 54 · Phase 2 · secondary NCT00550446
  • 37.7% vs 11.5% 1 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 37.0% vs 27.1% 1 mg · wk 8 · n 54 · Phase 2 · secondary NCT00550446
  • 67.9% vs 21.4% 1 mg · wk 8 · n 28 · Phase 2 · secondary NCT00603512
  • 50% vs 33.3% 1 mg · wk 8 · n 70 · Phase 2 · secondary NCT00413660
  • 38.9% vs 25.4% 1 mg · wk 6 · n 54 · Phase 2 · secondary NCT00550446
  • 44.3% vs 37.7% 1 mg · wk 6 · n 70 · Phase 2 · secondary NCT00413660
  • 35.8% vs 9.6% 1 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 22.2% vs 27.1% 1 mg · wk 4 · n 54 · Phase 2 · secondary NCT00550446
  • 50% vs 10.7% 1 mg · wk 4 · n 28 · Phase 2 · secondary NCT00603512
  • 37.1% vs 24.6% 1 mg · wk 4 · n 70 · Phase 2 · secondary NCT00413660
  • 18.9% vs 5.8% 1 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 16.7% vs 15.3% 1 mg · wk 2 · n 54 · Phase 2 · secondary NCT00550446
  • 82.6% vs 65.2% wk 12 · n 50 · Phase 2 · secondary NCT01059864
  • 76% vs 76.6% wk 6 · n 50 · Phase 2 · secondary NCT01059864
  • 0% vs 47.1% 20 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 47.1% 20 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 43.1% 20 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 47.1% 3 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 47.1% 3 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 43.1% 3 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 47.1% 1 mg to 5 mg (R) · wk 24 · n 21 · Phase 2 · secondary NCT00413660
  • 0% vs 47.1% 1 mg to 5 mg (R) · wk 20 · n 21 · Phase 2 · secondary NCT00413660
  • 0% vs 43.1% 1 mg to 5 mg (R) · wk 16 · n 21 · Phase 2 · secondary NCT00413660
  • 32.1% vs 10.7% 1 mg · wk 2 · n 28 · Phase 2 · secondary NCT00603512
  • 21.4% vs 15.9% 1 mg · wk 2 · n 70 · Phase 2 · secondary NCT00413660
  • 28.6% vs 3.6% 1 mg · wk 1 · n 28 · Phase 2 · secondary NCT00603512
  • 60% vs 0% wk 4 · n 15 · Phase 2 · secondary NCT00976599
  • 68.7% vs 67.6% 5 mg BID · wk 26 · n 1455 · Phase 4 · secondary NCT02092467
  • 67.3% vs 63.6% 5 mg BID · wk 13 · n 1455 · Phase 4 · secondary NCT02092467
  • 70% vs 68% 5 mg BID · wk 39 · n 1455 · Phase 4 · secondary NCT02092467
  • 57.2% vs 56% 5 mg BID · wk 8.67 · n 1455 · Phase 4 · secondary NCT02092467
  • 71% vs 66.6% 5 mg BID · wk 52 · n 1455 · Phase 4 · secondary NCT02092467
  • 69.9% vs 66.8% 5 mg BID · wk 65 · n 1455 · Phase 4 · secondary NCT02092467
  • 67.4% vs 64.6% 5 mg BID · wk 78 · n 1455 · Phase 4 · secondary NCT02092467
  • 65.6% vs 65.4% 5 mg BID · wk 91 · n 1455 · Phase 4 · secondary NCT02092467
  • 65.7% vs 63.5% 5 mg BID · wk 104 · n 1455 · Phase 4 · secondary NCT02092467
  • 66% vs 62.9% 5 mg BID · wk 117 · n 1455 · Phase 4 · secondary NCT02092467
  • 64.1% vs 64.2% 5 mg BID · wk 130 · n 1455 · Phase 4 · secondary NCT02092467
  • 64.3% vs 63.5% 5 mg BID · wk 143 · n 1455 · Phase 4 · secondary NCT02092467
  • 62.3% vs 61.1% 5 mg BID · wk 156 · n 1455 · Phase 4 · secondary NCT02092467
  • 61.6% vs 61.1% 5 mg BID · wk 169 · n 1455 · Phase 4 · secondary NCT02092467
  • 62.2% vs 60.9% 5 mg BID · wk 182 · n 1455 · Phase 4 · secondary NCT02092467
  • 53.6% vs 54.4% 5 mg BID · wk 195 · n 1455 · Phase 4 · secondary NCT02092467
  • 44.9% vs 44% 5 mg BID · wk 208 · n 1455 · Phase 4 · secondary NCT02092467
  • 36.8% vs 35.7% 5 mg BID · wk 221 · n 1455 · Phase 4 · secondary NCT02092467
  • 29.8% vs 27.6% 5 mg BID · wk 234 · n 1455 · Phase 4 · secondary NCT02092467
  • 23.2% vs 20.8% 5 mg BID · wk 247 · n 1455 · Phase 4 · secondary NCT02092467
  • 16.7% vs 16% 5 mg BID · wk 260 · n 1455 · Phase 4 · secondary NCT02092467
  • 11.2% vs 11.1% 5 mg BID · wk 273 · n 1455 · Phase 4 · secondary NCT02092467
  • 5.8% vs 6.1% 5 mg BID · wk 286 · n 1455 · Phase 4 · secondary NCT02092467
  • 1.8% vs 2.5% 5 mg BID · wk 299 · n 1455 · Phase 4 · secondary NCT02092467
  • 0.3% vs 0.7% 5 mg BID · wk 312 · n 1455 · Phase 4 · secondary NCT02092467
  • 69.5% vs 67.6% 10 mg BID · wk 26 · n 1456 · Phase 4 · secondary NCT02092467
  • 68.1% vs 63.6% 10 mg BID · wk 13 · n 1456 · Phase 4 · secondary NCT02092467
  • 69% vs 68% 10 mg BID · wk 39 · n 1456 · Phase 4 · secondary NCT02092467
  • 59.5% vs 56% 10 mg BID · wk 8.67 · n 1456 · Phase 4 · secondary NCT02092467
  • 68.1% vs 66.6% 10 mg BID · wk 52 · n 1456 · Phase 4 · secondary NCT02092467
  • 68.9% vs 66.8% 10 mg BID · wk 65 · n 1456 · Phase 4 · secondary NCT02092467
  • 66.9% vs 64.6% 10 mg BID · wk 78 · n 1456 · Phase 4 · secondary NCT02092467
  • 65.5% vs 65.4% 10 mg BID · wk 91 · n 1456 · Phase 4 · secondary NCT02092467
  • 63.3% vs 63.5% 10 mg BID · wk 104 · n 1456 · Phase 4 · secondary NCT02092467
  • 63% vs 62.9% 10 mg BID · wk 117 · n 1456 · Phase 4 · secondary NCT02092467
  • 61.7% vs 64.2% 10 mg BID · wk 130 · n 1456 · Phase 4 · secondary NCT02092467
  • 61% vs 63.5% 10 mg BID · wk 143 · n 1456 · Phase 4 · secondary NCT02092467
  • 60.5% vs 61.1% 10 mg BID · wk 156 · n 1456 · Phase 4 · secondary NCT02092467
  • 57.9% vs 61.1% 10 mg BID · wk 169 · n 1456 · Phase 4 · secondary NCT02092467
  • 58.2% vs 60.9% 10 mg BID · wk 182 · n 1456 · Phase 4 · secondary NCT02092467
  • 49.3% vs 54.4% 10 mg BID · wk 195 · n 1456 · Phase 4 · secondary NCT02092467
  • 40.3% vs 44% 10 mg BID · wk 208 · n 1456 · Phase 4 · secondary NCT02092467
  • 33.3% vs 35.7% 10 mg BID · wk 221 · n 1456 · Phase 4 · secondary NCT02092467
  • 27.2% vs 27.6% 10 mg BID · wk 234 · n 1456 · Phase 4 · secondary NCT02092467
  • 22% vs 20.8% 10 mg BID · wk 247 · n 1456 · Phase 4 · secondary NCT02092467
  • 16.3% vs 16% 10 mg BID · wk 260 · n 1456 · Phase 4 · secondary NCT02092467
  • 11.4% vs 11.1% 10 mg BID · wk 273 · n 1456 · Phase 4 · secondary NCT02092467
  • 6.9% vs 6.1% 10 mg BID · wk 286 · n 1456 · Phase 4 · secondary NCT02092467
  • 2.5% vs 2.5% 10 mg BID · wk 299 · n 1456 · Phase 4 · secondary NCT02092467
  • 1% vs 0.7% 10 mg BID · wk 312 · n 1456 · Phase 4 · secondary NCT02092467
upadacitinib
63.8% vs 35.7%+28.1 vs placebo15 mg · wk 12 · n 221NCT02675426
49 other results
  • 64.6% vs 28.4% 15 mg · wk 12 · n 164 · Phase 3 · primary NCT02706847
  • 71.6% vs 31.4% 15 mg · wk 12 · n 169 · Phase 3 · primary NCT02955212
  • 66.2% vs 35.7% 30 mg · wk 12 · n 219 · Phase 3 · primary NCT02675426
  • 56.4% vs 28.4% 30 mg · wk 12 · n 165 · Phase 3 · primary NCT02706847
  • 83.7% vs 42.9% 15 mg · wk 12 · n 49 · Phase 2/3 · primary NCT02720523
  • 80% vs 42.9% 30 mg · wk 12 · n 50 · Phase 2/3 · primary NCT02720523
  • 75.5% vs 42.9% 7.5 mg · wk 12 · n 49 · Phase 2/3 · primary NCT02720523
  • 67.7% vs 41.2% 15 mg · wk 14 · n 217 · Phase 3 · primary NCT02706951
  • 75.7% vs 54.1% 15 mg · wk 12 · n 317 · Phase 3 · primary NCT02706873
  • 71.2% vs 41.2% 30 mg · wk 14 · n 215 · Phase 3 · primary NCT02706951
  • 77.1% vs 54.1% 30 mg · wk 12 · n 314 · Phase 3 · primary NCT02706873
  • 22.2% vs 8.6% 15 mg · wk 1 · n 221 · Phase 3 · secondary NCT02675426
  • 27.4% vs 10.7% 15 mg · wk 1 · n 164 · Phase 3 · secondary NCT02706847
  • 25.4% vs 5.9% 15 mg · wk 1 · n 169 · Phase 3 · secondary NCT02955212
  • 28.3% vs 8.6% 30 mg · wk 1 · n 219 · Phase 3 · secondary NCT02675426
  • 24.8% vs 10.7% 30 mg · wk 1 · n 165 · Phase 3 · secondary NCT02706847
  • 24.5% vs 8.2% 15 mg · wk 1 · n 49 · Phase 2/3 · secondary NCT02720523
  • 34% vs 8.2% 30 mg · wk 1 · n 50 · Phase 2/3 · secondary NCT02720523
  • 30.6% vs 8.2% 7.5 mg · wk 1 · n 49 · Phase 2/3 · secondary NCT02720523
  • 78.9% vs 58.6% 15 mg · wk 24 · n 317 · Phase 3 · secondary NCT02706873
  • 78% vs 58.6% 30 mg · wk 24 · n 314 · Phase 3 · secondary NCT02706873
  • 85.2% vs 57.1% 15 mg · wk 12 · n 27 · Phase 3 · secondary NCT02706873
  • 78.6% vs 57.1% 30 mg · wk 12 · n 28 · Phase 3 · secondary NCT02706873
  • 85.5% vs 57.1% 7.5 mg · wk 12 · n 55 · Phase 3 · secondary NCT02706873
  • 81.6% vs 50% 24 mg QD · wk 12 · n 49 · Phase 2 · primary NCT02066389
  • 76.6% vs 50% 18 mg BID · wk 12 · n 47 · Phase 2 · primary NCT02066389
  • 70.9% vs 35.2% 18 mg BID · wk 12 · n 55 · Phase 2 · primary NCT01960855
  • 81.6% vs 50% 12 mg BID · wk 12 · n 49 · Phase 2 · primary NCT02066389
  • 72.7% vs 35.2% 12 mg BID · wk 12 · n 55 · Phase 2 · primary NCT01960855
  • 73.5% vs 50% 6 mg BID · wk 12 · n 49 · Phase 2 · primary NCT02066389
  • 63.5% vs 35.2% 6 mg BID · wk 12 · n 52 · Phase 2 · primary NCT01960855
  • 64.6% vs 50% 3 mg BID · wk 12 · n 48 · Phase 2 · primary NCT02066389
  • 55.6% vs 35.2% 3 mg BID · wk 12 · n 54 · Phase 2 · primary NCT01960855
  • 41.5% vs 47.4% 60 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 39% vs 36.8% 60 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 29.3% vs 42.1% 60 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 24.4% vs 21.1% 60 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705
  • 30.8% vs 47.4% 20 mg · wk 12 · n 39 · Phase 2 · secondary NCT03682705
  • 30.8% vs 36.8% 20 mg · wk 8 · n 39 · Phase 2 · secondary NCT03682705
  • 23.1% vs 42.1% 20 mg · wk 4 · n 39 · Phase 2 · secondary NCT03682705
  • 12.8% vs 21.1% 20 mg · wk 2 · n 39 · Phase 2 · secondary NCT03682705
  • 64.5% vs 47.4% 15 mg/60 mg · wk 12 · n 62 · Phase 2 · secondary NCT03682705
  • 64.5% vs 36.8% 15 mg/60 mg · wk 8 · n 62 · Phase 2 · secondary NCT03682705
  • 51.6% vs 42.1% 15 mg/60 mg · wk 4 · n 62 · Phase 2 · secondary NCT03682705
  • 45.2% vs 21.1% 15 mg/60 mg · wk 2 · n 62 · Phase 2 · secondary NCT03682705
  • 34.1% vs 47.4% 5 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 39% vs 36.8% 5 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 22% vs 42.1% 5 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 14.6% vs 21.1% 5 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705

ACR50

tofacitinib
33.8% vs 12.7%+21 vs placebo5 mg · wk 26 · n 311NCT00856544
275 other results
  • 36.7% vs 12.3% 5 mg twice daily · wk 26 · n 196 · Phase 3 · secondary NCT00853385
  • 32.4% vs 8.4% 5 mg · wk 26 · n 309 · Phase 3 · secondary NCT00847613
  • 28.0% vs 8.3% 5 mg · wk 19.5 · n 311 · Phase 3 · secondary NCT00856544
  • 31.1% vs 12.5% 5 mg · wk 13 · n 241 · Phase 3 · secondary NCT00814307
  • 27.3% vs 9.6% 5 mg · wk 13 · n 311 · Phase 3 · secondary NCT00856544
  • 34.2% vs 6.6% 5 mg twice daily · wk 13 · n 196 · Phase 3 · secondary NCT00853385
  • 28.8% vs 7.8% 5 mg · wk 13 · n 309 · Phase 3 · secondary NCT00847613
  • 26.5% vs 8.4% 5 mg · wk 13 · n 132 · Phase 3 · secondary NCT00960440
  • 32.7% vs 20% 5 mg · wk 39 · n 309 · Phase 3 · secondary NCT00847613
  • 26.1% vs 5.8% 5 mg · wk 8.67 · n 241 · Phase 3 · secondary NCT00814307
  • 23.1% vs 4.5% 5 mg · wk 8.67 · n 311 · Phase 3 · secondary NCT00856544
  • 17.4% vs 4.2% 5 mg · wk 4.33 · n 241 · Phase 3 · secondary NCT00814307
  • 11.6% vs 1.3% 5 mg · wk 4.33 · n 311 · Phase 3 · secondary NCT00856544
  • 14.9% vs 4.7% 5 mg twice daily · wk 4.33 · n 196 · Phase 3 · secondary NCT00853385
  • 16.8% vs 1.3% 5 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00847613
  • 12.9% vs 6.1% 5 mg · wk 4.33 · n 132 · Phase 3 · secondary NCT00960440
  • 5.8% vs 4.2% 5 mg · wk 2 · n 241 · Phase 3 · secondary NCT00814307
  • 5.8% vs 1.3% 5 mg · wk 2 · n 311 · Phase 3 · secondary NCT00856544
  • 7.7% vs 1.6% 5 mg · wk 2 · n 132 · Phase 3 · secondary NCT00960440
  • 32.7% vs 16% 5 mg · wk 52 · n 309 · Phase 3 · secondary NCT00847613
  • 36.6% vs 12.7% 10 mg · wk 26 · n 309 · Phase 3 · secondary NCT00856544
  • 34.7% vs 12.3% 10 mg twice daily · wk 26 · n 196 · Phase 3 · secondary NCT00853385
  • 43.7% vs 8.4% 10 mg · wk 26 · n 309 · Phase 3 · secondary NCT00847613
  • 33.3% vs 8.3% 10 mg · wk 19.5 · n 309 · Phase 3 · secondary NCT00856544
  • 36.8% vs 12.5% 10 mg · wk 13 · n 242 · Phase 3 · secondary NCT00814307
  • 34.0% vs 9.6% 10 mg · wk 13 · n 309 · Phase 3 · secondary NCT00856544
  • 27.6% vs 6.6% 10 mg twice daily · wk 13 · n 196 · Phase 3 · secondary NCT00853385
  • 36.3% vs 7.8% 10 mg · wk 13 · n 309 · Phase 3 · secondary NCT00847613
  • 27.8% vs 8.4% 10 mg · wk 13 · n 133 · Phase 3 · secondary NCT00960440
  • 44.0% vs 20% 10 mg · wk 39 · n 309 · Phase 3 · secondary NCT00847613
  • 33.9% vs 5.8% 10 mg · wk 8.67 · n 242 · Phase 3 · secondary NCT00814307
  • 29.8% vs 4.5% 10 mg · wk 8.67 · n 309 · Phase 3 · secondary NCT00856544
  • 24.0% vs 4.2% 10 mg · wk 4.33 · n 242 · Phase 3 · secondary NCT00814307
  • 18.1% vs 1.3% 10 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00856544
  • 16.3% vs 4.7% 10 mg twice daily · wk 4.33 · n 196 · Phase 3 · secondary NCT00853385
  • 18.4% vs 1.3% 10 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00847613
  • 17.3% vs 6.1% 10 mg · wk 4.33 · n 133 · Phase 3 · secondary NCT00960440
  • 12.9% vs 4.2% 10 mg · wk 2 · n 242 · Phase 3 · secondary NCT00814307
  • 8.1% vs 1.3% 10 mg · wk 2 · n 309 · Phase 3 · secondary NCT00856544
  • 5.5% vs 1.6% 10 mg · wk 2 · n 133 · Phase 3 · secondary NCT00960440
  • 41.1% vs 16% 10 mg · wk 52 · n 309 · Phase 3 · secondary NCT00847613
  • 46.6% vs 26.6% 5 mg BID · wk 26 · n 369 · Phase 3 · secondary NCT01039688
  • 40.1% vs 20.1% 5 mg BID · wk 13 · n 369 · Phase 3 · secondary NCT01039688
  • 35.7% vs 29.1% 5 mg twice daily · wk 39 · n 196 · Phase 3 · secondary NCT00853385
  • 49.9% vs 35.3% 5 mg BID · wk 39 · n 369 · Phase 3 · secondary NCT01039688
  • 32.6% vs 11.4% 5 mg BID · wk 8.67 · n 369 · Phase 3 · secondary NCT01039688
  • 18.0% vs 3.8% 5 mg BID · wk 4.33 · n 369 · Phase 3 · secondary NCT01039688
  • 36.7% vs 33.7% 5 mg twice daily · wk 52 · n 196 · Phase 3 · secondary NCT00853385
  • 49.9% vs 33.7% 5 mg BID · wk 52 · n 369 · Phase 3 · secondary NCT01039688
  • 50.7% vs 33.1% 5 mg BID · wk 65 · n 369 · Phase 3 · secondary NCT01039688
  • 48.0% vs 30.4% 5 mg BID · wk 78 · n 369 · Phase 3 · secondary NCT01039688
  • 49.0% vs 30.4% 5 mg BID · wk 91 · n 369 · Phase 3 · secondary NCT01039688
  • 49.3% vs 28.3% 5 mg BID · wk 104 · n 369 · Phase 3 · secondary NCT01039688
  • 56.4% vs 26.6% 10 mg BID · wk 26 · n 394 · Phase 3 · secondary NCT01039688
  • 50% vs 20.1% 10 mg BID · wk 13 · n 394 · Phase 3 · secondary NCT01039688
  • 37.2% vs 29.1% 10 mg twice daily · wk 39 · n 196 · Phase 3 · secondary NCT00853385
  • 56.9% vs 35.3% 10 mg BID · wk 39 · n 394 · Phase 3 · secondary NCT01039688
  • 40.1% vs 11.4% 10 mg BID · wk 8.67 · n 394 · Phase 3 · secondary NCT01039688
  • 28.0% vs 3.8% 10 mg BID · wk 4.33 · n 394 · Phase 3 · secondary NCT01039688
  • 35.7% vs 33.7% 10 mg twice daily · wk 52 · n 196 · Phase 3 · secondary NCT00853385
  • 55.6% vs 33.7% 10 mg BID · wk 52 · n 394 · Phase 3 · secondary NCT01039688
  • 54.3% vs 33.1% 10 mg BID · wk 65 · n 394 · Phase 3 · secondary NCT01039688
  • 51.8% vs 30.4% 10 mg BID · wk 78 · n 394 · Phase 3 · secondary NCT01039688
  • 50.5% vs 30.4% 10 mg BID · wk 91 · n 394 · Phase 3 · secondary NCT01039688
  • 49.2% vs 28.3% 10 mg BID · wk 104 · n 394 · Phase 3 · secondary NCT01039688
  • 36.7% vs 17.6% 5 mg · wk 24 · n 49 · Phase 2 · secondary NCT00550446
  • 39.4% vs 31.4% 5 mg · wk 24 · n 71 · Phase 2 · secondary NCT00413660
  • 32.7% vs 17.6% 5 mg · wk 20 · n 49 · Phase 2 · secondary NCT00550446
  • 38% vs 31.4% 5 mg · wk 20 · n 71 · Phase 2 · secondary NCT00413660
  • 34.7% vs 20.6% 5 mg · wk 16 · n 49 · Phase 2 · secondary NCT00550446
  • 38% vs 21.6% 5 mg · wk 16 · n 71 · Phase 2 · secondary NCT00413660
  • 46.2% vs 7.7% 5 mg · wk 12 · n 52 · Phase 2 · secondary NCT00687193
  • 38.8% vs 10.2% 5 mg · wk 12 · n 49 · Phase 2 · secondary NCT00550446
  • 81.5% vs 14.3% 5 mg · wk 12 · n 27 · Phase 2 · secondary NCT00603512
  • 36.6% vs 17.4% 5 mg · wk 12 · n 71 · Phase 2 · secondary NCT00413660
  • 34.7% vs 6.8% 5 mg · wk 10 · n 49 · Phase 2 · secondary NCT00550446
  • 44.2% vs 1.9% 5 mg · wk 8 · n 52 · Phase 2 · secondary NCT00687193
  • 24.5% vs 8.5% 5 mg · wk 8 · n 49 · Phase 2 · secondary NCT00550446
  • 70.4% vs 7.1% 5 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • 32.4% vs 17.4% 5 mg · wk 8 · n 71 · Phase 2 · secondary NCT00413660
  • 17.9% vs 13.3% 5 mg BID · wk 8 · n 61 · Phase 2 · secondary NCT00147498
  • 14.3% vs 6.8% 5 mg · wk 6 · n 49 · Phase 2 · secondary NCT00550446
  • 31.0% vs 8.7% 5 mg · wk 6 · n 71 · Phase 2 · secondary NCT00413660
  • 32.8% vs 6.2% 5 mg BID · wk 6 · n 61 · Phase 2 · secondary NCT00147498
  • 28.8% vs 1.9% 5 mg · wk 4 · n 52 · Phase 2 · secondary NCT00687193
  • 10.2% vs 5.1% 5 mg · wk 4 · n 49 · Phase 2 · secondary NCT00550446
  • 29.6% vs 3.6% 5 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • 11.3% vs 2.9% 5 mg · wk 4 · n 71 · Phase 2 · secondary NCT00413660
  • 32.8% vs 6.2% 5 mg BID · wk 4 · n 61 · Phase 2 · secondary NCT00147498
  • 11.5% vs 0% 5 mg · wk 2 · n 52 · Phase 2 · secondary NCT00687193
  • 8.2% vs 1.7% 5 mg · wk 2 · n 49 · Phase 2 · secondary NCT00550446
  • 25.9% vs 0% 5 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • 5.6% vs 2.9% 5 mg · wk 2 · n 71 · Phase 2 · secondary NCT00413660
  • 9.8% vs 3.1% 5 mg BID · wk 2 · n 61 · Phase 2 · secondary NCT00147498
  • 0% vs 0% 5 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • 6.6% vs 3.1% 5 mg BID · wk 1 · n 61 · Phase 2 · secondary NCT00147498
  • 45.9% vs 17.6% 10 mg · wk 24 · n 61 · Phase 2 · secondary NCT00550446
  • 39.2% vs 31.4% 10 mg · wk 24 · n 74 · Phase 2 · secondary NCT00413660
  • 42.6% vs 17.6% 10 mg · wk 20 · n 61 · Phase 2 · secondary NCT00550446
  • 40.5% vs 31.4% 10 mg · wk 20 · n 74 · Phase 2 · secondary NCT00413660
  • 42.6% vs 20.6% 10 mg · wk 16 · n 61 · Phase 2 · secondary NCT00550446
  • 36.5% vs 21.6% 10 mg · wk 16 · n 74 · Phase 2 · secondary NCT00413660
  • 69.8% vs 7.7% 10 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • 45.9% vs 10.2% 10 mg · wk 12 · n 61 · Phase 2 · secondary NCT00550446
  • 50.8% vs 6.8% 10 mg · wk 10 · n 61 · Phase 2 · secondary NCT00550446
  • 62.3% vs 1.9% 10 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 29.5% vs 8.5% 10 mg · wk 8 · n 61 · Phase 2 · secondary NCT00550446
  • 36.1% vs 6.8% 10 mg · wk 6 · n 61 · Phase 2 · secondary NCT00550446
  • 54.7% vs 1.9% 10 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 31.1% vs 5.1% 10 mg · wk 4 · n 61 · Phase 2 · secondary NCT00550446
  • 32.1% vs 0% 10 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 18.0% vs 1.7% 10 mg · wk 2 · n 61 · Phase 2 · secondary NCT00550446
  • 25% vs 2.9% 20 mg · wk 4 · n 80 · Phase 2 · secondary NCT00413660
  • 15% vs 2.9% 20 mg · wk 2 · n 80 · Phase 2 · secondary NCT00413660
  • 57.7% vs 14.3% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT00603512
  • 28.4% vs 17.4% 10 mg · wk 12 · n 74 · Phase 2 · secondary NCT00413660
  • 50% vs 7.1% 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT00603512
  • 28.4% vs 17.4% 10 mg · wk 8 · n 74 · Phase 2 · secondary NCT00413660
  • 27.0% vs 8.7% 10 mg · wk 6 · n 74 · Phase 2 · secondary NCT00413660
  • 34.6% vs 3.6% 10 mg · wk 4 · n 26 · Phase 2 · secondary NCT00603512
  • 20.3% vs 2.9% 10 mg · wk 4 · n 74 · Phase 2 · secondary NCT00413660
  • 26.9% vs 0% 10 mg · wk 2 · n 26 · Phase 2 · secondary NCT00603512
  • 4.0% vs 2.9% 10 mg · wk 2 · n 74 · Phase 2 · secondary NCT00413660
  • 45.1% vs 13.3% 30 mg BID · wk 8 · n 69 · Phase 2 · secondary NCT00147498
  • 50.7% vs 6.2% 30 mg BID · wk 6 · n 69 · Phase 2 · secondary NCT00147498
  • 42.0% vs 6.2% 30 mg BID · wk 4 · n 69 · Phase 2 · secondary NCT00147498
  • 29.0% vs 3.1% 30 mg BID · wk 2 · n 69 · Phase 2 · secondary NCT00147498
  • 18.8% vs 3.1% 30 mg BID · wk 1 · n 69 · Phase 2 · secondary NCT00147498
  • 46.3% vs 31.4% 20 mg · wk 24 · n 80 · Phase 2 · secondary NCT00413660
  • 47.8% vs 31.4% 20 mg · wk 20 · n 80 · Phase 2 · secondary NCT00413660
  • 41.8% vs 21.6% 20 mg · wk 16 · n 80 · Phase 2 · secondary NCT00413660
  • 36.3% vs 17.4% 20 mg · wk 12 · n 80 · Phase 2 · secondary NCT00413660
  • 32.5% vs 17.4% 20 mg · wk 8 · n 80 · Phase 2 · secondary NCT00413660
  • 27.5% vs 8.7% 20 mg · wk 6 · n 80 · Phase 2 · secondary NCT00413660
  • 7.7% vs 0% 10 mg · wk 1 · n 26 · Phase 2 · secondary NCT00603512
  • 54.4% vs 17.6% 15 mg · wk 24 · n 57 · Phase 2 · secondary NCT00550446
  • 46.7% vs 31.4% 15 mg · wk 24 · n 75 · Phase 2 · secondary NCT00413660
  • 59.6% vs 17.6% 15 mg · wk 20 · n 57 · Phase 2 · secondary NCT00550446
  • 48% vs 31.4% 15 mg · wk 20 · n 75 · Phase 2 · secondary NCT00413660
  • 56.1% vs 20.6% 15 mg · wk 16 · n 57 · Phase 2 · secondary NCT00550446
  • 40% vs 21.6% 15 mg · wk 16 · n 75 · Phase 2 · secondary NCT00413660
  • 72.2% vs 7.7% 15 mg · wk 12 · n 54 · Phase 2 · secondary NCT00687193
  • 50.9% vs 10.2% 15 mg · wk 12 · n 57 · Phase 2 · secondary NCT00550446
  • 44% vs 17.4% 15 mg · wk 12 · n 75 · Phase 2 · secondary NCT00413660
  • 43.9% vs 6.8% 15 mg · wk 10 · n 57 · Phase 2 · secondary NCT00550446
  • 66.7% vs 1.9% 15 mg · wk 8 · n 54 · Phase 2 · secondary NCT00687193
  • 49.1% vs 8.5% 15 mg · wk 8 · n 57 · Phase 2 · secondary NCT00550446
  • 41.3% vs 17.4% 15 mg · wk 8 · n 75 · Phase 2 · secondary NCT00413660
  • 30.4% vs 13.3% 15 mg BID · wk 8 · n 69 · Phase 2 · secondary NCT00147498
  • 42.1% vs 6.8% 15 mg · wk 6 · n 57 · Phase 2 · secondary NCT00550446
  • 32% vs 8.7% 15 mg · wk 6 · n 75 · Phase 2 · secondary NCT00413660
  • 53.6% vs 6.2% 15 mg BID · wk 6 · n 69 · Phase 2 · secondary NCT00147498
  • 46.3% vs 1.9% 15 mg · wk 4 · n 54 · Phase 2 · secondary NCT00687193
  • 40.4% vs 5.1% 15 mg · wk 4 · n 57 · Phase 2 · secondary NCT00550446
  • 26.7% vs 2.9% 15 mg · wk 4 · n 75 · Phase 2 · secondary NCT00413660
  • 42.0% vs 6.2% 15 mg BID · wk 4 · n 69 · Phase 2 · secondary NCT00147498
  • 22.2% vs 0% 15 mg · wk 2 · n 54 · Phase 2 · secondary NCT00687193
  • 17.5% vs 1.7% 15 mg · wk 2 · n 57 · Phase 2 · secondary NCT00550446
  • 17.3% vs 2.9% 15 mg · wk 2 · n 75 · Phase 2 · secondary NCT00413660
  • 23.2% vs 3.1% 15 mg BID · wk 2 · n 69 · Phase 2 · secondary NCT00147498
  • 8.7% vs 3.1% 15 mg BID · wk 1 · n 69 · Phase 2 · secondary NCT00147498
  • 44.1% vs 17.6% 3 mg · wk 24 · n 51 · Phase 2 · secondary NCT00550446
  • 34.5% vs 31.4% 3 mg · wk 24 · n 68 · Phase 2 · secondary NCT00413660
  • 44.1% vs 17.6% 3 mg · wk 20 · n 51 · Phase 2 · secondary NCT00550446
  • 45.5% vs 31.4% 3 mg · wk 20 · n 68 · Phase 2 · secondary NCT00413660
  • 38.2% vs 20.6% 3 mg · wk 16 · n 51 · Phase 2 · secondary NCT00550446
  • 43.6% vs 21.6% 3 mg · wk 16 · n 68 · Phase 2 · secondary NCT00413660
  • 26.4% vs 7.7% 3 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • 25.5% vs 10.2% 3 mg · wk 12 · n 51 · Phase 2 · secondary NCT00550446
  • 44.4% vs 14.3% 3 mg · wk 12 · n 27 · Phase 2 · secondary NCT00603512
  • 29.4% vs 17.4% 3 mg · wk 12 · n 68 · Phase 2 · secondary NCT00413660
  • 17.6% vs 6.8% 3 mg · wk 10 · n 51 · Phase 2 · secondary NCT00550446
  • 37.7% vs 1.9% 3 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 21.6% vs 8.5% 3 mg · wk 8 · n 51 · Phase 2 · secondary NCT00550446
  • 29.6% vs 7.1% 3 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • 32.4% vs 17.4% 3 mg · wk 8 · n 68 · Phase 2 · secondary NCT00413660
  • 15.7% vs 6.8% 3 mg · wk 6 · n 51 · Phase 2 · secondary NCT00550446
  • 29.4% vs 8.7% 3 mg · wk 6 · n 68 · Phase 2 · secondary NCT00413660
  • 22.6% vs 1.9% 3 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 13.7% vs 5.1% 3 mg · wk 4 · n 51 · Phase 2 · secondary NCT00550446
  • 22.2% vs 3.6% 3 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • 16.2% vs 2.9% 3 mg · wk 4 · n 68 · Phase 2 · secondary NCT00413660
  • 9.4% vs 0% 3 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 7.8% vs 1.7% 3 mg · wk 2 · n 51 · Phase 2 · secondary NCT00550446
  • 7.4% vs 0% 3 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • 5.9% vs 2.9% 3 mg · wk 2 · n 68 · Phase 2 · secondary NCT00413660
  • 3.7% vs 0% 3 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • 10.8% vs 17.6% 1 mg · wk 24 · n 54 · Phase 2 · secondary NCT00550446
  • 44.9% vs 31.4% 1 mg · wk 24 · n 70 · Phase 2 · secondary NCT00413660
  • 18.9% vs 17.6% 1 mg · wk 20 · n 54 · Phase 2 · secondary NCT00550446
  • 38.8% vs 31.4% 1 mg · wk 20 · n 70 · Phase 2 · secondary NCT00413660
  • 18.9% vs 20.6% 1 mg · wk 16 · n 54 · Phase 2 · secondary NCT00550446
  • 38.8% vs 21.6% 1 mg · wk 16 · n 70 · Phase 2 · secondary NCT00413660
  • 13.5% vs 7.7% 1 mg · wk 12 · n 52 · Phase 2 · secondary NCT00687193
  • 11.1% vs 10.2% 1 mg · wk 12 · n 54 · Phase 2 · secondary NCT00550446
  • 32.1% vs 14.3% 1 mg · wk 12 · n 28 · Phase 2 · secondary NCT00603512
  • 22.9% vs 17.4% 1 mg · wk 12 · n 70 · Phase 2 · secondary NCT00413660
  • 13.0% vs 6.8% 1 mg · wk 10 · n 54 · Phase 2 · secondary NCT00550446
  • 11.5% vs 1.9% 1 mg · wk 8 · n 52 · Phase 2 · secondary NCT00687193
  • 13.0% vs 8.5% 1 mg · wk 8 · n 54 · Phase 2 · secondary NCT00550446
  • 28.6% vs 7.1% 1 mg · wk 8 · n 28 · Phase 2 · secondary NCT00603512
  • 17.1% vs 17.4% 1 mg · wk 8 · n 70 · Phase 2 · secondary NCT00413660
  • 14.8% vs 6.8% 1 mg · wk 6 · n 54 · Phase 2 · secondary NCT00550446
  • 10% vs 8.7% 1 mg · wk 6 · n 70 · Phase 2 · secondary NCT00413660
  • 9.6% vs 1.9% 1 mg · wk 4 · n 52 · Phase 2 · secondary NCT00687193
  • 9.3% vs 5.1% 1 mg · wk 4 · n 54 · Phase 2 · secondary NCT00550446
  • 10.7% vs 3.6% 1 mg · wk 4 · n 28 · Phase 2 · secondary NCT00603512
  • 4.3% vs 2.9% 1 mg · wk 4 · n 70 · Phase 2 · secondary NCT00413660
  • 1.9% vs 0% 1 mg · wk 2 · n 52 · Phase 2 · secondary NCT00687193
  • 1.9% vs 1.7% 1 mg · wk 2 · n 54 · Phase 2 · secondary NCT00550446
  • 7.1% vs 0% 1 mg · wk 2 · n 28 · Phase 2 · secondary NCT00603512
  • 1.4% vs 2.9% 1 mg · wk 2 · n 70 · Phase 2 · secondary NCT00413660
  • 67.4% vs 45.7% wk 12 · n 50 · Phase 2 · secondary NCT01059864
  • 48% vs 42.6% wk 6 · n 50 · Phase 2 · secondary NCT01059864
  • 0% vs 31.4% 20 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 31.4% 20 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 21.6% 20 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 31.4% 3 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 31.4% 3 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 21.6% 3 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 31.4% 1 mg to 5 mg (R) · wk 24 · n 21 · Phase 2 · secondary NCT00413660
  • 0% vs 31.4% 1 mg to 5 mg (R) · wk 20 · n 21 · Phase 2 · secondary NCT00413660
  • 0% vs 21.6% 1 mg to 5 mg (R) · wk 16 · n 21 · Phase 2 · secondary NCT00413660
  • 7.1% vs 0% 1 mg · wk 1 · n 28 · Phase 2 · secondary NCT00603512
  • 40% vs 0% wk 4 · n 15 · Phase 2 · secondary NCT00976599
  • 41.6% vs 36.7% 5 mg BID · wk 26 · n 1455 · Phase 4 · secondary NCT02092467
  • 36.3% vs 31.7% 5 mg BID · wk 13 · n 1455 · Phase 4 · secondary NCT02092467
  • 42.6% vs 39.8% 5 mg BID · wk 39 · n 1455 · Phase 4 · secondary NCT02092467
  • 27.6% vs 23.2% 5 mg BID · wk 8.67 · n 1455 · Phase 4 · secondary NCT02092467
  • 43.4% vs 39.8% 5 mg BID · wk 52 · n 1455 · Phase 4 · secondary NCT02092467
  • 44.8% vs 40.1% 5 mg BID · wk 65 · n 1455 · Phase 4 · secondary NCT02092467
  • 43.5% vs 42% 5 mg BID · wk 78 · n 1455 · Phase 4 · secondary NCT02092467
  • 41.7% vs 41.9% 5 mg BID · wk 91 · n 1455 · Phase 4 · secondary NCT02092467
  • 42.7% vs 40.8% 5 mg BID · wk 104 · n 1455 · Phase 4 · secondary NCT02092467
  • 42.6% vs 41.1% 5 mg BID · wk 117 · n 1455 · Phase 4 · secondary NCT02092467
  • 41.2% vs 42% 5 mg BID · wk 130 · n 1455 · Phase 4 · secondary NCT02092467
  • 40.2% vs 40.9% 5 mg BID · wk 143 · n 1455 · Phase 4 · secondary NCT02092467
  • 41.4% vs 40.8% 5 mg BID · wk 156 · n 1455 · Phase 4 · secondary NCT02092467
  • 40.9% vs 38.7% 5 mg BID · wk 169 · n 1455 · Phase 4 · secondary NCT02092467
  • 40.7% vs 40.5% 5 mg BID · wk 182 · n 1455 · Phase 4 · secondary NCT02092467
  • 35.8% vs 35.8% 5 mg BID · wk 195 · n 1455 · Phase 4 · secondary NCT02092467
  • 29% vs 29.2% 5 mg BID · wk 208 · n 1455 · Phase 4 · secondary NCT02092467
  • 24.1% vs 23.8% 5 mg BID · wk 221 · n 1455 · Phase 4 · secondary NCT02092467
  • 19.5% vs 18.5% 5 mg BID · wk 234 · n 1455 · Phase 4 · secondary NCT02092467
  • 13.7% vs 14.4% 5 mg BID · wk 247 · n 1455 · Phase 4 · secondary NCT02092467
  • 10.4% vs 10.3% 5 mg BID · wk 260 · n 1455 · Phase 4 · secondary NCT02092467
  • 6.9% vs 7.1% 5 mg BID · wk 273 · n 1455 · Phase 4 · secondary NCT02092467
  • 3.6% vs 3.8% 5 mg BID · wk 286 · n 1455 · Phase 4 · secondary NCT02092467
  • 1.1% vs 1.9% 5 mg BID · wk 299 · n 1455 · Phase 4 · secondary NCT02092467
  • 0.2% vs 0.5% 5 mg BID · wk 312 · n 1455 · Phase 4 · secondary NCT02092467
  • 42.2% vs 36.7% 10 mg BID · wk 26 · n 1456 · Phase 4 · secondary NCT02092467
  • 38.5% vs 31.7% 10 mg BID · wk 13 · n 1456 · Phase 4 · secondary NCT02092467
  • 44.7% vs 39.8% 10 mg BID · wk 39 · n 1456 · Phase 4 · secondary NCT02092467
  • 31% vs 23.2% 10 mg BID · wk 8.67 · n 1456 · Phase 4 · secondary NCT02092467
  • 44.9% vs 39.8% 10 mg BID · wk 52 · n 1456 · Phase 4 · secondary NCT02092467
  • 45.9% vs 40.1% 10 mg BID · wk 65 · n 1456 · Phase 4 · secondary NCT02092467
  • 44.2% vs 42% 10 mg BID · wk 78 · n 1456 · Phase 4 · secondary NCT02092467
  • 42.8% vs 41.9% 10 mg BID · wk 91 · n 1456 · Phase 4 · secondary NCT02092467
  • 42.3% vs 40.8% 10 mg BID · wk 104 · n 1456 · Phase 4 · secondary NCT02092467
  • 41.3% vs 41.1% 10 mg BID · wk 117 · n 1456 · Phase 4 · secondary NCT02092467
  • 41.8% vs 42% 10 mg BID · wk 130 · n 1456 · Phase 4 · secondary NCT02092467
  • 42% vs 40.9% 10 mg BID · wk 143 · n 1456 · Phase 4 · secondary NCT02092467
  • 38.9% vs 40.8% 10 mg BID · wk 156 · n 1456 · Phase 4 · secondary NCT02092467
  • 40.4% vs 38.7% 10 mg BID · wk 169 · n 1456 · Phase 4 · secondary NCT02092467
  • 39.7% vs 40.5% 10 mg BID · wk 182 · n 1456 · Phase 4 · secondary NCT02092467
  • 33% vs 35.8% 10 mg BID · wk 195 · n 1456 · Phase 4 · secondary NCT02092467
  • 26.4% vs 29.2% 10 mg BID · wk 208 · n 1456 · Phase 4 · secondary NCT02092467
  • 22% vs 23.8% 10 mg BID · wk 221 · n 1456 · Phase 4 · secondary NCT02092467
  • 18.6% vs 18.5% 10 mg BID · wk 234 · n 1456 · Phase 4 · secondary NCT02092467
  • 14.4% vs 14.4% 10 mg BID · wk 247 · n 1456 · Phase 4 · secondary NCT02092467
  • 10.4% vs 10.3% 10 mg BID · wk 260 · n 1456 · Phase 4 · secondary NCT02092467
  • 7.1% vs 7.1% 10 mg BID · wk 273 · n 1456 · Phase 4 · secondary NCT02092467
  • 4.7% vs 3.8% 10 mg BID · wk 286 · n 1456 · Phase 4 · secondary NCT02092467
  • 1.4% vs 1.9% 10 mg BID · wk 299 · n 1456 · Phase 4 · secondary NCT02092467
  • 0.4% vs 0.5% 10 mg BID · wk 312 · n 1456 · Phase 4 · secondary NCT02092467
upadacitinib
52.1% vs 28.3%vs Methotrexate15 mg · wk 12 · n 317NCT02706873
41 other results
  • 56.4% vs 28.3% 30 mg · wk 12 · n 314 · Phase 3 · primary NCT02706873
  • 38% vs 14.9% 15 mg · wk 12 · n 221 · Phase 3 · secondary NCT02675426
  • 34.1% vs 11.8% 15 mg · wk 12 · n 164 · Phase 3 · secondary NCT02706847
  • 40.8% vs 8.3% 15 mg · wk 12 · n 169 · Phase 3 · secondary NCT02955212
  • 43.4% vs 14.9% 30 mg · wk 12 · n 219 · Phase 3 · secondary NCT02675426
  • 35.8% vs 11.8% 30 mg · wk 12 · n 165 · Phase 3 · secondary NCT02706847
  • 65.3% vs 16.3% 15 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 58% vs 16.3% 30 mg · wk 12 · n 50 · Phase 2/3 · secondary NCT02720523
  • 40.8% vs 16.3% 7.5 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 60.3% vs 33.4% 15 mg · wk 24 · n 317 · Phase 3 · secondary NCT02706873
  • 41.9% vs 15.3% 15 mg · wk 14 · n 217 · Phase 3 · secondary NCT02706951
  • 65.6% vs 33.4% 30 mg · wk 24 · n 314 · Phase 3 · secondary NCT02706873
  • 52.1% vs 15.3% 30 mg · wk 14 · n 215 · Phase 3 · secondary NCT02706951
  • 66.7% vs 21.4% 15 mg · wk 12 · n 27 · Phase 3 · secondary NCT02706873
  • 71.4% vs 21.4% 30 mg · wk 12 · n 28 · Phase 3 · secondary NCT02706873
  • 60% vs 21.4% 7.5 mg · wk 12 · n 55 · Phase 3 · secondary NCT02706873
  • 29.3% vs 21.1% 60 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 19.5% vs 5.3% 60 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 17.1% vs 10.5% 60 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 4.9% vs 0% 60 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705
  • 43.8% vs 19.6% 24 mg QD · wk 12 · n 48 · Phase 2 · secondary NCT02066389
  • 12.8% vs 21.1% 20 mg · wk 12 · n 39 · Phase 2 · secondary NCT03682705
  • 12.8% vs 5.3% 20 mg · wk 8 · n 39 · Phase 2 · secondary NCT03682705
  • 2.6% vs 10.5% 20 mg · wk 4 · n 39 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 20 mg · wk 2 · n 39 · Phase 2 · secondary NCT03682705
  • 44.7% vs 19.6% 18 mg BID · wk 12 · n 47 · Phase 2 · secondary NCT02066389
  • 40% vs 17% 18 mg BID · wk 12 · n 55 · Phase 2 · secondary NCT01960855
  • 45.2% vs 21.1% 15 mg/60 mg · wk 12 · n 62 · Phase 2 · secondary NCT03682705
  • 41.9% vs 5.3% 15 mg/60 mg · wk 8 · n 62 · Phase 2 · secondary NCT03682705
  • 19.4% vs 10.5% 15 mg/60 mg · wk 4 · n 62 · Phase 2 · secondary NCT03682705
  • 16.1% vs 0% 15 mg/60 mg · wk 2 · n 62 · Phase 2 · secondary NCT03682705
  • 50% vs 19.6% 12 mg BID · wk 12 · n 50 · Phase 2 · secondary NCT02066389
  • 43.6% vs 17% 12 mg BID · wk 12 · n 55 · Phase 2 · secondary NCT01960855
  • 49% vs 19.6% 6 mg BID · wk 12 · n 49 · Phase 2 · secondary NCT02066389
  • 38.5% vs 17% 6 mg BID · wk 12 · n 52 · Phase 2 · secondary NCT01960855
  • 17.1% vs 21.1% 5 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 7.3% vs 5.3% 5 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 4.9% vs 10.5% 5 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 5 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705
  • 39.6% vs 19.6% 3 mg BID · wk 12 · n 48 · Phase 2 · secondary NCT02066389
  • 24.1% vs 17% 3 mg BID · wk 12 · n 54 · Phase 2 · secondary NCT01960855

ACR70

tofacitinib
25.4% vs 12.1%vs MTX5 mg BID · wk 24 · n 366NCT01039688
271 other results
  • 37.3% vs 12.1% 10 mg BID · wk 24 · n 391 · Phase 3 · primary NCT01039688
  • 13.2% vs 3.2% 5 mg · wk 26 · n 311 · Phase 3 · secondary NCT00856544
  • 19.9% vs 1.9% 5 mg twice daily · wk 26 · n 196 · Phase 3 · secondary NCT00853385
  • 14.6% vs 1.3% 5 mg · wk 26 · n 309 · Phase 3 · secondary NCT00847613
  • 11.9% vs 3.2% 5 mg · wk 19.5 · n 311 · Phase 3 · secondary NCT00856544
  • 15.3% vs 5.8% 5 mg · wk 13 · n 241 · Phase 3 · secondary NCT00814307
  • 8.4% vs 1.9% 5 mg · wk 13 · n 311 · Phase 3 · secondary NCT00856544
  • 12.2% vs 1.9% 5 mg twice daily · wk 13 · n 196 · Phase 3 · secondary NCT00853385
  • 10.7% vs 2.6% 5 mg · wk 13 · n 309 · Phase 3 · secondary NCT00847613
  • 13.6% vs 1.5% 5 mg · wk 13 · n 132 · Phase 3 · secondary NCT00960440
  • 10.0% vs 3.3% 5 mg · wk 8.67 · n 241 · Phase 3 · secondary NCT00814307
  • 9% vs 1.3% 5 mg · wk 8.67 · n 311 · Phase 3 · secondary NCT00856544
  • 5.0% vs 1.7% 5 mg · wk 4.33 · n 241 · Phase 3 · secondary NCT00814307
  • 3.5% vs 0% 5 mg · wk 4.33 · n 311 · Phase 3 · secondary NCT00856544
  • 2.6% vs 0.9% 5 mg twice daily · wk 4.33 · n 196 · Phase 3 · secondary NCT00853385
  • 3.9% vs 0% 5 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00847613
  • 7.6% vs 0% 5 mg · wk 4.33 · n 132 · Phase 3 · secondary NCT00960440
  • 2.1% vs 0% 5 mg · wk 2 · n 241 · Phase 3 · secondary NCT00814307
  • 0.3% vs 0% 5 mg · wk 2 · n 311 · Phase 3 · secondary NCT00856544
  • 2.3% vs 0% 5 mg · wk 2 · n 132 · Phase 3 · secondary NCT00960440
  • 16.2% vs 3.2% 10 mg · wk 26 · n 309 · Phase 3 · secondary NCT00856544
  • 21.9% vs 1.9% 10 mg twice daily · wk 26 · n 196 · Phase 3 · secondary NCT00853385
  • 22.3% vs 1.3% 10 mg · wk 26 · n 309 · Phase 3 · secondary NCT00847613
  • 18.1% vs 3.2% 10 mg · wk 19.5 · n 309 · Phase 3 · secondary NCT00856544
  • 20.3% vs 5.8% 10 mg · wk 13 · n 242 · Phase 3 · secondary NCT00814307
  • 14.2% vs 1.9% 10 mg · wk 13 · n 309 · Phase 3 · secondary NCT00856544
  • 14.8% vs 1.9% 10 mg twice daily · wk 13 · n 196 · Phase 3 · secondary NCT00853385
  • 17.1% vs 2.6% 10 mg · wk 13 · n 309 · Phase 3 · secondary NCT00847613
  • 10.5% vs 1.5% 10 mg · wk 13 · n 133 · Phase 3 · secondary NCT00960440
  • 19.0% vs 3.3% 10 mg · wk 8.67 · n 242 · Phase 3 · secondary NCT00814307
  • 10.4% vs 1.3% 10 mg · wk 8.67 · n 309 · Phase 3 · secondary NCT00856544
  • 9.1% vs 1.7% 10 mg · wk 4.33 · n 242 · Phase 3 · secondary NCT00814307
  • 7.1% vs 0% 10 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00856544
  • 4.1% vs 0.9% 10 mg twice daily · wk 4.33 · n 196 · Phase 3 · secondary NCT00853385
  • 3.6% vs 0% 10 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00847613
  • 6.8% vs 0% 10 mg · wk 4.33 · n 133 · Phase 3 · secondary NCT00960440
  • 4.6% vs 0% 10 mg · wk 2 · n 242 · Phase 3 · secondary NCT00814307
  • 2.3% vs 0% 10 mg · wk 2 · n 309 · Phase 3 · secondary NCT00856544
  • 2.3% vs 0% 10 mg · wk 2 · n 133 · Phase 3 · secondary NCT00960440
  • 19.9% vs 5.5% 5 mg BID · wk 13 · n 366 · Phase 3 · secondary NCT01039688
  • 18.4% vs 11.1% 5 mg twice daily · wk 39 · n 196 · Phase 3 · secondary NCT00853385
  • 29.2% vs 13.2% 5 mg BID · wk 39 · n 366 · Phase 3 · secondary NCT01039688
  • 16.2% vs 3.3% 5 mg BID · wk 8.67 · n 366 · Phase 3 · secondary NCT01039688
  • 5.2% vs 0.6% 5 mg BID · wk 4.33 · n 366 · Phase 3 · secondary NCT01039688
  • 23.0% vs 16.6% 5 mg twice daily · wk 52 · n 196 · Phase 3 · secondary NCT00853385
  • 28.7% vs 15.4% 5 mg BID · wk 52 · n 366 · Phase 3 · secondary NCT01039688
  • 30.1% vs 17.0% 5 mg BID · wk 65 · n 366 · Phase 3 · secondary NCT01039688
  • 32.2% vs 15.9% 5 mg BID · wk 78 · n 366 · Phase 3 · secondary NCT01039688
  • 32.2% vs 17.6% 5 mg BID · wk 91 · n 366 · Phase 3 · secondary NCT01039688
  • 34.1% vs 15.4% 5 mg BID · wk 104 · n 366 · Phase 3 · secondary NCT01039688
  • 26.6% vs 5.5% 10 mg BID · wk 13 · n 391 · Phase 3 · secondary NCT01039688
  • 21.9% vs 11.1% 10 mg twice daily · wk 39 · n 196 · Phase 3 · secondary NCT00853385
  • 37.9% vs 13.2% 10 mg BID · wk 39 · n 391 · Phase 3 · secondary NCT01039688
  • 23.0% vs 3.3% 10 mg BID · wk 8.67 · n 391 · Phase 3 · secondary NCT01039688
  • 9.2% vs 0.6% 10 mg BID · wk 4.33 · n 391 · Phase 3 · secondary NCT01039688
  • 23.5% vs 16.6% 10 mg twice daily · wk 52 · n 196 · Phase 3 · secondary NCT00853385
  • 37.9% vs 15.4% 10 mg BID · wk 52 · n 391 · Phase 3 · secondary NCT01039688
  • 37.9% vs 17.0% 10 mg BID · wk 65 · n 391 · Phase 3 · secondary NCT01039688
  • 36.6% vs 15.9% 10 mg BID · wk 78 · n 391 · Phase 3 · secondary NCT01039688
  • 36.8% vs 17.6% 10 mg BID · wk 91 · n 391 · Phase 3 · secondary NCT01039688
  • 37.6% vs 15.4% 10 mg BID · wk 104 · n 391 · Phase 3 · secondary NCT01039688
  • 22.4% vs 11.8% 5 mg · wk 24 · n 49 · Phase 2 · secondary NCT00550446
  • 21.1% vs 9.8% 5 mg · wk 24 · n 71 · Phase 2 · secondary NCT00413660
  • 18.4% vs 8.8% 5 mg · wk 20 · n 49 · Phase 2 · secondary NCT00550446
  • 23.9% vs 13.7% 5 mg · wk 20 · n 71 · Phase 2 · secondary NCT00413660
  • 20.4% vs 0% 5 mg · wk 16 · n 49 · Phase 2 · secondary NCT00550446
  • 18.3% vs 9.8% 5 mg · wk 16 · n 71 · Phase 2 · secondary NCT00413660
  • 26.9% vs 1.9% 5 mg · wk 12 · n 52 · Phase 2 · secondary NCT00687193
  • 14.3% vs 3.4% 5 mg · wk 12 · n 49 · Phase 2 · secondary NCT00550446
  • 33.3% vs 3.6% 5 mg · wk 12 · n 27 · Phase 2 · secondary NCT00603512
  • 18.3% vs 5.8% 5 mg · wk 12 · n 71 · Phase 2 · secondary NCT00413660
  • 16.3% vs 1.7% 5 mg · wk 10 · n 49 · Phase 2 · secondary NCT00550446
  • 25% vs 1.9% 5 mg · wk 8 · n 52 · Phase 2 · secondary NCT00687193
  • 8.2% vs 1.7% 5 mg · wk 8 · n 49 · Phase 2 · secondary NCT00550446
  • 33.3% vs 3.6% 5 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • 11.3% vs 5.8% 5 mg · wk 8 · n 71 · Phase 2 · secondary NCT00413660
  • 8.9% vs 8.9% 5 mg BID · wk 8 · n 61 · Phase 2 · secondary NCT00147498
  • 4.1% vs 1.7% 5 mg · wk 6 · n 49 · Phase 2 · secondary NCT00550446
  • 16.9% vs 4.3% 5 mg · wk 6 · n 71 · Phase 2 · secondary NCT00413660
  • 13.1% vs 3.1% 5 mg BID · wk 6 · n 61 · Phase 2 · secondary NCT00147498
  • 17.3% vs 0% 5 mg · wk 4 · n 52 · Phase 2 · secondary NCT00687193
  • 2.0% vs 1.7% 5 mg · wk 4 · n 49 · Phase 2 · secondary NCT00550446
  • 14.8% vs 0% 5 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • 0% vs 1.4% 5 mg · wk 4 · n 71 · Phase 2 · secondary NCT00413660
  • 9.8% vs 1.5% 5 mg BID · wk 4 · n 61 · Phase 2 · secondary NCT00147498
  • 1.9% vs 0% 5 mg · wk 2 · n 52 · Phase 2 · secondary NCT00687193
  • 2.0% vs 0% 5 mg · wk 2 · n 49 · Phase 2 · secondary NCT00550446
  • 11.1% vs 0% 5 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • 1.4% vs 0% 5 mg · wk 2 · n 71 · Phase 2 · secondary NCT00413660
  • 4.9% vs 1.5% 5 mg BID · wk 2 · n 61 · Phase 2 · secondary NCT00147498
  • 0% vs 0% 5 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • 1.6% vs 0% 5 mg BID · wk 1 · n 61 · Phase 2 · secondary NCT00147498
  • 37.7% vs 11.8% 10 mg · wk 24 · n 61 · Phase 2 · secondary NCT00550446
  • 18.9% vs 9.8% 10 mg · wk 24 · n 74 · Phase 2 · secondary NCT00413660
  • 31.1% vs 8.8% 10 mg · wk 20 · n 61 · Phase 2 · secondary NCT00550446
  • 24.3% vs 13.7% 10 mg · wk 20 · n 74 · Phase 2 · secondary NCT00413660
  • 29.5% vs 0% 10 mg · wk 16 · n 61 · Phase 2 · secondary NCT00550446
  • 18.9% vs 9.8% 10 mg · wk 16 · n 74 · Phase 2 · secondary NCT00413660
  • 49.1% vs 1.9% 10 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • 24.6% vs 3.4% 10 mg · wk 12 · n 61 · Phase 2 · secondary NCT00550446
  • 12.2% vs 5.8% 10 mg · wk 12 · n 74 · Phase 2 · secondary NCT00413660
  • 37.7% vs 1.9% 10 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 16.2% vs 5.8% 10 mg · wk 8 · n 74 · Phase 2 · secondary NCT00413660
  • 9.5% vs 4.3% 10 mg · wk 6 · n 74 · Phase 2 · secondary NCT00413660
  • 26.4% vs 0% 10 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 11.5% vs 1.7% 10 mg · wk 4 · n 61 · Phase 2 · secondary NCT00550446
  • 9.4% vs 0% 10 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 3.3% vs 0% 10 mg · wk 2 · n 61 · Phase 2 · secondary NCT00550446
  • 27.4% vs 8.9% 30 mg BID · wk 8 · n 69 · Phase 2 · secondary NCT00147498
  • 27.5% vs 3.1% 30 mg BID · wk 6 · n 69 · Phase 2 · secondary NCT00147498
  • 21.7% vs 1.5% 30 mg BID · wk 4 · n 69 · Phase 2 · secondary NCT00147498
  • 10.1% vs 1.5% 30 mg BID · wk 2 · n 69 · Phase 2 · secondary NCT00147498
  • 4.3% vs 0% 30 mg BID · wk 1 · n 69 · Phase 2 · secondary NCT00147498
  • 28.4% vs 9.8% 20 mg · wk 24 · n 80 · Phase 2 · secondary NCT00413660
  • 28.4% vs 13.7% 20 mg · wk 20 · n 80 · Phase 2 · secondary NCT00413660
  • 22.4% vs 9.8% 20 mg · wk 16 · n 80 · Phase 2 · secondary NCT00413660
  • 23.8% vs 5.8% 20 mg · wk 12 · n 80 · Phase 2 · secondary NCT00413660
  • 17.5% vs 5.8% 20 mg · wk 8 · n 80 · Phase 2 · secondary NCT00413660
  • 12.5% vs 4.3% 20 mg · wk 6 · n 80 · Phase 2 · secondary NCT00413660
  • 12.5% vs 1.4% 20 mg · wk 4 · n 80 · Phase 2 · secondary NCT00413660
  • 2.5% vs 0% 20 mg · wk 2 · n 80 · Phase 2 · secondary NCT00413660
  • 34.6% vs 3.6% 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT00603512
  • 26.2% vs 1.7% 10 mg · wk 10 · n 61 · Phase 2 · secondary NCT00550446
  • 18.0% vs 1.7% 10 mg · wk 8 · n 61 · Phase 2 · secondary NCT00550446
  • 26.9% vs 3.6% 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT00603512
  • 19.7% vs 1.7% 10 mg · wk 6 · n 61 · Phase 2 · secondary NCT00550446
  • 7.7% vs 0% 10 mg · wk 4 · n 26 · Phase 2 · secondary NCT00603512
  • 14.9% vs 1.4% 10 mg · wk 4 · n 74 · Phase 2 · secondary NCT00413660
  • 3.9% vs 0% 10 mg · wk 2 · n 26 · Phase 2 · secondary NCT00603512
  • 1.4% vs 0% 10 mg · wk 2 · n 74 · Phase 2 · secondary NCT00413660
  • 3.9% vs 0% 10 mg · wk 1 · n 26 · Phase 2 · secondary NCT00603512
  • 33.3% vs 11.8% 15 mg · wk 24 · n 57 · Phase 2 · secondary NCT00550446
  • 32% vs 9.8% 15 mg · wk 24 · n 75 · Phase 2 · secondary NCT00413660
  • 31.6% vs 8.8% 15 mg · wk 20 · n 57 · Phase 2 · secondary NCT00550446
  • 28% vs 13.7% 15 mg · wk 20 · n 75 · Phase 2 · secondary NCT00413660
  • 33.3% vs 0% 15 mg · wk 16 · n 57 · Phase 2 · secondary NCT00550446
  • 24% vs 9.8% 15 mg · wk 16 · n 75 · Phase 2 · secondary NCT00413660
  • 51.9% vs 1.9% 15 mg · wk 12 · n 54 · Phase 2 · secondary NCT00687193
  • 26.3% vs 3.4% 15 mg · wk 12 · n 57 · Phase 2 · secondary NCT00550446
  • 24% vs 5.8% 15 mg · wk 12 · n 75 · Phase 2 · secondary NCT00413660
  • 21.1% vs 1.7% 15 mg · wk 10 · n 57 · Phase 2 · secondary NCT00550446
  • 40.7% vs 1.9% 15 mg · wk 8 · n 54 · Phase 2 · secondary NCT00687193
  • 24.6% vs 1.7% 15 mg · wk 8 · n 57 · Phase 2 · secondary NCT00550446
  • 16% vs 5.8% 15 mg · wk 8 · n 75 · Phase 2 · secondary NCT00413660
  • 14.3% vs 8.9% 15 mg BID · wk 8 · n 69 · Phase 2 · secondary NCT00147498
  • 17.5% vs 1.7% 15 mg · wk 6 · n 57 · Phase 2 · secondary NCT00550446
  • 16% vs 4.3% 15 mg · wk 6 · n 75 · Phase 2 · secondary NCT00413660
  • 21.7% vs 3.1% 15 mg BID · wk 6 · n 69 · Phase 2 · secondary NCT00147498
  • 16.7% vs 0% 15 mg · wk 4 · n 54 · Phase 2 · secondary NCT00687193
  • 8.8% vs 1.7% 15 mg · wk 4 · n 57 · Phase 2 · secondary NCT00550446
  • 13.3% vs 1.4% 15 mg · wk 4 · n 75 · Phase 2 · secondary NCT00413660
  • 17.4% vs 1.5% 15 mg BID · wk 4 · n 69 · Phase 2 · secondary NCT00147498
  • 7.4% vs 0% 15 mg · wk 2 · n 54 · Phase 2 · secondary NCT00687193
  • 7.0% vs 0% 15 mg · wk 2 · n 57 · Phase 2 · secondary NCT00550446
  • 6.7% vs 0% 15 mg · wk 2 · n 75 · Phase 2 · secondary NCT00413660
  • 4.3% vs 1.5% 15 mg BID · wk 2 · n 69 · Phase 2 · secondary NCT00147498
  • 4.3% vs 0% 15 mg BID · wk 1 · n 69 · Phase 2 · secondary NCT00147498
  • 23.5% vs 11.8% 3 mg · wk 24 · n 51 · Phase 2 · secondary NCT00550446
  • 23.6% vs 9.8% 3 mg · wk 24 · n 68 · Phase 2 · secondary NCT00413660
  • 17.6% vs 8.8% 3 mg · wk 20 · n 51 · Phase 2 · secondary NCT00550446
  • 29.1% vs 13.7% 3 mg · wk 20 · n 68 · Phase 2 · secondary NCT00413660
  • 26.5% vs 0% 3 mg · wk 16 · n 51 · Phase 2 · secondary NCT00550446
  • 21.8% vs 9.8% 3 mg · wk 16 · n 68 · Phase 2 · secondary NCT00413660
  • 13.2% vs 1.9% 3 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • 11.8% vs 3.4% 3 mg · wk 12 · n 51 · Phase 2 · secondary NCT00550446
  • 14.8% vs 3.6% 3 mg · wk 12 · n 27 · Phase 2 · secondary NCT00603512
  • 20.6% vs 5.8% 3 mg · wk 12 · n 68 · Phase 2 · secondary NCT00413660
  • 7.8% vs 1.7% 3 mg · wk 10 · n 51 · Phase 2 · secondary NCT00550446
  • 13.2% vs 1.9% 3 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 3.9% vs 1.7% 3 mg · wk 8 · n 51 · Phase 2 · secondary NCT00550446
  • 7.4% vs 3.6% 3 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • 14.7% vs 5.8% 3 mg · wk 8 · n 68 · Phase 2 · secondary NCT00413660
  • 2.0% vs 1.7% 3 mg · wk 6 · n 51 · Phase 2 · secondary NCT00550446
  • 13.2% vs 4.3% 3 mg · wk 6 · n 68 · Phase 2 · secondary NCT00413660
  • 3.8% vs 0% 3 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 5.9% vs 1.7% 3 mg · wk 4 · n 51 · Phase 2 · secondary NCT00550446
  • 7.4% vs 0% 3 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • 7.3% vs 1.4% 3 mg · wk 4 · n 68 · Phase 2 · secondary NCT00413660
  • 0% vs 0% 3 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 2.0% vs 0% 3 mg · wk 2 · n 51 · Phase 2 · secondary NCT00550446
  • 3.7% vs 0% 3 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • 1.5% vs 0% 3 mg · wk 2 · n 68 · Phase 2 · secondary NCT00413660
  • 0% vs 0% 3 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • 8.1% vs 11.8% 1 mg · wk 24 · n 54 · Phase 2 · secondary NCT00550446
  • 28.6% vs 9.8% 1 mg · wk 24 · n 70 · Phase 2 · secondary NCT00413660
  • 10.8% vs 8.8% 1 mg · wk 20 · n 54 · Phase 2 · secondary NCT00550446
  • 20.4% vs 13.7% 1 mg · wk 20 · n 70 · Phase 2 · secondary NCT00413660
  • 10.8% vs 0% 1 mg · wk 16 · n 54 · Phase 2 · secondary NCT00550446
  • 16.3% vs 9.8% 1 mg · wk 16 · n 70 · Phase 2 · secondary NCT00413660
  • 7.5% vs 1.9% 1 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • 5.6% vs 3.4% 1 mg · wk 12 · n 54 · Phase 2 · secondary NCT00550446
  • 7.1% vs 3.6% 1 mg · wk 12 · n 28 · Phase 2 · secondary NCT00603512
  • 4.3% vs 5.8% 1 mg · wk 12 · n 70 · Phase 2 · secondary NCT00413660
  • 3.7% vs 1.7% 1 mg · wk 10 · n 54 · Phase 2 · secondary NCT00550446
  • 5.7% vs 1.9% 1 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • 9.3% vs 1.7% 1 mg · wk 8 · n 54 · Phase 2 · secondary NCT00550446
  • 3.6% vs 3.6% 1 mg · wk 8 · n 28 · Phase 2 · secondary NCT00603512
  • 8.6% vs 5.8% 1 mg · wk 8 · n 70 · Phase 2 · secondary NCT00413660
  • 3.7% vs 1.7% 1 mg · wk 6 · n 54 · Phase 2 · secondary NCT00550446
  • 1.4% vs 4.3% 1 mg · wk 6 · n 70 · Phase 2 · secondary NCT00413660
  • 1.9% vs 0% 1 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • 0% vs 1.7% 1 mg · wk 4 · n 54 · Phase 2 · secondary NCT00550446
  • 0% vs 0% 1 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • 1.9% vs 0% 1 mg · wk 2 · n 54 · Phase 2 · secondary NCT00550446
  • 34.8% vs 30.4% wk 12 · n 50 · Phase 2 · secondary NCT01059864
  • 20% vs 19.1% wk 6 · n 50 · Phase 2 · secondary NCT01059864
  • 0% vs 9.8% 20 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 13.7% 20 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 9.8% 20 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 9.8% 3 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 13.7% 3 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 9.8% 3 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • 0% vs 9.8% 1 mg to 5 mg (R) · wk 24 · n 21 · Phase 2 · secondary NCT00413660
  • 0% vs 13.7% 1 mg to 5 mg (R) · wk 20 · n 21 · Phase 2 · secondary NCT00413660
  • 0% vs 9.8% 1 mg to 5 mg (R) · wk 16 · n 21 · Phase 2 · secondary NCT00413660
  • 3.6% vs 0% 1 mg · wk 4 · n 28 · Phase 2 · secondary NCT00603512
  • 2.9% vs 1.4% 1 mg · wk 4 · n 70 · Phase 2 · secondary NCT00413660
  • 0% vs 0% 1 mg · wk 2 · n 28 · Phase 2 · secondary NCT00603512
  • 1.4% vs 0% 1 mg · wk 2 · n 70 · Phase 2 · secondary NCT00413660
  • 0% vs 0% 1 mg · wk 1 · n 28 · Phase 2 · secondary NCT00603512
  • 6.7% vs 0% wk 4 · n 15 · Phase 2 · secondary NCT00976599
  • 19.4% vs 16.1% 5 mg BID · wk 26 · n 1455 · Phase 4 · secondary NCT02092467
  • 17.4% vs 13.7% 5 mg BID · wk 13 · n 1455 · Phase 4 · secondary NCT02092467
  • 22.5% vs 20.1% 5 mg BID · wk 39 · n 1455 · Phase 4 · secondary NCT02092467
  • 10.4% vs 7.8% 5 mg BID · wk 8.67 · n 1455 · Phase 4 · secondary NCT02092467
  • 23.2% vs 19.6% 5 mg BID · wk 52 · n 1455 · Phase 4 · secondary NCT02092467
  • 24.7% vs 21% 5 mg BID · wk 65 · n 1455 · Phase 4 · secondary NCT02092467
  • 24.6% vs 22.4% 5 mg BID · wk 78 · n 1455 · Phase 4 · secondary NCT02092467
  • 24.9% vs 22.2% 5 mg BID · wk 91 · n 1455 · Phase 4 · secondary NCT02092467
  • 24% vs 22.6% 5 mg BID · wk 104 · n 1455 · Phase 4 · secondary NCT02092467
  • 25.7% vs 23.6% 5 mg BID · wk 117 · n 1455 · Phase 4 · secondary NCT02092467
  • 25.4% vs 24.7% 5 mg BID · wk 130 · n 1455 · Phase 4 · secondary NCT02092467
  • 24.5% vs 24.5% 5 mg BID · wk 143 · n 1455 · Phase 4 · secondary NCT02092467
  • 24.9% vs 24.2% 5 mg BID · wk 156 · n 1455 · Phase 4 · secondary NCT02092467
  • 25.5% vs 23.3% 5 mg BID · wk 169 · n 1455 · Phase 4 · secondary NCT02092467
  • 25.8% vs 23.6% 5 mg BID · wk 182 · n 1455 · Phase 4 · secondary NCT02092467
  • 21.5% vs 20.5% 5 mg BID · wk 195 · n 1455 · Phase 4 · secondary NCT02092467
  • 17.6% vs 16.4% 5 mg BID · wk 208 · n 1455 · Phase 4 · secondary NCT02092467
  • 14.8% vs 13.7% 5 mg BID · wk 221 · n 1455 · Phase 4 · secondary NCT02092467
  • 10.9% vs 11% 5 mg BID · wk 234 · n 1455 · Phase 4 · secondary NCT02092467
  • 8.8% vs 8.1% 5 mg BID · wk 247 · n 1455 · Phase 4 · secondary NCT02092467
  • 5.4% vs 6.3% 5 mg BID · wk 260 · n 1455 · Phase 4 · secondary NCT02092467
  • 4% vs 4.4% 5 mg BID · wk 273 · n 1455 · Phase 4 · secondary NCT02092467
  • 1.7% vs 2.4% 5 mg BID · wk 286 · n 1455 · Phase 4 · secondary NCT02092467
  • 0.5% vs 1% 5 mg BID · wk 299 · n 1455 · Phase 4 · secondary NCT02092467
  • 0.1% vs 0.3% 5 mg BID · wk 312 · n 1455 · Phase 4 · secondary NCT02092467
  • 22.7% vs 16.1% 10 mg BID · wk 26 · n 1456 · Phase 4 · secondary NCT02092467
  • 18.4% vs 13.7% 10 mg BID · wk 13 · n 1456 · Phase 4 · secondary NCT02092467
  • 25.2% vs 20.1% 10 mg BID · wk 39 · n 1456 · Phase 4 · secondary NCT02092467
  • 13.3% vs 7.8% 10 mg BID · wk 8.67 · n 1456 · Phase 4 · secondary NCT02092467
  • 25.6% vs 19.6% 10 mg BID · wk 52 · n 1456 · Phase 4 · secondary NCT02092467
  • 26.8% vs 21% 10 mg BID · wk 65 · n 1456 · Phase 4 · secondary NCT02092467
  • 26.2% vs 22.4% 10 mg BID · wk 78 · n 1456 · Phase 4 · secondary NCT02092467
  • 25.4% vs 22.2% 10 mg BID · wk 91 · n 1456 · Phase 4 · secondary NCT02092467
  • 26.5% vs 22.6% 10 mg BID · wk 104 · n 1456 · Phase 4 · secondary NCT02092467
  • 26.8% vs 23.6% 10 mg BID · wk 117 · n 1456 · Phase 4 · secondary NCT02092467
  • 27.3% vs 24.7% 10 mg BID · wk 130 · n 1456 · Phase 4 · secondary NCT02092467
  • 26.9% vs 24.5% 10 mg BID · wk 143 · n 1456 · Phase 4 · secondary NCT02092467
  • 23.6% vs 24.2% 10 mg BID · wk 156 · n 1456 · Phase 4 · secondary NCT02092467
  • 24.8% vs 23.3% 10 mg BID · wk 169 · n 1456 · Phase 4 · secondary NCT02092467
  • 23.5% vs 23.6% 10 mg BID · wk 182 · n 1456 · Phase 4 · secondary NCT02092467
  • 20.5% vs 20.5% 10 mg BID · wk 195 · n 1456 · Phase 4 · secondary NCT02092467
  • 15.7% vs 16.4% 10 mg BID · wk 208 · n 1456 · Phase 4 · secondary NCT02092467
  • 13.4% vs 13.7% 10 mg BID · wk 221 · n 1456 · Phase 4 · secondary NCT02092467
  • 11.2% vs 11% 10 mg BID · wk 234 · n 1456 · Phase 4 · secondary NCT02092467
  • 8.7% vs 8.1% 10 mg BID · wk 247 · n 1456 · Phase 4 · secondary NCT02092467
  • 5.7% vs 6.3% 10 mg BID · wk 260 · n 1456 · Phase 4 · secondary NCT02092467
  • 3.9% vs 4.4% 10 mg BID · wk 273 · n 1456 · Phase 4 · secondary NCT02092467
  • 2.6% vs 2.4% 10 mg BID · wk 286 · n 1456 · Phase 4 · secondary NCT02092467
  • 1% vs 1% 10 mg BID · wk 299 · n 1456 · Phase 4 · secondary NCT02092467
  • 0.3% vs 0.3% 10 mg BID · wk 312 · n 1456 · Phase 4 · secondary NCT02092467
upadacitinib
20.8% vs 5.9%+14.9 vs placebo15 mg · wk 12 · n 221NCT02675426
41 other results
  • 11.6% vs 6.5% 15 mg · wk 12 · n 164 · Phase 3 · secondary NCT02706847
  • 21.3% vs 3.6% 15 mg · wk 12 · n 169 · Phase 3 · secondary NCT02955212
  • 26.5% vs 5.9% 30 mg · wk 12 · n 219 · Phase 3 · secondary NCT02675426
  • 23% vs 6.5% 30 mg · wk 12 · n 165 · Phase 3 · secondary NCT02706847
  • 34.7% vs 2% 15 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 28% vs 2% 30 mg · wk 12 · n 50 · Phase 2/3 · secondary NCT02720523
  • 20.4% vs 2% 7.5 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 44.5% vs 18.5% 15 mg · wk 24 · n 317 · Phase 3 · secondary NCT02706873
  • 22.6% vs 2.8% 15 mg · wk 14 · n 217 · Phase 3 · secondary NCT02706951
  • 32.5% vs 14% 15 mg · wk 12 · n 317 · Phase 3 · secondary NCT02706873
  • 49.7% vs 18.5% 30 mg · wk 24 · n 314 · Phase 3 · secondary NCT02706873
  • 33% vs 2.8% 30 mg · wk 14 · n 215 · Phase 3 · secondary NCT02706951
  • 36.9% vs 14% 30 mg · wk 12 · n 314 · Phase 3 · secondary NCT02706873
  • 51.9% vs 0% 15 mg · wk 12 · n 27 · Phase 3 · secondary NCT02706873
  • 64.3% vs 0% 30 mg · wk 12 · n 28 · Phase 3 · secondary NCT02706873
  • 34.5% vs 0% 7.5 mg · wk 12 · n 55 · Phase 3 · secondary NCT02706873
  • 14.6% vs 15.8% 60 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 4.9% vs 0% 60 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 4.9% vs 0% 60 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 2.4% vs 0% 60 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705
  • 25% vs 6.5% 24 mg QD · wk 12 · n 48 · Phase 2 · secondary NCT02066389
  • 5.1% vs 15.8% 20 mg · wk 12 · n 39 · Phase 2 · secondary NCT03682705
  • 2.6% vs 0% 20 mg · wk 8 · n 39 · Phase 2 · secondary NCT03682705
  • 2.6% vs 0% 20 mg · wk 4 · n 39 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 20 mg · wk 2 · n 39 · Phase 2 · secondary NCT03682705
  • 27.7% vs 6.5% 18 mg BID · wk 12 · n 47 · Phase 2 · secondary NCT02066389
  • 21.8% vs 3.6% 18 mg BID · wk 12 · n 55 · Phase 2 · secondary NCT01960855
  • 25.8% vs 15.8% 15 mg/60 mg · wk 12 · n 62 · Phase 2 · secondary NCT03682705
  • 17.7% vs 0% 15 mg/60 mg · wk 8 · n 62 · Phase 2 · secondary NCT03682705
  • 9.7% vs 0% 15 mg/60 mg · wk 4 · n 62 · Phase 2 · secondary NCT03682705
  • 8.1% vs 0% 15 mg/60 mg · wk 2 · n 62 · Phase 2 · secondary NCT03682705
  • 16% vs 6.5% 12 mg BID · wk 12 · n 50 · Phase 2 · secondary NCT02066389
  • 21.8% vs 3.6% 12 mg BID · wk 12 · n 55 · Phase 2 · secondary NCT01960855
  • 30.6% vs 6.5% 6 mg BID · wk 12 · n 49 · Phase 2 · secondary NCT02066389
  • 26.9% vs 3.6% 6 mg BID · wk 12 · n 52 · Phase 2 · secondary NCT01960855
  • 9.8% vs 15.8% 5 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 5 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 5 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 5 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705
  • 23.4% vs 6.5% 3 mg BID · wk 12 · n 47 · Phase 2 · secondary NCT02066389
  • 13% vs 3.6% 3 mg BID · wk 12 · n 54 · Phase 2 · secondary NCT01960855

DAS28-CRP remission

tofacitinib
23.0% vs 5.2%+17.8 vs placebo5 mg · wk 26 · n 309NCT00847613
174 other results
  • 20.4% vs 5.2% 5 mg · wk 13 · n 309 · Phase 3 · secondary NCT00847613
  • 11.3% vs 2.0% 5 mg · wk 4.33 · n 309 · Phase 3 · secondary NCT00847613
  • 36.4% vs 5.2% 10 mg · wk 26 · n 308 · Phase 3 · secondary NCT00847613
  • 26.9% vs 5.2% 10 mg · wk 13 · n 308 · Phase 3 · secondary NCT00847613
  • 9.1% vs 2.0% 10 mg · wk 4.33 · n 308 · Phase 3 · secondary NCT00847613
  • 31.3% vs 15.2% 5 mg BID · wk 26 · n 367 · Phase 3 · secondary NCT01039688
  • 25.9% vs 9.8% 5 mg BID · wk 13 · n 367 · Phase 3 · secondary NCT01039688
  • 36.2% vs 17.4% 5 mg BID · wk 39 · n 367 · Phase 3 · secondary NCT01039688
  • 20.4% vs 5.4% 5 mg BID · wk 8.67 · n 367 · Phase 3 · secondary NCT01039688
  • 7.4% vs 2.7% 5 mg BID · wk 4.33 · n 367 · Phase 3 · secondary NCT01039688
  • 36.5% vs 20.6% 5 mg BID · wk 52 · n 367 · Phase 3 · secondary NCT01039688
  • 37.6% vs 19.6% 5 mg BID · wk 65 · n 367 · Phase 3 · secondary NCT01039688
  • 38.4% vs 19.0% 5 mg BID · wk 78 · n 367 · Phase 3 · secondary NCT01039688
  • 37.1% vs 17.4% 5 mg BID · wk 91 · n 367 · Phase 3 · secondary NCT01039688
  • 38.4% vs 18.5% 5 mg BID · wk 104 · n 367 · Phase 3 · secondary NCT01039688
  • 47.2% vs 15.2% 10 mg BID · wk 26 · n 394 · Phase 3 · secondary NCT01039688
  • 37.8% vs 9.8% 10 mg BID · wk 13 · n 394 · Phase 3 · secondary NCT01039688
  • 45.7% vs 17.4% 10 mg BID · wk 39 · n 394 · Phase 3 · secondary NCT01039688
  • 28.7% vs 5.4% 10 mg BID · wk 8.67 · n 394 · Phase 3 · secondary NCT01039688
  • 14.1% vs 2.7% 10 mg BID · wk 4.33 · n 394 · Phase 3 · secondary NCT01039688
  • 49.5% vs 20.6% 10 mg BID · wk 52 · n 394 · Phase 3 · secondary NCT01039688
  • 49.2% vs 19.6% 10 mg BID · wk 65 · n 394 · Phase 3 · secondary NCT01039688
  • 44.7% vs 19.0% 10 mg BID · wk 78 · n 394 · Phase 3 · secondary NCT01039688
  • 44.7% vs 17.4% 10 mg BID · wk 91 · n 394 · Phase 3 · secondary NCT01039688
  • 43.9% vs 18.5% 10 mg BID · wk 104 · n 394 · Phase 3 · secondary NCT01039688
  • 65.9% vs 30% 5 mg · wk 24 · n 40 · Phase 2 · secondary NCT00550446
  • 22% vs 15% 5 mg · wk 24 · n 48 · Phase 2 · secondary NCT00550446
  • 41.5% vs 19.4% 5 mg · wk 24 · n 63 · Phase 2 · secondary NCT00413660
  • 68.9% vs 16.7% 5 mg · wk 20 · n 40 · Phase 2 · secondary NCT00550446
  • 20% vs 5.6% 5 mg · wk 20 · n 48 · Phase 2 · secondary NCT00550446
  • 35.1% vs 13.9% 5 mg · wk 20 · n 63 · Phase 2 · secondary NCT00413660
  • 69.6% vs 35% 5 mg · wk 16 · n 40 · Phase 2 · secondary NCT00550446
  • 28.3% vs 15% 5 mg · wk 16 · n 48 · Phase 2 · secondary NCT00550446
  • 24.1% vs 8.1% 5 mg · wk 16 · n 63 · Phase 2 · secondary NCT00413660
  • 62.2% vs 6.7% 5 mg · wk 12 · n 40 · Phase 2 · secondary NCT00550446
  • 24.4% vs 6.7% 5 mg · wk 12 · n 48 · Phase 2 · secondary NCT00550446
  • 16.7% vs 6.7% 5 mg · wk 12 · n 63 · Phase 2 · secondary NCT00413660
  • 65.8% vs 3.3% 5 mg · wk 10 · n 40 · Phase 2 · secondary NCT00550446
  • 21.7% vs 4.3% 5 mg · wk 10 · n 48 · Phase 2 · secondary NCT00550446
  • 66.7% vs 9.7% 5 mg · wk 8 · n 40 · Phase 2 · secondary NCT00550446
  • 14.9% vs 4.4% 5 mg · wk 8 · n 48 · Phase 2 · secondary NCT00550446
  • 19.4% vs 6.9% 5 mg · wk 8 · n 63 · Phase 2 · secondary NCT00413660
  • 56.4% vs 5.9% 5 mg · wk 6 · n 40 · Phase 2 · secondary NCT00550446
  • 8.9% vs 1.9% 5 mg · wk 6 · n 48 · Phase 2 · secondary NCT00550446
  • 13.6% vs 3.5% 5 mg · wk 6 · n 63 · Phase 2 · secondary NCT00413660
  • 62.2% vs 5.7% 5 mg · wk 4 · n 40 · Phase 2 · secondary NCT00550446
  • 4.4% vs 1.9% 5 mg · wk 4 · n 48 · Phase 2 · secondary NCT00550446
  • 8.1% vs 3.3% 5 mg · wk 4 · n 63 · Phase 2 · secondary NCT00413660
  • 62.5% vs 2.7% 5 mg · wk 2 · n 40 · Phase 2 · secondary NCT00550446
  • 4.2% vs 0% 5 mg · wk 2 · n 48 · Phase 2 · secondary NCT00550446
  • 1.6% vs 3.3% 5 mg · wk 2 · n 63 · Phase 2 · secondary NCT00413660
  • 72.7% vs 30% 10 mg · wk 24 · n 45 · Phase 2 · secondary NCT00550446
  • 36.4% vs 15% 10 mg · wk 24 · n 60 · Phase 2 · secondary NCT00550446
  • 36.5% vs 19.4% 10 mg · wk 24 · n 68 · Phase 2 · secondary NCT00413660
  • 88.7% vs 16.7% 10 mg · wk 20 · n 45 · Phase 2 · secondary NCT00550446
  • 43.4% vs 5.6% 10 mg · wk 20 · n 60 · Phase 2 · secondary NCT00550446
  • 37.1% vs 13.9% 10 mg · wk 20 · n 68 · Phase 2 · secondary NCT00413660
  • 78.2% vs 35% 10 mg · wk 16 · n 45 · Phase 2 · secondary NCT00550446
  • 36.4% vs 15% 10 mg · wk 16 · n 60 · Phase 2 · secondary NCT00550446
  • 30.2% vs 8.1% 10 mg · wk 16 · n 68 · Phase 2 · secondary NCT00413660
  • 75.6% vs 6.7% 10 mg · wk 12 · n 45 · Phase 2 · secondary NCT00550446
  • 33.3% vs 6.7% 10 mg · wk 12 · n 60 · Phase 2 · secondary NCT00550446
  • 32.3% vs 6.7% 10 mg · wk 12 · n 68 · Phase 2 · secondary NCT00413660
  • 90.7% vs 3.3% 10 mg · wk 10 · n 45 · Phase 2 · secondary NCT00550446
  • 31.6% vs 4.3% 10 mg · wk 10 · n 60 · Phase 2 · secondary NCT00550446
  • 78.6% vs 9.7% 10 mg · wk 8 · n 45 · Phase 2 · secondary NCT00550446
  • 21.4% vs 4.4% 10 mg · wk 8 · n 60 · Phase 2 · secondary NCT00550446
  • 21.3% vs 6.9% 10 mg · wk 8 · n 68 · Phase 2 · secondary NCT00413660
  • 79.5% vs 5.9% 10 mg · wk 6 · n 45 · Phase 2 · secondary NCT00550446
  • 24.1% vs 1.9% 10 mg · wk 6 · n 60 · Phase 2 · secondary NCT00550446
  • 24.2% vs 3.5% 10 mg · wk 6 · n 68 · Phase 2 · secondary NCT00413660
  • 83.7% vs 5.7% 10 mg · wk 4 · n 45 · Phase 2 · secondary NCT00550446
  • 17.5% vs 1.9% 10 mg · wk 4 · n 60 · Phase 2 · secondary NCT00550446
  • 19.1% vs 3.3% 10 mg · wk 4 · n 68 · Phase 2 · secondary NCT00413660
  • 71.1% vs 2.7% 10 mg · wk 2 · n 45 · Phase 2 · secondary NCT00550446
  • 5% vs 0% 10 mg · wk 2 · n 60 · Phase 2 · secondary NCT00550446
  • 4.4% vs 3.3% 10 mg · wk 2 · n 68 · Phase 2 · secondary NCT00413660
  • 32.7% vs 19.4% 20 mg · wk 24 · n 74 · Phase 2 · secondary NCT00413660
  • 30.9% vs 13.9% 20 mg · wk 20 · n 74 · Phase 2 · secondary NCT00413660
  • 29.1% vs 8.1% 20 mg · wk 16 · n 74 · Phase 2 · secondary NCT00413660
  • 24.6% vs 6.7% 20 mg · wk 12 · n 74 · Phase 2 · secondary NCT00413660
  • 20.9% vs 6.9% 20 mg · wk 8 · n 74 · Phase 2 · secondary NCT00413660
  • 10.1% vs 3.5% 20 mg · wk 6 · n 74 · Phase 2 · secondary NCT00413660
  • 10% vs 3.3% 20 mg · wk 4 · n 74 · Phase 2 · secondary NCT00413660
  • 4.0% vs 3.3% 20 mg · wk 2 · n 74 · Phase 2 · secondary NCT00413660
  • 84.6% vs 30% 15 mg · wk 24 · n 39 · Phase 2 · secondary NCT00550446
  • 50% vs 15% 15 mg · wk 24 · n 57 · Phase 2 · secondary NCT00550446
  • 39.3% vs 19.4% 15 mg · wk 24 · n 68 · Phase 2 · secondary NCT00413660
  • 76.9% vs 16.7% 15 mg · wk 20 · n 39 · Phase 2 · secondary NCT00550446
  • 42.3% vs 5.6% 15 mg · wk 20 · n 57 · Phase 2 · secondary NCT00550446
  • 38.6% vs 13.9% 15 mg · wk 20 · n 68 · Phase 2 · secondary NCT00413660
  • 82.4% vs 35% 15 mg · wk 16 · n 39 · Phase 2 · secondary NCT00550446
  • 43.1% vs 15% 15 mg · wk 16 · n 57 · Phase 2 · secondary NCT00550446
  • 37.9% vs 8.1% 15 mg · wk 16 · n 68 · Phase 2 · secondary NCT00413660
  • 68.6% vs 6.7% 15 mg · wk 12 · n 39 · Phase 2 · secondary NCT00550446
  • 40.4% vs 6.7% 15 mg · wk 12 · n 57 · Phase 2 · secondary NCT00550446
  • 37.1% vs 6.7% 15 mg · wk 12 · n 68 · Phase 2 · secondary NCT00413660
  • 79.4% vs 3.3% 15 mg · wk 10 · n 39 · Phase 2 · secondary NCT00550446
  • 38.5% vs 4.3% 15 mg · wk 10 · n 57 · Phase 2 · secondary NCT00550446
  • 75% vs 9.7% 15 mg · wk 8 · n 39 · Phase 2 · secondary NCT00550446
  • 41.5% vs 4.4% 15 mg · wk 8 · n 57 · Phase 2 · secondary NCT00550446
  • 23.9% vs 6.9% 15 mg · wk 8 · n 68 · Phase 2 · secondary NCT00413660
  • 67.6% vs 5.9% 15 mg · wk 6 · n 39 · Phase 2 · secondary NCT00550446
  • 32.7% vs 1.9% 15 mg · wk 6 · n 57 · Phase 2 · secondary NCT00550446
  • 22.7% vs 3.5% 15 mg · wk 6 · n 68 · Phase 2 · secondary NCT00413660
  • 62.2% vs 5.7% 15 mg · wk 4 · n 39 · Phase 2 · secondary NCT00550446
  • 15.1% vs 1.9% 15 mg · wk 4 · n 57 · Phase 2 · secondary NCT00550446
  • 16.9% vs 3.3% 15 mg · wk 4 · n 68 · Phase 2 · secondary NCT00413660
  • 66.7% vs 2.7% 15 mg · wk 2 · n 39 · Phase 2 · secondary NCT00550446
  • 7.0% vs 0% 15 mg · wk 2 · n 57 · Phase 2 · secondary NCT00550446
  • 13.2% vs 3.3% 15 mg · wk 2 · n 68 · Phase 2 · secondary NCT00413660
  • 46.4% vs 30% 3 mg · wk 24 · n 33 · Phase 2 · secondary NCT00550446
  • 39.3% vs 15% 3 mg · wk 24 · n 50 · Phase 2 · secondary NCT00550446
  • 35.7% vs 19.4% 3 mg · wk 24 · n 63 · Phase 2 · secondary NCT00413660
  • 58.6% vs 16.7% 3 mg · wk 20 · n 33 · Phase 2 · secondary NCT00550446
  • 20.7% vs 5.6% 3 mg · wk 20 · n 50 · Phase 2 · secondary NCT00550446
  • 43.2% vs 13.9% 3 mg · wk 20 · n 63 · Phase 2 · secondary NCT00413660
  • 53.3% vs 35% 3 mg · wk 16 · n 33 · Phase 2 · secondary NCT00550446
  • 30% vs 15% 3 mg · wk 16 · n 50 · Phase 2 · secondary NCT00550446
  • 41.9% vs 8.1% 3 mg · wk 16 · n 63 · Phase 2 · secondary NCT00413660
  • 42.9% vs 6.7% 3 mg · wk 12 · n 33 · Phase 2 · secondary NCT00550446
  • 8.9% vs 6.7% 3 mg · wk 12 · n 50 · Phase 2 · secondary NCT00550446
  • 30.9% vs 6.7% 3 mg · wk 12 · n 63 · Phase 2 · secondary NCT00413660
  • 53.3% vs 3.3% 3 mg · wk 10 · n 33 · Phase 2 · secondary NCT00550446
  • 8.5% vs 4.3% 3 mg · wk 10 · n 50 · Phase 2 · secondary NCT00550446
  • 46.7% vs 9.7% 3 mg · wk 8 · n 33 · Phase 2 · secondary NCT00550446
  • 12.8% vs 4.4% 3 mg · wk 8 · n 50 · Phase 2 · secondary NCT00550446
  • 22.0% vs 6.9% 3 mg · wk 8 · n 63 · Phase 2 · secondary NCT00413660
  • 43.3% vs 5.9% 3 mg · wk 6 · n 33 · Phase 2 · secondary NCT00550446
  • 12.8% vs 1.9% 3 mg · wk 6 · n 50 · Phase 2 · secondary NCT00550446
  • 19.7% vs 3.5% 3 mg · wk 6 · n 63 · Phase 2 · secondary NCT00413660
  • 33.3% vs 5.7% 3 mg · wk 4 · n 33 · Phase 2 · secondary NCT00550446
  • 6.5% vs 1.9% 3 mg · wk 4 · n 50 · Phase 2 · secondary NCT00550446
  • 14.8% vs 3.3% 3 mg · wk 4 · n 63 · Phase 2 · secondary NCT00413660
  • 33.3% vs 2.7% 3 mg · wk 2 · n 33 · Phase 2 · secondary NCT00550446
  • 4% vs 0% 3 mg · wk 2 · n 50 · Phase 2 · secondary NCT00550446
  • 3.2% vs 3.3% 3 mg · wk 2 · n 63 · Phase 2 · secondary NCT00413660
  • 33.3% vs 30% 1 mg · wk 24 · n 43 · Phase 2 · secondary NCT00550446
  • 16.7% vs 15% 1 mg · wk 24 · n 53 · Phase 2 · secondary NCT00550446
  • 23.1% vs 19.4% 1 mg · wk 24 · n 64 · Phase 2 · secondary NCT00413660
  • 46.2% vs 16.7% 1 mg · wk 20 · n 43 · Phase 2 · secondary NCT00550446
  • 19.2% vs 5.6% 1 mg · wk 20 · n 53 · Phase 2 · secondary NCT00550446
  • 20.5% vs 13.9% 1 mg · wk 20 · n 64 · Phase 2 · secondary NCT00413660
  • 48.1% vs 35% 1 mg · wk 16 · n 43 · Phase 2 · secondary NCT00550446
  • 22.2% vs 15% 1 mg · wk 16 · n 53 · Phase 2 · secondary NCT00550446
  • 14.3% vs 8.1% 1 mg · wk 16 · n 64 · Phase 2 · secondary NCT00413660
  • 22.2% vs 6.7% 1 mg · wk 12 · n 43 · Phase 2 · secondary NCT00550446
  • 9.3% vs 6.7% 1 mg · wk 12 · n 53 · Phase 2 · secondary NCT00550446
  • 6.6% vs 6.7% 1 mg · wk 12 · n 64 · Phase 2 · secondary NCT00413660
  • 26.3% vs 3.3% 1 mg · wk 10 · n 43 · Phase 2 · secondary NCT00550446
  • 10.9% vs 4.3% 1 mg · wk 10 · n 53 · Phase 2 · secondary NCT00550446
  • 25.6% vs 9.7% 1 mg · wk 8 · n 43 · Phase 2 · secondary NCT00550446
  • 2.1% vs 4.4% 1 mg · wk 8 · n 53 · Phase 2 · secondary NCT00550446
  • 7.9% vs 6.9% 1 mg · wk 8 · n 64 · Phase 2 · secondary NCT00413660
  • 20.5% vs 5.9% 1 mg · wk 6 · n 43 · Phase 2 · secondary NCT00550446
  • 8.5% vs 1.9% 1 mg · wk 6 · n 53 · Phase 2 · secondary NCT00550446
  • 3.2% vs 3.5% 1 mg · wk 6 · n 64 · Phase 2 · secondary NCT00413660
  • 30% vs 5.7% 1 mg · wk 4 · n 43 · Phase 2 · secondary NCT00550446
  • 6% vs 1.9% 1 mg · wk 4 · n 53 · Phase 2 · secondary NCT00550446
  • 4.6% vs 3.3% 1 mg · wk 4 · n 64 · Phase 2 · secondary NCT00413660
  • 25.6% vs 2.7% 1 mg · wk 2 · n 43 · Phase 2 · secondary NCT00550446
  • 1.9% vs 0% 1 mg · wk 2 · n 53 · Phase 2 · secondary NCT00550446
  • 1.6% vs 3.3% 1 mg · wk 2 · n 64 · Phase 2 · secondary NCT00413660
  • 16.7% vs 19.4% 20 mg to 5 mg (R) · wk 24 · n 12 · Phase 2 · secondary NCT00413660
  • 0% vs 13.9% 20 mg to 5 mg (R) · wk 20 · n 12 · Phase 2 · secondary NCT00413660
  • 11.1% vs 8.1% 20 mg to 5 mg (R) · wk 16 · n 12 · Phase 2 · secondary NCT00413660
  • 15.4% vs 19.4% 3 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • 15.4% vs 13.9% 3 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • 23.1% vs 8.1% 3 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • 25% vs 19.4% 1 mg to 5 mg (R) · wk 24 · n 21 · Phase 2 · secondary NCT00413660
  • 28.6% vs 13.9% 1 mg to 5 mg (R) · wk 20 · n 21 · Phase 2 · secondary NCT00413660
  • 9.5% vs 8.1% 1 mg to 5 mg (R) · wk 16 · n 21 · Phase 2 · secondary NCT00413660
  • 24% vs 22.4% 11mg MR · wk 24 · n 100 · Phase 2 · secondary NCT04413617
  • 40.8% vs 22.4% 400mg MR + 11mg MR · wk 24 · n 103 · Phase 2 · secondary NCT04413617
upadacitinib
48.3% vs 18.5%vs Methotrexate15 mg · wk 24 · n 317NCT02706873
22 other results
  • 50% vs 18.5% 30 mg · wk 24 · n 314 · Phase 3 · primary NCT02706873
  • 30.8% vs 10% 15 mg · wk 12 · n 221 · Phase 3 · secondary NCT02675426
  • 29.6% vs 5.3% 15 mg · wk 12 · n 169 · Phase 3 · secondary NCT02955212
  • 28.3% vs 10% 30 mg · wk 12 · n 219 · Phase 3 · secondary NCT02675426
  • 57.1% vs 6.1% 15 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 50% vs 6.1% 30 mg · wk 12 · n 50 · Phase 2/3 · secondary NCT02720523
  • 36.7% vs 6.1% 7.5 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 28.1% vs 8.3% 15 mg · wk 14 · n 217 · Phase 3 · secondary NCT02706951
  • 30% vs 13.3% 15 mg QD · wk 12 · n 303 · Phase 3 · secondary NCT03086343
  • 40.5% vs 8.3% 30 mg · wk 14 · n 215 · Phase 3 · secondary NCT02706951
  • 70.4% vs 17.9% 15 mg · wk 24 · n 27 · Phase 3 · secondary NCT02706873
  • 82.1% vs 17.9% 30 mg · wk 24 · n 28 · Phase 3 · secondary NCT02706873
  • 67.3% vs 17.9% 7.5 mg · wk 24 · n 55 · Phase 3 · secondary NCT02706873
  • 19.5% vs 10.5% 60 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 22.4% vs 14.9% 24 mg QD · wk 12 · n 49 · Phase 2 · secondary NCT02066389
  • 7.7% vs 10.5% 20 mg · wk 12 · n 39 · Phase 2 · secondary NCT03682705
  • 42.9% vs 14.9% 18 mg BID · wk 12 · n 49 · Phase 2 · secondary NCT02066389
  • 32.3% vs 10.5% 15 mg/60 mg · wk 12 · n 62 · Phase 2 · secondary NCT03682705
  • 34% vs 14.9% 12 mg BID · wk 12 · n 50 · Phase 2 · secondary NCT02066389
  • 38.8% vs 14.9% 6 mg BID · wk 12 · n 49 · Phase 2 · secondary NCT02066389
  • 9.8% vs 10.5% 5 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 36.7% vs 14.9% 3 mg BID · wk 12 · n 49 · Phase 2 · secondary NCT02066389

HAQ-DI, change

tofacitinib
-0.5 vs -0.2−0.3 vs placebo5 mg · wk 13 · n 240NCT00814307
233 other results
  • -0.5 vs -0.2 5 mg · wk 13 · n 311 · Phase 3 · primary NCT00856544
  • -0.5 vs -0.2 5 mg twice daily · wk 13 · n 201 · Phase 3 · primary NCT00853385
  • -0.3 vs -0.1 5 mg · wk 13 · n 315 · Phase 3 · primary NCT00847613
  • -0.4 vs -0.2 5 mg · wk 13 · n 132 · Phase 3 · primary NCT00960440
  • -0.5 vs -0.2 10 mg · wk 13 · n 241 · Phase 3 · primary NCT00814307
  • -0.5 vs -0.2 10 mg · wk 13 · n 315 · Phase 3 · primary NCT00856544
  • -0.6 vs -0.2 10 mg twice daily · wk 13 · n 199 · Phase 3 · primary NCT00853385
  • -0.4 vs -0.1 10 mg · wk 13 · n 309 · Phase 3 · primary NCT00847613
  • -0.4 vs -0.2 10 mg · wk 13 · n 134 · Phase 3 · primary NCT00960440
  • -0.8 vs -0.6 5 mg BID · wk 26 · n 365 · Phase 3 · secondary NCT01039688
  • -0.8 vs -0.5 5 mg BID · wk 13 · n 365 · Phase 3 · secondary NCT01039688
  • -0.8 vs -0.7 5 mg BID · wk 39 · n 365 · Phase 3 · secondary NCT01039688
  • -0.7 vs -0.3 5 mg BID · wk 8.67 · n 365 · Phase 3 · secondary NCT01039688
  • -0.5 vs -0.2 5 mg BID · wk 4.33 · n 365 · Phase 3 · secondary NCT01039688
  • -0.9 vs -0.7 5 mg BID · wk 52 · n 365 · Phase 3 · secondary NCT01039688
  • -0.9 vs -0.7 5 mg BID · wk 65 · n 365 · Phase 3 · secondary NCT01039688
  • -0.9 vs -0.7 5 mg BID · wk 78 · n 365 · Phase 3 · secondary NCT01039688
  • -0.9 vs -0.7 5 mg BID · wk 91 · n 365 · Phase 3 · secondary NCT01039688
  • -0.9 vs -0.7 5 mg BID · wk 104 · n 365 · Phase 3 · secondary NCT01039688
  • -0.9 vs -0.6 10 mg BID · wk 26 · n 391 · Phase 3 · secondary NCT01039688
  • -0.8 vs -0.5 10 mg BID · wk 13 · n 391 · Phase 3 · secondary NCT01039688
  • -0.9 vs -0.7 10 mg BID · wk 39 · n 391 · Phase 3 · secondary NCT01039688
  • -0.8 vs -0.3 10 mg BID · wk 8.67 · n 391 · Phase 3 · secondary NCT01039688
  • -0.6 vs -0.2 10 mg BID · wk 4.33 · n 391 · Phase 3 · secondary NCT01039688
  • -1.0 vs -0.7 10 mg BID · wk 52 · n 391 · Phase 3 · secondary NCT01039688
  • -1.0 vs -0.7 10 mg BID · wk 65 · n 391 · Phase 3 · secondary NCT01039688
  • -1.0 vs -0.7 10 mg BID · wk 78 · n 391 · Phase 3 · secondary NCT01039688
  • -1 vs -0.7 10 mg BID · wk 91 · n 391 · Phase 3 · secondary NCT01039688
  • -1.0 vs -0.7 10 mg BID · wk 104 · n 391 · Phase 3 · secondary NCT01039688
  • -0.5 vs -0.4 5 mg · wk 24 · n 48 · Phase 2 · secondary NCT00550446
  • -0.6 vs -0.4 5 mg · wk 24 · n 68 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.3 5 mg · wk 20 · n 48 · Phase 2 · secondary NCT00550446
  • -0.6 vs -0.4 5 mg · wk 20 · n 68 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.3 5 mg · wk 16 · n 48 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.3 5 mg · wk 16 · n 68 · Phase 2 · secondary NCT00413660
  • -0.6 vs 0.2 5 mg · wk 12 · n 52 · Phase 2 · secondary NCT00687193
  • -0.4 vs -0.2 5 mg · wk 12 · n 48 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.1 5 mg · wk 12 · n 27 · Phase 2 · secondary NCT00603512
  • -0.5 vs -0.1 5 mg · wk 12 · n 68 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.2 5 mg · wk 10 · n 48 · Phase 2 · secondary NCT00550446
  • -0.5 vs 0.2 5 mg · wk 8 · n 52 · Phase 2 · secondary NCT00687193
  • -0.4 vs -0.2 5 mg · wk 8 · n 48 · Phase 2 · secondary NCT00550446
  • -0.5 vs 0.0 5 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • -0.4 vs -0.1 5 mg · wk 8 · n 68 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.2 5 mg BID · wk 8 · n 59 · Phase 2 · secondary NCT00147498
  • -0.3 vs -0.2 5 mg · wk 6 · n 48 · Phase 2 · secondary NCT00550446
  • -0.4 vs -0.1 5 mg · wk 6 · n 68 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.2 5 mg BID · wk 6 · n 59 · Phase 2 · secondary NCT00147498
  • -0.4 vs 0.0 5 mg · wk 4 · n 52 · Phase 2 · secondary NCT00687193
  • -0.3 vs -0.1 5 mg · wk 4 · n 48 · Phase 2 · secondary NCT00550446
  • -0.4 vs -0.1 5 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • -0.3 vs -0.1 5 mg · wk 4 · n 68 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.1 5 mg BID · wk 4 · n 59 · Phase 2 · secondary NCT00147498
  • -0.3 vs 0.1 5 mg · wk 2 · n 52 · Phase 2 · secondary NCT00687193
  • -0.2 vs -0.0 5 mg · wk 2 · n 48 · Phase 2 · secondary NCT00550446
  • -0.3 vs -0.0 5 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • -0.2 vs -0.1 5 mg · wk 2 · n 68 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.1 5 mg BID · wk 2 · n 59 · Phase 2 · secondary NCT00147498
  • -0.1 vs 0 5 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • -0.3 vs -0.1 5 mg BID · wk 1 · n 59 · Phase 2 · secondary NCT00147498
  • -0.6 vs -0.4 10 mg · wk 24 · n 59 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.4 10 mg · wk 24 · n 73 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.3 10 mg · wk 20 · n 59 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.4 10 mg · wk 20 · n 73 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.3 10 mg · wk 16 · n 59 · Phase 2 · secondary NCT00550446
  • -0.4 vs -0.3 10 mg · wk 16 · n 73 · Phase 2 · secondary NCT00413660
  • -0.7 vs 0.2 10 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • -0.6 vs -0.2 10 mg · wk 12 · n 59 · Phase 2 · secondary NCT00550446
  • -0.6 vs -0.2 10 mg · wk 10 · n 59 · Phase 2 · secondary NCT00550446
  • -0.6 vs 0.2 10 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • -0.5 vs -0.2 10 mg · wk 8 · n 59 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.2 10 mg · wk 6 · n 59 · Phase 2 · secondary NCT00550446
  • -0.3 vs -0.1 10 mg · wk 6 · n 73 · Phase 2 · secondary NCT00413660
  • -0.5 vs 0.0 10 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • -0.4 vs -0.1 10 mg · wk 4 · n 59 · Phase 2 · secondary NCT00550446
  • -0.4 vs 0.1 10 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • -0.3 vs -0.0 10 mg · wk 2 · n 59 · Phase 2 · secondary NCT00550446
  • -0.3 vs -0.1 20 mg · wk 4 · n 79 · Phase 2 · secondary NCT00413660
  • -0.2 vs -0.1 20 mg · wk 2 · n 79 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.1 10 mg · wk 12 · n 26 · Phase 2 · secondary NCT00603512
  • -0.4 vs -0.1 10 mg · wk 12 · n 73 · Phase 2 · secondary NCT00413660
  • -0.5 vs 0.0 10 mg · wk 8 · n 26 · Phase 2 · secondary NCT00603512
  • -0.4 vs -0.1 10 mg · wk 8 · n 73 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.1 10 mg · wk 4 · n 26 · Phase 2 · secondary NCT00603512
  • -0.3 vs -0.1 10 mg · wk 4 · n 73 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.0 10 mg · wk 2 · n 26 · Phase 2 · secondary NCT00603512
  • -0.2 vs -0.1 10 mg · wk 2 · n 73 · Phase 2 · secondary NCT00413660
  • -0.7 vs -0.2 30 mg BID · wk 8 · n 64 · Phase 2 · secondary NCT00147498
  • -0.7 vs -0.2 30 mg BID · wk 6 · n 64 · Phase 2 · secondary NCT00147498
  • -0.7 vs -0.1 30 mg BID · wk 4 · n 64 · Phase 2 · secondary NCT00147498
  • -0.6 vs -0.1 30 mg BID · wk 2 · n 64 · Phase 2 · secondary NCT00147498
  • -0.4 vs -0.1 30 mg BID · wk 1 · n 64 · Phase 2 · secondary NCT00147498
  • -0.7 vs -0.4 20 mg · wk 24 · n 79 · Phase 2 · secondary NCT00413660
  • -0.7 vs -0.4 20 mg · wk 20 · n 79 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.3 20 mg · wk 16 · n 79 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.1 20 mg · wk 12 · n 79 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.1 20 mg · wk 8 · n 79 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.1 20 mg · wk 6 · n 79 · Phase 2 · secondary NCT00413660
  • -0.3 vs 0 10 mg · wk 1 · n 26 · Phase 2 · secondary NCT00603512
  • -0.8 vs -0.4 15 mg · wk 24 · n 57 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.4 15 mg · wk 24 · n 73 · Phase 2 · secondary NCT00413660
  • -0.9 vs -0.3 15 mg · wk 20 · n 57 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.4 15 mg · wk 20 · n 73 · Phase 2 · secondary NCT00413660
  • -0.9 vs -0.3 15 mg · wk 16 · n 57 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.3 15 mg · wk 16 · n 73 · Phase 2 · secondary NCT00413660
  • -0.7 vs 0.2 15 mg · wk 12 · n 54 · Phase 2 · secondary NCT00687193
  • -0.8 vs -0.2 15 mg · wk 12 · n 57 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.1 15 mg · wk 12 · n 73 · Phase 2 · secondary NCT00413660
  • -0.8 vs -0.2 15 mg · wk 10 · n 57 · Phase 2 · secondary NCT00550446
  • -0.6 vs 0.2 15 mg · wk 8 · n 54 · Phase 2 · secondary NCT00687193
  • -0.7 vs -0.2 15 mg · wk 8 · n 57 · Phase 2 · secondary NCT00550446
  • -0.4 vs -0.1 15 mg · wk 8 · n 73 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.2 15 mg BID · wk 8 · n 68 · Phase 2 · secondary NCT00147498
  • -0.7 vs -0.2 15 mg · wk 6 · n 57 · Phase 2 · secondary NCT00550446
  • -0.3 vs -0.1 15 mg · wk 6 · n 73 · Phase 2 · secondary NCT00413660
  • -0.7 vs -0.2 15 mg BID · wk 6 · n 68 · Phase 2 · secondary NCT00147498
  • -0.5 vs 0.0 15 mg · wk 4 · n 54 · Phase 2 · secondary NCT00687193
  • -0.6 vs -0.1 15 mg · wk 4 · n 57 · Phase 2 · secondary NCT00550446
  • -0.3 vs -0.1 15 mg · wk 4 · n 73 · Phase 2 · secondary NCT00413660
  • -0.6 vs -0.1 15 mg BID · wk 4 · n 68 · Phase 2 · secondary NCT00147498
  • -0.4 vs 0.1 15 mg · wk 2 · n 54 · Phase 2 · secondary NCT00687193
  • -0.4 vs -0.0 15 mg · wk 2 · n 57 · Phase 2 · secondary NCT00550446
  • -0.2 vs -0.1 15 mg · wk 2 · n 73 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.1 15 mg BID · wk 2 · n 68 · Phase 2 · secondary NCT00147498
  • -0.3 vs -0.1 15 mg BID · wk 1 · n 68 · Phase 2 · secondary NCT00147498
  • -0.5 vs -0.4 3 mg · wk 24 · n 51 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.4 3 mg · wk 24 · n 66 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.3 3 mg · wk 20 · n 51 · Phase 2 · secondary NCT00550446
  • -0.6 vs -0.4 3 mg · wk 20 · n 66 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.3 3 mg · wk 16 · n 51 · Phase 2 · secondary NCT00550446
  • -0.6 vs -0.3 3 mg · wk 16 · n 66 · Phase 2 · secondary NCT00413660
  • -0.4 vs 0.2 3 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • -0.4 vs -0.2 3 mg · wk 12 · n 51 · Phase 2 · secondary NCT00550446
  • -0.4 vs -0.1 3 mg · wk 12 · n 27 · Phase 2 · secondary NCT00603512
  • -0.5 vs -0.1 3 mg · wk 12 · n 66 · Phase 2 · secondary NCT00413660
  • -0.3 vs -0.2 3 mg · wk 10 · n 51 · Phase 2 · secondary NCT00550446
  • -0.4 vs 0.2 3 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • -0.4 vs -0.2 3 mg · wk 8 · n 51 · Phase 2 · secondary NCT00550446
  • -0.3 vs 0.0 3 mg · wk 8 · n 27 · Phase 2 · secondary NCT00603512
  • -0.4 vs -0.1 3 mg · wk 8 · n 66 · Phase 2 · secondary NCT00413660
  • -0.3 vs -0.2 3 mg · wk 6 · n 51 · Phase 2 · secondary NCT00550446
  • -0.4 vs -0.1 3 mg · wk 6 · n 66 · Phase 2 · secondary NCT00413660
  • -0.3 vs 0.0 3 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • -0.3 vs -0.1 3 mg · wk 4 · n 51 · Phase 2 · secondary NCT00550446
  • -0.3 vs -0.1 3 mg · wk 4 · n 27 · Phase 2 · secondary NCT00603512
  • -0.4 vs -0.1 3 mg · wk 4 · n 66 · Phase 2 · secondary NCT00413660
  • -0.1 vs 0.1 3 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • -0.3 vs -0.0 3 mg · wk 2 · n 51 · Phase 2 · secondary NCT00550446
  • -0.2 vs -0.0 3 mg · wk 2 · n 27 · Phase 2 · secondary NCT00603512
  • -0.2 vs -0.1 3 mg · wk 2 · n 66 · Phase 2 · secondary NCT00413660
  • -0.1 vs 0 3 mg · wk 1 · n 27 · Phase 2 · secondary NCT00603512
  • -0.6 vs -0.4 1 mg · wk 24 · n 54 · Phase 2 · secondary NCT00550446
  • -0.6 vs -0.4 1 mg · wk 24 · n 68 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.3 1 mg · wk 20 · n 54 · Phase 2 · secondary NCT00550446
  • -0.6 vs -0.4 1 mg · wk 20 · n 68 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.3 1 mg · wk 16 · n 54 · Phase 2 · secondary NCT00550446
  • -0.5 vs -0.3 1 mg · wk 16 · n 68 · Phase 2 · secondary NCT00413660
  • -0.2 vs 0.2 1 mg · wk 12 · n 53 · Phase 2 · secondary NCT00687193
  • -0.3 vs -0.2 1 mg · wk 12 · n 54 · Phase 2 · secondary NCT00550446
  • -0.4 vs -0.1 1 mg · wk 12 · n 28 · Phase 2 · secondary NCT00603512
  • -0.4 vs -0.1 1 mg · wk 12 · n 68 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.2 1 mg · wk 10 · n 54 · Phase 2 · secondary NCT00550446
  • -0.2 vs 0.2 1 mg · wk 8 · n 53 · Phase 2 · secondary NCT00687193
  • -0.3 vs -0.2 1 mg · wk 8 · n 54 · Phase 2 · secondary NCT00550446
  • -0.4 vs 0.0 1 mg · wk 8 · n 28 · Phase 2 · secondary NCT00603512
  • -0.3 vs -0.1 1 mg · wk 8 · n 68 · Phase 2 · secondary NCT00413660
  • -0.3 vs -0.2 1 mg · wk 6 · n 54 · Phase 2 · secondary NCT00550446
  • -0.3 vs -0.1 1 mg · wk 6 · n 68 · Phase 2 · secondary NCT00413660
  • -0.1 vs 0.0 1 mg · wk 4 · n 53 · Phase 2 · secondary NCT00687193
  • -0.1 vs -0.1 1 mg · wk 4 · n 54 · Phase 2 · secondary NCT00550446
  • -0.2 vs -0.1 1 mg · wk 4 · n 28 · Phase 2 · secondary NCT00603512
  • -0.2 vs -0.1 1 mg · wk 4 · n 68 · Phase 2 · secondary NCT00413660
  • -0.1 vs 0.1 1 mg · wk 2 · n 53 · Phase 2 · secondary NCT00687193
  • -0.1 vs -0.0 1 mg · wk 2 · n 54 · Phase 2 · secondary NCT00550446
  • -0.1 vs -0.0 1 mg · wk 2 · n 28 · Phase 2 · secondary NCT00603512
  • -0.1 vs -0.1 1 mg · wk 2 · n 68 · Phase 2 · secondary NCT00413660
  • -0.3 vs -0.2 wk 10 · n 90 · Phase 1 · secondary NCT01484561
  • 0.1 vs -0.1 wk 10 · n 90 · Phase 1 · secondary NCT01484561
  • -0.4 vs -0.0 wk 6 · n 93 · Phase 1 · secondary NCT01484561
  • -0.5 vs -0.4 20 mg to 5 mg (R) · wk 24 · n 12 · Phase 2 · secondary NCT00413660
  • -0.4 vs -0.4 20 mg to 5 mg (R) · wk 20 · n 12 · Phase 2 · secondary NCT00413660
  • -0.5 vs -0.3 20 mg to 5 mg (R) · wk 16 · n 12 · Phase 2 · secondary NCT00413660
  • -0.2 vs -0.4 3 mg to 5 mg (R) · wk 24 · n 13 · Phase 2 · secondary NCT00413660
  • -0.1 vs -0.4 3 mg to 5 mg (R) · wk 20 · n 13 · Phase 2 · secondary NCT00413660
  • -0.1 vs -0.3 3 mg to 5 mg (R) · wk 16 · n 13 · Phase 2 · secondary NCT00413660
  • -0.2 vs -0.4 1 mg to 5 mg (R) · wk 24 · n 21 · Phase 2 · secondary NCT00413660
  • -0.2 vs -0.4 1 mg to 5 mg (R) · wk 20 · n 21 · Phase 2 · secondary NCT00413660
  • -0.2 vs -0.3 1 mg to 5 mg (R) · wk 16 · n 21 · Phase 2 · secondary NCT00413660
  • -0.1 vs 0 1 mg · wk 1 · n 28 · Phase 2 · secondary NCT00603512
  • -0.5 vs -0.5 5 mg BID · wk 26 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.4 5 mg BID · wk 13 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 39 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.4 vs -0.4 5 mg BID · wk 8.67 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 52 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 65 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 78 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 91 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 104 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 117 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 130 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 143 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 156 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 169 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 182 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 195 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 208 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 221 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 234 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 247 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 260 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 5 mg BID · wk 273 · n 1409 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 26 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.4 10 mg BID · wk 13 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 39 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.4 10 mg BID · wk 8.67 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 52 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 65 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 78 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 91 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 104 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 117 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 130 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.6 vs -0.5 10 mg BID · wk 143 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 156 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 169 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 182 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 195 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 208 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 221 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 234 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 247 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 260 · n 1390 · Phase 4 · secondary NCT02092467
  • -0.5 vs -0.5 10 mg BID · wk 273 · n 1390 · Phase 4 · secondary NCT02092467
upadacitinib
-0.6 vs -0.3−0.3 vs placebo15 mg · wk 12 · n 216NCT02675426
32 other results
  • -0.4 vs -0.2 15 mg · wk 12 · n 163 · Phase 3 · secondary NCT02706847
  • -0.6 vs -0.2 15 mg · wk 12 · n 169 · Phase 3 · secondary NCT02955212
  • -0.5 vs -0.3 30 mg · wk 12 · n 219 · Phase 3 · secondary NCT02675426
  • -0.4 vs -0.2 30 mg · wk 12 · n 160 · Phase 3 · secondary NCT02706847
  • -0.5 vs -0.1 15 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • -0.5 vs -0.1 30 mg · wk 12 · n 50 · Phase 2/3 · secondary NCT02720523
  • -0.4 vs -0.1 7.5 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • -0.9 vs -0.6 15 mg · wk 24 · n 317 · Phase 3 · secondary NCT02706873
  • -0.7 vs -0.3 15 mg · wk 14 · n 216 · Phase 3 · secondary NCT02706951
  • -0.8 vs -0.5 15 mg · wk 12 · n 317 · Phase 3 · secondary NCT02706873
  • -0.9 vs -0.6 30 mg · wk 24 · n 310 · Phase 3 · secondary NCT02706873
  • -0.7 vs -0.3 30 mg · wk 14 · n 215 · Phase 3 · secondary NCT02706951
  • -0.9 vs -0.5 30 mg · wk 12 · n 310 · Phase 3 · secondary NCT02706873
  • -0.9 vs -0.2 15 mg · wk 12 · n 27 · Phase 3 · secondary NCT02706873
  • -0.9 vs -0.2 30 mg · wk 12 · n 28 · Phase 3 · secondary NCT02706873
  • -0.8 vs -0.2 7.5 mg · wk 12 · n 55 · Phase 3 · secondary NCT02706873
  • -0.3 vs -0.3 60 mg · wk 12 · n 39 · Phase 2 · secondary NCT03682705
  • -0.3 vs -0.2 60 mg · wk 8 · n 39 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.4 60 mg · wk 4 · n 39 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.2 60 mg · wk 2 · n 39 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.3 20 mg · wk 12 · n 35 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.2 20 mg · wk 8 · n 35 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.4 20 mg · wk 4 · n 35 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.2 20 mg · wk 2 · n 35 · Phase 2 · secondary NCT03682705
  • -0.5 vs -0.3 15 mg/60 mg · wk 12 · n 59 · Phase 2 · secondary NCT03682705
  • -0.5 vs -0.2 15 mg/60 mg · wk 8 · n 59 · Phase 2 · secondary NCT03682705
  • -0.4 vs -0.4 15 mg/60 mg · wk 4 · n 59 · Phase 2 · secondary NCT03682705
  • -0.3 vs -0.2 15 mg/60 mg · wk 2 · n 59 · Phase 2 · secondary NCT03682705
  • -0.2 vs -0.3 5 mg · wk 12 · n 40 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.2 5 mg · wk 8 · n 40 · Phase 2 · secondary NCT03682705
  • -0.2 vs -0.4 5 mg · wk 4 · n 40 · Phase 2 · secondary NCT03682705
  • -0.2 vs -0.2 5 mg · wk 2 · n 40 · Phase 2 · secondary NCT03682705

Modified Sharp score, change

tofacitinib
0.1 vs 0.5−0.3 vs placebo5 mg · wk 26 · n 286NCT00847613
7 other results
  • 0.1 vs 0.5 10 mg · wk 26 · n 295 · Phase 3 · primary NCT00847613
  • 0.2 vs 0.7 5 mg BID · wk 24 · n 346 · Phase 3 · primary NCT01039688
  • 0.1 vs 0.7 10 mg BID · wk 24 · n 370 · Phase 3 · primary NCT01039688
  • 0.4 vs 1.2 5 mg BID · wk 52 · n 346 · Phase 3 · secondary NCT01039688
  • 0.6 vs 2.1 5 mg BID · wk 104 · n 346 · Phase 3 · secondary NCT01039688
  • 0.2 vs 1.2 10 mg BID · wk 52 · n 371 · Phase 3 · secondary NCT01039688
  • 0.3 vs 2.1 10 mg BID · wk 104 · n 371 · Phase 3 · secondary NCT01039688
upadacitinib
0.1 vs 0.7vs Methotrexate15 mg · wk 24 · n 279NCT02706873
4 other results
  • 0.1 vs 0.7 30 mg · wk 24 · n 270 · Phase 3 · primary NCT02706873
  • 0.2 vs 2.6 15 mg · wk 24 · n 26 · Phase 3 · secondary NCT02706873
  • 0.2 vs 2.6 30 mg · wk 24 · n 24 · Phase 3 · secondary NCT02706873
  • 0.9 vs 2.6 7.5 mg · wk 24 · n 51 · Phase 3 · secondary NCT02706873
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
17 other shared endpoints and safety

Coverage. tofacitinib: 21 of 21 rows · upadacitinib: 21 of 21 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metrictofacitinib
Rows use multiple source trials
upadacitinib
Rows use multiple source trials
Boolean Remission
responder rate · % of participants
8.33% (n=1455) vs 13.33% (n=1451) TNFi @ 312wk5 mg BIDa,b,c,d
NCT02092467 · Phase 4
show 1 more dose
22.22% (n=1456) vs 13.33% (n=1451) TNFi @ 312wk10 mg BID
NCT02092467 · Phase 4
9.8% (n=41) vs 0% (n=19) placebo @ 12wk60 mga,b,c,d
NCT03682705 · Phase 2 · registry result, not featured evidence
show 3 more doses
2.6% (n=39) vs 0% (n=19) placebo @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
11.3% (n=62) vs 0% (n=19) placebo @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
2.4% (n=41) vs 0% (n=19) placebo @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
CDAI
absolute change · score
-31.23 vs -31.65 TNFi score @ 273wk5 mg BIDa,b,c,e
NCT02092467 · Phase 4
show 1 more dose
-31.08 vs -31.65 TNFi score @ 273wk10 mg BID
NCT02092467 · Phase 4
-17.5 vs -14.57 placebo score @ 12wk60 mga,b,c,e
NCT03682705 · Phase 2 · registry result, not featured evidence
show 3 more doses
-16.7 vs -14.57 placebo score @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-27 vs -14.57 placebo score @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-16.51 vs -14.57 placebo score @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
CDAI Clinical Remission
responder rate · % of participants
16.67% (n=1455) vs 13.33% (n=1451) TNFi @ 312wk5 mg BIDa,b,c,d
NCT02092467 · Phase 4
show 1 more dose
22.22% (n=1456) vs 13.33% (n=1451) TNFi @ 312wk10 mg BID
NCT02092467 · Phase 4
7.3% (n=41) vs 5.3% (n=19) placebo @ 12wk60 mga,b,c,d
NCT03682705 · Phase 2 · registry result, not featured evidence
show 3 more doses
5.1% (n=39) vs 5.3% (n=19) placebo @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
14.5% (n=62) vs 5.3% (n=19) placebo @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
0% (n=41) vs 5.3% (n=19) placebo @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
CDAI Low Disease Activity
responder rate · % of participants
50% (n=1455) vs 53.33% (n=1451) TNFi @ 312wk5 mg BIDa,f,c,g,d
NCT02092467 · Phase 4
show 1 more dose
66.67% (n=1456) vs 53.33% (n=1451) TNFi @ 312wk10 mg BID
NCT02092467 · Phase 4
40.3% (n=221) vs 19% (n=221) placebo @ 12wk15 mga,f,c,g,d
NCT02675426 · Phase 3
show 1 more dose
42% (n=219) vs 19% (n=221) placebo @ 12wk30 mg
NCT02675426 · Phase 3
CRP Change
absolute change · mg
-23.97 vs 8.22 placebo mg @ 12wk5 mga,c
NCT00687193 · Phase 2 · registry result, not featured evidence
show 4 more doses
-25.11 vs 8.22 placebo mg @ 12wk10 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
-26.14 vs 8.22 placebo mg @ 12wk15 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
-18.34 vs 8.22 placebo mg @ 12wk3 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
-8.88 vs 8.22 placebo mg @ 12wk1 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
-4.58 vs 1.45 placebo mg @ 12wk60 mga,c
NCT03682705 · Phase 2 · registry result, not featured evidence
show 3 more doses
-5.78 vs 1.45 placebo mg @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-10.95 vs 1.45 placebo mg @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-0.81 vs 1.45 placebo mg @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
DAS Low Disease Activity
responder rate · % of participants
52.32% (n=367) vs 29.35% (n=184) MTX @ 104wk5 mg BIDa,c,g,h
NCT01039688 · Phase 3
show 3 more doses
34.8% (n=342) vs 15.79% (n=171) MTX @ 104wk5 mg BID
NCT01039688 · Phase 3
56.85% (n=394) vs 29.35% (n=184) MTX @ 104wk10 mg BID
NCT01039688 · Phase 3
36.02% (n=372) vs 15.79% (n=171) MTX @ 104wk10 mg BID
NCT01039688 · Phase 3
59.9% (n=317) vs 32.2% (n=314) Methotrexate @ 24wk15 mga,c,g,h
NCT02706873 · Phase 3
show 1 more dose
65% (n=314) vs 32.2% (n=314) Methotrexate @ 24wk30 mg
NCT02706873 · Phase 3
DAS28-CRP
absolute change · score
-2.66 vs -2.53 PF-06651600 score @ 24wk11mg MRa,i,c
NCT04413617 · Phase 2 · registry result, not featured evidence
show 1 more dose
-3.05 vs -2.53 PF-06651600 score @ 24wk400mg MR + 11mg MR
NCT04413617 · Phase 2 · registry result, not featured evidence · combination
-3.07 vs -2.15 Methotrexate score @ 24wk15 mga,i,c
NCT02706873 · Phase 3
show 1 more dose
-3.34 vs -2.15 Methotrexate score @ 24wk30 mg
NCT02706873 · Phase 3
DAS28-CRP LDAS
responder rate · % of participants
50% (n=1455) vs 73.33% (n=1451) TNFi @ 312wk5 mg BIDa,b,c,d
NCT02092467 · Phase 4
show 1 more dose
61.11% (n=1456) vs 73.33% (n=1451) TNFi @ 312wk10 mg BID
NCT02092467 · Phase 4
22% (n=41) vs 21.1% (n=19) placebo @ 12wk60 mga,b,c,d
NCT03682705 · Phase 2 · registry result, not featured evidence
show 3 more doses
10.3% (n=39) vs 21.1% (n=19) placebo @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
41.9% (n=62) vs 21.1% (n=19) placebo @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
14.6% (n=41) vs 21.1% (n=19) placebo @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
DAS28-ESR
absolute change · score
-2.2 vs -0.1 placebo score @ 12wk5 mga,c
NCT00687193 · Phase 2 · registry result, not featured evidence
show 4 more doses
-3.05 vs -0.1 placebo score @ 12wk10 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
-2.98 vs -0.1 placebo score @ 12wk15 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
-1.74 vs -0.1 placebo score @ 12wk3 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
-1.1 vs -0.1 placebo score @ 12wk1 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
-1.41 vs -1.18 placebo score @ 12wk60 mga,c
NCT03682705 · Phase 2 · registry result, not featured evidence
show 3 more doses
-1.24 vs -1.18 placebo score @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-2.53 vs -1.18 placebo score @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-1.44 vs -1.18 placebo score @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
FACIT-Fatigue
absolute change · score
7.47 vs 3.33 placebo score @ 12wk5 mga,i,c,g
NCT00550446 · Phase 2 · registry result, not featured evidence
show 4 more doses
9.4 vs 3.33 placebo score @ 12wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
8.85 vs 3.33 placebo score @ 12wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
6 vs 3.33 placebo score @ 12wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
5.14 vs 3.33 placebo score @ 12wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
7.91 vs 2.96 placebo score @ 12wk15 mga,i,c,g
NCT02675426 · Phase 3
show 1 more dose
7.74 vs 2.96 placebo score @ 12wk30 mg
NCT02675426 · Phase 3
HAQ-DI
responder rate · % of participants
60.11% (n=366) vs 46.74% (n=184) MTX @ 104wk5 mg BIDa,j,c,k
NCT01039688 · Phase 3
show 5 more doses
56.83% (n=366) vs 43.48% (n=184) MTX @ 104wk5 mg BID
NCT01039688 · Phase 3
53.28% (n=366) vs 37.5% (n=184) MTX @ 104wk5 mg BID
NCT01039688 · Phase 3
65.05% (n=392) vs 46.74% (n=184) MTX @ 104wk10 mg BID
NCT01039688 · Phase 3
62.76% (n=392) vs 43.48% (n=184) MTX @ 104wk10 mg BID
NCT01039688 · Phase 3
59.44% (n=392) vs 37.5% (n=184) MTX @ 104wk10 mg BID
NCT01039688 · Phase 3
53.7% (n=41) vs 47.4% (n=19) placebo @ 12wk60 mga,j,c,k
NCT03682705 · Phase 2 · registry result, not featured evidence
show 3 more doses
43.6% (n=39) vs 47.4% (n=19) placebo @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
58.1% (n=62) vs 47.4% (n=19) placebo @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
43.9% (n=41) vs 47.4% (n=19) placebo @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
mTSS no Progression
responder rate · % of participants
79.89% (n=348) vs 64.91% (n=171) MTX @ 104wk5 mg BIDa,c,g,h
NCT01039688 · Phase 3
show 1 more dose
83.65% (n=373) vs 64.91% (n=171) MTX @ 104wk10 mg BID
NCT01039688 · Phase 3
87.5% (n=279) vs 77.7% (n=264) Methotrexate @ 24wk15 mga,c,g,h
NCT02706873 · Phase 3
show 4 more doses
80.8% (n=26) vs 46.2% (n=26) Methotrexate @ 24wk15 mg
NCT02706873 · Phase 3
89.3% (n=270) vs 77.7% (n=264) Methotrexate @ 24wk30 mg
NCT02706873 · Phase 3
79.2% (n=24) vs 46.2% (n=26) Methotrexate @ 24wk30 mg
NCT02706873 · Phase 3
82.4% (n=51) vs 46.2% (n=26) Methotrexate @ 24wk7.5 mg
NCT02706873 · Phase 3
Patient Assessment of Arthritis Pain
absolute change · score
-34.37 vs -1.06 placebo score @ 12wk5 mga,c
NCT00687193 · Phase 2 · registry result, not featured evidence
show 4 more doses
-42.91 vs -1.06 placebo score @ 12wk10 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
-43.79 vs -1.06 placebo score @ 12wk15 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
-22.33 vs -1.06 placebo score @ 12wk3 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
-18.38 vs -1.06 placebo score @ 12wk1 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
-19.52 vs -23.37 placebo score @ 12wk60 mga,c
NCT03682705 · Phase 2 · registry result, not featured evidence
show 3 more doses
-10.46 vs -23.37 placebo score @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-32.27 vs -23.37 placebo score @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-17.84 vs -23.37 placebo score @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
Patient Global Assessment
absolute change · score
-34.59 vs -1.02 placebo score @ 12wk5 mga,c
NCT00687193 · Phase 2 · registry result, not featured evidence
show 4 more doses
-43.55 vs -1.02 placebo score @ 12wk10 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
-41.86 vs -1.02 placebo score @ 12wk15 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
-20.91 vs -1.02 placebo score @ 12wk3 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
-16.29 vs -1.02 placebo score @ 12wk1 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
-19.47 vs -19.55 placebo score @ 12wk60 mga,c
NCT03682705 · Phase 2 · registry result, not featured evidence
show 3 more doses
-8.45 vs -19.55 placebo score @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-30.52 vs -19.55 placebo score @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-16.4 vs -19.55 placebo score @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
Physician Global Assessment
absolute change · score
-40.86 vs -38.62 PF-06651600 score @ 12wk11mg MRa,c
NCT04413617 · Phase 2 · registry result, not featured evidence
show 1 more dose
-43.5 vs -38.62 PF-06651600 score @ 12wk400mg MR + 11mg MR
NCT04413617 · Phase 2 · registry result, not featured evidence · combination
-30.15 vs -23.19 placebo score @ 12wk60 mga,c
NCT03682705 · Phase 2 · registry result, not featured evidence
show 3 more doses
-31.68 vs -23.19 placebo score @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-46.98 vs -23.19 placebo score @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-24.55 vs -23.19 placebo score @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
SDAI
absolute change · score
-32.27 vs -32.27 TNFi score @ 273wk5 mg BIDa,b,c,e
NCT02092467 · Phase 4
show 1 more dose
-32.12 vs -32.27 TNFi score @ 273wk10 mg BID
NCT02092467 · Phase 4
-18.01 vs -14.44 placebo score @ 12wk60 mga,b,c,e
NCT03682705 · Phase 2 · registry result, not featured evidence
show 3 more doses
-17.12 vs -14.44 placebo score @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-28.06 vs -14.44 placebo score @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-16.73 vs -14.44 placebo score @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
SF-36 PCS
absolute change · score
6.22 vs -1.04 placebo score @ 12wk5 mga,i,c,g
NCT00687193 · Phase 2 · registry result, not featured evidence
show 4 more doses
10.25 vs -1.04 placebo score @ 12wk10 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
10.27 vs -1.04 placebo score @ 12wk15 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
6.03 vs -1.04 placebo score @ 12wk3 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
3.27 vs -1.04 placebo score @ 12wk1 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
7.58 vs 3.03 placebo score @ 12wk15 mga,i,c,g
NCT02675426 · Phase 3
show 1 more dose
8.01 vs 3.03 placebo score @ 12wk30 mg
NCT02675426 · Phase 3
Dropout rate
0%l
NCT01262118 · Phase 1
show 80 more results
4.9%5 mg
NCT00814307 · Phase 3
11%10 mg
NCT00814307 · Phase 3
17.9%5 mg
NCT00856544 · Phase 3
—5 mg
NCT00856544 · Phase 3
—5 mg
NCT00856544 · Phase 3
—5 mg
NCT00856544 · Phase 3
20.8%10 mg
NCT00856544 · Phase 3
—10 mg
NCT00856544 · Phase 3
—10 mg
NCT00856544 · Phase 3
—10 mg
NCT00856544 · Phase 3
26.5%5 mg twice daily
NCT00853385 · Phase 3
—5 mg twice daily
NCT00853385 · Phase 3
—5 mg twice daily
NCT00853385 · Phase 3
—5 mg twice daily
NCT00853385 · Phase 3
21.4%10 mg twice daily
NCT00853385 · Phase 3
—10 mg twice daily
NCT00853385 · Phase 3
—10 mg twice daily
NCT00853385 · Phase 3
—10 mg twice daily
NCT00853385 · Phase 3
n/a: no completion milestone5 mg
NCT00847613 · Phase 3
—5 mg
NCT00847613 · Phase 3
—5 mg
NCT00847613 · Phase 3
—5 mg
NCT00847613 · Phase 3
n/a: no completion milestone10 mg
NCT00847613 · Phase 3
—10 mg
NCT00847613 · Phase 3
—10 mg
NCT00847613 · Phase 3
—10 mg
NCT00847613 · Phase 3
19.5%5 mg
NCT00960440 · Phase 3
—5 mg
NCT00960440 · Phase 3
—5 mg
NCT00960440 · Phase 3
23.1%10 mg
NCT00960440 · Phase 3
—10 mg
NCT00960440 · Phase 3
—10 mg
NCT00960440 · Phase 3
—5 mg BID
NCT01039688 · Phase 3
28%10 mg BID
NCT01039688 · Phase 3
27.7%5 mg BID
NCT02092467 · Phase 4
31.5%10 mg BID
NCT02092467 · Phase 4
—11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
—11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
10.2%11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
—5 mg
NCT00413699 · Phase 3 · registry result, not featured evidence
56.9%5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
50.8%10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
3.8%
NCT02281552 · Phase 3 · registry result, not featured evidence
36.6%5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
37.1%10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
6.9%11mg MR
NCT04413617 · Phase 2 · registry result, not featured evidence
7.8%400mg MR + 11mg MR
NCT04413617 · Phase 2 · registry result, not featured evidence · combination
9.1%5 mg Twice a Day
NCT02147587 · Phase 2 · registry result, not featured evidence
6.3%
NCT01359150 · Phase 2 · registry result, not featured evidence · combination
0%
NCT00976599 · Phase 2 · registry result, not featured evidence
—
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
3.8%5 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
7.5%10 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
3.7%15 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
7.5%3 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
3.8%1 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
8%5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.9%10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
5.3%15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
9.6%3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
18.5%1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
17.9%5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
25%10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
17.9%3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
7.1%1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
9.9%5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
10.7%10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
12.5%20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
—20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
12%15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
10.3%3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
—3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
9.9%1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
—1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
4.9%5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
24.6%30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
13%15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
9.3%
NCT01484561 · Phase 1 · registry result, not featured evidence
—CP-690,500
NCT01745055 · Phase 1 · registry result, not featured evidence
—Methotrexate + CP-690,500
NCT01745055 · Phase 1 · registry result, not featured evidence · combination
—15 mgl
NCT02675426 · Phase 3
show 55 more results
—15 mg
NCT02675426 · Phase 3
—15 mg
NCT02675426 · Phase 3
3.6%15 mg
NCT02675426 · Phase 3
—30 mg
NCT02675426 · Phase 3
—30 mg
NCT02675426 · Phase 3
8.2%30 mg
NCT02675426 · Phase 3
—15 mg
NCT02706873 · Phase 3 · monotherapy
12.6%15 mg
NCT02706873 · Phase 3
—15 mg
NCT02706873 · Phase 3 · monotherapy
—15 mg
NCT02706873 · Phase 3 · monotherapy
14%30 mg
NCT02706873 · Phase 3
—30 mg
NCT02706873 · Phase 3 · monotherapy
—30 mg
NCT02706873 · Phase 3 · monotherapy
7.3%7.5 mg
NCT02706873 · Phase 3
—7.5 mg
NCT02706873 · Phase 3 · monotherapy
—7.5 mg
NCT02706873 · Phase 3 · monotherapy
—15 mg QD
NCT03086343 · Phase 3
—15 mg QD
NCT03086343 · Phase 3
—30 mg QD
NCT03086343 · Phase 3
—30 mg QD
NCT03086343 · Phase 3
7.4%15 mg
NCT02706951 · Phase 3
—15 mg
NCT02706951 · Phase 3
—15 mg
NCT02706951 · Phase 3
4.7%30 mg
NCT02706951 · Phase 3
—30 mg
NCT02706951 · Phase 3
4.8%15 mg
NCT02706847 · Phase 3
—15 mg
NCT02706847 · Phase 3
—15 mg
NCT02706847 · Phase 3
—15 mg
NCT02706847 · Phase 3
9.7%30 mg
NCT02706847 · Phase 3
—30 mg
NCT02706847 · Phase 3
—30 mg
NCT02706847 · Phase 3
—15 mg
NCT02955212 · Phase 3 · registry result, not featured evidence
—15 mg
NCT02955212 · Phase 3 · registry result, not featured evidence
—15 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
4.1%15 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
—30 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
12%30 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
—7.5 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
0%7.5 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
—12 mg BID/30 mg QD
NCT02049138 · Phase 2 · registry result, not featured evidence
—6 mg BID/15 mg QD
NCT02049138 · Phase 2 · registry result, not featured evidence
7.3%60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
12.8%20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
6.5%15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
14.6%5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
10%24 mg QD
NCT02066389 · Phase 2 · registry result, not featured evidence
14%18 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
6%12 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
12%6 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
2%3 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
9.1%18 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
7.3%12 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
16.4%6 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
7.3%3 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—l
NCT01262118 · Phase 1
show 80 more results
1.2%5 mg
NCT00814307 · Phase 3
3.7%10 mg
NCT00814307 · Phase 3
6.3%5 mg
NCT00856544 · Phase 3
—5 mg
NCT00856544 · Phase 3
—5 mg
NCT00856544 · Phase 3
—5 mg
NCT00856544 · Phase 3
9.1%10 mg
NCT00856544 · Phase 3
—10 mg
NCT00856544 · Phase 3
—10 mg
NCT00856544 · Phase 3
—10 mg
NCT00856544 · Phase 3
11.8%5 mg twice daily
NCT00853385 · Phase 3
—5 mg twice daily
NCT00853385 · Phase 3
—5 mg twice daily
NCT00853385 · Phase 3
—5 mg twice daily
NCT00853385 · Phase 3
11.9%10 mg twice daily
NCT00853385 · Phase 3
—10 mg twice daily
NCT00853385 · Phase 3
—10 mg twice daily
NCT00853385 · Phase 3
—10 mg twice daily
NCT00853385 · Phase 3
11.2%5 mg
NCT00847613 · Phase 3
—5 mg
NCT00847613 · Phase 3
—5 mg
NCT00847613 · Phase 3
—5 mg
NCT00847613 · Phase 3
8.2%10 mg
NCT00847613 · Phase 3
—10 mg
NCT00847613 · Phase 3
—10 mg
NCT00847613 · Phase 3
—10 mg
NCT00847613 · Phase 3
9%5 mg
NCT00960440 · Phase 3
—5 mg
NCT00960440 · Phase 3
—5 mg
NCT00960440 · Phase 3
9%10 mg
NCT00960440 · Phase 3
—10 mg
NCT00960440 · Phase 3
—10 mg
NCT00960440 · Phase 3
—5 mg BID
NCT01039688 · Phase 3
9.8%10 mg BID
NCT01039688 · Phase 3
—5 mg BID
NCT02092467 · Phase 4
—10 mg BID
NCT02092467 · Phase 4
—11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
—11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
5.9%11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
—5 mg
NCT00413699 · Phase 3 · registry result, not featured evidence
25.9%5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
23.1%10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
2.9%
NCT02281552 · Phase 3 · registry result, not featured evidence
25.9%5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
22.9%10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
1%11mg MR
NCT04413617 · Phase 2 · registry result, not featured evidence
1%400mg MR + 11mg MR
NCT04413617 · Phase 2 · registry result, not featured evidence · combination
7.3%5 mg Twice a Day
NCT02147587 · Phase 2 · registry result, not featured evidence
3.6%
NCT01359150 · Phase 2 · registry result, not featured evidence · combination
—
NCT00976599 · Phase 2 · registry result, not featured evidence
—
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
3.8%5 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
5.7%10 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
0%15 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
1.9%3 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
0%1 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0%10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.5%15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.8%3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.7%1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
14.3%5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
14.3%10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
7.1%3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
0%1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
1.4%5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
5.3%10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
5%20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
—20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
8%15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
4.4%3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
—3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
1.4%1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
—1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
1.6%5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
10.1%30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
8.7%15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
1%
NCT01484561 · Phase 1 · registry result, not featured evidence
—CP-690,500
NCT01745055 · Phase 1 · registry result, not featured evidence
—Methotrexate + CP-690,500
NCT01745055 · Phase 1 · registry result, not featured evidence · combination
—15 mgl
NCT02675426 · Phase 3
show 55 more results
—15 mg
NCT02675426 · Phase 3
—15 mg
NCT02675426 · Phase 3
1.4%15 mg
NCT02675426 · Phase 3
—30 mg
NCT02675426 · Phase 3
—30 mg
NCT02675426 · Phase 3
4.1%30 mg
NCT02675426 · Phase 3
—15 mg
NCT02706873 · Phase 3 · monotherapy
5.7%15 mg
NCT02706873 · Phase 3
—15 mg
NCT02706873 · Phase 3 · monotherapy
—15 mg
NCT02706873 · Phase 3 · monotherapy
3.5%30 mg
NCT02706873 · Phase 3
—30 mg
NCT02706873 · Phase 3 · monotherapy
—30 mg
NCT02706873 · Phase 3 · monotherapy
5.5%7.5 mg
NCT02706873 · Phase 3
—7.5 mg
NCT02706873 · Phase 3 · monotherapy
—7.5 mg
NCT02706873 · Phase 3 · monotherapy
—15 mg QD
NCT03086343 · Phase 3
—15 mg QD
NCT03086343 · Phase 3
—30 mg QD
NCT03086343 · Phase 3
—30 mg QD
NCT03086343 · Phase 3
2.3%15 mg
NCT02706951 · Phase 3
—15 mg
NCT02706951 · Phase 3
—15 mg
NCT02706951 · Phase 3
1.4%30 mg
NCT02706951 · Phase 3
—30 mg
NCT02706951 · Phase 3
0.6%15 mg
NCT02706847 · Phase 3
—15 mg
NCT02706847 · Phase 3
—15 mg
NCT02706847 · Phase 3
—15 mg
NCT02706847 · Phase 3
7.3%30 mg
NCT02706847 · Phase 3
—30 mg
NCT02706847 · Phase 3
—30 mg
NCT02706847 · Phase 3
—15 mg
NCT02955212 · Phase 3 · registry result, not featured evidence
—15 mg
NCT02955212 · Phase 3 · registry result, not featured evidence
—15 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
2%15 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
—30 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
10%30 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
—7.5 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
0%7.5 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
—12 mg BID/30 mg QD
NCT02049138 · Phase 2 · registry result, not featured evidence
—6 mg BID/15 mg QD
NCT02049138 · Phase 2 · registry result, not featured evidence
2.4%60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
0%20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
1.6%15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
2.4%5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
2%24 mg QD
NCT02066389 · Phase 2 · registry result, not featured evidence
10%18 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
2%12 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
2%6 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
2%3 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
3.6%18 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
3.6%12 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
10.9%6 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
0%3 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
Serious AEs
0%l
NCT01262118 · Phase 1
show 80 more results
—5 mg
NCT00814307 · Phase 3
—10 mg
NCT00814307 · Phase 3
—5 mg
NCT00856544 · Phase 3
1.6%5 mg
NCT00856544 · Phase 3
2.2%5 mg
NCT00856544 · Phase 3
2.9%5 mg
NCT00856544 · Phase 3
—10 mg
NCT00856544 · Phase 3
2.2%10 mg
NCT00856544 · Phase 3
2.8%10 mg
NCT00856544 · Phase 3
2.5%10 mg
NCT00856544 · Phase 3
—5 mg twice daily
NCT00853385 · Phase 3
4.3%5 mg twice daily
NCT00853385 · Phase 3
4.2%5 mg twice daily
NCT00853385 · Phase 3
5.9%5 mg twice daily
NCT00853385 · Phase 3
—10 mg twice daily
NCT00853385 · Phase 3
3.2%10 mg twice daily
NCT00853385 · Phase 3
4%10 mg twice daily
NCT00853385 · Phase 3
5%10 mg twice daily
NCT00853385 · Phase 3
—5 mg
NCT00847613 · Phase 3
5%5 mg
NCT00847613 · Phase 3
3.5%5 mg
NCT00847613 · Phase 3
3.7%5 mg
NCT00847613 · Phase 3
—10 mg
NCT00847613 · Phase 3
2.3%10 mg
NCT00847613 · Phase 3
3.3%10 mg
NCT00847613 · Phase 3
3.2%10 mg
NCT00847613 · Phase 3
—5 mg
NCT00960440 · Phase 3
4%5 mg
NCT00960440 · Phase 3
1.5%5 mg
NCT00960440 · Phase 3
—10 mg
NCT00960440 · Phase 3
4%10 mg
NCT00960440 · Phase 3
1.5%10 mg
NCT00960440 · Phase 3
10.7%5 mg BID
NCT01039688 · Phase 3
10.8%10 mg BID
NCT01039688 · Phase 3
25.6%5 mg BID
NCT02092467 · Phase 4
28.8%10 mg BID
NCT02092467 · Phase 4
3.8%11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
1.9%11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
2.9%11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
10.4%5 mg
NCT00413699 · Phase 3 · registry result, not featured evidence
30.8%5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
29.7%10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
4.8%
NCT02281552 · Phase 3 · registry result, not featured evidence
29.1%5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
26.7%10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
2.9%11mg MR
NCT04413617 · Phase 2 · registry result, not featured evidence
0%400mg MR + 11mg MR
NCT04413617 · Phase 2 · registry result, not featured evidence · combination
5.5%5 mg Twice a Day
NCT02147587 · Phase 2 · registry result, not featured evidence
3.6%
NCT01359150 · Phase 2 · registry result, not featured evidence · combination
0%
NCT00976599 · Phase 2 · registry result, not featured evidence
0%
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
3.8%5 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
3.8%10 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
1.9%15 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
5.7%3 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
0%1 mg
NCT00687193 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.6%10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
7%15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
2.9%3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
5.4%1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.7%5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
7.7%10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.7%3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.6%1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
5.6%5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.4%10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
6%20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0%20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
8%15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
7.3%3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0%3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
2%1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
4.8%1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
1.6%5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
4.3%30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
7.2%15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
2.1%
NCT01484561 · Phase 1 · registry result, not featured evidence
0%CP-690,500
NCT01745055 · Phase 1 · registry result, not featured evidence
0%Methotrexate + CP-690,500
NCT01745055 · Phase 1 · registry result, not featured evidence · combination
28.1%15 mgl
NCT02675426 · Phase 3
show 55 more results
4.5%15 mg
NCT02675426 · Phase 3
10.6%15 mg
NCT02675426 · Phase 3
—15 mg
NCT02675426 · Phase 3
3.2%30 mg
NCT02675426 · Phase 3
31.8%30 mg
NCT02675426 · Phase 3
—30 mg
NCT02675426 · Phase 3
15.5%15 mg
NCT02706873 · Phase 3 · monotherapy
—15 mg
NCT02706873 · Phase 3
5%15 mg
NCT02706873 · Phase 3 · monotherapy
21.5%15 mg
NCT02706873 · Phase 3 · monotherapy
—30 mg
NCT02706873 · Phase 3
6.4%30 mg
NCT02706873 · Phase 3 · monotherapy
22.6%30 mg
NCT02706873 · Phase 3 · monotherapy
—7.5 mg
NCT02706873 · Phase 3
9.1%7.5 mg
NCT02706873 · Phase 3 · monotherapy
23.6%7.5 mg
NCT02706873 · Phase 3 · monotherapy
4%15 mg QD
NCT03086343 · Phase 3
23.6%15 mg QD
NCT03086343 · Phase 3
19%30 mg QD
NCT03086343 · Phase 3
35.3%30 mg QD
NCT03086343 · Phase 3
5.1%15 mg
NCT02706951 · Phase 3
10.7%15 mg
NCT02706951 · Phase 3
29.9%15 mg
NCT02706951 · Phase 3
2.8%30 mg
NCT02706951 · Phase 3
24.1%30 mg
NCT02706951 · Phase 3
—15 mg
NCT02706847 · Phase 3
15.2%15 mg
NCT02706847 · Phase 3
5.5%15 mg
NCT02706847 · Phase 3
36.9%15 mg
NCT02706847 · Phase 3
—30 mg
NCT02706847 · Phase 3
7.3%30 mg
NCT02706847 · Phase 3
29.6%30 mg
NCT02706847 · Phase 3
17.1%15 mg
NCT02955212 · Phase 3 · registry result, not featured evidence
7.1%15 mg
NCT02955212 · Phase 3 · registry result, not featured evidence
21.9%15 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
2%15 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
27.3%30 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
10%30 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
13.8%7.5 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
2%7.5 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
22.5%12 mg BID/30 mg QD
NCT02049138 · Phase 2 · registry result, not featured evidence
13.8%6 mg BID/15 mg QD
NCT02049138 · Phase 2 · registry result, not featured evidence
0%60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
5.1%20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
0%15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
7.3%5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
4.1%24 mg QD
NCT02066389 · Phase 2 · registry result, not featured evidence
6%18 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
2%12 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
4%6 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
0%3 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
1.8%18 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
0%12 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
3.6%6 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
3.6%3 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
l
upper respiratory tract infection 19.4%
headache 11.1%
urinary tract infection 8.3%
NCT01262118 · Phase 1
show 70 more results
5 mg
upper respiratory tract infection 4.1% (placebo 0%)
gastroenteritis 2.2% (placebo 0%)
nasopharyngitis 1.9% (placebo 0%)
NCT00856544 · Phase 3
5 mg
upper respiratory tract infection 3.5% (placebo 0%)
diarrhoea 1.9% (placebo 0%)
sinusitis 1.6% (placebo 2.5%)
NCT00856544 · Phase 3
5 mg
upper respiratory tract infection 6% (placebo 0%)
nasopharyngitis 5.1% (placebo 0%)
diarrhoea 4.4% (placebo 0%)
NCT00856544 · Phase 3
10 mg
nasopharyngitis 2.8% (placebo 0%)
upper respiratory tract infection 2.8% (placebo 0%)
oedema peripheral 2.5% (placebo 1.2%)
NCT00856544 · Phase 3
10 mg
upper respiratory tract infection 5.7% (placebo 0%)
blood creatine phosphokinase increased 2.2% (placebo 0%)
urinary tract infection 2.2% (placebo 1.2%)
NCT00856544 · Phase 3
10 mg
upper respiratory tract infection 7.2% (placebo 0%)
diarrhoea 3.1% (placebo 0%)
headache 3.1% (placebo 2.5%)
NCT00856544 · Phase 3
5 mg twice daily
nasopharyngitis 2.2% (placebo 1.7%)
urinary tract infection 2.2% (placebo 0%)
fall 1.7% (placebo 3.4%)
NCT00853385 · Phase 3
5 mg twice daily
upper respiratory tract infection 3.5% (placebo 0%)
nasopharyngitis 3.1% (placebo 1.7%)
bronchitis 2.7% (placebo 0%)
NCT00853385 · Phase 3
5 mg twice daily
upper respiratory tract infection 4.4% (placebo 0%)
headache 3.9% (placebo 0%)
nasopharyngitis 3.9% (placebo 1.7%)
NCT00853385 · Phase 3
10 mg twice daily
back pain 0.9% (placebo 0%)
fall 0.9% (placebo 3.4%)
nasopharyngitis 0.9% (placebo 1.7%)
NCT00853385 · Phase 3
10 mg twice daily
bronchitis 4% (placebo 0%)
abdominal pain upper 2.8% (placebo 0%)
arthralgia 2.8% (placebo 0%)
NCT00853385 · Phase 3
10 mg twice daily
upper respiratory tract infection 3.5% (placebo 0%)
headache 3% (placebo 0%)
herpes zoster 2.5% (placebo 0%)
NCT00853385 · Phase 3
5 mg
upper respiratory tract infection 4.7% (placebo 0%)
nasopharyngitis 3.6% (placebo 4.9%)
bronchitis 0.8% (placebo 0%)
NCT00847613 · Phase 3
5 mg
nasopharyngitis 5.5% (placebo 4.9%)
upper respiratory tract infection 3.2% (placebo 0%)
herpes zoster 2.5% (placebo 0%)
NCT00847613 · Phase 3
5 mg
headache 5.6% (placebo 0%)
nasopharyngitis 4.4% (placebo 4.9%)
hypertension 3.4% (placebo 0%)
NCT00847613 · Phase 3
10 mg
bronchitis 2.5% (placebo 0%)
nasopharyngitis 2.5% (placebo 4.9%)
upper respiratory tract infection 2.5% (placebo 0%)
NCT00847613 · Phase 3
10 mg
nasopharyngitis 5.6% (placebo 4.9%)
urinary tract infection 4.3% (placebo 0%)
upper respiratory tract infection 3.8% (placebo 0%)
NCT00847613 · Phase 3
10 mg
nasopharyngitis 4.1% (placebo 4.9%)
cough 2.8% (placebo 0%)
diarrhoea 2.5% (placebo 0%)
NCT00847613 · Phase 3
5 mg
rheumatoid arthritis 3.5% (placebo 3%)
bronchitis 3% (placebo 0%)
nasopharyngitis 3% (placebo 3%)
NCT00960440 · Phase 3
5 mg
diarrhoea 6% (placebo 3.8%)
nasopharyngitis 3.8% (placebo 3%)
upper respiratory tract infection 3.8% (placebo 3%)
NCT00960440 · Phase 3
10 mg
upper respiratory tract infection 4% (placebo 3%)
nasopharyngitis 2.5% (placebo 3%)
back pain 2% (placebo 1.5%)
NCT00960440 · Phase 3
10 mg
headache 6% (placebo 0.8%)
nasopharyngitis 4.5% (placebo 3%)
diarrhoea 3.7% (placebo 3.8%)
NCT00960440 · Phase 3
5 mg BID
upper respiratory tract infection 8%
nasopharyngitis 7.5%
nausea 7.2%
NCT01039688 · Phase 3
10 mg BID
nasopharyngitis 9.8%
blood creatine phosphokinase increased 9.1%
upper respiratory tract infection 9.1%
NCT01039688 · Phase 3
5 mg BID
upper respiratory tract infection 21.9%
bronchitis 15.2%
urinary tract infection 13.1%
NCT02092467 · Phase 4
10 mg BID
upper respiratory tract infection 21.8%
bronchitis 16.7%
urinary tract infection 15.1%
NCT02092467 · Phase 4
11 mg
arthralgia 2.7%
alanine aminotransferase increased 1.9%
aspartate aminotransferase increased 1.9%
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
11 mg
alanine aminotransferase increased 3.8%
bronchitis 2.6%
nasopharyngitis 2.6%
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
11 mg
nasopharyngitis 5%
upper respiratory tract infection 4.8%
nausea 2.9%
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
5 mg
bronchitis 1 6.3%
alanine aminotransferase increased 0%
anemia 0%
NCT00413699 · Phase 3 · registry result, not featured evidence
5 mg BID
upper respiratory tract infection 20.3%
urinary tract infection 14.3%
bronchitis 12.6%
NCT00413699 · Phase 3 · registry result, not featured evidence
10 mg BID
upper respiratory tract infection 18.3%
nasopharyngitis 15.4%
urinary tract infection 13.3%
NCT00413699 · Phase 3 · registry result, not featured evidence
nasopharyngitis 9.6%
NCT02281552 · Phase 3 · registry result, not featured evidence
5 mg BID
nasopharyngitis 58%
herpes zoster 15.5%
fall 13.4%
NCT00661661 · Phase 3 · registry result, not featured evidence
10 mg BID
nasopharyngitis 68.6%
herpes zoster 21%
fall 19%
NCT00661661 · Phase 3 · registry result, not featured evidence
11mg MR
sars-cov-2 test positive 6.9%
urinary tract infection 4.9%
headache 3.9%
NCT04413617 · Phase 2 · registry result, not featured evidence
400mg MR + 11mg MR
urinary tract infection 6.8%
sars-cov-2 test positive 3.9%
headache 2.9%
NCT04413617 · Phase 2 · registry result, not featured evidence · combination
5 mg Twice a Day
arthralgia 5.5% (placebo 0%)
rheumatoid arthritis 5.5% (placebo 15.8%)
NCT02147587 · Phase 2 · registry result, not featured evidence
upper respiratory tract infection 5.4% (placebo 7.2%)
headache 4.5% (placebo 0.9%)
dizziness 2.7% (placebo 0%)
NCT01359150 · Phase 2 · registry result, not featured evidence · combination
fatigue 13.3% (placebo 0%)
hypoaesthesia 13.3% (placebo 0%)
nausea 13.3% (placebo 7.1%)
NCT00976599 · Phase 2 · registry result, not featured evidence
dyspepsia 4% (placebo 2.1%)
oedema peripheral 4% (placebo 4.3%)
oropharyngeal pain 4% (placebo 0%)
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
5 mg
nasopharyngitis 11.5% (placebo 11.5%)
hypertension 5.8% (placebo 0%)
dental caries 3.8% (placebo 1.9%)
NCT00687193 · Phase 2 · registry result, not featured evidence
10 mg
hyperlipidaemia 11.3% (placebo 0%)
hypercholesterolaemia 5.7% (placebo 0%)
nasopharyngitis 5.7% (placebo 11.5%)
NCT00687193 · Phase 2 · registry result, not featured evidence
15 mg
nasopharyngitis 14.8% (placebo 11.5%)
low density lipoprotein increased 11.1% (placebo 0%)
constipation 5.6% (placebo 3.8%)
NCT00687193 · Phase 2 · registry result, not featured evidence
3 mg
nasopharyngitis 7.5% (placebo 11.5%)
headache 5.7% (placebo 1.9%)
hypercholesterolaemia 3.8% (placebo 0%)
NCT00687193 · Phase 2 · registry result, not featured evidence
1 mg
nasopharyngitis 11.3% (placebo 11.5%)
fall 5.7% (placebo 0%)
abdominal discomfort 3.8% (placebo 1.9%)
NCT00687193 · Phase 2 · registry result, not featured evidence
5 mg
urinary tract infection 10.2% (placebo 5.9%)
diarrhoea 6.1% (placebo 0%)
bronchitis 4.1% (placebo 0%)
NCT00550446 · Phase 2 · registry result, not featured evidence
10 mg
headache 9.8% (placebo 2.9%)
diarrhoea 6.6% (placebo 0%)
hypertension 4.9% (placebo 2.9%)
NCT00550446 · Phase 2 · registry result, not featured evidence
15 mg
urinary tract infection 10.5% (placebo 5.9%)
bronchitis 7% (placebo 0%)
back pain 5.3% (placebo 0%)
NCT00550446 · Phase 2 · registry result, not featured evidence
3 mg
diarrhoea 8.8% (placebo 0%)
back pain 5.9% (placebo 0%)
bronchitis 5.9% (placebo 0%)
NCT00550446 · Phase 2 · registry result, not featured evidence
1 mg
urinary tract infection 8.1% (placebo 5.9%)
diarrhoea 5.4% (placebo 0%)
dizziness 5.4% (placebo 2.9%)
NCT00550446 · Phase 2 · registry result, not featured evidence
5 mg
alanine aminotransferase increased 22.2% (placebo 3.6%)
aspartate aminotransferase increased 14.8% (placebo 3.6%)
stomach discomfort 11.1% (placebo 0%)
NCT00603512 · Phase 2 · registry result, not featured evidence
10 mg
nasopharyngitis 15.4% (placebo 14.3%)
alanine aminotransferase increased 7.7% (placebo 3.6%)
blood triglycerides increased 7.7% (placebo 0%)
NCT00603512 · Phase 2 · registry result, not featured evidence
3 mg
blood cholesterol increased 11.1% (placebo 0%)
alanine aminotransferase increased 7.4% (placebo 3.6%)
aspartate aminotransferase increased 7.4% (placebo 3.6%)
NCT00603512 · Phase 2 · registry result, not featured evidence
1 mg
nasopharyngitis 10.7% (placebo 14.3%)
headache 7.1% (placebo 3.6%)
stomatitis 7.1% (placebo 0%)
NCT00603512 · Phase 2 · registry result, not featured evidence
5 mg
diarrhoea 12.7% (placebo 3.9%)
nasopharyngitis 7% (placebo 5.9%)
upper respiratory tract infection 7% (placebo 2%)
NCT00413660 · Phase 2 · registry result, not featured evidence
10 mg
cough 8.1% (placebo 0%)
influenza 6.8% (placebo 2%)
nausea 6.8% (placebo 2%)
NCT00413660 · Phase 2 · registry result, not featured evidence
20 mg
headache 13.4% (placebo 2%)
urinary tract infection 9% (placebo 0%)
nasopharyngitis 6% (placebo 5.9%)
NCT00413660 · Phase 2 · registry result, not featured evidence
20 mg to 5 mg (R)
headache 23.1% (placebo 2%)
upper respiratory tract infection 15.4% (placebo 2%)
abdominal pain upper 7.7% (placebo 5.9%)
NCT00413660 · Phase 2 · registry result, not featured evidence
15 mg
nasopharyngitis 8% (placebo 5.9%)
alanine aminotransferase increased 6.7% (placebo 2%)
aspartate aminotransferase increased 6.7% (placebo 0%)
NCT00413660 · Phase 2 · registry result, not featured evidence
3 mg
nausea 5.5% (placebo 2%)
pharyngitis 5.5% (placebo 3.9%)
abdominal pain upper 3.6% (placebo 5.9%)
NCT00413660 · Phase 2 · registry result, not featured evidence
3 mg to 5 mg (R)
upper respiratory tract infection 23.1% (placebo 2%)
arthralgia 15.4% (placebo 0%)
headache 15.4% (placebo 2%)
NCT00413660 · Phase 2 · registry result, not featured evidence
1 mg
diarrhoea 14.3% (placebo 3.9%)
abdominal pain upper 4.1% (placebo 5.9%)
headache 4.1% (placebo 2%)
NCT00413660 · Phase 2 · registry result, not featured evidence
1 mg to 5 mg (R)
gastritis 9.5% (placebo 0%)
nasopharyngitis 9.5% (placebo 5.9%)
oral herpes 9.5% (placebo 0%)
NCT00413660 · Phase 2 · registry result, not featured evidence
5 mg BID
headache 16.4% (placebo 9.2%)
abdominal pain upper 6.6% (placebo 0%)
nausea 6.6% (placebo 4.6%)
NCT00147498 · Phase 2 · registry result, not featured evidence
30 mg BID
headache 24.6% (placebo 9.2%)
leukopenia 10.1% (placebo 1.5%)
nausea 8.7% (placebo 4.6%)
NCT00147498 · Phase 2 · registry result, not featured evidence
15 mg BID
headache 11.6% (placebo 9.2%)
dizziness 5.8% (placebo 1.5%)
hypercholesterolaemia 5.8% (placebo 0%)
NCT00147498 · Phase 2 · registry result, not featured evidence
nasopharyngitis 8.2% (placebo 5.9%)
headache 6.2% (placebo 2%)
nausea 5.2% (placebo 3.9%)
NCT01484561 · Phase 1 · registry result, not featured evidence
nausea 16.7%
arthralgia 8.3%
back pain 8.3%
NCT01745055 · Phase 1 · registry result, not featured evidence
anemia 16.7%
arthralgia 8.3%
back pain 8.3%
NCT01745055 · Phase 1 · registry result, not featured evidence · combination
15 mgl
upper respiratory tract infection 19.8% (placebo 4.1%)
nasopharyngitis 18.5% (placebo 4.1%)
urinary tract infection 17% (placebo 3.6%)
NCT02675426 · Phase 3
show 48 more results
15 mg
nausea 6.8% (placebo 3.2%)
nasopharyngitis 5.4% (placebo 4.1%)
upper respiratory tract infection 5.4% (placebo 4.1%)
NCT02675426 · Phase 3
15 mg
covid-19 8.9% (placebo 0%)
rheumatoid arthritis 4.5% (placebo 4.5%)
fall 2.8% (placebo 0.5%)
NCT02675426 · Phase 3
30 mg
nasopharyngitis 5.9% (placebo 4.1%)
upper respiratory tract infection 5.5% (placebo 4.1%)
headache 3.7% (placebo 5.4%)
NCT02675426 · Phase 3
30 mg
upper respiratory tract infection 17.8% (placebo 4.1%)
urinary tract infection 14.3% (placebo 3.6%)
nasopharyngitis 14% (placebo 4.1%)
NCT02675426 · Phase 3
15 mg
covid-19 10.5%
rheumatoid arthritis 9.4%
urinary tract infection 7.2%
NCT02706873 · Phase 3 · monotherapy
15 mg
upper respiratory tract infection 6.3%
nasopharyngitis 5.7%
nausea 5.7%
NCT02706873 · Phase 3 · monotherapy
15 mg
upper respiratory tract infection 15.5%
nasopharyngitis 15.1%
urinary tract infection 13.6%
NCT02706873 · Phase 3 · monotherapy
30 mg
blood creatine phosphokinase increased 10.8%
upper respiratory tract infection 7.3%
urinary tract infection 5.7%
NCT02706873 · Phase 3 · monotherapy
30 mg
blood creatine phosphokinase increased 16.2%
nasopharyngitis 16.2%
hypertension 14%
NCT02706873 · Phase 3 · monotherapy
7.5 mg
nasopharyngitis 9.1%
pharyngitis 9.1%
stomatitis 7.3%
NCT02706873 · Phase 3 · monotherapy
7.5 mg
nasopharyngitis 40%
herpes zoster 21.8%
pharyngitis 21.8%
NCT02706873 · Phase 3 · monotherapy
15 mg QD
upper respiratory tract infection 8.6%
nasopharyngitis 7.3%
urinary tract infection 6.6%
NCT03086343 · Phase 3
15 mg QD
covid-19 23.6%
urinary tract infection 14.8%
nasopharyngitis 13.7%
NCT03086343 · Phase 3
30 mg QD
rheumatoid arthritis 14.3%
arthralgia 9.5%
cough 9.5%
NCT03086343 · Phase 3
30 mg QD
hypertension 23.5%
upper respiratory tract infection 23.5%
bronchitis 17.6%
NCT03086343 · Phase 3
15 mg
urinary tract infection 4.6%
upper respiratory tract infection 4.1%
blood creatine phosphokinase increased 2.3%
NCT02706951 · Phase 3
15 mg
covid-19 9.8%
urinary tract infection 6.3%
rheumatoid arthritis 4.4%
NCT02706951 · Phase 3
15 mg
nasopharyngitis 17.6%
rheumatoid arthritis 14.2%
urinary tract infection 13.5%
NCT02706951 · Phase 3
30 mg
urinary tract infection 4.7%
blood creatine phosphokinase increased 4.2%
upper respiratory tract infection 2.8%
NCT02706951 · Phase 3
30 mg
blood creatine phosphokinase increased 18.6%
urinary tract infection 15.1%
upper respiratory tract infection 14.8%
NCT02706951 · Phase 3
15 mg
rheumatoid arthritis 9.4% (placebo 5.9%)
urinary tract infection 8% (placebo 5.9%)
back pain 5.8% (placebo 2.4%)
NCT02706847 · Phase 3
15 mg
urinary tract infection 9.8% (placebo 5.9%)
upper respiratory tract infection 7.9% (placebo 7.7%)
bronchitis 4.3% (placebo 2.4%)
NCT02706847 · Phase 3
15 mg
upper respiratory tract infection 31.4% (placebo 7.7%)
urinary tract infection 18.2% (placebo 5.9%)
nasopharyngitis 14.4% (placebo 6.5%)
NCT02706847 · Phase 3
30 mg
upper respiratory tract infection 6.7% (placebo 7.7%)
nasopharyngitis 5.5% (placebo 6.5%)
urinary tract infection 5.5% (placebo 5.9%)
NCT02706847 · Phase 3
30 mg
upper respiratory tract infection 27.9% (placebo 7.7%)
urinary tract infection 20.4% (placebo 5.9%)
nasopharyngitis 17.1% (placebo 6.5%)
NCT02706847 · Phase 3
15 mg
upper respiratory tract infection 20.2% (placebo 6.5%)
alanine aminotransferase increased 9.3% (placebo 1.2%)
blood creatine phosphokinase increased 9% (placebo 0%)
NCT02955212 · Phase 3 · registry result, not featured evidence
15 mg
upper respiratory tract infection 9.5% (placebo 6.5%)
alanine aminotransferase increased 5.3% (placebo 1.2%)
anaemia 0% (placebo 0%)
NCT02955212 · Phase 3 · registry result, not featured evidence
15 mg
nasopharyngitis 54.7% (placebo 10.2%)
herpes zoster 14.1% (placebo 2%)
influenza 14.1% (placebo 4.1%)
NCT02720523 · Phase 2/3 · registry result, not featured evidence
15 mg
nasopharyngitis 12.2% (placebo 10.2%)
liver function test increased 6.1% (placebo 0%)
constipation 4.1% (placebo 0%)
NCT02720523 · Phase 2/3 · registry result, not featured evidence
30 mg
nasopharyngitis 43.9% (placebo 10.2%)
constipation 15.2% (placebo 0%)
herpes zoster 15.2% (placebo 2%)
NCT02720523 · Phase 2/3 · registry result, not featured evidence
30 mg
nasopharyngitis 18% (placebo 10.2%)
blood creatine phosphokinase increased 6% (placebo 0%)
headache 6% (placebo 0%)
NCT02720523 · Phase 2/3 · registry result, not featured evidence
7.5 mg
nasopharyngitis 53.8% (placebo 10.2%)
stomatitis 20% (placebo 6.1%)
hypertension 12.3% (placebo 0%)
NCT02720523 · Phase 2/3 · registry result, not featured evidence
7.5 mg
nasopharyngitis 10.2% (placebo 10.2%)
hypertension 6.1% (placebo 0%)
stomatitis 6.1% (placebo 6.1%)
NCT02720523 · Phase 2/3 · registry result, not featured evidence
12 mg BID/30 mg QD
upper respiratory tract infection 20.3%
urinary tract infection 15%
herpes zoster 11.2%
NCT02049138 · Phase 2 · registry result, not featured evidence
6 mg BID/15 mg QD
upper respiratory tract infection 9.9%
nasopharyngitis 9.5%
urinary tract infection 9.5%
NCT02049138 · Phase 2 · registry result, not featured evidence
60 mg
urinary tract infection 9.8% (placebo 0%)
diarrhoea 7.3% (placebo 0%)
rheumatoid arthritis 7.3% (placebo 10.5%)
NCT03682705 · Phase 2 · registry result, not featured evidence
20 mg
rheumatoid arthritis 7.7% (placebo 10.5%)
upper respiratory tract infection 7.7% (placebo 5.3%)
alopecia 5.1% (placebo 0%)
NCT03682705 · Phase 2 · registry result, not featured evidence
15 mg/60 mg
upper respiratory tract infection 6.5% (placebo 5.3%)
arthralgia 1.6% (placebo 5.3%)
cough 1.6% (placebo 0%)
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
5 mg
rheumatoid arthritis 7.3% (placebo 10.5%)
upper respiratory tract infection 4.9% (placebo 5.3%)
urinary tract infection 4.9% (placebo 0%)
NCT03682705 · Phase 2 · registry result, not featured evidence
24 mg QD
nasopharyngitis 6.1% (placebo 2%)
back pain 2% (placebo 0%)
blood creatine phosphokinase increased 2% (placebo 0%)
NCT02066389 · Phase 2 · registry result, not featured evidence
18 mg BID
blood creatine phosphokinase increased 4% (placebo 0%)
nasopharyngitis 4% (placebo 2%)
cough 2% (placebo 0%)
NCT02066389 · Phase 2 · registry result, not featured evidence
12 mg BID
influenza 8% (placebo 0%)
nasopharyngitis 8% (placebo 2%)
blood creatine phosphokinase increased 6% (placebo 0%)
NCT02066389 · Phase 2 · registry result, not featured evidence
6 mg BID
back pain 6% (placebo 0%)
nasopharyngitis 4% (placebo 2%)
cough 2% (placebo 0%)
NCT02066389 · Phase 2 · registry result, not featured evidence
3 mg BID
headache 4% (placebo 2%)
back pain 2% (placebo 0%)
cough 2% (placebo 0%)
NCT02066389 · Phase 2 · registry result, not featured evidence
18 mg BID
urinary tract infection 12.7% (placebo 3.6%)
blood creatine phosphokinase increased 9.1% (placebo 0%)
constipation 7.3% (placebo 0%)
NCT01960855 · Phase 2 · registry result, not featured evidence
12 mg BID
upper respiratory tract infection 7.3% (placebo 1.8%)
headache 5.5% (placebo 1.8%)
leukopenia 5.5% (placebo 0%)
NCT01960855 · Phase 2 · registry result, not featured evidence
6 mg BID
headache 5.5% (placebo 1.8%)
hyperlipidaemia 3.6% (placebo 1.8%)
constipation 1.8% (placebo 0%)
NCT01960855 · Phase 2 · registry result, not featured evidence
3 mg BID
nausea 7.3% (placebo 1.8%)
arthralgia 5.5% (placebo 0%)
headache 5.5% (placebo 1.8%)
NCT01960855 · Phase 2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 2 versus Phase 4.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dAssessment timepoints differ: 12 weeks versus 312 weeks.
  5. eAssessment timepoints differ: 12 weeks versus 273 weeks.
  6. fTrial phases differ: Phase 3 versus Phase 4.
  7. gTreatment context has not been resolved for both arms.
  8. hAssessment timepoints differ: 24 weeks versus 104 weeks.
  9. iTrial phases differ: Phase 3 versus Phase 2.
  10. jTrial phases differ: Phase 2 versus Phase 3.
  11. kAssessment timepoints differ: 12 weeks versus 104 weeks.
  12. lPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

tofacitinib

DAS28-ESR Remission 6.11% (n=229) vs 4.81% (n=104) placebo @ 12wk5 mg
responder rate · % of participants
NCT00814307 · Phase 3
show 35 more results
9.13% (n=263) vs 2.7% (n=148) placebo @ 24wk5 mg
NCT00856544 · Phase 3
6.21% (n=177) vs 1.09% (n=92) placebo @ 24wk5 mg twice daily
NCT00853385 · Phase 3
7.17% (n=265) vs 1.55% (n=129) placebo @ 24wk5 mg
NCT00847613 · Phase 3
1.55% (n=265) vs 0% (n=129) placebo @ 4.33wk5 mg
NCT00847613 · Phase 3
5.28% (n=265) vs 1.55% (n=129) placebo @ 13wk5 mg
NCT00847613 · Phase 3
7.17% (n=265) vs 1.55% (n=129) placebo @ 26wk5 mg
NCT00847613 · Phase 3
6.72% (n=119) vs 1.67% (n=120) placebo @ 12wk5 mg
NCT00960440 · Phase 3
2.07% (n=342) vs 0% (n=171) MTX @ 4.33wk5 mg BID
NCT01039688 · Phase 3
9.06% (n=342) vs 2.35% (n=171) MTX @ 8.67wk5 mg BID
NCT01039688 · Phase 3
13.74% (n=342) vs 4.68% (n=171) MTX @ 13wk5 mg BID
NCT01039688 · Phase 3
14.62% (n=342) vs 7.6% (n=171) MTX @ 26wk5 mg BID
NCT01039688 · Phase 3
16.37% (n=342) vs 9.94% (n=171) MTX @ 39wk5 mg BID
NCT01039688 · Phase 3
18.71% (n=342) vs 11.7% (n=171) MTX @ 52wk5 mg BID
NCT01039688 · Phase 3
16.37% (n=342) vs 12.87% (n=171) MTX @ 65wk5 mg BID
NCT01039688 · Phase 3
16.96% (n=342) vs 11.11% (n=171) MTX @ 78wk5 mg BID
NCT01039688 · Phase 3
18.42% (n=342) vs 8.77% (n=171) MTX @ 91wk5 mg BID
NCT01039688 · Phase 3
20.76% (n=342) vs 9.94% (n=171) MTX @ 104wk5 mg BID
NCT01039688 · Phase 3
10.05% (n=219) vs 4.81% (n=104) placebo @ 12wk10 mg
NCT00814307 · Phase 3
13.33% (n=270) vs 2.7% (n=148) placebo @ 24wk10 mg
NCT00856544 · Phase 3
12.5% (n=176) vs 1.09% (n=92) placebo @ 24wk10 mg twice daily
NCT00853385 · Phase 3
15.95% (n=257) vs 1.55% (n=129) placebo @ 24wk10 mg
NCT00847613 · Phase 3
2.8% (n=257) vs 0% (n=129) placebo @ 4.33wk10 mg
NCT00847613 · Phase 3
11.28% (n=257) vs 1.55% (n=129) placebo @ 13wk10 mg
NCT00847613 · Phase 3
15.95% (n=257) vs 1.55% (n=129) placebo @ 26wk10 mg
NCT00847613 · Phase 3
11.2% (n=125) vs 1.67% (n=120) placebo @ 12wk10 mg
NCT00960440 · Phase 3
5.69% (n=372) vs 0% (n=171) MTX @ 4.33wk10 mg BID
NCT01039688 · Phase 3
12.9% (n=372) vs 2.35% (n=171) MTX @ 8.67wk10 mg BID
NCT01039688 · Phase 3
17.47% (n=372) vs 4.68% (n=171) MTX @ 13wk10 mg BID
NCT01039688 · Phase 3
21.77% (n=372) vs 7.6% (n=171) MTX @ 26wk10 mg BID
NCT01039688 · Phase 3
23.66% (n=372) vs 9.94% (n=171) MTX @ 39wk10 mg BID
NCT01039688 · Phase 3
23.39% (n=372) vs 11.7% (n=171) MTX @ 52wk10 mg BID
NCT01039688 · Phase 3
24.19% (n=372) vs 12.87% (n=171) MTX @ 65wk10 mg BID
NCT01039688 · Phase 3
19.89% (n=372) vs 11.11% (n=171) MTX @ 78wk10 mg BID
NCT01039688 · Phase 3
21.42% (n=372) vs 8.77% (n=171) MTX @ 91wk10 mg BID
NCT01039688 · Phase 3
22.31% (n=372) vs 9.94% (n=171) MTX @ 104wk10 mg BID
NCT01039688 · Phase 3
ACR20 69.29% (n=241) @ 17.33wk5 mg
responder rate · % of participants
No placebo or comparator arm
NCT00814307 · Phase 3
show 76 more results
68.46% (n=241) @ 21.67wk5 mg
NCT00814307 · Phase 3
69.29% (n=241) @ 26wk5 mg
NCT00814307 · Phase 3
50.48% (n=311) @ 39wk5 mg
NCT00856544 · Phase 3
51.45% (n=311) @ 52wk5 mg
NCT00856544 · Phase 3
47.9% (n=309) @ 39wk5 mg
NCT00847613 · Phase 3
48.54% (n=309) @ 52wk5 mg
NCT00847613 · Phase 3
54.55% (n=132) @ 19.5wk5 mg
NCT00960440 · Phase 3
51.52% (n=132) @ 26wk5 mg
NCT00960440 · Phase 3
80.2% (n=381) @ 2wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
87.1% (n=381) @ 4wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
90% (n=381) @ 8wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
91.9% (n=381) @ 12wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
90.8% (n=381) @ 24wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
94.1% (n=381) @ 36wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
93.7% (n=381) @ 48wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
92.3% (n=381) @ 60wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
92.4% (n=381) @ 72wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
93.2% (n=381) @ 84wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
92.2% (n=381) @ 96wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
91.9% (n=381) @ 108wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
91.3% (n=381) @ 120wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
92.2% (n=381) @ 132wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
89.7% (n=381) @ 144wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
91.3% (n=381) @ 156wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
92.5% (n=381) @ 168wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
92.8% (n=381) @ 180wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
92.8% (n=381) @ 192wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
92.7% (n=381) @ 204wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
96.1% (n=381) @ 216wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
91.2% (n=381) @ 228wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
93.8% (n=381) @ 240wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
92.3% (n=381) @ 252wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
89.8% (n=381) @ 264wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
95.5% (n=381) @ 276wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
100% (n=381) @ 288wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
73.86% (n=264) @ 36wk11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
73.11% (n=264) @ 48wk11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
69.01% (n=242) @ 17.33wk10 mg
NCT00814307 · Phase 3
69.83% (n=242) @ 21.67wk10 mg
NCT00814307 · Phase 3
71.07% (n=242) @ 26wk10 mg
NCT00814307 · Phase 3
62.14% (n=309) @ 39wk10 mg
NCT00856544 · Phase 3
56.63% (n=309) @ 52wk10 mg
NCT00856544 · Phase 3
62.46% (n=309) @ 39wk10 mg
NCT00847613 · Phase 3
56.96% (n=309) @ 52wk10 mg
NCT00847613 · Phase 3
47.37% (n=133) @ 19.5wk10 mg
NCT00960440 · Phase 3
54.89% (n=133) @ 26wk10 mg
NCT00960440 · Phase 3
68.6% (n=105) @ 2wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
70.5% (n=105) @ 4wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
72.4% (n=105) @ 8wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
77.1% (n=105) @ 12wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
85.6% (n=105) @ 24wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
87.3% (n=105) @ 36wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
88.2% (n=105) @ 48wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
90.2% (n=105) @ 60wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
86.9% (n=105) @ 72wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
87% (n=105) @ 84wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
92% (n=105) @ 96wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
86.9% (n=105) @ 108wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
88.8% (n=105) @ 120wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
84.8% (n=105) @ 132wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
86.8% (n=105) @ 144wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
84.9% (n=105) @ 156wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
82.9% (n=105) @ 168wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
86% (n=105) @ 180wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
85.7% (n=105) @ 192wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
90% (n=105) @ 204wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
84.6% (n=105) @ 216wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
80% (n=105) @ 228wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
80% (n=105) @ 240wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
80% (n=105) @ 252wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
80% (n=105) @ 264wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
100% (n=105) @ 276wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
0% (n=105) @ 288wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
80.83% (n=266) @ 36wk11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
79.7% (n=266) @ 48wk11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
84.5% (n=103) @ 12wk*
NCT02281552 · Phase 3 · registry result, not featured evidence · converted to % from 87 participants as posted
ACR50 37.34% (n=241) @ 17.33wk5 mg
responder rate · % of participants
No placebo or comparator arm
NCT00814307 · Phase 3
show 72 more results
39.42% (n=241) @ 21.67wk5 mg
NCT00814307 · Phase 3
41.91% (n=241) @ 26wk5 mg
NCT00814307 · Phase 3
31.51% (n=311) @ 39wk5 mg
NCT00856544 · Phase 3
33.44% (n=311) @ 52wk5 mg
NCT00856544 · Phase 3
28.79% (n=132) @ 19.5wk5 mg
NCT00960440 · Phase 3
37.12% (n=132) @ 26wk5 mg
NCT00960440 · Phase 3
59.5% (n=381) @ 2wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
63.8% (n=381) @ 4wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
70.4% (n=381) @ 8wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
70.8% (n=381) @ 12wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
76.2% (n=381) @ 24wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
77.3% (n=381) @ 36wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
77.3% (n=381) @ 48wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
77.1% (n=381) @ 60wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
77.8% (n=381) @ 72wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
78.6% (n=381) @ 84wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
78.3% (n=381) @ 96wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
79.9% (n=381) @ 108wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
76.4% (n=381) @ 120wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
77.2% (n=381) @ 132wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
78.1% (n=381) @ 144wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
79.5% (n=381) @ 156wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
79.3% (n=381) @ 168wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
82.2% (n=381) @ 180wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
79.7% (n=381) @ 192wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
84.4% (n=381) @ 204wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
86.8% (n=381) @ 216wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
76.5% (n=381) @ 228wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
83.1% (n=381) @ 240wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
86.2% (n=381) @ 252wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
84.7% (n=381) @ 264wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
81.8% (n=381) @ 276wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
100% (n=381) @ 288wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
53.79% (n=264) @ 36wk11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
55.3% (n=264) @ 48wk11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
42.98% (n=242) @ 17.33wk10 mg
NCT00814307 · Phase 3
45.45% (n=242) @ 21.67wk10 mg
NCT00814307 · Phase 3
46.69% (n=242) @ 26wk10 mg
NCT00814307 · Phase 3
43.04% (n=309) @ 39wk10 mg
NCT00856544 · Phase 3
42.72% (n=309) @ 52wk10 mg
NCT00856544 · Phase 3
28.57% (n=133) @ 19.5wk10 mg
NCT00960440 · Phase 3
30.08% (n=133) @ 26wk10 mg
NCT00960440 · Phase 3
36.2% (n=105) @ 2wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
35.2% (n=105) @ 4wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
47.6% (n=105) @ 8wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
46.7% (n=105) @ 12wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
62.5% (n=105) @ 24wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
56.9% (n=105) @ 36wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
59.8% (n=105) @ 48wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
66.7% (n=105) @ 60wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
74.7% (n=105) @ 72wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
64.1% (n=105) @ 84wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
60.9% (n=105) @ 96wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
72.6% (n=105) @ 108wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
68.8% (n=105) @ 120wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
72.2% (n=105) @ 132wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
69.7% (n=105) @ 144wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
65.8% (n=105) @ 156wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
67.1% (n=105) @ 168wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
71.9% (n=105) @ 180wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
61.9% (n=105) @ 192wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
80% (n=105) @ 204wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
53.8% (n=105) @ 216wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
80% (n=105) @ 228wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
40% (n=105) @ 240wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
40% (n=105) @ 252wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
40% (n=105) @ 264wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
100% (n=105) @ 276wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
0% (n=105) @ 288wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
66.54% (n=266) @ 36wk11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
67.29% (n=266) @ 48wk11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
68% (n=103) @ 12wk*
NCT02281552 · Phase 3 · registry result, not featured evidence · converted to % from 70 participants as posted
ACR70 19.92% (n=241) @ 17.33wk5 mg
responder rate · % of participants
No placebo or comparator arm
NCT00814307 · Phase 3
show 76 more results
21.16% (n=241) @ 21.67wk5 mg
NCT00814307 · Phase 3
21.99% (n=241) @ 26wk5 mg
NCT00814307 · Phase 3
14.15% (n=311) @ 39wk5 mg
NCT00856544 · Phase 3
19.29% (n=311) @ 52wk5 mg
NCT00856544 · Phase 3
18.45% (n=309) @ 39wk5 mg
NCT00847613 · Phase 3
18.77% (n=309) @ 52wk5 mg
NCT00847613 · Phase 3
10.61% (n=132) @ 19.5wk5 mg
NCT00960440 · Phase 3
15.91% (n=132) @ 26wk5 mg
NCT00960440 · Phase 3
37% (n=381) @ 2wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
44.8% (n=381) @ 4wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
47.7% (n=381) @ 8wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
50% (n=381) @ 12wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
54.1% (n=381) @ 24wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
56.6% (n=381) @ 36wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
59.8% (n=381) @ 48wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
59.1% (n=381) @ 60wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
61.9% (n=381) @ 72wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
60.2% (n=381) @ 84wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
59.4% (n=381) @ 96wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
60.6% (n=381) @ 108wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
62% (n=381) @ 120wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
60.8% (n=381) @ 132wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
61.2% (n=381) @ 144wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
61.6% (n=381) @ 156wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
62.9% (n=381) @ 168wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
63.9% (n=381) @ 180wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
63.8% (n=381) @ 192wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
62.4% (n=381) @ 204wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
69.7% (n=381) @ 216wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
63.2% (n=381) @ 228wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
69.2% (n=381) @ 240wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
73.8% (n=381) @ 252wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
71.2% (n=381) @ 264wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
68.2% (n=381) @ 276wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
66.7% (n=381) @ 288wk5 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
35.61% (n=264) @ 36wk11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
37.88% (n=264) @ 48wk11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
26.03% (n=242) @ 17.33wk10 mg
NCT00814307 · Phase 3
28.51% (n=242) @ 21.67wk10 mg
NCT00814307 · Phase 3
29.34% (n=242) @ 26wk10 mg
NCT00814307 · Phase 3
25.24% (n=309) @ 39wk10 mg
NCT00856544 · Phase 3
25.57% (n=309) @ 52wk10 mg
NCT00856544 · Phase 3
28.48% (n=309) @ 39wk10 mg
NCT00847613 · Phase 3
27.51% (n=309) @ 52wk10 mg
NCT00847613 · Phase 3
12.78% (n=133) @ 19.5wk10 mg
NCT00960440 · Phase 3
15.79% (n=133) @ 26wk10 mg
NCT00960440 · Phase 3
19% (n=105) @ 2wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
20.2% (n=105) @ 4wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
21% (n=105) @ 8wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
16.2% (n=105) @ 12wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
27.9% (n=105) @ 24wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
24.5% (n=105) @ 36wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
34.3% (n=105) @ 48wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
37.3% (n=105) @ 60wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
38.4% (n=105) @ 72wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
35.9% (n=105) @ 84wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
42.5% (n=105) @ 96wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
42.9% (n=105) @ 108wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
37.5% (n=105) @ 120wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
40.5% (n=105) @ 132wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
35.5% (n=105) @ 144wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
41.1% (n=105) @ 156wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
41.4% (n=105) @ 168wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
47.4% (n=105) @ 180wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
42.9% (n=105) @ 192wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
56.7% (n=105) @ 204wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
30.8% (n=105) @ 216wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
20% (n=105) @ 228wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
20% (n=105) @ 240wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
20% (n=105) @ 252wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
20% (n=105) @ 264wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
0% (n=105) @ 276wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
0% (n=105) @ 288wk10 mg BID
NCT00661661 · Phase 3 · registry result, not featured evidence
40.98% (n=266) @ 36wk11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
42.86% (n=266) @ 48wk11 mg
NCT02831855 · Phase 4 · registry result, not featured evidence · combination
31.1% (n=103) @ 12wk*
NCT02281552 · Phase 3 · registry result, not featured evidence · converted to % from 32 participants as posted
DAS28-ESR 4.78 vs 5.54 placebo score @ 13wk5 mg
absolute value · score
NCT00814307 · Phase 3
show 113 more results
4.41 vs 5.32 placebo score @ 13wk5 mg
NCT00856544 · Phase 3
4.14 vs 4.34 placebo score @ 26wk5 mg
NCT00856544 · Phase 3
5.23 vs 5.93 placebo score @ 4.33wk5 mg twice daily
NCT00853385 · Phase 3
4.64 vs 5.6 placebo score @ 13wk5 mg twice daily
NCT00853385 · Phase 3
4.4 vs 4.61 placebo score @ 26wk5 mg twice daily
NCT00853385 · Phase 3
4 vs 4.2 Adalimumab score @ 39wk5 mg twice daily
NCT00853385 · Phase 3
3.85 vs 3.95 Adalimumab score @ 52wk5 mg twice daily
NCT00853385 · Phase 3
5.12 vs 5.83 placebo score @ 4.33wk5 mg
NCT00847613 · Phase 3
4.58 vs 5.57 placebo score @ 13wk5 mg
NCT00847613 · Phase 3
4.34 vs 4.81 placebo score @ 26wk5 mg
NCT00847613 · Phase 3
4.58 vs 5.56 placebo score @ 13wk5 mg
NCT00960440 · Phase 3
5.18 vs 5.84 MTX score @ 4.33wk5 mg BID
NCT01039688 · Phase 3
4.54 vs 5.35 MTX score @ 8.67wk5 mg BID
NCT01039688 · Phase 3
4.21 vs 4.98 MTX score @ 13wk5 mg BID
NCT01039688 · Phase 3
4.05 vs 4.61 MTX score @ 26wk5 mg BID
NCT01039688 · Phase 3
3.84 vs 4.27 MTX score @ 39wk5 mg BID
NCT01039688 · Phase 3
3.69 vs 4.23 MTX score @ 52wk5 mg BID
NCT01039688 · Phase 3
3.59 vs 4.17 MTX score @ 65wk5 mg BID
NCT01039688 · Phase 3
3.51 vs 4.05 MTX score @ 78wk5 mg BID
NCT01039688 · Phase 3
3.49 vs 4.09 MTX score @ 91wk5 mg BID
NCT01039688 · Phase 3
3.43 vs 3.99 MTX score @ 104wk5 mg BID
NCT01039688 · Phase 3
5.61 vs 6.04 placebo score @ 2wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
5.23 vs 5.7 placebo score @ 4wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.9 vs 5.64 placebo score @ 6wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.7 vs 5.56 placebo score @ 8wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.5 vs 5.54 placebo score @ 10wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.37 vs 5.39 placebo score @ 12wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.25 vs 4.53 placebo score @ 16wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.47 vs 4.47 placebo score @ 20wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.33 vs 4.51 placebo score @ 24wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
5.09 vs 5.46 placebo score @ 1wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
4.48 vs 5.34 placebo score @ 2wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
4.03 vs 5.49 placebo score @ 4wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.49 vs 5.22 placebo score @ 8wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.13 vs 5.07 placebo score @ 12wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
4.55 vs 5.54 placebo score @ 13wk10 mg
NCT00814307 · Phase 3
4.2 vs 5.32 placebo score @ 13wk10 mg
NCT00856544 · Phase 3
3.84 vs 4.34 placebo score @ 26wk10 mg
NCT00856544 · Phase 3
5.14 vs 5.93 placebo score @ 4.33wk10 mg twice daily
NCT00853385 · Phase 3
4.66 vs 5.6 placebo score @ 13wk10 mg twice daily
NCT00853385 · Phase 3
4.21 vs 4.61 placebo score @ 26wk10 mg twice daily
NCT00853385 · Phase 3
4.08 vs 4.2 Adalimumab score @ 39wk10 mg twice daily
NCT00853385 · Phase 3
3.88 vs 3.95 Adalimumab score @ 52wk10 mg twice daily
NCT00853385 · Phase 3
4.84 vs 5.83 placebo score @ 4.33wk10 mg
NCT00847613 · Phase 3
4.19 vs 5.57 placebo score @ 13wk10 mg
NCT00847613 · Phase 3
3.9 vs 4.81 placebo score @ 26wk10 mg
NCT00847613 · Phase 3
4.26 vs 5.56 placebo score @ 13wk10 mg
NCT00960440 · Phase 3
4.7 vs 5.84 MTX score @ 4.33wk10 mg BID
NCT01039688 · Phase 3
4.17 vs 5.35 MTX score @ 8.67wk10 mg BID
NCT01039688 · Phase 3
3.94 vs 4.98 MTX score @ 13wk10 mg BID
NCT01039688 · Phase 3
3.62 vs 4.61 MTX score @ 26wk10 mg BID
NCT01039688 · Phase 3
3.53 vs 4.27 MTX score @ 39wk10 mg BID
NCT01039688 · Phase 3
3.37 vs 4.23 MTX score @ 52wk10 mg BID
NCT01039688 · Phase 3
3.32 vs 4.17 MTX score @ 65wk10 mg BID
NCT01039688 · Phase 3
3.33 vs 4.05 MTX score @ 78wk10 mg BID
NCT01039688 · Phase 3
3.33 vs 4.09 MTX score @ 91wk10 mg BID
NCT01039688 · Phase 3
3.29 vs 3.99 MTX score @ 104wk10 mg BID
NCT01039688 · Phase 3
5.2 vs 6.04 placebo score @ 2wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.69 vs 5.7 placebo score @ 4wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.33 vs 5.64 placebo score @ 6wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.22 vs 5.56 placebo score @ 8wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.93 vs 5.54 placebo score @ 10wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.95 vs 5.39 placebo score @ 12wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.86 vs 4.53 placebo score @ 16wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.67 vs 4.47 placebo score @ 20wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.62 vs 4.51 placebo score @ 24wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.88 vs 5.46 placebo score @ 1wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
4.28 vs 5.34 placebo score @ 2wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.72 vs 5.49 placebo score @ 4wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.13 vs 5.22 placebo score @ 8wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
2.83 vs 5.07 placebo score @ 12wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
5.2 vs 6.04 placebo score @ 2wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.46 vs 5.7 placebo score @ 4wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.02 vs 5.64 placebo score @ 6wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.8 vs 5.56 placebo score @ 8wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.71 vs 5.54 placebo score @ 10wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.77 vs 5.39 placebo score @ 12wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.63 vs 4.53 placebo score @ 16wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.54 vs 4.47 placebo score @ 20wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.61 vs 4.51 placebo score @ 24wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
5.57 vs 6.04 placebo score @ 2wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
5.1 vs 5.7 placebo score @ 4wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.91 vs 5.64 placebo score @ 6wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.89 vs 5.56 placebo score @ 8wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.81 vs 5.54 placebo score @ 10wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.78 vs 5.39 placebo score @ 12wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.96 vs 4.53 placebo score @ 16wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.08 vs 4.47 placebo score @ 20wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.72 vs 4.51 placebo score @ 24wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
5.33 vs 5.46 placebo score @ 1wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
5.03 vs 5.34 placebo score @ 2wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
4.54 vs 5.49 placebo score @ 4wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
4 vs 5.22 placebo score @ 8wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.9 vs 5.07 placebo score @ 12wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
5.92 vs 6.04 placebo score @ 2wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
5.73 vs 5.7 placebo score @ 4wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
5.36 vs 5.64 placebo score @ 6wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
5.31 vs 5.56 placebo score @ 8wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
5.22 vs 5.54 placebo score @ 10wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
5.41 vs 5.39 placebo score @ 12wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.39 vs 4.53 placebo score @ 16wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.76 vs 4.47 placebo score @ 20wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.87 vs 4.51 placebo score @ 24wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
5.42 vs 5.46 placebo score @ 1wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
5.29 vs 5.34 placebo score @ 2wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
5 vs 5.49 placebo score @ 4wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
4.37 vs 5.22 placebo score @ 8wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
4.07 vs 5.07 placebo score @ 12wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
6.55 vs 6.32 placebo score @ 0.14wk
NCT00976599 · Phase 2 · registry result, not featured evidence
4.9 vs 6.03 placebo score @ 4wk
NCT00976599 · Phase 2 · registry result, not featured evidence
6.6 vs 6.44 placebo score @ 0wk
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
4.33 vs 4.26 placebo score @ 6wk
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
3.84 vs 3.81 placebo score @ 12wk
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
DAS28-ESR 4.33 score @ 24wk5 mg
absolute value · score
No placebo or comparator arm
NCT00814307 · Phase 3
show 9 more results
3.82 score @ 48wk5 mg
NCT00856544 · Phase 3
4.12 score @ 39wk5 mg
NCT00847613 · Phase 3
4.09 score @ 52wk5 mg
NCT00847613 · Phase 3
3.99 score @ 24wk5 mg
NCT00960440 · Phase 3
4.01 score @ 24wk10 mg
NCT00814307 · Phase 3
3.5 score @ 48wk10 mg
NCT00856544 · Phase 3
3.84 score @ 39wk10 mg
NCT00847613 · Phase 3
3.79 score @ 52wk10 mg
NCT00847613 · Phase 3
3.7 score @ 24wk10 mg
NCT00960440 · Phase 3
DAS28-CRP 4.79 vs 5.3 placebo score @ 2wk5 mg
absolute value · score
NCT00814307 · Phase 3
show 203 more results
4.41 vs 4.98 placebo score @ 4.33wk5 mg
NCT00814307 · Phase 3
4.02 vs 4.85 placebo score @ 8.67wk5 mg
NCT00814307 · Phase 3
3.89 vs 4.68 placebo score @ 13wk5 mg
NCT00814307 · Phase 3
4.41 vs 4.92 placebo score @ 2wk5 mg
NCT00856544 · Phase 3
4.08 vs 4.68 placebo score @ 4.33wk5 mg
NCT00856544 · Phase 3
3.7 vs 4.59 placebo score @ 8.67wk5 mg
NCT00856544 · Phase 3
3.62 vs 4.51 placebo score @ 13wk5 mg
NCT00856544 · Phase 3
3.46 vs 3.92 placebo score @ 19.5wk5 mg
NCT00856544 · Phase 3
3.39 vs 3.6 placebo score @ 26wk5 mg
NCT00856544 · Phase 3
4.26 vs 5.09 placebo score @ 4.33wk5 mg twice daily
NCT00853385 · Phase 3
3.78 vs 4.83 placebo score @ 13wk5 mg twice daily
NCT00853385 · Phase 3
3.51 vs 3.85 placebo score @ 26wk5 mg twice daily
NCT00853385 · Phase 3
3.13 vs 3.46 Adalimumab score @ 39wk5 mg twice daily
NCT00853385 · Phase 3
3.05 vs 3.18 Adalimumab score @ 52wk5 mg twice daily
NCT00853385 · Phase 3
4.04 vs 4.73 placebo score @ 4.33wk5 mg
NCT00847613 · Phase 3
3.62 vs 4.54 placebo score @ 13wk5 mg
NCT00847613 · Phase 3
3.33 vs 3.79 placebo score @ 26wk5 mg
NCT00847613 · Phase 3
4.46 vs 5.1 placebo score @ 2wk5 mg
NCT00960440 · Phase 3
4.14 vs 4.92 placebo score @ 4.33wk5 mg
NCT00960440 · Phase 3
3.74 vs 4.78 placebo score @ 13wk5 mg
NCT00960440 · Phase 3
4.21 vs 4.96 MTX score @ 4.33wk5 mg BID
NCT01039688 · Phase 3
3.67 vs 4.5 MTX score @ 8.67wk5 mg BID
NCT01039688 · Phase 3
3.41 vs 4.14 MTX score @ 13wk5 mg BID
NCT01039688 · Phase 3
3.21 vs 3.85 MTX score @ 26wk5 mg BID
NCT01039688 · Phase 3
3.05 vs 3.49 MTX score @ 39wk5 mg BID
NCT01039688 · Phase 3
2.92 vs 3.42 MTX score @ 52wk5 mg BID
NCT01039688 · Phase 3
2.78 vs 3.38 MTX score @ 65wk5 mg BID
NCT01039688 · Phase 3
2.7 vs 3.32 MTX score @ 78wk5 mg BID
NCT01039688 · Phase 3
2.67 vs 3.33 MTX score @ 91wk5 mg BID
NCT01039688 · Phase 3
2.65 vs 3.22 MTX score @ 104wk5 mg BID
NCT01039688 · Phase 3
4.63 vs 5.24 placebo score @ 2wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.36 vs 5.01 placebo score @ 4wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.16 vs 4.92 placebo score @ 6wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.01 vs 4.84 placebo score @ 8wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.8 vs 4.83 placebo score @ 10wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.76 vs 4.83 placebo score @ 12wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.55 vs 3.93 placebo score @ 16wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.68 vs 3.97 placebo score @ 20wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.64 vs 3.96 placebo score @ 24wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.09 vs 4.61 placebo score @ 1wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.46 vs 4.43 placebo score @ 2wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.21 vs 4.56 placebo score @ 4wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
2.77 vs 4.31 placebo score @ 8wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
2.55 vs 4.15 placebo score @ 12wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
4.26 vs 4.91 placebo score @ 2wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
4.03 vs 4.6 placebo score @ 4wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.68 vs 4.35 placebo score @ 6wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.54 vs 4.3 placebo score @ 8wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.57 vs 4.37 placebo score @ 12wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.19 vs 3.93 placebo score @ 16wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.09 vs 3.81 placebo score @ 20wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.03 vs 3.48 placebo score @ 24wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
4.42 vs 5.3 placebo score @ 2wk10 mg
NCT00814307 · Phase 3
3.99 vs 4.98 placebo score @ 4.33wk10 mg
NCT00814307 · Phase 3
3.64 vs 4.85 placebo score @ 8.67wk10 mg
NCT00814307 · Phase 3
3.59 vs 4.68 placebo score @ 13wk10 mg
NCT00814307 · Phase 3
4.18 vs 4.92 placebo score @ 2wk10 mg
NCT00856544 · Phase 3
3.83 vs 4.68 placebo score @ 4.33wk10 mg
NCT00856544 · Phase 3
3.49 vs 4.59 placebo score @ 8.67wk10 mg
NCT00856544 · Phase 3
3.44 vs 4.51 placebo score @ 13wk10 mg
NCT00856544 · Phase 3
3.15 vs 3.92 placebo score @ 19.5wk10 mg
NCT00856544 · Phase 3
3.09 vs 3.6 placebo score @ 26wk10 mg
NCT00856544 · Phase 3
4.21 vs 5.09 placebo score @ 4.33wk10 mg twice daily
NCT00853385 · Phase 3
3.77 vs 4.83 placebo score @ 13wk10 mg twice daily
NCT00853385 · Phase 3
3.29 vs 3.85 placebo score @ 26wk10 mg twice daily
NCT00853385 · Phase 3
3.2 vs 3.46 Adalimumab score @ 39wk10 mg twice daily
NCT00853385 · Phase 3
3 vs 3.18 Adalimumab score @ 52wk10 mg twice daily
NCT00853385 · Phase 3
3.84 vs 4.73 placebo score @ 4.33wk10 mg
NCT00847613 · Phase 3
3.29 vs 4.54 placebo score @ 13wk10 mg
NCT00847613 · Phase 3
2.96 vs 3.79 placebo score @ 26wk10 mg
NCT00847613 · Phase 3
4.13 vs 5.1 placebo score @ 2wk10 mg
NCT00960440 · Phase 3
3.92 vs 4.92 placebo score @ 4.33wk10 mg
NCT00960440 · Phase 3
3.45 vs 4.78 placebo score @ 13wk10 mg
NCT00960440 · Phase 3
3.77 vs 4.96 MTX score @ 4.33wk10 mg BID
NCT01039688 · Phase 3
3.31 vs 4.5 MTX score @ 8.67wk10 mg BID
NCT01039688 · Phase 3
3.05 vs 4.14 MTX score @ 13wk10 mg BID
NCT01039688 · Phase 3
2.76 vs 3.85 MTX score @ 26wk10 mg BID
NCT01039688 · Phase 3
2.69 vs 3.49 MTX score @ 39wk10 mg BID
NCT01039688 · Phase 3
2.52 vs 3.42 MTX score @ 52wk10 mg BID
NCT01039688 · Phase 3
2.5 vs 3.38 MTX score @ 65wk10 mg BID
NCT01039688 · Phase 3
2.47 vs 3.32 MTX score @ 78wk10 mg BID
NCT01039688 · Phase 3
2.48 vs 3.33 MTX score @ 91wk10 mg BID
NCT01039688 · Phase 3
2.44 vs 3.22 MTX score @ 104wk10 mg BID
NCT01039688 · Phase 3
4.16 vs 5.24 placebo score @ 2wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.71 vs 5.01 placebo score @ 4wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.45 vs 4.92 placebo score @ 6wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.37 vs 4.84 placebo score @ 8wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.06 vs 4.83 placebo score @ 10wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.11 vs 4.83 placebo score @ 12wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.06 vs 3.93 placebo score @ 16wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
2.85 vs 3.97 placebo score @ 20wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
2.92 vs 3.96 placebo score @ 24wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.74 vs 4.61 placebo score @ 1wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.25 vs 4.43 placebo score @ 2wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
2.8 vs 4.56 placebo score @ 4wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
2.52 vs 4.31 placebo score @ 8wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
2.14 vs 4.15 placebo score @ 12wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
4.18 vs 4.91 placebo score @ 2wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.66 vs 4.6 placebo score @ 4wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.59 vs 4.35 placebo score @ 6wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.61 vs 4.3 placebo score @ 8wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.4 vs 4.37 placebo score @ 12wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.34 vs 3.93 placebo score @ 16wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.14 vs 3.81 placebo score @ 20wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.15 vs 3.48 placebo score @ 24wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
4.28 vs 4.91 placebo score @ 2wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 4.91 placebo score @ 2wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.99 vs 4.6 placebo score @ 4wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 4.6 placebo score @ 4wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.94 vs 4.35 placebo score @ 6wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 4.35 placebo score @ 6wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.72 vs 4.3 placebo score @ 8wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 4.3 placebo score @ 8wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.61 vs 4.37 placebo score @ 12wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 4.37 placebo score @ 12wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.14 vs 3.93 placebo score @ 16wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
4.65 vs 3.93 placebo score @ 16wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.08 vs 3.81 placebo score @ 20wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
4.82 vs 3.81 placebo score @ 20wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.07 vs 3.48 placebo score @ 24wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
4.51 vs 3.48 placebo score @ 24wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
4.32 vs 5.24 placebo score @ 2wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.71 vs 5.01 placebo score @ 4wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.34 vs 4.92 placebo score @ 6wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.13 vs 4.84 placebo score @ 8wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.05 vs 4.83 placebo score @ 10wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.06 vs 4.83 placebo score @ 12wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
2.92 vs 3.93 placebo score @ 16wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
2.93 vs 3.97 placebo score @ 20wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
2.82 vs 3.96 placebo score @ 24wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.18 vs 4.91 placebo score @ 2wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.75 vs 4.6 placebo score @ 4wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.6 vs 4.35 placebo score @ 6wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.38 vs 4.3 placebo score @ 8wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.28 vs 4.37 placebo score @ 12wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.12 vs 3.93 placebo score @ 16wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
2.94 vs 3.81 placebo score @ 20wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
2.91 vs 3.48 placebo score @ 24wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
4.6 vs 5.24 placebo score @ 2wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.16 vs 5.01 placebo score @ 4wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.02 vs 4.92 placebo score @ 6wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4 vs 4.84 placebo score @ 8wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.92 vs 4.83 placebo score @ 10wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.96 vs 4.83 placebo score @ 12wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.3 vs 3.93 placebo score @ 16wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.26 vs 3.97 placebo score @ 20wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.11 vs 3.96 placebo score @ 24wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.3 vs 4.61 placebo score @ 1wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.95 vs 4.43 placebo score @ 2wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.63 vs 4.56 placebo score @ 4wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.03 vs 4.31 placebo score @ 8wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.14 vs 4.15 placebo score @ 12wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
4.46 vs 4.91 placebo score @ 2wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 4.91 placebo score @ 2wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
4.03 vs 4.6 placebo score @ 4wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 4.6 placebo score @ 4wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.74 vs 4.35 placebo score @ 6wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 4.35 placebo score @ 6wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.63 vs 4.3 placebo score @ 8wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 4.3 placebo score @ 8wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.46 vs 4.37 placebo score @ 12wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 4.37 placebo score @ 12wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.11 vs 3.93 placebo score @ 16wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
4.19 vs 3.93 placebo score @ 16wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.06 vs 3.81 placebo score @ 20wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
4.24 vs 3.81 placebo score @ 20wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.14 vs 3.48 placebo score @ 24wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
4.08 vs 3.48 placebo score @ 24wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
4.96 vs 5.24 placebo score @ 2wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.77 vs 5.01 placebo score @ 4wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.42 vs 4.92 placebo score @ 6wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.52 vs 4.84 placebo score @ 8wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.37 vs 4.83 placebo score @ 10wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.57 vs 4.83 placebo score @ 12wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.63 vs 3.93 placebo score @ 16wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
3.94 vs 3.97 placebo score @ 20wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.11 vs 3.96 placebo score @ 24wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
4.3 vs 4.61 placebo score @ 1wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
4.23 vs 4.43 placebo score @ 2wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.96 vs 4.56 placebo score @ 4wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.43 vs 4.31 placebo score @ 8wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
3.21 vs 4.15 placebo score @ 12wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
4.88 vs 4.91 placebo score @ 2wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 4.91 placebo score @ 2wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
4.45 vs 4.6 placebo score @ 4wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 4.6 placebo score @ 4wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
4.32 vs 4.35 placebo score @ 6wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 4.35 placebo score @ 6wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
4.21 vs 4.3 placebo score @ 8wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 4.3 placebo score @ 8wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.98 vs 4.37 placebo score @ 12wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 4.37 placebo score @ 12wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.59 vs 3.93 placebo score @ 16wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
4.33 vs 3.93 placebo score @ 16wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.48 vs 3.81 placebo score @ 20wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.83 vs 3.81 placebo score @ 20wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
3.39 vs 3.48 placebo score @ 24wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
3.88 vs 3.48 placebo score @ 24wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
5.57 vs 5.22 placebo score @ 0.14wk
NCT00976599 · Phase 2 · registry result, not featured evidence
4.06 vs 4.91 placebo score @ 4wk
NCT00976599 · Phase 2 · registry result, not featured evidence
5.38 vs 5.23 placebo score @ 0wk
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
3.44 vs 3.33 placebo score @ 6wk
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
3.06 vs 2.99 placebo score @ 12wk
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
DAS28-CRP 3.65 score @ 17.33wk5 mg
absolute value · score
No placebo or comparator arm
NCT00814307 · Phase 3
show 17 more results
3.54 score @ 21.67wk5 mg
NCT00814307 · Phase 3
3.48 score @ 26wk5 mg
NCT00814307 · Phase 3
3.21 score @ 39wk5 mg
NCT00856544 · Phase 3
3.08 score @ 52wk5 mg
NCT00856544 · Phase 3
3.11 score @ 39wk5 mg
NCT00847613 · Phase 3
3.07 score @ 52wk5 mg
NCT00847613 · Phase 3
3.43 score @ 19.5wk5 mg
NCT00960440 · Phase 3
3.36 score @ 26wk5 mg
NCT00960440 · Phase 3
3.26 score @ 17.33wk10 mg
NCT00814307 · Phase 3
3.12 score @ 21.67wk10 mg
NCT00814307 · Phase 3
3.11 score @ 26wk10 mg
NCT00814307 · Phase 3
2.88 score @ 39wk10 mg
NCT00856544 · Phase 3
2.81 score @ 52wk10 mg
NCT00856544 · Phase 3
2.88 score @ 39wk10 mg
NCT00847613 · Phase 3
2.75 score @ 52wk10 mg
NCT00847613 · Phase 3
3.3 score @ 19.5wk10 mg
NCT00960440 · Phase 3
3.07 score @ 26wk10 mg
NCT00960440 · Phase 3
HAQ-DI 1.27 vs 1.43 placebo score @ 2wk5 mg
absolute value · score
NCT00814307 · Phase 3
show 216 more results
1.18 vs 1.4 placebo score @ 4.33wk5 mg
NCT00814307 · Phase 3
1.05 vs 1.4 placebo score @ 8.67wk5 mg
NCT00814307 · Phase 3
1.05 vs 1.35 placebo score @ 13wk5 mg
NCT00814307 · Phase 3
1.24 vs 1.28 placebo score @ 2wk5 mg
NCT00856544 · Phase 3
1.12 vs 1.2 placebo score @ 4.33wk5 mg
NCT00856544 · Phase 3
1.03 vs 1.2 placebo score @ 8.67wk5 mg
NCT00856544 · Phase 3
0.98 vs 1.16 placebo score @ 13wk5 mg
NCT00856544 · Phase 3
0.97 vs 0.95 placebo score @ 19.5wk5 mg
NCT00856544 · Phase 3
0.91 vs 0.93 placebo score @ 26wk5 mg
NCT00856544 · Phase 3
1.15 vs 1.32 placebo score @ 4.33wk5 mg twice daily
NCT00853385 · Phase 3
1 vs 1.25 placebo score @ 13wk5 mg twice daily
NCT00853385 · Phase 3
0.92 vs 1.15 placebo score @ 26wk5 mg twice daily
NCT00853385 · Phase 3
0.86 vs 0.97 Adalimumab score @ 39wk5 mg twice daily
NCT00853385 · Phase 3
0.83 vs 0.9 Adalimumab score @ 52wk5 mg twice daily
NCT00853385 · Phase 3
1.16 vs 1.25 placebo score @ 4.33wk5 mg
NCT00847613 · Phase 3
1 vs 1.19 placebo score @ 13wk5 mg
NCT00847613 · Phase 3
0.94 vs 1.09 placebo score @ 26wk5 mg
NCT00847613 · Phase 3
1.38 vs 1.49 placebo score @ 2wk5 mg
NCT00960440 · Phase 3
1.37 vs 1.38 placebo score @ 4.33wk5 mg
NCT00960440 · Phase 3
1.2 vs 1.44 placebo score @ 13wk5 mg
NCT00960440 · Phase 3
1.05 vs 1.3 MTX score @ 4.33wk5 mg BID
NCT01039688 · Phase 3
0.89 vs 1.17 MTX score @ 8.67wk5 mg BID
NCT01039688 · Phase 3
0.78 vs 1.03 MTX score @ 13wk5 mg BID
NCT01039688 · Phase 3
0.69 vs 0.92 MTX score @ 26wk5 mg BID
NCT01039688 · Phase 3
0.66 vs 0.83 MTX score @ 39wk5 mg BID
NCT01039688 · Phase 3
0.64 vs 0.79 MTX score @ 52wk5 mg BID
NCT01039688 · Phase 3
0.59 vs 0.83 MTX score @ 65wk5 mg BID
NCT01039688 · Phase 3
0.58 vs 0.74 MTX score @ 78wk5 mg BID
NCT01039688 · Phase 3
0.59 vs 0.76 MTX score @ 91wk5 mg BID
NCT01039688 · Phase 3
0.58 vs 0.77 MTX score @ 104wk5 mg BID
NCT01039688 · Phase 3
1.22 vs 1.49 placebo score @ 2wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.14 vs 1.38 placebo score @ 4wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.14 vs 1.31 placebo score @ 6wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.99 vs 1.24 placebo score @ 8wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.94 vs 1.24 placebo score @ 10wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.94 vs 1.24 placebo score @ 12wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.91 vs 1.28 placebo score @ 16wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.96 vs 1.3 placebo score @ 20wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.95 vs 1.2 placebo score @ 24wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.05 vs 1.25 placebo score @ 1wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
0.88 vs 1.18 placebo score @ 2wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
0.79 vs 1.07 placebo score @ 4wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
0.72 vs 1.21 placebo score @ 8wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
0.56 vs 1.13 placebo score @ 12wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
1.2 vs 1.15 placebo score @ 2wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.13 vs 1.14 placebo score @ 4wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.03 vs 1.07 placebo score @ 6wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.06 vs 1.05 placebo score @ 8wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0.94 vs 1.08 placebo score @ 12wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0.92 vs 0.8 placebo score @ 16wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0.78 vs 0.73 placebo score @ 20wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0.78 vs 0.74 placebo score @ 24wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.46 vs 1.63 placebo score @ 1wk5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
1.32 vs 1.53 placebo score @ 2wk5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
1.17 vs 1.54 placebo score @ 4wk5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
1.12 vs 1.47 placebo score @ 6wk5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
1.3 vs 1.52 placebo score @ 8wk5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
1.21 vs 1.43 placebo score @ 2wk10 mg
NCT00814307 · Phase 3
1.09 vs 1.4 placebo score @ 4.33wk10 mg
NCT00814307 · Phase 3
0.97 vs 1.4 placebo score @ 8.67wk10 mg
NCT00814307 · Phase 3
0.97 vs 1.35 placebo score @ 13wk10 mg
NCT00814307 · Phase 3
1.14 vs 1.28 placebo score @ 2wk10 mg
NCT00856544 · Phase 3
1.01 vs 1.2 placebo score @ 4.33wk10 mg
NCT00856544 · Phase 3
0.93 vs 1.2 placebo score @ 8.67wk10 mg
NCT00856544 · Phase 3
0.88 vs 1.16 placebo score @ 13wk10 mg
NCT00856544 · Phase 3
0.84 vs 0.95 placebo score @ 19.5wk10 mg
NCT00856544 · Phase 3
0.81 vs 0.93 placebo score @ 26wk10 mg
NCT00856544 · Phase 3
1.11 vs 1.32 placebo score @ 4.33wk10 mg twice daily
NCT00853385 · Phase 3
0.94 vs 1.25 placebo score @ 13wk10 mg twice daily
NCT00853385 · Phase 3
0.89 vs 1.15 placebo score @ 26wk10 mg twice daily
NCT00853385 · Phase 3
0.85 vs 0.97 Adalimumab score @ 39wk10 mg twice daily
NCT00853385 · Phase 3
0.81 vs 0.9 Adalimumab score @ 52wk10 mg twice daily
NCT00853385 · Phase 3
1.02 vs 1.25 placebo score @ 4.33wk10 mg
NCT00847613 · Phase 3
0.84 vs 1.19 placebo score @ 13wk10 mg
NCT00847613 · Phase 3
0.79 vs 1.09 placebo score @ 26wk10 mg
NCT00847613 · Phase 3
1.28 vs 1.49 placebo score @ 2wk10 mg
NCT00960440 · Phase 3
1.19 vs 1.38 placebo score @ 4.33wk10 mg
NCT00960440 · Phase 3
1.1 vs 1.44 placebo score @ 13wk10 mg
NCT00960440 · Phase 3
0.89 vs 1.3 MTX score @ 4.33wk10 mg BID
NCT01039688 · Phase 3
0.74 vs 1.17 MTX score @ 8.67wk10 mg BID
NCT01039688 · Phase 3
0.67 vs 1.03 MTX score @ 13wk10 mg BID
NCT01039688 · Phase 3
0.57 vs 0.92 MTX score @ 26wk10 mg BID
NCT01039688 · Phase 3
0.56 vs 0.83 MTX score @ 39wk10 mg BID
NCT01039688 · Phase 3
0.51 vs 0.79 MTX score @ 52wk10 mg BID
NCT01039688 · Phase 3
0.51 vs 0.83 MTX score @ 65wk10 mg BID
NCT01039688 · Phase 3
0.48 vs 0.74 MTX score @ 78wk10 mg BID
NCT01039688 · Phase 3
0.49 vs 0.76 MTX score @ 91wk10 mg BID
NCT01039688 · Phase 3
0.48 vs 0.77 MTX score @ 104wk10 mg BID
NCT01039688 · Phase 3
1.22 vs 1.49 placebo score @ 2wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.04 vs 1.38 placebo score @ 4wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1 vs 1.31 placebo score @ 6wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.97 vs 1.24 placebo score @ 8wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.86 vs 1.24 placebo score @ 10wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.81 vs 1.24 placebo score @ 12wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.85 vs 1.28 placebo score @ 16wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.8 vs 1.3 placebo score @ 20wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.81 vs 1.2 placebo score @ 24wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.85 vs 1.25 placebo score @ 1wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
0.79 vs 1.18 placebo score @ 2wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
0.77 vs 1.07 placebo score @ 4wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
0.64 vs 1.21 placebo score @ 8wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
0.59 vs 1.13 placebo score @ 12wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
1.16 vs 1.15 placebo score @ 2wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.08 vs 1.14 placebo score @ 4wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.02 vs 1.07 placebo score @ 6wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0.89 vs 1.05 placebo score @ 8wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0.95 vs 1.08 placebo score @ 12wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0.91 vs 0.8 placebo score @ 16wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0.84 vs 0.73 placebo score @ 20wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0.85 vs 0.74 placebo score @ 24wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.19 vs 1.63 placebo score @ 1wk30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
1.06 vs 1.53 placebo score @ 2wk30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
0.92 vs 1.54 placebo score @ 4wk30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
0.86 vs 1.47 placebo score @ 6wk30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
0.92 vs 1.52 placebo score @ 8wk30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
1.23 vs 1.15 placebo score @ 2wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 1.15 placebo score @ 2wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
1.14 vs 1.14 placebo score @ 4wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 1.14 placebo score @ 4wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
1.05 vs 1.07 placebo score @ 6wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 1.07 placebo score @ 6wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
0.98 vs 1.05 placebo score @ 8wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 1.05 placebo score @ 8wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
0.9 vs 1.08 placebo score @ 12wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 1.08 placebo score @ 12wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
0.81 vs 0.8 placebo score @ 16wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.36 vs 0.8 placebo score @ 16wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
0.75 vs 0.73 placebo score @ 20wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.42 vs 0.73 placebo score @ 20wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
0.72 vs 0.74 placebo score @ 24wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.34 vs 0.74 placebo score @ 24wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
1.26 vs 1.49 placebo score @ 2wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.08 vs 1.38 placebo score @ 4wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.93 vs 1.31 placebo score @ 6wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.86 vs 1.24 placebo score @ 8wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.81 vs 1.24 placebo score @ 10wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.78 vs 1.24 placebo score @ 12wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.73 vs 1.28 placebo score @ 16wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.71 vs 1.3 placebo score @ 20wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.79 vs 1.2 placebo score @ 24wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.15 vs 1.15 placebo score @ 2wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.12 vs 1.14 placebo score @ 4wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.05 vs 1.07 placebo score @ 6wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0.98 vs 1.05 placebo score @ 8wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0.96 vs 1.08 placebo score @ 12wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0.97 vs 0.8 placebo score @ 16wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0.92 vs 0.73 placebo score @ 20wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
0.88 vs 0.74 placebo score @ 24wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.37 vs 1.63 placebo score @ 1wk15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
1.17 vs 1.53 placebo score @ 2wk15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
1.07 vs 1.54 placebo score @ 4wk15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
0.95 vs 1.47 placebo score @ 6wk15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
1.06 vs 1.52 placebo score @ 8wk15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
1.28 vs 1.49 placebo score @ 2wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.23 vs 1.38 placebo score @ 4wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.24 vs 1.31 placebo score @ 6wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.12 vs 1.24 placebo score @ 8wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.2 vs 1.24 placebo score @ 10wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.09 vs 1.24 placebo score @ 12wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.04 vs 1.28 placebo score @ 16wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1 vs 1.3 placebo score @ 20wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
0.96 vs 1.2 placebo score @ 24wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.23 vs 1.25 placebo score @ 1wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
1.12 vs 1.18 placebo score @ 2wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
1.04 vs 1.07 placebo score @ 4wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
0.96 vs 1.21 placebo score @ 8wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
0.81 vs 1.13 placebo score @ 12wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
1.14 vs 1.15 placebo score @ 2wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 1.15 placebo score @ 2wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
1.03 vs 1.14 placebo score @ 4wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 1.14 placebo score @ 4wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
0.96 vs 1.07 placebo score @ 6wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 1.07 placebo score @ 6wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
0.93 vs 1.05 placebo score @ 8wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 1.05 placebo score @ 8wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
0.92 vs 1.08 placebo score @ 12wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 1.08 placebo score @ 12wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
0.82 vs 0.8 placebo score @ 16wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.18 vs 0.8 placebo score @ 16wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
0.77 vs 0.73 placebo score @ 20wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.13 vs 0.73 placebo score @ 20wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
0.85 vs 0.74 placebo score @ 24wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.05 vs 0.74 placebo score @ 24wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
1.45 vs 1.49 placebo score @ 2wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.45 vs 1.38 placebo score @ 4wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.3 vs 1.31 placebo score @ 6wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.29 vs 1.24 placebo score @ 8wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.25 vs 1.24 placebo score @ 10wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.28 vs 1.24 placebo score @ 12wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.02 vs 1.28 placebo score @ 16wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.05 vs 1.3 placebo score @ 20wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.02 vs 1.2 placebo score @ 24wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
1.05 vs 1.25 placebo score @ 1wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
1.04 vs 1.18 placebo score @ 2wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
0.94 vs 1.07 placebo score @ 4wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
0.8 vs 1.21 placebo score @ 8wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
0.78 vs 1.13 placebo score @ 12wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
1.41 vs 1.15 placebo score @ 2wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 1.15 placebo score @ 2wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
1.32 vs 1.14 placebo score @ 4wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 1.14 placebo score @ 4wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
1.23 vs 1.07 placebo score @ 6wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 1.07 placebo score @ 6wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
1.22 vs 1.05 placebo score @ 8wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 1.05 placebo score @ 8wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
1.19 vs 1.08 placebo score @ 12wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 1.08 placebo score @ 12wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
1.05 vs 0.8 placebo score @ 16wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.42 vs 0.8 placebo score @ 16wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
0.95 vs 0.73 placebo score @ 20wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.33 vs 0.73 placebo score @ 20wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
0.99 vs 0.74 placebo score @ 24wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
1.38 vs 0.74 placebo score @ 24wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
1.54 vs 1.46 placebo score @ 0wk
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
0.88 vs 0.88 placebo score @ 6wk
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
0.74 vs 0.92 placebo score @ 12wk
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
HAQ-DI 0.97 score @ 17.33wk5 mg
absolute value · score
No placebo or comparator arm
NCT00814307 · Phase 3
show 96 more results
0.95 score @ 21.67wk5 mg
NCT00814307 · Phase 3
0.94 score @ 26wk5 mg
NCT00814307 · Phase 3
0.89 score @ 39wk5 mg
NCT00856544 · Phase 3
0.86 score @ 52wk5 mg
NCT00856544 · Phase 3
0.91 score @ 39wk5 mg
NCT00847613 · Phase 3
0.9 score @ 52wk5 mg
NCT00847613 · Phase 3
1.19 score @ 19.5wk5 mg
NCT00960440 · Phase 3
1.1 score @ 26wk5 mg
NCT00960440 · Phase 3
-0.57 score @ 4.33wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.58 score @ 8.67wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.58 score @ 13wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.58 score @ 26wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.58 score @ 39wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.58 score @ 52wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.61 score @ 65wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.6 score @ 78wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.6 score @ 91wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.6 score @ 104wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.62 score @ 117wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.58 score @ 130wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.6 score @ 143wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.63 score @ 156wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.59 score @ 169wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.59 score @ 182wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.59 score @ 195wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.58 score @ 208wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.59 score @ 221wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.57 score @ 234wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.57 score @ 247wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.59 score @ 260wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.57 score @ 273wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.54 score @ 286wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.55 score @ 299wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.57 score @ 312wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.57 score @ 325wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.54 score @ 338wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.55 score @ 351wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.53 score @ 364wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.53 score @ 377wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.52 score @ 390wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.52 score @ 403wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.54 score @ 416wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.53 score @ 429wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.61 score @ 442wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.65 score @ 455wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.89 score @ 468wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-1.29 score @ 481wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.13 score @ 494wk5 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
0.88 score @ 17.33wk10 mg
NCT00814307 · Phase 3
0.87 score @ 21.67wk10 mg
NCT00814307 · Phase 3
0.86 score @ 26wk10 mg
NCT00814307 · Phase 3
0.71 score @ 39wk10 mg
NCT00856544 · Phase 3
0.73 score @ 52wk10 mg
NCT00856544 · Phase 3
0.75 score @ 39wk10 mg
NCT00847613 · Phase 3
0.76 score @ 52wk10 mg
NCT00847613 · Phase 3
1.1 score @ 19.5wk10 mg
NCT00960440 · Phase 3
1.02 score @ 26wk10 mg
NCT00960440 · Phase 3
-0.61 score @ 4.33wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.65 score @ 8.67wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.66 score @ 13wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.65 score @ 26wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.66 score @ 39wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.66 score @ 52wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.68 score @ 65wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.68 score @ 78wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.69 score @ 91wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.69 score @ 104wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.69 score @ 117wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.68 score @ 130wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.67 score @ 143wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.67 score @ 156wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.68 score @ 169wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.66 score @ 182wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.64 score @ 195wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.64 score @ 208wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.63 score @ 221wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.65 score @ 234wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.66 score @ 247wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.66 score @ 260wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.68 score @ 273wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.67 score @ 286wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.66 score @ 299wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.62 score @ 312wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.58 score @ 325wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.61 score @ 338wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.64 score @ 351wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.56 score @ 364wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.53 score @ 377wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.54 score @ 390wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.5 score @ 403wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.48 score @ 416wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.44 score @ 429wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.29 score @ 442wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
-0.5 score @ 455wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
0.13 score @ 468wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
0.25 score @ 481wk10 mg BID
NCT00413699 · Phase 3 · registry result, not featured evidence
Patient Pain VAS 45.92 vs 55.61 placebo mm @ 2wk5 mg
absolute value · mm
NCT00814307 · Phase 3
show 210 more results
40.68 vs 52.47 placebo mm @ 4.33wk5 mg
NCT00814307 · Phase 3
36.39 vs 52.38 placebo mm @ 8.67wk5 mg
NCT00814307 · Phase 3
34.93 vs 49.84 placebo mm @ 13wk5 mg
NCT00814307 · Phase 3
46.81 vs 51.01 placebo mm @ 2wk5 mg
NCT00856544 · Phase 3
40.17 vs 45.69 placebo mm @ 4.33wk5 mg
NCT00856544 · Phase 3
36.4 vs 47.3 placebo mm @ 8.67wk5 mg
NCT00856544 · Phase 3
34.92 vs 46.59 placebo mm @ 13wk5 mg
NCT00856544 · Phase 3
34.43 vs 40.23 placebo mm @ 19.5wk5 mg
NCT00856544 · Phase 3
31.07 vs 34.19 placebo mm @ 26wk5 mg
NCT00856544 · Phase 3
39.71 vs 49.92 placebo mm @ 4.33wk5 mg twice daily
NCT00853385 · Phase 3
32.98 vs 48.53 placebo mm @ 13wk5 mg twice daily
NCT00853385 · Phase 3
30.4 vs 35.04 placebo mm @ 26wk5 mg twice daily
NCT00853385 · Phase 3
27.04 vs 32.7 Adalimumab mm @ 39wk5 mg twice daily
NCT00853385 · Phase 3
26.99 vs 27.94 Adalimumab mm @ 52wk5 mg twice daily
NCT00853385 · Phase 3
41.61 vs 49.22 placebo mm @ 4.33wk5 mg
NCT00847613 · Phase 3
34.47 vs 46.96 placebo mm @ 13wk5 mg
NCT00847613 · Phase 3
32.79 vs 36.76 placebo mm @ 26wk5 mg
NCT00847613 · Phase 3
36.62 vs 46.34 MTX mm @ 4.33wk5 mg BID
NCT01039688 · Phase 3
31.97 vs 39.74 MTX mm @ 8.67wk5 mg BID
NCT01039688 · Phase 3
29.41 vs 36.83 MTX mm @ 13wk5 mg BID
NCT01039688 · Phase 3
27.07 vs 30.94 MTX mm @ 26wk5 mg BID
NCT01039688 · Phase 3
26.11 vs 31.22 MTX mm @ 39wk5 mg BID
NCT01039688 · Phase 3
26.09 vs 29.91 MTX mm @ 52wk5 mg BID
NCT01039688 · Phase 3
24.25 vs 29.85 MTX mm @ 65wk5 mg BID
NCT01039688 · Phase 3
23.66 vs 27.81 MTX mm @ 78wk5 mg BID
NCT01039688 · Phase 3
23.3 vs 29.18 MTX mm @ 91wk5 mg BID
NCT01039688 · Phase 3
23.03 vs 27.52 MTX mm @ 104wk5 mg BID
NCT01039688 · Phase 3
47.1 vs 55.26 placebo mm @ 2wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
43.65 vs 50.89 placebo mm @ 4wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
39.24 vs 49.63 placebo mm @ 6wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
33.91 vs 47.26 placebo mm @ 8wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
34.67 vs 44.96 placebo mm @ 10wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
32.7 vs 43.93 placebo mm @ 12wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
31.39 vs 37.55 placebo mm @ 16wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
33.13 vs 36.95 placebo mm @ 20wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
31.81 vs 31.35 placebo mm @ 24wk5 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
40.19 vs 49.36 placebo mm @ 1wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
33.19 vs 48.58 placebo mm @ 2wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
25.19 vs 49.72 placebo mm @ 4wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
22.59 vs 48.88 placebo mm @ 8wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
17.58 vs 44.96 placebo mm @ 12wk5 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
44.35 vs 46.91 placebo mm @ 2wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
40.03 vs 42.02 placebo mm @ 4wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
33.33 vs 42.21 placebo mm @ 6wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
36.55 vs 41.34 placebo mm @ 8wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
28.88 vs 41.02 placebo mm @ 12wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
28.98 vs 30.08 placebo mm @ 16wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
25.91 vs 25.08 placebo mm @ 20wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
24.45 vs 27.14 placebo mm @ 24wk5 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
51.76 vs 62.51 placebo mm @ 1wk5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
45.59 vs 60.65 placebo mm @ 2wk5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
37.77 vs 56.96 placebo mm @ 4wk5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
35.57 vs 52.75 placebo mm @ 6wk5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
42.44 vs 49.06 placebo mm @ 8wk5 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
42.13 vs 55.61 placebo mm @ 2wk10 mg
NCT00814307 · Phase 3
36.86 vs 52.47 placebo mm @ 4.33wk10 mg
NCT00814307 · Phase 3
31.66 vs 52.38 placebo mm @ 8.67wk10 mg
NCT00814307 · Phase 3
31.37 vs 49.84 placebo mm @ 13wk10 mg
NCT00814307 · Phase 3
41.85 vs 51.01 placebo mm @ 2wk10 mg
NCT00856544 · Phase 3
37.08 vs 45.69 placebo mm @ 4.33wk10 mg
NCT00856544 · Phase 3
32.84 vs 47.3 placebo mm @ 8.67wk10 mg
NCT00856544 · Phase 3
32.96 vs 46.59 placebo mm @ 13wk10 mg
NCT00856544 · Phase 3
32.62 vs 40.23 placebo mm @ 19.5wk10 mg
NCT00856544 · Phase 3
29.94 vs 34.19 placebo mm @ 26wk10 mg
NCT00856544 · Phase 3
36.77 vs 49.92 placebo mm @ 4.33wk10 mg twice daily
NCT00853385 · Phase 3
31.27 vs 48.53 placebo mm @ 13wk10 mg twice daily
NCT00853385 · Phase 3
28.36 vs 35.04 placebo mm @ 26wk10 mg twice daily
NCT00853385 · Phase 3
27.99 vs 32.7 Adalimumab mm @ 39wk10 mg twice daily
NCT00853385 · Phase 3
24.55 vs 27.94 Adalimumab mm @ 52wk10 mg twice daily
NCT00853385 · Phase 3
33.91 vs 49.22 placebo mm @ 4.33wk10 mg
NCT00847613 · Phase 3
29.23 vs 46.96 placebo mm @ 13wk10 mg
NCT00847613 · Phase 3
29.05 vs 36.76 placebo mm @ 26wk10 mg
NCT00847613 · Phase 3
32.78 vs 46.34 MTX mm @ 4.33wk10 mg BID
NCT01039688 · Phase 3
30.33 vs 39.74 MTX mm @ 8.67wk10 mg BID
NCT01039688 · Phase 3
27.07 vs 36.83 MTX mm @ 13wk10 mg BID
NCT01039688 · Phase 3
24.22 vs 30.94 MTX mm @ 26wk10 mg BID
NCT01039688 · Phase 3
23.76 vs 31.22 MTX mm @ 39wk10 mg BID
NCT01039688 · Phase 3
22.64 vs 29.91 MTX mm @ 52wk10 mg BID
NCT01039688 · Phase 3
23.72 vs 29.85 MTX mm @ 65wk10 mg BID
NCT01039688 · Phase 3
22.72 vs 27.81 MTX mm @ 78wk10 mg BID
NCT01039688 · Phase 3
22.85 vs 29.18 MTX mm @ 91wk10 mg BID
NCT01039688 · Phase 3
21.09 vs 27.52 MTX mm @ 104wk10 mg BID
NCT01039688 · Phase 3
43.9 vs 55.26 placebo mm @ 2wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
33.28 vs 50.89 placebo mm @ 4wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
33.68 vs 49.63 placebo mm @ 6wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
33.05 vs 47.26 placebo mm @ 8wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
28.11 vs 44.96 placebo mm @ 10wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
28.14 vs 43.93 placebo mm @ 12wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
29.05 vs 37.55 placebo mm @ 16wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
27.43 vs 36.95 placebo mm @ 20wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
22.85 vs 31.35 placebo mm @ 24wk10 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
37.08 vs 49.36 placebo mm @ 1wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
31.4 vs 48.58 placebo mm @ 2wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
30.46 vs 49.72 placebo mm @ 4wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
19.43 vs 48.88 placebo mm @ 8wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
16.9 vs 44.96 placebo mm @ 12wk10 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
41.26 vs 46.91 placebo mm @ 2wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
39.34 vs 42.02 placebo mm @ 4wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
34.38 vs 42.21 placebo mm @ 6wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
34.6 vs 41.34 placebo mm @ 8wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
33.78 vs 41.02 placebo mm @ 12wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
30.33 vs 30.08 placebo mm @ 16wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
33.66 vs 25.08 placebo mm @ 20wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
28.65 vs 27.14 placebo mm @ 24wk10 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
37.71 vs 62.51 placebo mm @ 1wk30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
30.83 vs 60.65 placebo mm @ 2wk30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
26.76 vs 56.96 placebo mm @ 4wk30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
23.39 vs 52.75 placebo mm @ 6wk30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
31.12 vs 49.06 placebo mm @ 8wk30 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
40.57 vs 46.91 placebo mm @ 2wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 46.91 placebo mm @ 2wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
34.39 vs 42.02 placebo mm @ 4wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 42.02 placebo mm @ 4wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
33.65 vs 42.21 placebo mm @ 6wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 42.21 placebo mm @ 6wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
31.16 vs 41.34 placebo mm @ 8wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 41.34 placebo mm @ 8wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
31.09 vs 41.02 placebo mm @ 12wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 41.02 placebo mm @ 12wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
24.56 vs 30.08 placebo mm @ 16wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
51.25 vs 30.08 placebo mm @ 16wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
24.58 vs 25.08 placebo mm @ 20wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
43.92 vs 25.08 placebo mm @ 20wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
19.92 vs 27.14 placebo mm @ 24wk20 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
35.33 vs 27.14 placebo mm @ 24wk20 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
41.28 vs 55.26 placebo mm @ 2wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
32.69 vs 50.89 placebo mm @ 4wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
30.24 vs 49.63 placebo mm @ 6wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
26.74 vs 47.26 placebo mm @ 8wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
23.38 vs 44.96 placebo mm @ 10wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
27.26 vs 43.93 placebo mm @ 12wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
24.24 vs 37.55 placebo mm @ 16wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
23.21 vs 36.95 placebo mm @ 20wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
25.31 vs 31.35 placebo mm @ 24wk15 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
37.82 vs 46.91 placebo mm @ 2wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
35.81 vs 42.02 placebo mm @ 4wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
32.97 vs 42.21 placebo mm @ 6wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
30.26 vs 41.34 placebo mm @ 8wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
31.48 vs 41.02 placebo mm @ 12wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
27.07 vs 30.08 placebo mm @ 16wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
24.69 vs 25.08 placebo mm @ 20wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
24.47 vs 27.14 placebo mm @ 24wk15 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
46.11 vs 62.51 placebo mm @ 1wk15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
40.14 vs 60.65 placebo mm @ 2wk15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
30.42 vs 56.96 placebo mm @ 4wk15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
28.35 vs 52.75 placebo mm @ 6wk15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
37.62 vs 49.06 placebo mm @ 8wk15 mg BID
NCT00147498 · Phase 2 · registry result, not featured evidence
45.25 vs 55.26 placebo mm @ 2wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
41.91 vs 50.89 placebo mm @ 4wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
42.75 vs 49.63 placebo mm @ 6wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
41.21 vs 47.26 placebo mm @ 8wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
43.24 vs 44.96 placebo mm @ 10wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
42.3 vs 43.93 placebo mm @ 12wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
34.97 vs 37.55 placebo mm @ 16wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
34.66 vs 36.95 placebo mm @ 20wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
30.62 vs 31.35 placebo mm @ 24wk3 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
43.5 vs 49.36 placebo mm @ 1wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
40.52 vs 48.58 placebo mm @ 2wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
34.88 vs 49.72 placebo mm @ 4wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
30.04 vs 48.88 placebo mm @ 8wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
27.17 vs 44.96 placebo mm @ 12wk3 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
43.33 vs 46.91 placebo mm @ 2wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 46.91 placebo mm @ 2wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
37.83 vs 42.02 placebo mm @ 4wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 42.02 placebo mm @ 4wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
33.75 vs 42.21 placebo mm @ 6wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 42.21 placebo mm @ 6wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
28.81 vs 41.34 placebo mm @ 8wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 41.34 placebo mm @ 8wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
30.9 vs 41.02 placebo mm @ 12wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 41.02 placebo mm @ 12wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
29.67 vs 30.08 placebo mm @ 16wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
39.31 vs 30.08 placebo mm @ 16wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
26.63 vs 25.08 placebo mm @ 20wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
42.31 vs 25.08 placebo mm @ 20wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
25.98 vs 27.14 placebo mm @ 24wk3 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
35.62 vs 27.14 placebo mm @ 24wk3 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
53.76 vs 55.26 placebo mm @ 2wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
51.72 vs 50.89 placebo mm @ 4wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
47.31 vs 49.63 placebo mm @ 6wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
47.28 vs 47.26 placebo mm @ 8wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
45.7 vs 44.96 placebo mm @ 10wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
47.25 vs 43.93 placebo mm @ 12wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
35 vs 37.55 placebo mm @ 16wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
39.67 vs 36.95 placebo mm @ 20wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
44.13 vs 31.35 placebo mm @ 24wk1 mg
NCT00550446 · Phase 2 · registry result, not featured evidence
45.36 vs 49.36 placebo mm @ 1wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
45.11 vs 48.58 placebo mm @ 2wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
42.44 vs 49.72 placebo mm @ 4wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
32.65 vs 48.88 placebo mm @ 8wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
32.19 vs 44.96 placebo mm @ 12wk1 mg
NCT00603512 · Phase 2 · registry result, not featured evidence
49.53 vs 46.91 placebo mm @ 2wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 46.91 placebo mm @ 2wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
45.57 vs 42.02 placebo mm @ 4wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 42.02 placebo mm @ 4wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
38.74 vs 42.21 placebo mm @ 6wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 42.21 placebo mm @ 6wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
38.97 vs 41.34 placebo mm @ 8wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 41.34 placebo mm @ 8wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
35.92 vs 41.02 placebo mm @ 12wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
NA vs 41.02 placebo mm @ 12wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
27.83 vs 30.08 placebo mm @ 16wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
40.38 vs 30.08 placebo mm @ 16wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
29.28 vs 25.08 placebo mm @ 20wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
35.71 vs 25.08 placebo mm @ 20wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
25.53 vs 27.14 placebo mm @ 24wk1 mg
NCT00413660 · Phase 2 · registry result, not featured evidence
38.15 vs 27.14 placebo mm @ 24wk1 mg to 5 mg (R)
NCT00413660 · Phase 2 · registry result, not featured evidence
65.66 vs 64.41 placebo mm @ 0wk
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
30.18 vs 31.26 placebo mm @ 6wk
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
25.72 vs 29.09 placebo mm @ 12wk
NCT01059864 · Phase 2 · registry result, not featured evidence · combination
Patient Pain VAS 33.18 mm @ 17.33wk5 mg
absolute value · mm
No placebo or comparator arm
NCT00814307 · Phase 3
show 13 more results
32.63 mm @ 21.67wk5 mg
NCT00814307 · Phase 3
32.6 mm @ 26wk5 mg
NCT00814307 · Phase 3
30.78 mm @ 39wk5 mg
NCT00856544 · Phase 3
30.18 mm @ 52wk5 mg
NCT00856544 · Phase 3
31.59 mm @ 39wk5 mg
NCT00847613 · Phase 3
30.54 mm @ 52wk5 mg
NCT00847613 · Phase 3
29.7 mm @ 17.33wk10 mg
NCT00814307 · Phase 3
29.1 mm @ 21.67wk10 mg
NCT00814307 · Phase 3
27.89 mm @ 26wk10 mg
NCT00814307 · Phase 3
27.13 mm @ 39wk10 mg
NCT00856544 · Phase 3
25.43 mm @ 52wk10 mg
NCT00856544 · Phase 3
27.14 mm @ 39wk10 mg
NCT00847613 · Phase 3
27.45 mm @ 52wk10 mg
NCT00847613 · Phase 3

+ 660 further endpoints in the CSV export.

upadacitinib

Morning Stiffness Duration -85.28 vs -34.27 placebo minutes @ 12wk15 mg
absolute change · minutes
NCT02675426 · Phase 3
show 3 more results
-94.56 vs -53.03 Methotrexate minutes @ 14wk15 mg
NCT02706951 · Phase 3
-85.13 vs -34.27 placebo minutes @ 12wk30 mg
NCT02675426 · Phase 3
-102.34 vs -53.03 Methotrexate minutes @ 14wk30 mg
NCT02706951 · Phase 3
RA Work Instability Scale -2.74 vs -0.69 placebo score @ 12wk15 mg
absolute change · score
NCT02720523 · Phase 2/3 · registry result, not featured evidence
show 2 more results
-2.24 vs -0.69 placebo score @ 12wk30 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
-3.22 vs -0.69 placebo score @ 12wk7.5 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
Morning Stiffness Severity -2.84 vs -1.02 placebo score @ 12wk15 mg
absolute change · score
NCT02720523 · Phase 2/3 · registry result, not featured evidence
show 18 more results
-2.98 vs -1.02 placebo score @ 12wk30 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
-2.83 vs -1.02 placebo score @ 12wk7.5 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
-0.91 vs -1.76 placebo score @ 2wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-0.82 vs -1.76 placebo score @ 4wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-1.3 vs -1.67 placebo score @ 8wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-1.27 vs -1.61 placebo score @ 12wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-0.68 vs -1.76 placebo score @ 2wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-0.83 vs -1.76 placebo score @ 4wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-0.97 vs -1.67 placebo score @ 8wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-1.3 vs -1.61 placebo score @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-2.02 vs -1.76 placebo score @ 2wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-2.71 vs -1.76 placebo score @ 4wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-3.07 vs -1.67 placebo score @ 8wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-3.23 vs -1.61 placebo score @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-0.59 vs -1.76 placebo score @ 2wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-1.08 vs -1.76 placebo score @ 4wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-1.5 vs -1.67 placebo score @ 8wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-1.66 vs -1.61 placebo score @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
Tender Joint Count -3.65 vs -2.47 placebo count @ 2wk60 mg
absolute change · count
NCT03682705 · Phase 2 · registry result, not featured evidence
show 15 more results
-5.16 vs -9.21 placebo count @ 4wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-8.43 vs -8.82 placebo count @ 8wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-9.14 vs -8.47 placebo count @ 12wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-3.86 vs -2.47 placebo count @ 2wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-5.39 vs -9.21 placebo count @ 4wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-10.83 vs -8.82 placebo count @ 8wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-9.33 vs -8.47 placebo count @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-8.42 vs -2.47 placebo count @ 2wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-11.86 vs -9.21 placebo count @ 4wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-15.44 vs -8.82 placebo count @ 8wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-16.33 vs -8.47 placebo count @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-4.88 vs -2.47 placebo count @ 2wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-8.08 vs -9.21 placebo count @ 4wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-9.08 vs -8.82 placebo count @ 8wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-12.58 vs -8.47 placebo count @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
Swollen Joint Count -3.61 vs -3.12 placebo count @ 2wk60 mg
absolute change · count
NCT03682705 · Phase 2 · registry result, not featured evidence
show 15 more results
-5.11 vs -4.7 placebo count @ 4wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-6.15 vs -4.32 placebo count @ 8wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-6.68 vs -5.58 placebo count @ 12wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-3.3 vs -3.12 placebo count @ 2wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-4.67 vs -4.7 placebo count @ 4wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-8.08 vs -4.32 placebo count @ 8wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-7.85 vs -5.58 placebo count @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-6.06 vs -3.12 placebo count @ 2wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-7.96 vs -4.7 placebo count @ 4wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-10.28 vs -4.32 placebo count @ 8wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-10.86 vs -5.58 placebo count @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-4.13 vs -3.12 placebo count @ 2wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-6.05 vs -4.7 placebo count @ 4wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-7.58 vs -4.32 placebo count @ 8wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-8.59 vs -5.58 placebo count @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
DAS Low Disease Activity 45.5% (n=55) vs 25.5% (n=55) placebo @ 12wk18 mg BID
event count · % of participants
NCT01960855 · Phase 2 · registry result, not featured evidence · converted to % from 25 Participants as posted
show 3 more results
52.7% (n=55) vs 25.5% (n=55) placebo @ 12wk*12 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence · converted to % from 29 Participants as posted
37.7% (n=53) vs 25.5% (n=55) placebo @ 12wk*6 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence · converted to % from 20 Participants as posted
33.3% (n=54) vs 25.5% (n=55) placebo @ 12wk*3 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence · converted to % from 18 Participants as posted
DAS Remission 30.9% (n=55) vs 12.7% (n=55) placebo @ 12wk18 mg BID
responder rate · % of participants
NCT01960855 · Phase 2 · registry result, not featured evidence · converted to % from 17 Participants as posted
show 3 more results
32.7% (n=55) vs 12.7% (n=55) placebo @ 12wk*12 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence · converted to % from 18 Participants as posted
26.4% (n=53) vs 12.7% (n=55) placebo @ 12wk*6 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence · converted to % from 14 Participants as posted
24.1% (n=54) vs 12.7% (n=55) placebo @ 12wk*3 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence · converted to % from 13 Participants as posted

Ulcerative Colitis

Shared mechanism: JAK · full Ulcerative Colitis pipeline

tofacitinib · Xeljanz

Marketed by Pfizer

Approved in Ulcerative ColitisSmall molecule (pan-JAK inhibitor)
Reliable signal

NCT01458951 · Phase 3 · completed

Design meets the 'strong' test: randomized, quadruple-blinded, placebo-controlled, adequately powered (429 vs 112), with a hard clinical/endoscopic composite primary endpoint (Mayo remission including endoscopic subscore) that was statistically significant in the favorable direction (p=0.0005, 13% absolute difference).

Next expected readout: March 2027 · NCT04624230 (registry estimate)

Reported efficacy

Percentage of Participants In Remission at Week 52: Percentage of Participants In Remission at Week 52 (Week 52): Tofacitinib 5 mg BID 34.3% vs Tofacitinib 10 mg BID 40.6% vs Placebo 11.1%; p=<0.0001 (Tofacitinib 5 mg BID vs Placebo), p=<0.0001 (Tofacitinib 10 mg BID vs Placebo) (met)

Result source: NCT01458574

upadacitinib · Rinvoq

Marketed by AbbVie

Approved in Ulcerative ColitisSmall molecule (JAK1-selective inhibitor)
Reliable signal

NCT02819635 · Phase 2/3 · completed

Randomized, quadruple-blinded, placebo-controlled, adequately powered (n=1302) trial with a hard clinical/endoscopic composite primary endpoint (Adapted Mayo Score remission, incorporating endoscopy); all primary comparisons across all three substudies and all active doses achieved statistical significance in the favorable direction (p<0.001 to 0.049), satisfying the 'strong' definition.

Next expected readout: March 2027 · NCT07546097 (registry estimate)

Reported efficacy

Percentage of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8: Percentage of Participants Who Achieved Clinical Remission Per Adapted Mayo Score at Week 8 (Week 8): Upadacitinib 45 mg 33.5% (95% CI 28.5-38.5) vs Placebo 4.1% (95% CI 1.1-7.1); p=<0.001 (Upadacitinib 45 mg vs Placebo) (met)

Result source: NCT03653026

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointtofacitinibupadacitinib
Clinical remission (induction)16.6% vs 3.6%+13 vs placebo10 mg BID · wk 8 · n 429NCT01458951
2 other results
  • 16.8% vs 3.6% 10 mg BID · wk 8 · n 429 · Phase 3 · secondary NCT01458951
  • 18.5% vs 8.2% 10 mg BID · wk 8 · n 476 · Phase 3 · secondary NCT01465763
26.1% vs 4.8%+21.3 vs placebo45 mg · wk 8 · n 319NCT02819635
11 other results
  • 33.5% vs 4.1% 45 mg · wk 8 · n 341 · Phase 3 · primary NCT03653026
  • 21.4% vs 0% 45 mg · wk 8 · n 56 · Phase 2/3 · primary NCT02819635
  • 13.5% vs 0% 30 mg · wk 8 · n 52 · Phase 2/3 · primary NCT02819635
  • 14.3% vs 0% 15 mg · wk 8 · n 49 · Phase 2/3 · primary NCT02819635
  • 8.5% vs 0% 7.5 mg · wk 8 · n 47 · Phase 2/3 · primary NCT02819635
  • 19.6% vs 0% 45 mg · wk 8 · n 56 · Phase 2/3 · secondary NCT02819635
  • 11.5% vs 0% 30 mg · wk 8 · n 52 · Phase 2/3 · secondary NCT02819635
  • 69.7% vs 22.2% 30 mg · wk 52 · n 58 · Phase 2/3 · secondary NCT02819635
  • 10.2% vs 0% 15 mg · wk 8 · n 49 · Phase 2/3 · secondary NCT02819635
  • 59.2% vs 22.2% 15 mg · wk 52 · n 47 · Phase 2/3 · secondary NCT02819635
  • 10.6% vs 0% 7.5 mg · wk 8 · n 47 · Phase 2/3 · secondary NCT02819635
Clinical remission (maintenance)40.6% vs 11.1%+29.5 vs placebo10 mg BID · wk 52 · n 197NCT01458574
11 other results
  • 34.3% vs 11.1% 5 mg BID · wk 52 · n 198 · Phase 3 · primary NCT01458574
  • 41.1% vs 11.1% 10 mg BID · wk 52 · n 197 · Phase 3 · secondary NCT01458574
  • 35.5% vs 11.1% 10 mg BID · wk 24 · n 197 · Phase 3 · secondary NCT01458574
  • 35.5% vs 11.1% 10 mg BID · wk 24 · n 197 · Phase 3 · secondary NCT01458574
  • 34.3% vs 11.1% 5 mg BID · wk 52 · n 198 · Phase 3 · secondary NCT01458574
  • 33.8% vs 11.1% 5 mg BID · wk 24 · n 198 · Phase 3 · secondary NCT01458574
  • 34.3% vs 11.1% 5 mg BID · wk 24 · n 198 · Phase 3 · secondary NCT01458574
  • 56.4% vs 10.2% 10 mg BID · wk 52 · n 55 · Phase 3 · secondary NCT01458574
  • 63.6% vs 15.3% 10 mg BID · wk 24 · n 55 · Phase 3 · secondary NCT01458574
  • 46.2% vs 10.2% 5 mg BID · wk 52 · n 65 · Phase 3 · secondary NCT01458574
  • 55.4% vs 15.3% 5 mg BID · wk 24 · n 65 · Phase 3 · secondary NCT01458574
51.7% vs 12.1%+39.6 vs placebo30 mg · wk 52 · n 154NCT02819635
1 other result
  • 42.3% vs 12.1% 15 mg · wk 52 · n 148 · Phase 2/3 · primary NCT02819635
Clinical response (induction)55% vs 28.6%+26.4 vs placebo10 mg BID · wk 8 · n 429NCT01458951
1 other result
  • 59.9% vs 32.8% 10 mg BID · wk 8 · n 476 · Phase 3 · secondary NCT01465763
72.6% vs 27.3%+45.3 vs placebo45 mg · wk 8 · n 319NCT02819635
13 other results
  • 74.5% vs 25.4% 45 mg · wk 8 · n 341 · Phase 3 · secondary NCT03653026
  • 60.1% vs 27.3% 45 mg · wk 2 · n 319 · Phase 2/3 · secondary NCT02819635
  • 63.3% vs 25.9% 45 mg · wk 2 · n 341 · Phase 3 · secondary NCT03653026
  • 55.4% vs 13% 45 mg · wk 8 · n 56 · Phase 2/3 · secondary NCT02819635
  • 55.4% vs 17.4% 45 mg · wk 2 · n 56 · Phase 2/3 · secondary NCT02819635
  • 46.2% vs 13% 30 mg · wk 8 · n 52 · Phase 2/3 · secondary NCT02819635
  • 36.5% vs 17.4% 30 mg · wk 2 · n 52 · Phase 2/3 · secondary NCT02819635
  • 76.6% vs 18.8% 30 mg · wk 52 · n 144 · Phase 2/3 · secondary NCT02819635
  • 49% vs 13% 15 mg · wk 8 · n 49 · Phase 2/3 · secondary NCT02819635
  • 34.7% vs 17.4% 15 mg · wk 2 · n 49 · Phase 2/3 · secondary NCT02819635
  • 63% vs 18.8% 15 mg · wk 52 · n 135 · Phase 2/3 · secondary NCT02819635
  • 29.8% vs 13% 7.5 mg · wk 8 · n 47 · Phase 2/3 · secondary NCT02819635
  • 23.4% vs 17.4% 7.5 mg · wk 2 · n 47 · Phase 2/3 · secondary NCT02819635
Endoscopic improvement (induction)28.4% vs 11.6%+16.8 vs placebo10 mg BID · wk 8 · n 429NCT01458951
1 other result
  • 31.3% vs 15.6% 10 mg BID · wk 8 · n 476 · Phase 3 · secondary NCT01465763
36.3% vs 7.4%+28.9 vs placebo45 mg · wk 8 · n 319NCT02819635
7 other results
  • 44% vs 8.3% 45 mg · wk 8 · n 341 · Phase 3 · secondary NCT03653026
  • 35.7% vs 2.2% 45 mg · wk 8 · n 56 · Phase 2/3 · secondary NCT02819635
  • 26.9% vs 2.2% 30 mg · wk 8 · n 52 · Phase 2/3 · secondary NCT02819635
  • 69.5% vs 19.2% 30 mg · wk 52 · n 79 · Phase 2/3 · secondary NCT02819635
  • 30.6% vs 2.2% 15 mg · wk 8 · n 49 · Phase 2/3 · secondary NCT02819635
  • 61.6% vs 19.2% 15 mg · wk 52 · n 63 · Phase 2/3 · secondary NCT02819635
  • 14.9% vs 2.2% 7.5 mg · wk 8 · n 47 · Phase 2/3 · secondary NCT02819635
Corticosteroid-free remission (maintenance)—Trial running · NCT04624230—Trial running · NCT06660693

Clinical remission (induction)

tofacitinib
16.6% vs 3.6%+13 vs placebo10 mg BID · wk 8 · n 429NCT01458951
2 other results
  • 16.8% vs 3.6% 10 mg BID · wk 8 · n 429 · Phase 3 · secondary NCT01458951
  • 18.5% vs 8.2% 10 mg BID · wk 8 · n 476 · Phase 3 · secondary NCT01465763
upadacitinib
26.1% vs 4.8%+21.3 vs placebo45 mg · wk 8 · n 319NCT02819635
11 other results
  • 33.5% vs 4.1% 45 mg · wk 8 · n 341 · Phase 3 · primary NCT03653026
  • 21.4% vs 0% 45 mg · wk 8 · n 56 · Phase 2/3 · primary NCT02819635
  • 13.5% vs 0% 30 mg · wk 8 · n 52 · Phase 2/3 · primary NCT02819635
  • 14.3% vs 0% 15 mg · wk 8 · n 49 · Phase 2/3 · primary NCT02819635
  • 8.5% vs 0% 7.5 mg · wk 8 · n 47 · Phase 2/3 · primary NCT02819635
  • 19.6% vs 0% 45 mg · wk 8 · n 56 · Phase 2/3 · secondary NCT02819635
  • 11.5% vs 0% 30 mg · wk 8 · n 52 · Phase 2/3 · secondary NCT02819635
  • 69.7% vs 22.2% 30 mg · wk 52 · n 58 · Phase 2/3 · secondary NCT02819635
  • 10.2% vs 0% 15 mg · wk 8 · n 49 · Phase 2/3 · secondary NCT02819635
  • 59.2% vs 22.2% 15 mg · wk 52 · n 47 · Phase 2/3 · secondary NCT02819635
  • 10.6% vs 0% 7.5 mg · wk 8 · n 47 · Phase 2/3 · secondary NCT02819635

Clinical remission (maintenance)

tofacitinib
40.6% vs 11.1%+29.5 vs placebo10 mg BID · wk 52 · n 197NCT01458574
11 other results
  • 34.3% vs 11.1% 5 mg BID · wk 52 · n 198 · Phase 3 · primary NCT01458574
  • 41.1% vs 11.1% 10 mg BID · wk 52 · n 197 · Phase 3 · secondary NCT01458574
  • 35.5% vs 11.1% 10 mg BID · wk 24 · n 197 · Phase 3 · secondary NCT01458574
  • 35.5% vs 11.1% 10 mg BID · wk 24 · n 197 · Phase 3 · secondary NCT01458574
  • 34.3% vs 11.1% 5 mg BID · wk 52 · n 198 · Phase 3 · secondary NCT01458574
  • 33.8% vs 11.1% 5 mg BID · wk 24 · n 198 · Phase 3 · secondary NCT01458574
  • 34.3% vs 11.1% 5 mg BID · wk 24 · n 198 · Phase 3 · secondary NCT01458574
  • 56.4% vs 10.2% 10 mg BID · wk 52 · n 55 · Phase 3 · secondary NCT01458574
  • 63.6% vs 15.3% 10 mg BID · wk 24 · n 55 · Phase 3 · secondary NCT01458574
  • 46.2% vs 10.2% 5 mg BID · wk 52 · n 65 · Phase 3 · secondary NCT01458574
  • 55.4% vs 15.3% 5 mg BID · wk 24 · n 65 · Phase 3 · secondary NCT01458574
upadacitinib
51.7% vs 12.1%+39.6 vs placebo30 mg · wk 52 · n 154NCT02819635
1 other result
  • 42.3% vs 12.1% 15 mg · wk 52 · n 148 · Phase 2/3 · primary NCT02819635

Clinical response (induction)

tofacitinib
55% vs 28.6%+26.4 vs placebo10 mg BID · wk 8 · n 429NCT01458951
1 other result
  • 59.9% vs 32.8% 10 mg BID · wk 8 · n 476 · Phase 3 · secondary NCT01465763
upadacitinib
72.6% vs 27.3%+45.3 vs placebo45 mg · wk 8 · n 319NCT02819635
13 other results
  • 74.5% vs 25.4% 45 mg · wk 8 · n 341 · Phase 3 · secondary NCT03653026
  • 60.1% vs 27.3% 45 mg · wk 2 · n 319 · Phase 2/3 · secondary NCT02819635
  • 63.3% vs 25.9% 45 mg · wk 2 · n 341 · Phase 3 · secondary NCT03653026
  • 55.4% vs 13% 45 mg · wk 8 · n 56 · Phase 2/3 · secondary NCT02819635
  • 55.4% vs 17.4% 45 mg · wk 2 · n 56 · Phase 2/3 · secondary NCT02819635
  • 46.2% vs 13% 30 mg · wk 8 · n 52 · Phase 2/3 · secondary NCT02819635
  • 36.5% vs 17.4% 30 mg · wk 2 · n 52 · Phase 2/3 · secondary NCT02819635
  • 76.6% vs 18.8% 30 mg · wk 52 · n 144 · Phase 2/3 · secondary NCT02819635
  • 49% vs 13% 15 mg · wk 8 · n 49 · Phase 2/3 · secondary NCT02819635
  • 34.7% vs 17.4% 15 mg · wk 2 · n 49 · Phase 2/3 · secondary NCT02819635
  • 63% vs 18.8% 15 mg · wk 52 · n 135 · Phase 2/3 · secondary NCT02819635
  • 29.8% vs 13% 7.5 mg · wk 8 · n 47 · Phase 2/3 · secondary NCT02819635
  • 23.4% vs 17.4% 7.5 mg · wk 2 · n 47 · Phase 2/3 · secondary NCT02819635

Endoscopic improvement (induction)

tofacitinib
28.4% vs 11.6%+16.8 vs placebo10 mg BID · wk 8 · n 429NCT01458951
1 other result
  • 31.3% vs 15.6% 10 mg BID · wk 8 · n 476 · Phase 3 · secondary NCT01465763
upadacitinib
36.3% vs 7.4%+28.9 vs placebo45 mg · wk 8 · n 319NCT02819635
7 other results
  • 44% vs 8.3% 45 mg · wk 8 · n 341 · Phase 3 · secondary NCT03653026
  • 35.7% vs 2.2% 45 mg · wk 8 · n 56 · Phase 2/3 · secondary NCT02819635
  • 26.9% vs 2.2% 30 mg · wk 8 · n 52 · Phase 2/3 · secondary NCT02819635
  • 69.5% vs 19.2% 30 mg · wk 52 · n 79 · Phase 2/3 · secondary NCT02819635
  • 30.6% vs 2.2% 15 mg · wk 8 · n 49 · Phase 2/3 · secondary NCT02819635
  • 61.6% vs 19.2% 15 mg · wk 52 · n 63 · Phase 2/3 · secondary NCT02819635
  • 14.9% vs 2.2% 7.5 mg · wk 8 · n 47 · Phase 2/3 · secondary NCT02819635

Corticosteroid-free remission (maintenance)

tofacitinib
—Trial running · NCT04624230
upadacitinib
—Trial running · NCT06660693
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
4 other shared endpoints and safety

Coverage. tofacitinib: 8 of 8 rows · upadacitinib: 8 of 8 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metrictofacitinib
Rows use multiple source trials
upadacitinib
Endoscopic Improvement
responder rate · % of participants
Maintenance
45.7% (n=197) vs 13.1% (n=198) placebo @ 52wk10 mg BIDa,b,c,d
NCT01458574 · Phase 3
show 1 more dose
37.4% (n=198) vs 13.1% (n=198) placebo @ 52wk5 mg BID
NCT01458574 · Phase 3
61.6% (n=154) vs 14.5% (n=149) placebo @ 52wk30 mga,b,c,d
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
show 1 more dose
48.7% (n=148) vs 14.5% (n=149) placebo @ 52wk15 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
Endoscopic Remission
responder rate · % of participants
Induction
7% (n=429) vs 1.8% (n=112) placebo @ 8wk10 mg BIDb,e
NCT01458951 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
1 other source trial
6.7% (n=476) vs 1.6% (n=122) placebo @ 8wk10 mg BID
NCT01465763 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
17.9% (n=56) vs 0% (n=46) placebo @ 8wk45 mga,b,e
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
show 4 more doses
13.7% (n=319) vs 1.3% (n=154) placebo @ 8wk45 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
9.6% (n=52) vs 0% (n=46) placebo @ 8wk30 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
4.1% (n=49) vs 0% (n=46) placebo @ 8wk15 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
6.4% (n=47) vs 0% (n=46) placebo @ 8wk7.5 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
Endoscopic Remission
responder rate · % of participants
Maintenance
16.8% (n=197) vs 4% (n=198) placebo @ 52wk10 mg BIDa,b,c,d
NCT01458574 · Phase 3
show 1 more dose
14.6% (n=198) vs 4% (n=198) placebo @ 52wk5 mg BID
NCT01458574 · Phase 3
25.9% (n=154) vs 5.6% (n=149) placebo @ 52wk30 mga,b,c,d
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
show 1 more dose
24.2% (n=148) vs 5.6% (n=149) placebo @ 52wk15 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
Total Mayo
absolute change · score
Induction
-3.7 vs -2 placebo score @ 8wk10 mg BIDb,e
NCT01458951 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
1 other source trial
-3.8 vs -1.9 placebo score @ 8wk10 mg BID
NCT01465763 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
-4.606 vs -0.741 placebo score @ 8wk45 mga,b,e
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
show 3 more doses
-4.211 vs -0.741 placebo score @ 8wk30 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
-3.589 vs -0.741 placebo score @ 8wk15 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
-2.87 vs -0.741 placebo score @ 8wk7.5 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
Dropout rate
7.5%10 mg BIDf
NCT01458951 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 7 more results
16.7%15 mg BID
NCT01458951 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
6.5%10 mg BID
NCT01465763 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
6.3%15 mg BID
NCT01465763 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
36%10 mg BID
NCT01458574 · Phase 3
43.9%5 mg BID
NCT01458574 · Phase 3
86.5%10 mg BID
NCT01470612 · Phase 3 · monotherapy
48%5 mg BID
NCT01470612 · Phase 3 · monotherapy
8.1%45 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
show 13 more results
12.9%45 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
—45 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
4.1%45 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
10.3%30 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
—30 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
—30 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
8.2%15 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
—15 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
—15 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
4.3%7.5 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
—7.5 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
3.2%45 mg
NCT03653026 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
—45 mg
NCT03653026 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Discontinued due to AEs
1.6%10 mg BIDf
NCT01458951 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 7 more results
0%15 mg BID
NCT01458951 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
1.9%10 mg BID
NCT01465763 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
0%15 mg BID
NCT01465763 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
4.6%10 mg BID
NCT01458574 · Phase 3
2.5%5 mg BID
NCT01458574 · Phase 3
10.4%10 mg BID
NCT01470612 · Phase 3 · monotherapy
11.4%5 mg BID
NCT01470612 · Phase 3 · monotherapy
3.3%45 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
show 13 more results
5.8%45 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
—45 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
1.9%45 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
4.3%30 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
—30 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
—30 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
6.1%15 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
—15 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
—15 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
2.1%7.5 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
—7.5 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
1.4%45 mg
NCT03653026 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
—45 mg
NCT03653026 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Serious AEs
4.2%10 mg BIDf
NCT01458951 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 7 more results
0%15 mg BID
NCT01458951 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
3.4%10 mg BID
NCT01465763 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
0%15 mg BID
NCT01465763 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
5.6%10 mg BID
NCT01458574 · Phase 3
5.1%5 mg BID
NCT01458574 · Phase 3
19.1%10 mg BID
NCT01470612 · Phase 3 · monotherapy
22.3%5 mg BID
NCT01470612 · Phase 3 · monotherapy
4.9%45 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
show 13 more results
2.4%45 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
2.5%45 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
3.4%45 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
4.3%30 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
—30 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
7.9%30 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
4.1%15 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
—15 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
7.4%15 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
0%7.5 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
0%7.5 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
3.2%45 mg
NCT03653026 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
1.5%45 mg
NCT03653026 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Most frequent reported AEs
10 mg BIDf
headache 7.7% (placebo 8%)
anaemia 2.6% (placebo 1.8%)
arthralgia 2.6% (placebo 5.4%)
NCT01458951 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 7 more results
15 mg BID
abdominal pain upper 16.7% (placebo 0%)
anaemia 16.7% (placebo 1.8%)
contusion 16.7% (placebo 0%)
NCT01458951 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
10 mg BID
headache 7.8% (placebo 6.6%)
nasopharyngitis 7.1% (placebo 7.4%)
nausea 3.2% (placebo 4.1%)
NCT01465763 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
15 mg BID
acne 18.8% (placebo 0%)
nasopharyngitis 18.8% (placebo 7.4%)
sinusitis 12.5% (placebo 0.8%)
NCT01465763 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
10 mg BID
colitis ulcerative 14.8% (placebo 32.3%)
nasopharyngitis 13.8% (placebo 5.6%)
arthralgia 8.7% (placebo 9.6%)
NCT01458574 · Phase 3
5 mg BID
colitis ulcerative 17.7% (placebo 32.3%)
nasopharyngitis 9.6% (placebo 5.6%)
arthralgia 8.6% (placebo 9.6%)
NCT01458574 · Phase 3
10 mg BID
nasopharyngitis 20.4%
colitis ulcerative 17%
blood creatine phosphokinase increased 11.1%
NCT01470612 · Phase 3 · monotherapy
5 mg BID
colitis ulcerative 25.1%
nasopharyngitis 23.4%
influenza 13.1%
NCT01470612 · Phase 3 · monotherapy
45 mg
blood creatine phosphokinase increased 6.5% (placebo 0%)
headache 6.5% (placebo 10.9%)
acne 4.9% (placebo 0%)
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
show 11 more results
45 mg
pyrexia 7.1% (placebo 2.2%)
anaemia 5.9% (placebo 6.5%)
blood creatine phosphokinase increased 5.9% (placebo 0%)
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
45 mg
blood creatine phosphokinase increased 5% (placebo 0%)
acne 4.7% (placebo 0%)
nasopharyngitis 4.7% (placebo 6.5%)
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
45 mg
blood creatine phosphokinase increased 6.8% (placebo 0%)
herpes zoster 5.1% (placebo 0%)
abdominal pain 3.4% (placebo 2.2%)
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
30 mg
headache 7.7% (placebo 10.9%)
nausea 6.8% (placebo 4.3%)
acne 5.1% (placebo 0%)
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
30 mg
nasopharyngitis 9.5% (placebo 6.5%)
colitis ulcerative 7.6% (placebo 8.7%)
blood creatine phosphokinase increased 6.6% (placebo 0%)
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
15 mg
headache 8.2% (placebo 10.9%)
upper respiratory tract infection 8.2% (placebo 0%)
anaemia 6.1% (placebo 6.5%)
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
15 mg
colitis ulcerative 12.4% (placebo 8.7%)
nasopharyngitis 9.6% (placebo 6.5%)
blood creatine phosphokinase increased 6.2% (placebo 0%)
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
7.5 mg
headache 8.5% (placebo 10.9%)
abdominal distension 6.4% (placebo 0%)
arthralgia 4.3% (placebo 2.2%)
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
7.5 mg
arthralgia 20% (placebo 2.2%)
colitis ulcerative 15% (placebo 8.7%)
constipation 10% (placebo 2.2%)
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
45 mg
acne 7% (placebo 1.7%)
headache 2.3% (placebo 5.1%)
anaemia 0% (placebo 0%)
NCT03653026 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
45 mg
anaemia 5.9% (placebo 0%)
blood creatine phosphokinase increased 5.9% (placebo 0%)
pyrexia 5.9% (placebo 0%)
NCT03653026 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 2/3 versus Phase 3.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dTreatment context has not been resolved for both arms.
  5. ePopulation context differs: baseline_threshold differs (adapted_mayo<=9, adapted_mayo>=5 versus none recorded).
  6. fPopulation comparability has not been reviewed for 4 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

tofacitinib

Symptomatic Remission 10.7% (n=429) vs 2.7% (n=112) placebo @ 8wk10 mg BID
responder rate · % of participants
NCT01458951 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 5 more results
11.8% (n=476) vs 5.7% (n=122) placebo @ 8wk10 mg BID
NCT01465763 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
21.8% (n=197) vs 6.6% (n=198) placebo @ 24wk10 mg BID
NCT01458574 · Phase 3
26.9% (n=197) vs 7.1% (n=198) placebo @ 52wk10 mg BID
NCT01458574 · Phase 3
23.7% (n=198) vs 6.6% (n=198) placebo @ 24wk5 mg BID
NCT01458574 · Phase 3
22.7% (n=198) vs 7.1% (n=198) placebo @ 52wk5 mg BID
NCT01458574 · Phase 3
Deep Remission 5.1% (n=429) vs 1.8% (n=112) placebo @ 8wk10 mg BID
responder rate · % of participants
NCT01458951 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 5 more results
6.5% (n=476) vs 0% (n=122) placebo @ 8wk10 mg BID
NCT01465763 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
10.7% (n=197) vs 4% (n=198) placebo @ 24wk10 mg BID
NCT01458574 · Phase 3
15.2% (n=197) vs 4% (n=198) placebo @ 52wk10 mg BID
NCT01458574 · Phase 3
14.1% (n=198) vs 4% (n=198) placebo @ 24wk5 mg BID
NCT01458574 · Phase 3
14.6% (n=198) vs 4% (n=198) placebo @ 52wk5 mg BID
NCT01458574 · Phase 3
Partial Mayo -2 vs -1 placebo score @ 2wk10 mg BID
absolute change · score
NCT01458951 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
show 5 more results
-2.7 vs -1.5 placebo score @ 4wk10 mg BID
NCT01458951 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
-3 vs -1.7 placebo score @ 8wk10 mg BID
NCT01458951 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
-2.1 vs -1.2 placebo score @ 2wk10 mg BID
NCT01465763 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
-2.8 vs -1.6 placebo score @ 4wk10 mg BID
NCT01465763 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
-3.1 vs -1.6 placebo score @ 8wk10 mg BID
NCT01465763 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Remission 18.5% (n=476) vs 8.2% (n=122) placebo @ 8wk10 mg BID
responder rate · % of participants
NCT01465763 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Partial Mayo 4.2 vs 5.2 placebo score @ 2wk10 mg BID
absolute value · score
At Week 2: (n= 465, 122)
NCT01465763 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Partial Mayo 3.5 vs 4.8 placebo score @ 4wk10 mg BID
absolute value · score
At Week 4: (n= 461, 118)
NCT01465763 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Partial Mayo 3.2 vs 4.8 placebo score @ 8wk10 mg BID
absolute value · score
At week 8: (n= 449, 119)
NCT01465763 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
Sustained Steroid-Free Remission 47.3% (n=55) vs 5.1% (n=59) placebo @ 52wk10 mg BID
responder rate · % of participants
NCT01458574 · Phase 3
show 3 more results
16.1% (n=87) vs 5% (n=101) placebo @ 52wk10 mg BID
NCT01458574 · Phase 3
35.4% (n=65) vs 5.1% (n=59) placebo @ 52wk5 mg BID
NCT01458574 · Phase 3
12.9% (n=101) vs 5% (n=101) placebo @ 52wk5 mg BID
NCT01458574 · Phase 3
Sustained Clinical Remission 25.4% (n=197) vs 5.1% (n=198) placebo @ 52wk10 mg BID
responder rate · % of participants
NCT01458574 · Phase 3
show 5 more results
25.9% (n=197) vs 5.1% (n=198) placebo @ 52wk10 mg BID
NCT01458574 · Phase 3
47.3% (n=55) vs 5.1% (n=59) placebo @ 52wk10 mg BID
NCT01458574 · Phase 3
22.2% (n=198) vs 5.1% (n=198) placebo @ 52wk5 mg BID
NCT01458574 · Phase 3
22.2% (n=198) vs 5.1% (n=198) placebo @ 52wk5 mg BID
NCT01458574 · Phase 3
36.9% (n=65) vs 5.1% (n=59) placebo @ 52wk5 mg BID
NCT01458574 · Phase 3
Sustained Mucosal Healing 33% (n=197) vs 6.6% (n=198) placebo @ 52wk10 mg BID
responder rate · % of participants
NCT01458574 · Phase 3
show 7 more results
66.3% (n=89) vs 21.8% (n=101) placebo @ 24wk10 mg BID
NCT01458574 · Phase 3
55.1% (n=89) vs 11.9% (n=101) placebo @ 52wk10 mg BID
NCT01458574 · Phase 3
49.4% (n=89) vs 8.9% (n=101) placebo @ 52wk10 mg BID
NCT01458574 · Phase 3
27.8% (n=198) vs 6.6% (n=198) placebo @ 52wk5 mg BID
NCT01458574 · Phase 3
52.4% (n=105) vs 21.8% (n=101) placebo @ 24wk5 mg BID
NCT01458574 · Phase 3
41.9% (n=105) vs 11.9% (n=101) placebo @ 52wk5 mg BID
NCT01458574 · Phase 3
33.3% (n=105) vs 8.9% (n=101) placebo @ 52wk5 mg BID
NCT01458574 · Phase 3
Sustained Clinical 59.4% (n=197) vs 19.2% (n=198) placebo @ 52wk10 mg BID
responder rate · % of participants
NCT01458574 · Phase 3
show 1 more result
49% (n=198) vs 19.2% (n=198) placebo @ 52wk5 mg BID
NCT01458574 · Phase 3
Sustained Deep Remission 3.6% (n=197) vs 0.5% (n=198) placebo @ 52wk10 mg BID
responder rate · % of participants
NCT01458574 · Phase 3
show 1 more result
6.1% (n=198) vs 0.5% (n=198) placebo @ 52wk5 mg BID
NCT01458574 · Phase 3

+ 8 further endpoints in the CSV export.

upadacitinib

Histologic Improvement 48.2% (n=56) vs 6.5% (n=46) placebo @ 8wk45 mg
responder rate · % of participants
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
show 5 more results
55% (n=319) vs 22.5% (n=154) placebo @ 8wk45 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
62.2% (n=341) vs 24.5% (n=174) placebo @ 8wk45 mg
NCT03653026 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
44.2% (n=52) vs 6.5% (n=46) placebo @ 8wk30 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
51% (n=49) vs 6.5% (n=46) placebo @ 8wk15 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
31.9% (n=47) vs 6.5% (n=46) placebo @ 8wk7.5 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
Histologic-Endoscopic Mucosal Improvement 30.1% (n=319) vs 6.6% (n=154) placebo @ 8wk45 mg
responder rate · % of participants
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
show 3 more results
36.7% (n=341) vs 5.9% (n=174) placebo @ 8wk45 mg
NCT03653026 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
49.8% (n=154) vs 11.9% (n=149) placebo @ 52wk30 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
35% (n=148) vs 11.9% (n=149) placebo @ 52wk15 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
Bowel Urgency Absent 48.4% (n=319) vs 21.4% (n=154) placebo @ 8wk45 mg
responder rate · % of participants
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
show 2 more results
63.6% (n=154) vs 17.4% (n=149) placebo @ 52wk30 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
56.1% (n=148) vs 17.4% (n=149) placebo @ 52wk15 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
Abdominal Pain Absent 46.6% (n=319) vs 23.4% (n=154) placebo @ 8wk45 mg
responder rate · % of participants
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
show 2 more results
55.3% (n=154) vs 20.8% (n=149) placebo @ 52wk30 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
45.9% (n=148) vs 20.8% (n=149) placebo @ 52wk15 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
IBDQ Total 55.3 vs 21.7 placebo score @ 8wk45 mg
absolute change · score
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
show 2 more results
58.9 vs 17.9 placebo score @ 52wk30 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
49.2 vs 17.9 placebo score @ 52wk15 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
Mucosal Healing 10.7% (n=319) vs 1.3% (n=154) placebo @ 8wk45 mg
responder rate · % of participants
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
show 3 more results
13.5% (n=341) vs 1.7% (n=174) placebo @ 8wk45 mg
NCT03653026 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
19% (n=154) vs 4.7% (n=149) placebo @ 52wk30 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
17.6% (n=148) vs 4.7% (n=149) placebo @ 52wk15 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
FACIT-Fatigue 9.5 vs 2.8 placebo score @ 8wk45 mg
absolute change · score
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
show 3 more results
9.4 vs 3.5 placebo score @ 8wk45 mg
NCT03653026 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3
9.5 vs 3.7 placebo score @ 52wk30 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
8.7 vs 3.7 placebo score @ 52wk15 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
Clinical Remission 69.7% (n=58) vs 22.2% (n=54) placebo @ 52wk30 mg
responder rate · % of participants
Induction
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
show 1 more result
59.2% (n=47) vs 22.2% (n=54) placebo @ 52wk15 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
Corticosteroid-free Clinical Remission 68% (n=58) vs 22.2% (n=54) placebo @ 52wk30 mg
responder rate · % of participants
Induction
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
show 1 more result
57.1% (n=47) vs 22.2% (n=54) placebo @ 52wk15 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
Endoscopic Improvement 69.5% (n=79) vs 19.2% (n=73) placebo @ 52wk30 mg
responder rate · % of participants
Induction
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
show 1 more result
61.6% (n=63) vs 19.2% (n=73) placebo @ 52wk15 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
Clinical Response 76.6% (n=144) vs 18.8% (n=134) placebo @ 52wk30 mg
responder rate · % of participants
Induction
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
show 1 more result
63% (n=135) vs 18.8% (n=134) placebo @ 52wk15 mg
NCT02819635 · Phase 2/3 · monotherapy · Ulcerative Colitis · phase 2/3
Bowel Urgency Resolution 53.7% (n=341) vs 25.9% (n=174) placebo @ 8wk45 mg
responder rate · % of participants
NCT03653026 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3

+ 2 further endpoints in the CSV export.

Psoriatic Arthritis

Shared mechanism: JAK · full Psoriatic Arthritis pipeline

tofacitinib · Xeljanz

Marketed by Pfizer

Approved in Psoriatic ArthritisSmall molecule (pan-JAK inhibitor)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

upadacitinib · Rinvoq

Marketed by AbbVie

Approved in Psoriatic ArthritisSmall molecule (JAK1-selective inhibitor)
Reliable signal

NCT03104400 · Phase 3 · completed

This was a large randomized, double-blind trial with both a placebo and an adalimumab arm. A power calculation planned about 1,640 patients and 1,705 were enrolled, and both upadacitinib doses met the primary endpoint against placebo, ACR20 response at week 12 (70.6% and 78.5% vs 36.2%, p<0.0001).

Next expected readout: September 2028 · NCT06454188 (registry estimate)

Reported efficacy

Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 (Baseline and Week 12): Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 (Baseline and Week 12): Upadacitinib 15 mg 70.6% (95% CI 66.3 to 74.9) | Upadacitinib 30 mg 78.5% (95% CI 74.6 to 82.4) vs Placebo 36.2% (95% CI 31.6 to 40.7) | Adalimumab 40 mg 65% (95% CI 60.5 to 69.5) (met)

Result source: NCT03104400

Results for Psoriatic Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointtofacitinibupadacitinib
ACR2050.5% vs 33.3%+17.1 vs placebo5 mg twice daily · wk 12 · n 107NCT01877668
27 other results
  • 49.6% vs 23.7% 5 mg Twice Daily · wk 12 · n 131 · Phase 3 · primary NCT01882439
  • 60.6% vs 33.3% 10 mg twice daily · wk 12 · n 104 · Phase 3 · primary NCT01877668
  • 47.0% vs 23.7% 10 mg, Twice Daily · wk 12 · n 132 · Phase 3 · primary NCT01882439
  • 43.9% vs 26.7% 5 mg twice daily · wk 8.67 · n 107 · Phase 3 · secondary NCT01877668
  • 48.1% vs 25.9% 5 mg Twice Daily · wk 8.67 · n 131 · Phase 3 · secondary NCT01882439
  • 34.6% vs 10.5% 5 mg twice daily · wk 4.33 · n 107 · Phase 3 · secondary NCT01877668
  • 34.4% vs 22.1% 5 mg Twice Daily · wk 4.33 · n 131 · Phase 3 · secondary NCT01882439
  • 22.4% vs 5.7% 5 mg twice daily · wk 2 · n 107 · Phase 3 · secondary NCT01877668
  • 26.7% vs 13.0% 5 mg Twice Daily · wk 2 · n 131 · Phase 3 · secondary NCT01882439
  • 54.8% vs 26.7% 10 mg twice daily · wk 8.67 · n 104 · Phase 3 · secondary NCT01877668
  • 47.7% vs 25.9% 10 mg, Twice Daily · wk 8.67 · n 132 · Phase 3 · secondary NCT01882439
  • 48.1% vs 10.5% 10 mg twice daily · wk 4.33 · n 104 · Phase 3 · secondary NCT01877668
  • 42.4% vs 22.1% 10 mg, Twice Daily · wk 4.33 · n 132 · Phase 3 · secondary NCT01882439
  • 31.7% vs 5.7% 10 mg twice daily · wk 2 · n 104 · Phase 3 · secondary NCT01877668
  • 28.8% vs 13.0% 10 mg, Twice Daily · wk 2 · n 132 · Phase 3 · secondary NCT01882439
  • 60.8% vs 57.5% 5 mg twice daily · wk 17.33 · n 107 · Phase 3 · secondary NCT01877668
  • 59.5% 5 mg Twice Daily · wk 17.33 · n 131 · Phase 3 · secondary NCT01882439
  • 58.9% vs 64.2% 5 mg twice daily · wk 26 · n 107 · Phase 3 · secondary NCT01877668
  • 59.5% 5 mg Twice Daily · wk 26 · n 131 · Phase 3 · secondary NCT01882439
  • 68.2% vs 68.9% 5 mg twice daily · wk 39 · n 107 · Phase 3 · secondary NCT01877668
  • 68.2% vs 60.4% 5 mg twice daily · wk 52 · n 107 · Phase 3 · secondary NCT01877668
  • 57.7% vs 57.5% 10 mg twice daily · wk 17.33 · n 104 · Phase 3 · secondary NCT01877668
  • 52.3% 10 mg, Twice Daily · wk 17.33 · n 132 · Phase 3 · secondary NCT01882439
  • 67.3% vs 64.2% 10 mg twice daily · wk 26 · n 104 · Phase 3 · secondary NCT01877668
  • 49.2% 10 mg, Twice Daily · wk 26 · n 132 · Phase 3 · secondary NCT01882439
  • 73.1% vs 68.9% 10 mg twice daily · wk 39 · n 104 · Phase 3 · secondary NCT01877668
  • 70.2% vs 60.4% 10 mg twice daily · wk 52 · n 104 · Phase 3 · secondary NCT01877668
70.6% vs 36.2%+34.4 vs placebo15 mg · wk 12 · n 429NCT03104400
11 other results
  • 56.9% vs 24.1% 15 mg · wk 12 · n 211 · Phase 3 · primary NCT03104374
  • 78.5% vs 36.2% 30 mg · wk 12 · n 423 · Phase 3 · primary NCT03104400
  • 63.8% vs 24.1% 30 mg · wk 12 · n 218 · Phase 3 · primary NCT03104374
  • 70.6% vs 36.2% 15 mg · wk 12 · n 429 · Phase 3 · secondary NCT03104400
  • 70.6% vs 36.2% 15 mg · wk 12 · n 429 · Phase 3 · secondary NCT03104400
  • 28.2% vs 12.1% 15 mg · wk 2 · n 429 · Phase 3 · secondary NCT03104400
  • 32.7% vs 10.8% 15 mg · wk 2 · n 211 · Phase 3 · secondary NCT03104374
  • 78.5% vs 36.2% 30 mg · wk 12 · n 423 · Phase 3 · secondary NCT03104400
  • 78.5% vs 36.2% 30 mg · wk 12 · n 423 · Phase 3 · secondary NCT03104400
  • 38.3% vs 12.1% 30 mg · wk 2 · n 423 · Phase 3 · secondary NCT03104400
  • 33.5% vs 10.8% 30 mg · wk 2 · n 218 · Phase 3 · secondary NCT03104374
ACR5028.0% vs 9.5%+18.5 vs placebo5 mg twice daily · wk 13 · n 107NCT01877668
27 other results
  • 29.8% vs 14.5% 5 mg Twice Daily · wk 13 · n 131 · Phase 3 · secondary NCT01882439
  • 21.5% vs 7.6% 5 mg twice daily · wk 8.67 · n 107 · Phase 3 · secondary NCT01877668
  • 25.2% vs 10.7% 5 mg Twice Daily · wk 8.67 · n 131 · Phase 3 · secondary NCT01882439
  • 12.2% vs 4.8% 5 mg twice daily · wk 4.33 · n 107 · Phase 3 · secondary NCT01877668
  • 17.6% vs 6.1% 5 mg Twice Daily · wk 4.33 · n 131 · Phase 3 · secondary NCT01882439
  • 6.5% vs 0.9% 5 mg twice daily · wk 2 · n 107 · Phase 3 · secondary NCT01877668
  • 6.1% vs 3.0% 5 mg Twice Daily · wk 2 · n 131 · Phase 3 · secondary NCT01882439
  • 40.4% vs 9.5% 10 mg twice daily · wk 13 · n 104 · Phase 3 · secondary NCT01877668
  • 28.0% vs 14.5% 10 mg, Twice Daily · wk 13 · n 132 · Phase 3 · secondary NCT01882439
  • 32.7% vs 7.6% 10 mg twice daily · wk 8.67 · n 104 · Phase 3 · secondary NCT01877668
  • 22.7% vs 10.7% 10 mg, Twice Daily · wk 8.67 · n 132 · Phase 3 · secondary NCT01882439
  • 19.2% vs 4.8% 10 mg twice daily · wk 4.33 · n 104 · Phase 3 · secondary NCT01877668
  • 10.6% vs 6.1% 10 mg, Twice Daily · wk 4.33 · n 132 · Phase 3 · secondary NCT01882439
  • 6.7% vs 0.9% 10 mg twice daily · wk 2 · n 104 · Phase 3 · secondary NCT01877668
  • 9.8% vs 3.0% 10 mg, Twice Daily · wk 2 · n 132 · Phase 3 · secondary NCT01882439
  • 44.9% vs 40.6% 5 mg twice daily · wk 52 · n 107 · Phase 3 · secondary NCT01877668
  • 42.1% vs 46.2% 5 mg twice daily · wk 39 · n 107 · Phase 3 · secondary NCT01877668
  • 38.3% vs 42.5% 5 mg twice daily · wk 26 · n 107 · Phase 3 · secondary NCT01877668
  • 38.2% 5 mg Twice Daily · wk 26 · n 131 · Phase 3 · secondary NCT01882439
  • 35.5% vs 32.1% 5 mg twice daily · wk 17.33 · n 107 · Phase 3 · secondary NCT01877668
  • 38.2% 5 mg Twice Daily · wk 17.33 · n 131 · Phase 3 · secondary NCT01882439
  • 48.1% vs 40.6% 10 mg twice daily · wk 52 · n 104 · Phase 3 · secondary NCT01877668
  • 46.1% vs 46.2% 10 mg twice daily · wk 39 · n 104 · Phase 3 · secondary NCT01877668
  • 46.1% vs 42.5% 10 mg twice daily · wk 26 · n 104 · Phase 3 · secondary NCT01877668
  • 29.6% 10 mg, Twice Daily · wk 26 · n 132 · Phase 3 · secondary NCT01882439
  • 37.5% vs 32.1% 10 mg twice daily · wk 17.33 · n 104 · Phase 3 · secondary NCT01877668
  • 28.8% 10 mg, Twice Daily · wk 17.33 · n 132 · Phase 3 · secondary NCT01882439
37.5% vs 13.2%+24.3 vs placebo15 mg · wk 12 · n 429NCT03104400
3 other results
  • 31.8% vs 4.7% 15 mg · wk 12 · n 211 · Phase 3 · secondary NCT03104374
  • 51.8% vs 13.2% 30 mg · wk 12 · n 423 · Phase 3 · secondary NCT03104400
  • 37.6% vs 4.7% 30 mg · wk 12 · n 218 · Phase 3 · secondary NCT03104374
PASI 7542.7% vs 14.6%+28.1 vs placebo5 mg twice daily · wk 13 · n 82NCT01877668
15 other results
  • 21.3% vs 13.9% 5 mg Twice Daily · wk 13 · n 80 · Phase 3 · secondary NCT01882439
  • 23.2% vs 4.9% 5 mg twice daily · wk 4.33 · n 82 · Phase 3 · secondary NCT01877668
  • 15% vs 5.8% 5 mg Twice Daily · wk 4.33 · n 80 · Phase 3 · secondary NCT01882439
  • 44.3% vs 14.6% 10 mg twice daily · wk 13 · n 70 · Phase 3 · secondary NCT01877668
  • 43.2% vs 13.9% 10 mg, Twice Daily · wk 13 · n 81 · Phase 3 · secondary NCT01882439
  • 27.1% vs 4.9% 10 mg twice daily · wk 4.33 · n 70 · Phase 3 · secondary NCT01877668
  • 18.5% vs 5.8% 10 mg, Twice Daily · wk 4.33 · n 81 · Phase 3 · secondary NCT01882439
  • 56.1% vs 55.8% 5 mg twice daily · wk 52 · n 82 · Phase 3 · secondary NCT01877668
  • 43.9% vs 58.4% 5 mg twice daily · wk 39 · n 82 · Phase 3 · secondary NCT01877668
  • 46.3% vs 54.5% 5 mg twice daily · wk 26 · n 82 · Phase 3 · secondary NCT01877668
  • 33.8% 5 mg Twice Daily · wk 26 · n 80 · Phase 3 · secondary NCT01882439
  • 67.1% vs 55.8% 10 mg twice daily · wk 52 · n 70 · Phase 3 · secondary NCT01877668
  • 68.6% vs 58.4% 10 mg twice daily · wk 39 · n 70 · Phase 3 · secondary NCT01877668
  • 60% vs 54.5% 10 mg twice daily · wk 26 · n 70 · Phase 3 · secondary NCT01877668
  • 45.7% 10 mg, Twice Daily · wk 26 · n 81 · Phase 3 · secondary NCT01882439
62.6% vs 21.3%+41.3 vs placebo15 mg · wk 16 · n 214NCT03104400
3 other results
  • 52.3% vs 16% 15 mg · wk 16 · n 130 · Phase 3 · secondary NCT03104374
  • 62.4% vs 21.3% 30 mg · wk 16 · n 210 · Phase 3 · secondary NCT03104400
  • 56.5% vs 16% 30 mg · wk 16 · n 131 · Phase 3 · secondary NCT03104374
Minimal disease activity—Not reported36.6% vs 12.3%+24.3 vs placebo15 mg · wk 24 · n 429NCT03104400
3 other results
  • 25.1% vs 2.8% 15 mg · wk 24 · n 211 · Phase 3 · secondary NCT03104374
  • 45.4% vs 12.3% 30 mg · wk 24 · n 423 · Phase 3 · secondary NCT03104400
  • 28.9% vs 2.8% 30 mg · wk 24 · n 218 · Phase 3 · secondary NCT03104374
HAQ-DI, change-0.3 vs -0.2−0.2 vs placebo5 mg twice daily · wk 12 · n 107NCT01877668
27 other results
  • -0.4 vs -0.1 5 mg Twice Daily · wk 12 · n 129 · Phase 3 · primary NCT01882439
  • -0.4 vs -0.2 10 mg twice daily · wk 12 · n 104 · Phase 3 · primary NCT01877668
  • -0.4 vs -0.1 10 mg, Twice Daily · wk 12 · n 132 · Phase 3 · primary NCT01882439
  • -0.3 vs -0.2 5 mg twice daily · wk 8.67 · n 107 · Phase 3 · secondary NCT01877668
  • -0.4 vs -0.2 5 mg Twice Daily · wk 8.67 · n 129 · Phase 3 · secondary NCT01882439
  • -0.2 vs -0.1 5 mg twice daily · wk 4.33 · n 107 · Phase 3 · secondary NCT01877668
  • -0.3 vs -0.1 5 mg Twice Daily · wk 4.33 · n 129 · Phase 3 · secondary NCT01882439
  • -0.2 vs -0.1 5 mg twice daily · wk 2 · n 107 · Phase 3 · secondary NCT01877668
  • -0.2 vs -0.1 5 mg Twice Daily · wk 2 · n 129 · Phase 3 · secondary NCT01882439
  • -0.4 vs -0.2 10 mg twice daily · wk 8.67 · n 104 · Phase 3 · secondary NCT01877668
  • -0.3 vs -0.2 10 mg, Twice Daily · wk 8.67 · n 132 · Phase 3 · secondary NCT01882439
  • -0.3 vs -0.1 10 mg twice daily · wk 4.33 · n 104 · Phase 3 · secondary NCT01877668
  • -0.2 vs -0.1 10 mg, Twice Daily · wk 4.33 · n 132 · Phase 3 · secondary NCT01882439
  • -0.2 vs -0.1 10 mg twice daily · wk 2 · n 104 · Phase 3 · secondary NCT01877668
  • -0.2 vs -0.1 10 mg, Twice Daily · wk 2 · n 132 · Phase 3 · secondary NCT01882439
  • -0.4 vs -0.4 5 mg twice daily · wk 17.33 · n 107 · Phase 3 · secondary NCT01877668
  • -0.4 5 mg Twice Daily · wk 17.33 · n 129 · Phase 3 · secondary NCT01882439
  • -0.4 vs -0.4 5 mg twice daily · wk 26 · n 107 · Phase 3 · secondary NCT01877668
  • -0.4 5 mg Twice Daily · wk 26 · n 129 · Phase 3 · secondary NCT01882439
  • -0.5 vs -0.4 5 mg twice daily · wk 39 · n 107 · Phase 3 · secondary NCT01877668
  • -0.5 vs -0.4 5 mg twice daily · wk 52 · n 107 · Phase 3 · secondary NCT01877668
  • -0.4 vs -0.4 10 mg twice daily · wk 17.33 · n 104 · Phase 3 · secondary NCT01877668
  • -0.3 10 mg, Twice Daily · wk 17.33 · n 132 · Phase 3 · secondary NCT01882439
  • -0.5 vs -0.4 10 mg twice daily · wk 26 · n 104 · Phase 3 · secondary NCT01877668
  • -0.3 10 mg, Twice Daily · wk 26 · n 132 · Phase 3 · secondary NCT01882439
  • -0.5 vs -0.4 10 mg twice daily · wk 39 · n 104 · Phase 3 · secondary NCT01877668
  • -0.5 vs -0.4 10 mg twice daily · wk 52 · n 104 · Phase 3 · secondary NCT01877668
-0.4 vs -0.1−0.3 vs placebo15 mg · wk 12 · n 404NCT03104400
5 other results
  • -0.4 vs -0.1 15 mg · wk 12 · n 404 · Phase 3 · secondary NCT03104400
  • -0.3 vs -0.1 15 mg · wk 12 · n 199 · Phase 3 · secondary NCT03104374
  • -0.5 vs -0.1 30 mg · wk 12 · n 398 · Phase 3 · secondary NCT03104400
  • -0.5 vs -0.1 30 mg · wk 12 · n 398 · Phase 3 · secondary NCT03104400
  • -0.4 vs -0.1 30 mg · wk 12 · n 204 · Phase 3 · secondary NCT03104374

ACR20

tofacitinib
50.5% vs 33.3%+17.1 vs placebo5 mg twice daily · wk 12 · n 107NCT01877668
27 other results
  • 49.6% vs 23.7% 5 mg Twice Daily · wk 12 · n 131 · Phase 3 · primary NCT01882439
  • 60.6% vs 33.3% 10 mg twice daily · wk 12 · n 104 · Phase 3 · primary NCT01877668
  • 47.0% vs 23.7% 10 mg, Twice Daily · wk 12 · n 132 · Phase 3 · primary NCT01882439
  • 43.9% vs 26.7% 5 mg twice daily · wk 8.67 · n 107 · Phase 3 · secondary NCT01877668
  • 48.1% vs 25.9% 5 mg Twice Daily · wk 8.67 · n 131 · Phase 3 · secondary NCT01882439
  • 34.6% vs 10.5% 5 mg twice daily · wk 4.33 · n 107 · Phase 3 · secondary NCT01877668
  • 34.4% vs 22.1% 5 mg Twice Daily · wk 4.33 · n 131 · Phase 3 · secondary NCT01882439
  • 22.4% vs 5.7% 5 mg twice daily · wk 2 · n 107 · Phase 3 · secondary NCT01877668
  • 26.7% vs 13.0% 5 mg Twice Daily · wk 2 · n 131 · Phase 3 · secondary NCT01882439
  • 54.8% vs 26.7% 10 mg twice daily · wk 8.67 · n 104 · Phase 3 · secondary NCT01877668
  • 47.7% vs 25.9% 10 mg, Twice Daily · wk 8.67 · n 132 · Phase 3 · secondary NCT01882439
  • 48.1% vs 10.5% 10 mg twice daily · wk 4.33 · n 104 · Phase 3 · secondary NCT01877668
  • 42.4% vs 22.1% 10 mg, Twice Daily · wk 4.33 · n 132 · Phase 3 · secondary NCT01882439
  • 31.7% vs 5.7% 10 mg twice daily · wk 2 · n 104 · Phase 3 · secondary NCT01877668
  • 28.8% vs 13.0% 10 mg, Twice Daily · wk 2 · n 132 · Phase 3 · secondary NCT01882439
  • 60.8% vs 57.5% 5 mg twice daily · wk 17.33 · n 107 · Phase 3 · secondary NCT01877668
  • 59.5% 5 mg Twice Daily · wk 17.33 · n 131 · Phase 3 · secondary NCT01882439
  • 58.9% vs 64.2% 5 mg twice daily · wk 26 · n 107 · Phase 3 · secondary NCT01877668
  • 59.5% 5 mg Twice Daily · wk 26 · n 131 · Phase 3 · secondary NCT01882439
  • 68.2% vs 68.9% 5 mg twice daily · wk 39 · n 107 · Phase 3 · secondary NCT01877668
  • 68.2% vs 60.4% 5 mg twice daily · wk 52 · n 107 · Phase 3 · secondary NCT01877668
  • 57.7% vs 57.5% 10 mg twice daily · wk 17.33 · n 104 · Phase 3 · secondary NCT01877668
  • 52.3% 10 mg, Twice Daily · wk 17.33 · n 132 · Phase 3 · secondary NCT01882439
  • 67.3% vs 64.2% 10 mg twice daily · wk 26 · n 104 · Phase 3 · secondary NCT01877668
  • 49.2% 10 mg, Twice Daily · wk 26 · n 132 · Phase 3 · secondary NCT01882439
  • 73.1% vs 68.9% 10 mg twice daily · wk 39 · n 104 · Phase 3 · secondary NCT01877668
  • 70.2% vs 60.4% 10 mg twice daily · wk 52 · n 104 · Phase 3 · secondary NCT01877668
upadacitinib
70.6% vs 36.2%+34.4 vs placebo15 mg · wk 12 · n 429NCT03104400
11 other results
  • 56.9% vs 24.1% 15 mg · wk 12 · n 211 · Phase 3 · primary NCT03104374
  • 78.5% vs 36.2% 30 mg · wk 12 · n 423 · Phase 3 · primary NCT03104400
  • 63.8% vs 24.1% 30 mg · wk 12 · n 218 · Phase 3 · primary NCT03104374
  • 70.6% vs 36.2% 15 mg · wk 12 · n 429 · Phase 3 · secondary NCT03104400
  • 70.6% vs 36.2% 15 mg · wk 12 · n 429 · Phase 3 · secondary NCT03104400
  • 28.2% vs 12.1% 15 mg · wk 2 · n 429 · Phase 3 · secondary NCT03104400
  • 32.7% vs 10.8% 15 mg · wk 2 · n 211 · Phase 3 · secondary NCT03104374
  • 78.5% vs 36.2% 30 mg · wk 12 · n 423 · Phase 3 · secondary NCT03104400
  • 78.5% vs 36.2% 30 mg · wk 12 · n 423 · Phase 3 · secondary NCT03104400
  • 38.3% vs 12.1% 30 mg · wk 2 · n 423 · Phase 3 · secondary NCT03104400
  • 33.5% vs 10.8% 30 mg · wk 2 · n 218 · Phase 3 · secondary NCT03104374

ACR50

tofacitinib
28.0% vs 9.5%+18.5 vs placebo5 mg twice daily · wk 13 · n 107NCT01877668
27 other results
  • 29.8% vs 14.5% 5 mg Twice Daily · wk 13 · n 131 · Phase 3 · secondary NCT01882439
  • 21.5% vs 7.6% 5 mg twice daily · wk 8.67 · n 107 · Phase 3 · secondary NCT01877668
  • 25.2% vs 10.7% 5 mg Twice Daily · wk 8.67 · n 131 · Phase 3 · secondary NCT01882439
  • 12.2% vs 4.8% 5 mg twice daily · wk 4.33 · n 107 · Phase 3 · secondary NCT01877668
  • 17.6% vs 6.1% 5 mg Twice Daily · wk 4.33 · n 131 · Phase 3 · secondary NCT01882439
  • 6.5% vs 0.9% 5 mg twice daily · wk 2 · n 107 · Phase 3 · secondary NCT01877668
  • 6.1% vs 3.0% 5 mg Twice Daily · wk 2 · n 131 · Phase 3 · secondary NCT01882439
  • 40.4% vs 9.5% 10 mg twice daily · wk 13 · n 104 · Phase 3 · secondary NCT01877668
  • 28.0% vs 14.5% 10 mg, Twice Daily · wk 13 · n 132 · Phase 3 · secondary NCT01882439
  • 32.7% vs 7.6% 10 mg twice daily · wk 8.67 · n 104 · Phase 3 · secondary NCT01877668
  • 22.7% vs 10.7% 10 mg, Twice Daily · wk 8.67 · n 132 · Phase 3 · secondary NCT01882439
  • 19.2% vs 4.8% 10 mg twice daily · wk 4.33 · n 104 · Phase 3 · secondary NCT01877668
  • 10.6% vs 6.1% 10 mg, Twice Daily · wk 4.33 · n 132 · Phase 3 · secondary NCT01882439
  • 6.7% vs 0.9% 10 mg twice daily · wk 2 · n 104 · Phase 3 · secondary NCT01877668
  • 9.8% vs 3.0% 10 mg, Twice Daily · wk 2 · n 132 · Phase 3 · secondary NCT01882439
  • 44.9% vs 40.6% 5 mg twice daily · wk 52 · n 107 · Phase 3 · secondary NCT01877668
  • 42.1% vs 46.2% 5 mg twice daily · wk 39 · n 107 · Phase 3 · secondary NCT01877668
  • 38.3% vs 42.5% 5 mg twice daily · wk 26 · n 107 · Phase 3 · secondary NCT01877668
  • 38.2% 5 mg Twice Daily · wk 26 · n 131 · Phase 3 · secondary NCT01882439
  • 35.5% vs 32.1% 5 mg twice daily · wk 17.33 · n 107 · Phase 3 · secondary NCT01877668
  • 38.2% 5 mg Twice Daily · wk 17.33 · n 131 · Phase 3 · secondary NCT01882439
  • 48.1% vs 40.6% 10 mg twice daily · wk 52 · n 104 · Phase 3 · secondary NCT01877668
  • 46.1% vs 46.2% 10 mg twice daily · wk 39 · n 104 · Phase 3 · secondary NCT01877668
  • 46.1% vs 42.5% 10 mg twice daily · wk 26 · n 104 · Phase 3 · secondary NCT01877668
  • 29.6% 10 mg, Twice Daily · wk 26 · n 132 · Phase 3 · secondary NCT01882439
  • 37.5% vs 32.1% 10 mg twice daily · wk 17.33 · n 104 · Phase 3 · secondary NCT01877668
  • 28.8% 10 mg, Twice Daily · wk 17.33 · n 132 · Phase 3 · secondary NCT01882439
upadacitinib
37.5% vs 13.2%+24.3 vs placebo15 mg · wk 12 · n 429NCT03104400
3 other results
  • 31.8% vs 4.7% 15 mg · wk 12 · n 211 · Phase 3 · secondary NCT03104374
  • 51.8% vs 13.2% 30 mg · wk 12 · n 423 · Phase 3 · secondary NCT03104400
  • 37.6% vs 4.7% 30 mg · wk 12 · n 218 · Phase 3 · secondary NCT03104374

PASI 75

tofacitinib
42.7% vs 14.6%+28.1 vs placebo5 mg twice daily · wk 13 · n 82NCT01877668
15 other results
  • 21.3% vs 13.9% 5 mg Twice Daily · wk 13 · n 80 · Phase 3 · secondary NCT01882439
  • 23.2% vs 4.9% 5 mg twice daily · wk 4.33 · n 82 · Phase 3 · secondary NCT01877668
  • 15% vs 5.8% 5 mg Twice Daily · wk 4.33 · n 80 · Phase 3 · secondary NCT01882439
  • 44.3% vs 14.6% 10 mg twice daily · wk 13 · n 70 · Phase 3 · secondary NCT01877668
  • 43.2% vs 13.9% 10 mg, Twice Daily · wk 13 · n 81 · Phase 3 · secondary NCT01882439
  • 27.1% vs 4.9% 10 mg twice daily · wk 4.33 · n 70 · Phase 3 · secondary NCT01877668
  • 18.5% vs 5.8% 10 mg, Twice Daily · wk 4.33 · n 81 · Phase 3 · secondary NCT01882439
  • 56.1% vs 55.8% 5 mg twice daily · wk 52 · n 82 · Phase 3 · secondary NCT01877668
  • 43.9% vs 58.4% 5 mg twice daily · wk 39 · n 82 · Phase 3 · secondary NCT01877668
  • 46.3% vs 54.5% 5 mg twice daily · wk 26 · n 82 · Phase 3 · secondary NCT01877668
  • 33.8% 5 mg Twice Daily · wk 26 · n 80 · Phase 3 · secondary NCT01882439
  • 67.1% vs 55.8% 10 mg twice daily · wk 52 · n 70 · Phase 3 · secondary NCT01877668
  • 68.6% vs 58.4% 10 mg twice daily · wk 39 · n 70 · Phase 3 · secondary NCT01877668
  • 60% vs 54.5% 10 mg twice daily · wk 26 · n 70 · Phase 3 · secondary NCT01877668
  • 45.7% 10 mg, Twice Daily · wk 26 · n 81 · Phase 3 · secondary NCT01882439
upadacitinib
62.6% vs 21.3%+41.3 vs placebo15 mg · wk 16 · n 214NCT03104400
3 other results
  • 52.3% vs 16% 15 mg · wk 16 · n 130 · Phase 3 · secondary NCT03104374
  • 62.4% vs 21.3% 30 mg · wk 16 · n 210 · Phase 3 · secondary NCT03104400
  • 56.5% vs 16% 30 mg · wk 16 · n 131 · Phase 3 · secondary NCT03104374

Minimal disease activity

tofacitinib
—Not reported
upadacitinib
36.6% vs 12.3%+24.3 vs placebo15 mg · wk 24 · n 429NCT03104400
3 other results
  • 25.1% vs 2.8% 15 mg · wk 24 · n 211 · Phase 3 · secondary NCT03104374
  • 45.4% vs 12.3% 30 mg · wk 24 · n 423 · Phase 3 · secondary NCT03104400
  • 28.9% vs 2.8% 30 mg · wk 24 · n 218 · Phase 3 · secondary NCT03104374

HAQ-DI, change

tofacitinib
-0.3 vs -0.2−0.2 vs placebo5 mg twice daily · wk 12 · n 107NCT01877668
27 other results
  • -0.4 vs -0.1 5 mg Twice Daily · wk 12 · n 129 · Phase 3 · primary NCT01882439
  • -0.4 vs -0.2 10 mg twice daily · wk 12 · n 104 · Phase 3 · primary NCT01877668
  • -0.4 vs -0.1 10 mg, Twice Daily · wk 12 · n 132 · Phase 3 · primary NCT01882439
  • -0.3 vs -0.2 5 mg twice daily · wk 8.67 · n 107 · Phase 3 · secondary NCT01877668
  • -0.4 vs -0.2 5 mg Twice Daily · wk 8.67 · n 129 · Phase 3 · secondary NCT01882439
  • -0.2 vs -0.1 5 mg twice daily · wk 4.33 · n 107 · Phase 3 · secondary NCT01877668
  • -0.3 vs -0.1 5 mg Twice Daily · wk 4.33 · n 129 · Phase 3 · secondary NCT01882439
  • -0.2 vs -0.1 5 mg twice daily · wk 2 · n 107 · Phase 3 · secondary NCT01877668
  • -0.2 vs -0.1 5 mg Twice Daily · wk 2 · n 129 · Phase 3 · secondary NCT01882439
  • -0.4 vs -0.2 10 mg twice daily · wk 8.67 · n 104 · Phase 3 · secondary NCT01877668
  • -0.3 vs -0.2 10 mg, Twice Daily · wk 8.67 · n 132 · Phase 3 · secondary NCT01882439
  • -0.3 vs -0.1 10 mg twice daily · wk 4.33 · n 104 · Phase 3 · secondary NCT01877668
  • -0.2 vs -0.1 10 mg, Twice Daily · wk 4.33 · n 132 · Phase 3 · secondary NCT01882439
  • -0.2 vs -0.1 10 mg twice daily · wk 2 · n 104 · Phase 3 · secondary NCT01877668
  • -0.2 vs -0.1 10 mg, Twice Daily · wk 2 · n 132 · Phase 3 · secondary NCT01882439
  • -0.4 vs -0.4 5 mg twice daily · wk 17.33 · n 107 · Phase 3 · secondary NCT01877668
  • -0.4 5 mg Twice Daily · wk 17.33 · n 129 · Phase 3 · secondary NCT01882439
  • -0.4 vs -0.4 5 mg twice daily · wk 26 · n 107 · Phase 3 · secondary NCT01877668
  • -0.4 5 mg Twice Daily · wk 26 · n 129 · Phase 3 · secondary NCT01882439
  • -0.5 vs -0.4 5 mg twice daily · wk 39 · n 107 · Phase 3 · secondary NCT01877668
  • -0.5 vs -0.4 5 mg twice daily · wk 52 · n 107 · Phase 3 · secondary NCT01877668
  • -0.4 vs -0.4 10 mg twice daily · wk 17.33 · n 104 · Phase 3 · secondary NCT01877668
  • -0.3 10 mg, Twice Daily · wk 17.33 · n 132 · Phase 3 · secondary NCT01882439
  • -0.5 vs -0.4 10 mg twice daily · wk 26 · n 104 · Phase 3 · secondary NCT01877668
  • -0.3 10 mg, Twice Daily · wk 26 · n 132 · Phase 3 · secondary NCT01882439
  • -0.5 vs -0.4 10 mg twice daily · wk 39 · n 104 · Phase 3 · secondary NCT01877668
  • -0.5 vs -0.4 10 mg twice daily · wk 52 · n 104 · Phase 3 · secondary NCT01877668
upadacitinib
-0.4 vs -0.1−0.3 vs placebo15 mg · wk 12 · n 404NCT03104400
5 other results
  • -0.4 vs -0.1 15 mg · wk 12 · n 404 · Phase 3 · secondary NCT03104400
  • -0.3 vs -0.1 15 mg · wk 12 · n 199 · Phase 3 · secondary NCT03104374
  • -0.5 vs -0.1 30 mg · wk 12 · n 398 · Phase 3 · secondary NCT03104400
  • -0.5 vs -0.1 30 mg · wk 12 · n 398 · Phase 3 · secondary NCT03104400
  • -0.4 vs -0.1 30 mg · wk 12 · n 204 · Phase 3 · secondary NCT03104374
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
4 other shared endpoints and safety

Coverage. tofacitinib: 8 of 8 rows · upadacitinib: 8 of 8 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metrictofacitinibupadacitinib
ACR70
responder rate · % of participants
23.36% (n=107) vs NA placebo @ 52wk5 mg twice dailya,b,c,d
NCT01877668 · Phase 3
show 1 more dose
30.77% (n=104) vs NA placebo @ 52wk10 mg twice daily
NCT01877668 · Phase 3
15.6% (n=429) vs 2.4% (n=423) placebo @ 12wk15 mga,b,c,d
NCT03104400 · Phase 3
show 1 more dose
25.3% (n=423) vs 2.4% (n=423) placebo @ 12wk30 mg
NCT03104400 · Phase 3
FACIT-Fatigue
absolute change · score
8.5 vs NA placebo score @ 52wk5 mg twice dailya,b,c,d
NCT01877668 · Phase 3
show 1 more dose
8.4 vs NA placebo score @ 52wk10 mg twice daily
NCT01877668 · Phase 3
6.3 vs 2.8 placebo score @ 12wk15 mga,b,c,d
NCT03104400 · Phase 3
show 1 more dose
7.1 vs 2.8 placebo score @ 12wk30 mg
NCT03104400 · Phase 3
Modified Sharp
absolute change · score
0.01 vs -0.07 Adalimumab score @ 48wk5 mg twice dailya,b,c,e
NCT01877668 · Phase 3
show 1 more dose
-0.01 vs -0.07 Adalimumab score @ 48wk10 mg twice daily
NCT01877668 · Phase 3
-0.04 vs 0.25 placebo score @ 24wk15 mga,b,c,e
NCT03104400 · Phase 3
show 1 more dose
0.03 vs 0.25 placebo score @ 24wk30 mg
NCT03104400 · Phase 3
SF-36 PCS
absolute change · score
7.61 vs NA placebo score @ 52wk5 mg twice dailya,b,c,d
NCT01877668 · Phase 3
show 1 more dose
7.67 vs NA placebo score @ 52wk10 mg twice daily
NCT01877668 · Phase 3
7.86 vs 3.19 placebo score @ 12wk15 mga,b,c,d
NCT03104400 · Phase 3
show 1 more dose
8.9 vs 3.19 placebo score @ 12wk30 mg
NCT03104400 · Phase 3
Dropout rate
10.3%5 mg twice dailyf
NCT01877668 · Phase 3
show 11 more results
7.7%10 mg twice daily
NCT01877668 · Phase 3
6.9%5 mg Twice Daily
NCT01882439 · Phase 3
15.9%10 mg, Twice Daily
NCT01882439 · Phase 3
5.1%Tofacitinib
NCT03486457 · Phase 3 · registry result, not featured evidence
—Tofacitinib: Up to Month 3
NCT03486457 · Phase 3 · registry result, not featured evidence
—Tofacitinib: Up to Month 6
NCT03486457 · Phase 3 · registry result, not featured evidence
—5 mg BID
NCT01976364 · Phase 3 · registry result, not featured evidence
—5 mg BID
NCT01976364 · Phase 3 · registry result, not featured evidence · combination
32.2%Tofacitinib
NCT01976364 · Phase 3 · registry result, not featured evidence · background therapy
14.9%5 mg BID
NCT01519089 · Phase 3 · registry result, not featured evidence
31.3%10 mg BID
NCT01519089 · Phase 3 · registry result, not featured evidence
11.9%15 mgf
NCT03104400 · Phase 3
show 12 more results
—15 mg
NCT03104400 · Phase 3
—15 mg
NCT03104400 · Phase 3
13.5%30 mg
NCT03104400 · Phase 3
—30 mg / 15 mg
NCT03104400 · Phase 3
—30 mg
NCT03104400 · Phase 3
—30 mg
NCT03104400 · Phase 3
—15 mg
NCT03104374 · Phase 3
—15 mg
NCT03104374 · Phase 3
20.9%15 mg
NCT03104374 · Phase 3
—30 mg
NCT03104374 · Phase 3
—30 mg
NCT03104374 · Phase 3
24.2%30 mg
NCT03104374 · Phase 3
Discontinued due to AEs
5.6%5 mg twice dailyf
NCT01877668 · Phase 3
show 11 more results
2.9%10 mg twice daily
NCT01877668 · Phase 3
3.8%5 mg Twice Daily
NCT01882439 · Phase 3
7.6%10 mg, Twice Daily
NCT01882439 · Phase 3
1.5%Tofacitinib
NCT03486457 · Phase 3 · registry result, not featured evidence
—Tofacitinib: Up to Month 3
NCT03486457 · Phase 3 · registry result, not featured evidence
—Tofacitinib: Up to Month 6
NCT03486457 · Phase 3 · registry result, not featured evidence
—5 mg BID
NCT01976364 · Phase 3 · registry result, not featured evidence
—5 mg BID
NCT01976364 · Phase 3 · registry result, not featured evidence · combination
9.2%Tofacitinib
NCT01976364 · Phase 3 · registry result, not featured evidence · background therapy
8.5%5 mg BID
NCT01519089 · Phase 3 · registry result, not featured evidence
8.3%10 mg BID
NCT01519089 · Phase 3 · registry result, not featured evidence
2.1%15 mgf
NCT03104400 · Phase 3
show 12 more results
—15 mg
NCT03104400 · Phase 3
—15 mg
NCT03104400 · Phase 3
5%30 mg
NCT03104400 · Phase 3
—30 mg / 15 mg
NCT03104400 · Phase 3
—30 mg
NCT03104400 · Phase 3
—30 mg
NCT03104400 · Phase 3
—15 mg
NCT03104374 · Phase 3
—15 mg
NCT03104374 · Phase 3
5.7%15 mg
NCT03104374 · Phase 3
—30 mg
NCT03104374 · Phase 3
—30 mg
NCT03104374 · Phase 3
6.4%30 mg
NCT03104374 · Phase 3
Serious AEs
7.5%5 mg twice dailyf
NCT01877668 · Phase 3
show 11 more results
3.8%10 mg twice daily
NCT01877668 · Phase 3
3.8%5 mg Twice Daily
NCT01882439 · Phase 3
6.1%10 mg, Twice Daily
NCT01882439 · Phase 3
—Tofacitinib
NCT03486457 · Phase 3 · registry result, not featured evidence
0%Tofacitinib: Up to Month 3
NCT03486457 · Phase 3 · registry result, not featured evidence
1.5%Tofacitinib: Up to Month 6
NCT03486457 · Phase 3 · registry result, not featured evidence
4.4%5 mg BID
NCT01976364 · Phase 3 · registry result, not featured evidence
3.4%5 mg BID
NCT01976364 · Phase 3 · registry result, not featured evidence · combination
—Tofacitinib
NCT01976364 · Phase 3 · registry result, not featured evidence · background therapy
6.4%5 mg BID
NCT01519089 · Phase 3 · registry result, not featured evidence
6.4%10 mg BID
NCT01519089 · Phase 3 · registry result, not featured evidence
—15 mgf
NCT03104400 · Phase 3
show 12 more results
6.5%15 mg
NCT03104400 · Phase 3
28.8%15 mg
NCT03104400 · Phase 3
—30 mg
NCT03104400 · Phase 3
12.4%30 mg / 15 mg
NCT03104400 · Phase 3
10.9%30 mg
NCT03104400 · Phase 3
18%30 mg
NCT03104400 · Phase 3
10.4%15 mg
NCT03104374 · Phase 3
14.4%15 mg
NCT03104374 · Phase 3
—15 mg
NCT03104374 · Phase 3
11.4%30 mg
NCT03104374 · Phase 3
11.5%30 mg
NCT03104374 · Phase 3
—30 mg
NCT03104374 · Phase 3
Most frequent reported AEs
5 mg twice dailyf
upper respiratory tract infection 9.3%
nasopharyngitis 7.5%
blood creatine phosphokinase increased 4.7%
NCT01877668 · Phase 3
show 9 more results
10 mg twice daily
nasopharyngitis 11.5%
headache 10.6%
upper respiratory tract infection 10.6%
NCT01877668 · Phase 3
5 mg Twice Daily
nasopharyngitis 10.7%
upper respiratory tract infection 9.2%
diarrhoea 7.6%
NCT01882439 · Phase 3
10 mg, Twice Daily
headache 9.1%
nasopharyngitis 9.1%
diarrhoea 6.1%
NCT01882439 · Phase 3
upper respiratory tract infection 18.4% (placebo 10.3%)
abdominal discomfort 6.6% (placebo 1.5%)
blood creatine phosphokinase increased 6.6% (placebo 1.5%)
NCT03486457 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 26.5% (placebo 10.3%)
blood creatine phosphokinase increased 14.7% (placebo 1.5%)
hyperlipidaemia 10.3% (placebo 2.9%)
NCT03486457 · Phase 3 · registry result, not featured evidence
5 mg BID
upper respiratory tract infection 4.4%
urinary tract infection 4.4%
bronchitis 3.3%
NCT01976364 · Phase 3 · registry result, not featured evidence
5 mg BID
upper respiratory tract infection 6.7%
pharyngitis 3.4%
psoriatic arthropathy 3.4%
NCT01976364 · Phase 3 · registry result, not featured evidence · combination
5 mg BID
nasopharyngitis 29.8%
psoriasis 8.5%
tinea pedis 8.5%
NCT01519089 · Phase 3 · registry result, not featured evidence
10 mg BID
nasopharyngitis 29.8%
herpes zoster 21.3%
psoriasis 12.8%
NCT01519089 · Phase 3 · registry result, not featured evidence
15 mgf
upper respiratory tract infection 15.6% (placebo 8%)
blood creatine phosphokinase increased 12.1% (placebo 1.4%)
nasopharyngitis 8.4% (placebo 5%)
NCT03104400 · Phase 3
show 8 more results
15 mg
covid-19 34.9% (placebo 0%)
upper respiratory tract infection 14.8% (placebo 8%)
blood creatine phosphokinase increased 11.4% (placebo 1.4%)
NCT03104400 · Phase 3
30 mg / 15 mg
covid-19 26.4% (placebo 0%)
upper respiratory tract infection 11.1% (placebo 8%)
blood creatine phosphokinase increased 8.8% (placebo 1.4%)
NCT03104400 · Phase 3
30 mg
upper respiratory tract infection 17% (placebo 8%)
blood creatine phosphokinase increased 15.8% (placebo 1.4%)
nasopharyngitis 10.6% (placebo 5%)
NCT03104400 · Phase 3
30 mg
covid-19 13.9% (placebo 0%)
upper respiratory tract infection 10.9% (placebo 8%)
blood creatine phosphokinase increased 9% (placebo 1.4%)
NCT03104400 · Phase 3
15 mg
nasopharyngitis 11.4% (placebo 8%)
upper respiratory tract infection 10.4% (placebo 4.7%)
urinary tract infection 9% (placebo 5.7%)
NCT03104374 · Phase 3
15 mg
covid-19 12.6% (placebo 0%)
hypertension 11.4% (placebo 4.7%)
urinary tract infection 10.2% (placebo 5.7%)
NCT03104374 · Phase 3
30 mg
nasopharyngitis 13.2% (placebo 8%)
upper respiratory tract infection 13.2% (placebo 4.7%)
blood creatine phosphokinase increased 10% (placebo 1.9%)
NCT03104374 · Phase 3
30 mg
psoriatic arthropathy 9.7% (placebo 5.2%)
urinary tract infection 8.5% (placebo 5.7%)
herpes zoster 7.9% (placebo 0.9%)
NCT03104374 · Phase 3

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 12 weeks versus 52 weeks.
  5. eAssessment timepoints differ: 24 weeks versus 48 weeks.
  6. fPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

tofacitinib

mTSS Progression 4.08% (n=98) vs 2.11% (n=95) Adalimumab @ 48wk5 mg twice daily
responder rate · % of participants
NCT01877668 · Phase 3
show 1 more result
5.05% (n=99) vs 2.11% (n=95) Adalimumab @ 48wk10 mg twice daily
NCT01877668 · Phase 3
CRP Change -5.5981 vs -0.8643 placebo mg @ 12wk5 mg twice daily
absolute change · mg
NCT01877668 · Phase 3
show 3 more results
-5.4657 vs 1.0233 placebo mg @ 12wk5 mg Twice Daily
NCT01882439 · Phase 3
-6.6004 vs -0.8643 placebo mg @ 12wk10 mg twice daily
NCT01877668 · Phase 3
-5.9156 vs 1.0233 placebo mg @ 12wk10 mg, Twice Daily
NCT01882439 · Phase 3
Patient Assessment of Arthritis Pain -21.49 vs -10.22 placebo mm @ 12wk5 mg twice daily
absolute change · mm
NCT01877668 · Phase 3
show 3 more results
-21.66 vs -7.72 placebo mm @ 12wk5 mg Twice Daily
NCT01882439 · Phase 3
-27.1 vs -10.22 placebo mm @ 12wk10 mg twice daily
NCT01877668 · Phase 3
-20.88 vs -7.72 placebo mm @ 12wk10 mg, Twice Daily
NCT01882439 · Phase 3
Patient Global Assessment -20.08 vs -11.4 placebo mm @ 12wk5 mg twice daily
absolute change · mm
NCT01877668 · Phase 3
show 3 more results
-21.59 vs -7.14 placebo mm @ 12wk5 mg Twice Daily
NCT01882439 · Phase 3
-25.5 vs -11.4 placebo mm @ 12wk10 mg twice daily
NCT01877668 · Phase 3
-19.88 vs -7.14 placebo mm @ 12wk10 mg, Twice Daily
NCT01882439 · Phase 3
Physician Global Assessment -27.44 vs -22.26 placebo mm @ 12wk5 mg twice daily
absolute change · mm
NCT01877668 · Phase 3
show 3 more results
-27.25 vs -15.88 placebo mm @ 12wk5 mg Twice Daily
NCT01882439 · Phase 3
-33.74 vs -22.26 placebo mm @ 12wk10 mg twice daily
NCT01877668 · Phase 3
-28.95 vs -15.88 placebo mm @ 12wk10 mg, Twice Daily
NCT01882439 · Phase 3
Swollen Joint Count -6.5 vs -4.8 placebo Joints @ 12wk5 mg twice daily
absolute change · Joints
NCT01877668 · Phase 3
show 3 more results
-7.6 vs -2.7 placebo Joints @ 12wk5 mg Twice Daily
NCT01882439 · Phase 3
-7.6 vs -4.8 placebo Joints @ 12wk10 mg twice daily
NCT01877668 · Phase 3
-6.7 vs -2.7 placebo Joints @ 12wk10 mg, Twice Daily
NCT01882439 · Phase 3
Tender Joint Count -8.7 vs -6.9 placebo Joints @ 12wk5 mg twice daily
absolute change · Joints
NCT01877668 · Phase 3
show 3 more results
-9.9 vs -4.5 placebo Joints @ 12wk5 mg Twice Daily
NCT01882439 · Phase 3
-11 vs -6.9 placebo Joints @ 12wk10 mg twice daily
NCT01877668 · Phase 3
-9.7 vs -4.5 placebo Joints @ 12wk10 mg, Twice Daily
NCT01882439 · Phase 3
PsARC 31.78% (n=107) vs 9.52% (n=105) placebo @ 2wk5 mg twice daily
responder rate · % of participants
NCT01877668 · Phase 3
show 27 more results
42.06% (n=107) vs 21.9% (n=105) placebo @ 4.33wk5 mg twice daily
NCT01877668 · Phase 3
50.47% (n=107) vs 34.29% (n=105) placebo @ 8.67wk5 mg twice daily
NCT01877668 · Phase 3
51.4% (n=107) vs 44.76% (n=105) placebo @ 13wk5 mg twice daily
NCT01877668 · Phase 3
63.55% (n=107) vs NA placebo @ 17.33wk5 mg twice daily
NCT01877668 · Phase 3
57.01% (n=107) vs NA placebo @ 26wk5 mg twice daily
NCT01877668 · Phase 3
70.09% (n=107) vs NA placebo @ 39wk5 mg twice daily
NCT01877668 · Phase 3
64.49% (n=107) vs NA placebo @ 52wk5 mg twice daily
NCT01877668 · Phase 3
32.82% (n=131) vs 17.56% (n=131) placebo @ 2wk5 mg Twice Daily
NCT01882439 · Phase 3
42.75% (n=131) vs 34.35% (n=131) placebo @ 4.33wk5 mg Twice Daily
NCT01882439 · Phase 3
51.15% (n=131) vs 32.82% (n=131) placebo @ 8.67wk5 mg Twice Daily
NCT01882439 · Phase 3
58.78% (n=131) vs 29.01% (n=131) placebo @ 13wk5 mg Twice Daily
NCT01882439 · Phase 3
56.49% (n=131) vs NA placebo @ 17.33wk5 mg Twice Daily
NCT01882439 · Phase 3
58.78% (n=131) vs NA placebo @ 26wk5 mg Twice Daily
NCT01882439 · Phase 3
40.38% (n=104) vs 9.52% (n=105) placebo @ 2wk10 mg twice daily
NCT01877668 · Phase 3
49.04% (n=104) vs 21.9% (n=105) placebo @ 4.33wk10 mg twice daily
NCT01877668 · Phase 3
66.35% (n=104) vs 34.29% (n=105) placebo @ 8.67wk10 mg twice daily
NCT01877668 · Phase 3
70.19% (n=104) vs 44.76% (n=105) placebo @ 13wk10 mg twice daily
NCT01877668 · Phase 3
65.38% (n=104) vs NA placebo @ 17.33wk10 mg twice daily
NCT01877668 · Phase 3
72.12% (n=104) vs NA placebo @ 26wk10 mg twice daily
NCT01877668 · Phase 3
70.19% (n=104) vs NA placebo @ 39wk10 mg twice daily
NCT01877668 · Phase 3
73.08% (n=104) vs NA placebo @ 52wk10 mg twice daily
NCT01877668 · Phase 3
34.09% (n=132) vs 17.56% (n=131) placebo @ 2wk10 mg, Twice Daily
NCT01882439 · Phase 3
50% (n=132) vs 34.35% (n=131) placebo @ 4.33wk10 mg, Twice Daily
NCT01882439 · Phase 3
54.55% (n=132) vs 32.82% (n=131) placebo @ 8.67wk10 mg, Twice Daily
NCT01882439 · Phase 3
48.48% (n=132) vs 29.01% (n=131) placebo @ 13wk10 mg, Twice Daily
NCT01882439 · Phase 3
56.82% (n=132) vs NA placebo @ 17.33wk10 mg, Twice Daily
NCT01882439 · Phase 3
51.52% (n=132) vs NA placebo @ 26wk10 mg, Twice Daily
NCT01882439 · Phase 3
PGA -0.7 vs -0.2 placebo score @ 4.33wk5 mg twice daily
absolute change · score
NCT01877668 · Phase 3
show 15 more results
-1 vs -0.4 placebo score @ 13wk5 mg twice daily
NCT01877668 · Phase 3
-0.9 vs NA placebo score @ 26wk5 mg twice daily
NCT01877668 · Phase 3
-1 vs NA placebo score @ 39wk5 mg twice daily
NCT01877668 · Phase 3
-1.2 vs NA placebo score @ 52wk5 mg twice daily
NCT01877668 · Phase 3
-0.5 vs -0.2 placebo score @ 4.33wk5 mg Twice Daily
NCT01882439 · Phase 3
-0.7 vs -0.4 placebo score @ 13wk5 mg Twice Daily
NCT01882439 · Phase 3
-0.9 vs NA placebo score @ 26wk5 mg Twice Daily
NCT01882439 · Phase 3
-0.8 vs -0.2 placebo score @ 4.33wk10 mg twice daily
NCT01877668 · Phase 3
-1.2 vs -0.4 placebo score @ 13wk10 mg twice daily
NCT01877668 · Phase 3
-1.3 vs NA placebo score @ 26wk10 mg twice daily
NCT01877668 · Phase 3
-1.5 vs NA placebo score @ 39wk10 mg twice daily
NCT01877668 · Phase 3
-1.5 vs NA placebo score @ 52wk10 mg twice daily
NCT01877668 · Phase 3
-0.8 vs -0.2 placebo score @ 4.33wk10 mg, Twice Daily
NCT01882439 · Phase 3
-1.1 vs -0.4 placebo score @ 13wk10 mg, Twice Daily
NCT01882439 · Phase 3
-1.1 vs NA placebo score @ 26wk10 mg, Twice Daily
NCT01882439 · Phase 3
Dactylitis -1.8 vs 0.6 placebo score @ 4.33wk5 mg twice daily
absolute change · score
NCT01877668 · Phase 3
show 9 more results
-3.5 vs -2 placebo score @ 13wk5 mg twice daily
NCT01877668 · Phase 3
-5.2 vs NA placebo score @ 26wk5 mg twice daily
NCT01877668 · Phase 3
-7 vs NA placebo score @ 39wk5 mg twice daily
NCT01877668 · Phase 3
-7.4 vs NA placebo score @ 52wk5 mg twice daily
NCT01877668 · Phase 3
-3.1 vs 0.6 placebo score @ 4.33wk10 mg twice daily
NCT01877668 · Phase 3
-5.5 vs -2 placebo score @ 13wk10 mg twice daily
NCT01877668 · Phase 3
-6.4 vs NA placebo score @ 26wk10 mg twice daily
NCT01877668 · Phase 3
-7.2 vs NA placebo score @ 39wk10 mg twice daily
NCT01877668 · Phase 3
-7.5 vs NA placebo score @ 52wk10 mg twice daily
NCT01877668 · Phase 3
SPARCC Enthesitis Index -0.83 vs -0.58 placebo score @ 4.33wk5 mg twice daily
absolute change · score
NCT01877668 · Phase 3
show 15 more results
-1.84 vs -1.17 placebo score @ 13wk5 mg twice daily
NCT01877668 · Phase 3
-2.4 vs NA placebo score @ 26wk5 mg twice daily
NCT01877668 · Phase 3
-2.9 vs NA placebo score @ 39wk5 mg twice daily
NCT01877668 · Phase 3
-3.2 vs NA placebo score @ 52wk5 mg twice daily
NCT01877668 · Phase 3
-1.9 vs -1 placebo score @ 4.33wk5 mg Twice Daily
NCT01882439 · Phase 3
-2.5 vs -1.3 placebo score @ 13wk5 mg Twice Daily
NCT01882439 · Phase 3
-2.6 vs NA placebo score @ 26wk5 mg Twice Daily
NCT01882439 · Phase 3
-1.27 vs -0.58 placebo score @ 4.33wk10 mg twice daily
NCT01877668 · Phase 3
-2.41 vs -1.17 placebo score @ 13wk10 mg twice daily
NCT01877668 · Phase 3
-2.6 vs NA placebo score @ 26wk10 mg twice daily
NCT01877668 · Phase 3
-2.6 vs NA placebo score @ 39wk10 mg twice daily
NCT01877668 · Phase 3
-3.1 vs NA placebo score @ 52wk10 mg twice daily
NCT01877668 · Phase 3
-1.9 vs -1 placebo score @ 4.33wk10 mg, Twice Daily
NCT01882439 · Phase 3
-2.8 vs -1.3 placebo score @ 13wk10 mg, Twice Daily
NCT01882439 · Phase 3
-3.1 vs NA placebo score @ 26wk10 mg, Twice Daily
NCT01882439 · Phase 3
Leeds Enthesitis Index -0.41 vs -0.26 placebo score @ 4.33wk5 mg twice daily
absolute change · score
NCT01877668 · Phase 3
show 15 more results
-0.82 vs -0.43 placebo score @ 13wk5 mg twice daily
NCT01877668 · Phase 3
-1.3 vs NA placebo score @ 26wk5 mg twice daily
NCT01877668 · Phase 3
-1.4 vs NA placebo score @ 39wk5 mg twice daily
NCT01877668 · Phase 3
-1.7 vs NA placebo score @ 52wk5 mg twice daily
NCT01877668 · Phase 3
-1 vs -0.5 placebo score @ 4.33wk5 mg Twice Daily
NCT01882439 · Phase 3
-1.3 vs -0.5 placebo score @ 13wk5 mg Twice Daily
NCT01882439 · Phase 3
-1.5 vs NA placebo score @ 26wk5 mg Twice Daily
NCT01882439 · Phase 3
-0.57 vs -0.26 placebo score @ 4.33wk10 mg twice daily
NCT01877668 · Phase 3
-1.46 vs -0.43 placebo score @ 13wk10 mg twice daily
NCT01877668 · Phase 3
-1.2 vs NA placebo score @ 26wk10 mg twice daily
NCT01877668 · Phase 3
-1.3 vs NA placebo score @ 39wk10 mg twice daily
NCT01877668 · Phase 3
-1.6 vs NA placebo score @ 52wk10 mg twice daily
NCT01877668 · Phase 3
-0.8 vs -0.5 placebo score @ 4.33wk10 mg, Twice Daily
NCT01882439 · Phase 3
-1.3 vs -0.5 placebo score @ 13wk10 mg, Twice Daily
NCT01882439 · Phase 3
-1.6 vs NA placebo score @ 26wk10 mg, Twice Daily
NCT01882439 · Phase 3

+ 95 further endpoints in the CSV export.

upadacitinib

ISGA 0/1 41.9% (n=322) vs 10.9% (n=313) placebo @ 16wk15 mg
responder rate · % of participants
NCT03104400 · Phase 3
show 3 more results
36.8% (n=171) vs 9.2% (n=163) placebo @ 16wk15 mg
NCT03104374 · Phase 3
54% (n=324) vs 10.9% (n=313) placebo @ 16wk30 mg
NCT03104400 · Phase 3
40.2% (n=164) vs 9.2% (n=163) placebo @ 16wk30 mg
NCT03104374 · Phase 3
MDA 36.6% (n=429) vs 12.3% (n=423) placebo @ 24wk15 mg
responder rate · % of participants
NCT03104400 · Phase 3
show 3 more results
25.1% (n=211) vs 2.8% (n=212) placebo @ 24wk15 mg
NCT03104374 · Phase 3
45.4% (n=423) vs 12.3% (n=423) placebo @ 24wk30 mg
NCT03104400 · Phase 3
28.9% (n=218) vs 2.8% (n=212) placebo @ 24wk30 mg
NCT03104374 · Phase 3
Enthesitis Resolution 53.7% (n=270) vs 32.4% (n=241) placebo @ 24wk15 mg
responder rate · % of participants
NCT03104400 · Phase 3
show 1 more result
57.7% (n=267) vs 32.4% (n=241) placebo @ 24wk30 mg
NCT03104400 · Phase 3
Dactylitis Resolution 76.5% (n=136) vs 39.7% (n=126) placebo @ 24wk15 mg
responder rate · % of participants
NCT03104400 · Phase 3
show 1 more result
79.5% (n=127) vs 39.7% (n=126) placebo @ 24wk30 mg
NCT03104400 · Phase 3
Patient Assessment of Arthritis Pain -2.3 vs -0.9 placebo score @ 12wk15 mg
absolute change · score
NCT03104400 · Phase 3
show 1 more result
-2.7 vs -0.9 placebo score @ 12wk30 mg
NCT03104400 · Phase 3
SAPS -25.3 vs -8.2 placebo score @ 16wk15 mg
absolute change · score
NCT03104400 · Phase 3
show 1 more result
-28.1 vs -8.2 placebo score @ 16wk30 mg
NCT03104400 · Phase 3
SAPS HD -24.4 vs -1.5 placebo score @ 16wk15 mg
absolute change · score
NCT03104374 · Phase 3
show 1 more result
-29.7 vs -1.5 placebo score @ 16wk30 mg
NCT03104374 · Phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: tofacitinib's landscape · upadacitinib's landscape